[
  {
    "chunk_id": 0,
    "text": "CLINICAL PRACTICE GUIDELINES potassium/DOQI CLINICAL PRACTICE GUIDELINES For Chronic Kidney Disease: Evaluation, Classification and Stratification For Chronic Kidney Disease Made possible through an educational grant from Amgen, Founding and Principal Sponsor of National Kidney Foundation-potassium/DOQI. Additional implementation support was received from Ortho Biotech Products, L. P. and Bayer Diagnostics. 30 East 33rd Street New York, NY 10016 Phone 800 622-9010 www. Kidney. org ISBN 1-931472-10-6 National Kidney Foundation Order No. potassium/DOQI-156 Amgen Part No. P35181 potassium/DOQI Learning System (KLS) Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification and Stratification potassium/DOQI Disclaimer Theseguidelinesarebaseduponthebestinformationavailableatthetimeofpublication. Theyaredesignedtoprovideinformationandassistdecisionmaking. Theyare notintendedtodefineastandardofcare, andshouldnotbeconstruedasdoingso. Neithershouldtheybeinterpretedasprescribinganexclusivecourseofmanagement. Variationsinpracticewillinevitablyandappropriatelyoccurwhenclinicianstake into account the needs of individual patients, available resources, and limitations uniquetoaninstitutionortypeofpractice. Everyhealthcareprofessionalmakinguse oftheseguidelinesisresponsibleforevaluatingtheappropriatenessofapplyingthem inthesettingofanyparticularclinicalsituation. Therecommendationsforresearchcontainedwithinthisdocumentaregeneral andnotmeanttoimplyaspecificprotocol. GENERALACKNOWLEDGEMENTS TheNKFgratefullyacknowledgesthesupportofAmgen, Inc. , FoundingandPrincipal SponsorofK/DOQI. WealsothankBayerDiagnosticsandOrthoBiotechProducts, L. P. , potassium/DOQIImplementationPartners. National Kidney Foundation-DOQIandK/DOQIaretrademarksoftheNationalKidneyFoundation, Inc. Incitingthisdocument, pleaserefertotheoriginalsourceasfollows: NationalKidneyFoundation. potassium/DOQIClinicalPracticeGuidelinesforChronicKidneyDisease: Evaluation, ClassificationandStratification. AmJKidneyDis39: S1-S266, 2002(suppl1) These Guidelines, as well as all other potassium/DOQI guidelines, can be accessed on the Internetat: www. Kidney Disease Outcomes Quality Initiative. org (cid: 1)2002NationalKidneyFoundation, Inc. ISBN1-931472-10-6 AllRightsReserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage retrieval system, without permission in writing from the National KidneyFoundation, Inc. NationalKidneyFoundation, Inc. 30E. 33rdStreet NewYork, NY10016 212-889-2210 ii NationalKidneyFoundation potassium/DOQI Chronic Kidney Disease Work Group and Evidence Review Team Membership AndrewS. Levey, MD, Chair NewEnglandMedicalCenter Boston, MA JosefCoresh, MD, PhD, ViceChair JohnsHopkinsMedicalInstitutions Baltimore, MD Adult Work Group Members KlineBolton, MD, FACP JohnKusek, PhD UniversityofVirginiaHospital NationalInstitutesofDiabetesand Charlotesville, VA DigestiveandKidneyDiseases Bethesda, MD BruceCulleton, MD FoothillsHospital, Universityof AdeeraLevin, MD, FRCP Calgary St. PaulsHospital Calgary, Alberta Vancouver, BritishColumbia Canada Canada KathySchiroHarvey, MS, RD, CSR KennethL. Minaker, MD PugetSoundKidneyCenter MassachusettsGeneralHospital MountlakeTerrace, WA Boston, MA T. AlpIkizler, MD RobertNelson, MD, PhD VanderbiltUniversityMedicalCenter NationalInstitutesofDiabetesand Nashville, TN DigestiveandKidneyDiseases Phoenix, AZ CyndaAnnJohnson, MD, MBA UniversityofIowa HelmutRennke, MD IowaCity, IA BrighamWomensHospital Boston, MA AnnamariaKausz, MD, MS NewEnglandMedicalCenter MichaelSteffes, MD, PhD Boston, MA UniversityofMinnesota Minneapolis, membranous nephropathy PaulL. Kimmel, MD NationalInstitutesofDiabetesand BethWitten, MSW, ACSW, LSCSW DigestiveandKidneyDiseases WittenandAssociates, LLC Bethesda, MD OverlandPark, KS potassium/DOQI NationalKidneyFoundation iii Pediatric Work Group Members RonaldJ. Hogg, MD, Chair MedicalCityHospital Dallas, transplant SusanFurth, MD, PhD RonaldJ. Portman, MD JohnsHopkinsUniversity UniversityofTexasHealthSciences Baltimore, MD CenterHouston Houston, transplant KevinV. Lemley, MD, PhD StanfordUniversitySchoolofMedicine GeorgeSchwartz, MD Stanford, computed tomography UniversityofRochesterSchoolofMedicine Rochester, NY Evidence Review Team JosephLau, MD, Director NewEnglandMedicalCenter Boston, MA EthanBalk, MD, MPH, AssistantDirector NewEnglandMedicalCenter Boston, MA RonaldD. Perrone, MD PriscillaChew, MPH TauqeerKarim, MD BradC.",
    "word_count": 400,
    "char_count": 4563,
    "sentence_count": 29,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 0,
      "total_chunks": 77,
      "position": "1/77",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "nephropathy",
        "potassium",
        "classification"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 1,
    "text": "Perrone, MD PriscillaChew, MPH TauqeerKarim, MD BradC. Astor, PhD, MPH LaraRayan, MD DeirdreDeVine, MLitt InasAl-Massry, MD potassium/DOQI Support Group GarabedEknoyan, MD, Co-Chair BaylorCollegeofMedicine Houston, transplant NathanLevin, MD, FACP, Co-Chair RenalResearchInstitute NewYork, NY SallyBurrows-Hudson, RN DonnaMapes, DNSc, RN WilliamKeane, MD EdithOberley, MA AlanKliger, MD KerryWillis, PhD DerrickLatos, MD, FACP iv NationalKidneyFoundation potassium/DOQI potassium/DOQI Advisory Board Members Garabed Eknoyan, MD, Co-Chair Baylor College of Medicine Houston, transplant Nathan Levin, MD, FACP, Co-Chair Renal Research Institute New York, NY George Bailie, PharmD, PhD Sally McCulloch, MSN, RN, CNN Gavin Becker, MD, MBBS Maureen Michael, BSN, MBA Jerrilynn Burrowes, MS, RD, CDN Joseph V. Nally, MD David Churchill, MD, FACP John M. Newmann, PhD, MPH Allan Collins, MD, FACP Allen Nissenson, MD William Couser, MD Keith Norris, MD Dick DeZeeuw, MD, PhD William Owen, Jr. , MD Alan Garber, MD, PhD Thakor G. Patel, MD, MACP Thomas Golper, MD Glenda Payne, MS, RN, CNN Frank Gotch, MD Rosa A. Rivera-Mizzoni, MSW, Antonio Gotto, MD LCSW Joel W. Greer, PhD David Smith Richard Grimm, Jr. , MD Robert Star, MD Ramon G. Hannah, MD, MS Michael Steffes, MD, PhD Jaime Herrera Acosta, MD Theodore Steinman, MD Ronald Hogg, MD Fernando Valderrabano, MD, PhD Lawrence Hunsicker, MD John Walls, MB, FRCP Cynda Ann Johnson, MD, MBA Jean-Pierre Wauters, MD Michael Klag, MD, MPH Nanette Wenger, MD Saulo Klahr, MD Ex-Officio Caya Lewis, MPH Edmund Lowrie, MD Josephine Briggs, MD Arthur Matas, MD potassium/DOQI NationalKidneyFoundation v potassium/DOQI CLINICAL PRACTICE GUIDELINES FOR CHRONICKIDNEYDISEASE: EVALUATION CLASSIFICATIONANDSTRATIFICATION Table of Contents Tables viii Figuresxiii AcronymsandAbbreviations xvii Foreword xxiii Part1. ExecutiveSummary 1 Part2. Background 23 Part3. ChronicKidneyDiseaseasaPublicHealthProblem 29 Part4. DefinitionandClassificationofStagesofChronicKidneyDisease Guideline1. DefinitionandStagesofChronicKidneyDisease43 Guideline2. EvaluationandTreatment 66 Guideline3. IndividualsatIncreasedRiskofChronicKidneyDisease 75 Part5. EvaluationofLaboratoryMeasurementsforClinical AssessmentofKidneyDisease Guideline4. EstimationofGFR 81 Guideline5. AssessmentofProteinuria 100 Guideline6. MarkersofChronicKidneyDiseaseOtherThanProteinuria 112 Part6. AssociationofLevelofGFRWithComplicationsinAdults Guideline7. AssociationofLevelofGFRWithHypertension 124 Guideline8. AssociationofLevelofGFRWithAnemia 136 Guideline9. AssociationofLevelofGFRWithNutritionalStatus 145 Guideline10. AssociationofLevelofGFRWithBoneDiseaseand DisordersofCalciumandPhosphorusMetabolism163 Guideline11. AssociationofLevelofGFRWithNeuropathy 180 Guideline12. AssociationofLevelofGFRWithIndicesofFunctioning andWell-Being 186 Part7. StratificationofRiskforProgressionofKidneyDiseaseandDevelopment ofCardiovascularDisease Guideline13. FactorsAssociatedWithLossofKidneyFunctioninChronic KidneyDisease 197 Guideline14. AssociationofChronicKidneyDiseaseWithDiabetic Complications 230 Guideline15. AssociationofChronicKidneyDiseaseWithCardiovascular Disease 238 potassium/DOQI NationalKidneyFoundation vii Part8. RecommendationsforClinicalPerformanceMeasures 251 Part9. ApproachtoChronicKidneyDiseaseUsingTheseGuidelines 255 Part10. Appendices Appendix1. MethodsforReviewofArticles 265 Appendix2. KidneyFunctionandAssociatedConditionsinthe UnitedStates: MethodsandFindingsFromtheThirdNationalHealthand NutritionExaminationSurvey(1988to1994) 279 Appendix3. MethodologicalAspectsofEvaluatingEquationstoPredict GFRandCalculationsUsing24-HourUrineSamples 283 Part11. WorkGroupMembers 287 Part12. Acknowledgements295 Bibliography 299 Tables Table1 GoalsoftheCKDWorkGroup 2 Table2 DefinitionofChronicKidneyDisease 3 Table3 StagesofChronicKidneyDisease: AClinicalActionPlan 4 Table4 StagesandPrevalenceofChronicKidneyDisease(Age(cid: 1)20) 5 Table5 PotentiallyModifiableRiskFactorsforDevelopment andProgressionofChronicKidneyDiseaseAccordingtoStage 7 Table6 ApproachtotheEvidenceReview 7 Table7 PublishedGuidelinesandRecommendationforChronic KidneyDisease27 Table8 QuestionsandMethods 30 Table9 TypesofRiskFactorsforAdverseOutcomesofChronic KidneyDisease32 Table10 StagesofChronicKidneyDisease 44 Table11 DefinitionofChronicKidneyDisease 44 Table12 DefinitionandStagesofChronicKidneyDisease 45 Table13 PrevalenceofGFRCategories: NHANESIII19881994 USAdultsAge(cid: 1)20 47 Table14 PrevalenceofStagesofChronicKidneyDiseaseandLevels ofKidneyFunctionintheUS 47 Table15 DefinitionsofProteinuriaandAlbuminuria 49 Table16 AlbuminExcretionRate: NormalRangeinChildren 50 Table17 UrineAlbumin-to-CreatinineRatio: NormalRangeinChildren 51 Table18 PrevalenceofAlbuminuriainAdults: NHANESIII 52 Table19 PrevalenceofAlbuminuriabyAgeGroup: NHANESIII 52 Table20 PrevalenceofAlbuminuriaAmongIndividualsWithaHistoryof Diabetes: NHANESIII 53 Table21 PrevalenceofAlbuminuriaAmongIndividualsWithouta HistoryofDiabetes: NHANESIII 53 viii NationalKidneyFoundation potassium/DOQI Table22 Proteinuria: PrevalenceinNondiabeticChildren 54 Table23 Albuminuria: PrevalenceinNondiabeticChildren 54 Table24 NormalGFRinChildrenandYoungAdults 55 Table25 NormalGFRinAdultsExtrapolatedFromDatain72HealthyMen 56 Table26 PrevalenceofGFRCategoriesinAdults 57 Table27 DescriptionofMDRDStudyParticipantsWhoDevelopedKidney Failure: KidneyFunction 61 Table28 DescriptionofMDRDStudyParticipantsWhoDevelopedKidney Failure: DietaryIntakeandNutritionalStatus 62 Table29 ComparisonofKidneyFunctionMeasurementsinMDRDStudy ParticipantsWhoDevelopedKidneyFailure 62 Table30 GFRatStartofHemodialysis 63 Table31 CreatinineClearanceatStartofHemodialysis 64 Table32 SerumCreatinineatStartofHemodialysis 64 Table33 StagesofChronicKidneyDisease: AClinicalActionPlan 67 Table34 ClassificationofChronicKidneyDiseasebyPathology, Etiology andPrevalenceinPatientsWithEnd-StageRenalDisease 69 Table35 ClassificationandManagementofComorbidConditionsin ChronicKidneyDisease 70 Table36 AssociationofStagesofChronicKidneyDiseaseWith Complications 72 Table37 FactorsLinkedWithNoncomplianceinChronicKidneyDisease 73 Table38 ClassificationofRiskFactors 76 Table39 TypesandExamplesofRiskFactorsforChronicKidneyDisease76 Table40 PotentialRiskFactorsforSusceptibilitytoandInitiation ofChronicKidneyDisease77 Table41 RelationshipBetweenTypesofKidneyDiseaseandRisk FactorsforInitiationandSusceptibilitytoChronic KidneyDisease77 Table42 PrevalenceofIndividualsatIncreasedRiskforChronic KidneyDisease78 Table43 FactorsAffectingSerumCreatinineConcentration 87 Table44 EquationsDevelopedtoPredictGFRinAdultsBasedon SerumCreatinine 89 Table45 EquationsDevelopedtoPredictGFRinChildrenBasedon SerumCreatinine 90 Table46 EstimatingGFRinAdultsUsingtheCockcroft-GaultEquation: AccuracyandBias 91 Table47 EstimatingGFRinAdultsUsingtheMDRDStudyEquation: AccuracyandBias 92 potassium/DOQI NationalKidneyFoundation ix Table48 AbbreviatedMDRDStudyEquation 92 Table49 SerumCreatinineCorrespondingtoanEstimatedGFRof60mL/min/ 1. 73m2bytheAbbreviatedMDRDStudyandCockcroft-Gault Equations93 Table50 EstimatingGFRinChildrenUsingtheSchwartzEquation: AccuracyandBias 94 Table51 EstimatingGFRinChildrenUsingtheCounahan-Barrattor ModifiedCounahan-BarrattEquations: AccuracyandBias 95 Table52 ClinicalSituationsinWhichClearanceMeasuresMayBeNecessary toEstimateGFR 98 Table53 SpotUrineProteinvs. TimedUrineProteininAdults 104 Table54 SpotUrineAlbuminvs. TimedUrineAlbumininAdults 104 Table55 SpotUrineDipstickAlbuminvs. TimedUrineAlbumininAdults 105 Table56 SpotUrineProtein-to-CreatinineRatiovs. TimedUrineProtein inAdults 105 Table57 SpotUrineAlbumin-to-CreatinineRatiovs. TimedUrineAlbumin inAdults 106 Table58 SpotUrineProtein-to-CreatinineRatiovs. TimedUrineProteinin NondiabeticChildren 106 Table59 SpotUrineAlbumin-to-CreatinineRatiovs.",
    "word_count": 584,
    "char_count": 7840,
    "sentence_count": 39,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 1,
      "total_chunks": 77,
      "position": "2/77",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "albuminuria",
        "proteinuria",
        "potassium"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 2,
    "text": "TimedUrineAlbumininAdults 105 Table56 SpotUrineProtein-to-CreatinineRatiovs. TimedUrineProtein inAdults 105 Table57 SpotUrineAlbumin-to-CreatinineRatiovs. TimedUrineAlbumin inAdults 106 Table58 SpotUrineProtein-to-CreatinineRatiovs. TimedUrineProteinin NondiabeticChildren 106 Table59 SpotUrineAlbumin-to-CreatinineRatiovs. TimedUrineAlbumin inChildren 107 Table60 ComparisonofMethodsforUrineCollectionforAssessmentof Proteinuria 107 Table61 CommonCausesofFalseResultsinRoutineMeasurementsofUrinary AlbuminorTotalProtein 108 Table62 InterpretationofProteinuriaandUrineSedimentAbnormalities asMarkersofChronicKidneyDisease 114 Table63 InterpretationofAbnormalitiesonImagingStudiesasMarkersof KidneyDamage 115 Table64 ClinicalPresentationsofKidneyDisease 116 Table65 RelationshipBetweenTypesofKidneyDiseaseandClinical Presentations 117 Table66 RetinolBindingProtein(RBP): AssociationWith VariousOutcomes 119 Table67 N-Acetyl-(cid: 1)-D-Glucosaminidase(NAG): AssociationWith VariousOutcomes 119 Table68 (cid: 1)-2-Microglobulin((cid: 1)-2-magnesium): AssociationWithVariousOutcomes 119 Table69 SodiumDodecylSulfate-PolyacrylamideGelElectrophoresis (SDS-PAGE): AssociationWithVariousOutcomes 119 Table70 UrinaryCellExcretion: AssociationWithVariousOutcomes 120 Table71 ClassificationofBloodPressureforAdults(cid: 1)18Years(JNC-VI) 126 x NationalKidneyFoundation potassium/DOQI Table72 PathogeneticMechanismsofHighBloodPressureinChronic KidneyDisease127 Table73 AssociationofMeanArterialPressureandCardiovascular DiseaseEventsinIncidentDialysisPatients 129 Table74 RecommendedResearchonHighBloodPressureinChronic KidneyDisease: ObservationalStudies 135 Table75 RecommendedResearchonHighBloodPressureinChronic KidneyDisease: ClinicalTrials 135 Table76 HemoglobinandKidneyFunction 139 Table77 HematocritandKidneyFunction 140 Table78 ErythropoietinLevelandKidneyFunction 142 Table79 FerritinandKidneyFunction 143 Table80 MiscellaneousHematologicalMeasuresandKidneyFunction 143 Table81 DailyCalorieIntakeandKidneyFunction 150 Table82 DailyProteinIntakeandKidneyFunction150 Table83 SerumAlbuminandKidneyFunction 153 Table84 SerumProteinandPrealbuminandKidneyFunction 154 Table85 TransferrinandKidneyFunction 155 Table86 SerumBicarbonateandKidneyFunction 156 Table87 LipidsandKidneyFunction 157 Table88 BodyMassIndexandKidneyFunction 159 Table89 IdealorStandardBodyWeightandKidneyFunction 159 Table90 BodyTissueComposition(Muscle)andKidneyFunction 160 Table91 BodyTissueComposition(Fat)andKidneyFunction 160 Table92 HistologicClassificationofBoneLesionsAssociatedWithKidney Disease 165 Table93 ParathyroidHormoneandKidneyFunction 168 Table94 FractionalExcretionofPhosphorusandKidneyFunction 169 Table95 SerumCalciumandKidneyFunction 171 Table96 SerumPhosphateandKidneyFunction 174 Table97 VitaminD andKidneyFunction 177 3 Table98 BoneDiseaseandKidneyFunction 178 Table99 NerveConductionVelocityandKidneyFunction182 Table100 MiscellaneousNeurologicalMeasurementsandKidneyFunction 183 Table101 AutonomicFunctionandKidneyFunction 184 Table102 DomainsofFunctioningandWell-BeingMeasuredbySpecific Instruments 187 Table103 SymptomsandHealthPerceptionandKidneyFunction 189 Table104 PhysicalFunctioningandKidneyFunction 190 Table105 MentalHealth, Depression, andWell-BeingandKidneyFunction 192 Table106 Employment, HomeManagement, Recreation, andPastimesand KidneyFunction 193 potassium/DOQI NationalKidneyFoundation xi Table107 SocialFunctioningandKidneyFunction 193 Table108 FunctioningandWell-BeingMeasures 196 Table109 MeanRateofDeclineofGFRforVariousCausesofKidneyDisease 200 Table110 YearsUntilKidneyFailure(glomerular filtration rate(cid: 2)15mL/min/1. 73m2)BasedonLevel ofGFRandRateofGFRDecline 202 Table111 KidneyDiseaseTypeasPredictorofProgression 205 Table112 BlackRaceasaPredictorofProgression 206 Table113 LowBaselineKidneyFunctionasaPredictorofProgression 207 Table114 MaleGenderasaPredictorofProgression 208 Table115 OlderAgeasaPredictorofProgression 209 Table116 ProteinuriaorAlbuminuriaasPredictorsofProgression 210 Table117 LowSerumAlbuminasaPredictorofProgression 211 Table118 BloodPressureasaPredictorofProgression 212 Table119 ElevatedHgbA asaPredictorofProgression 215 1c Table120 TobaccoUseasaPredictorofProgression 216 Table121 DyslipidemiaasPredictorsofProgression 217 Table122 AnemiaasaPredictorofProgression 219 Table123 RecommendationsforGlycemicControlforPeopleWithDiabetes. . 220 Table124 RiskStratificationandIndicationforAntihypertensiveTreatment 221 Table125 BloodPressure, Goals, Nonpharmacologic, andPharmacologic TherapyRecommendedbytheNKFTaskForceonCardiovascular DiseaseinChronicRenalDisease 222 Table126 ResearchClassificationofDiabeticPolyneuropathy 233 Table127 PrevalenceofAtheroscleroticCardiovascularDiseaseAccording totheStageofKidneyDiseaseinVariousRacial/EthnicGroupsWith Type2Diabetes 234 Table128 PrevalenceofRetinopathyAccordingtotheStageofKidney DiseaseinVariousRacial/EthnicGroupsWithType2Diabetes 236 Table129 GuidelinesandPositionStatementsonCareofDiabetic Complications 237 Table130 Traditionalvs. ChronicKidneyDisease-RelatedFactors PotentiallyRelatedtoanIncreasedRiskforCardiovascularDisease. . 240 Table131 LipoproteinAbnormalitiesintheGeneralPopulationandin PatientsWithChronicKidneyDisease 242 Table132 DecreasedGFRasaPredictorofCardiovascularDisease 242 Table133 DecreasedGFRasaPredictorofMortality 243 Table134 ProteinuriaasaPredictorofCardiovascularDisease 245 Table135 ProteinuriaasaPredictorofCardiovascularMortality 245 Table136 ProteinuriaasaPredictorofTotalMortality 246 Table137 potassium/DOQICKDClinicalPracticeGuidelinesandPerformance Measures 252 xii NationalKidneyFoundation potassium/DOQI Table138 ClinicalEvaluationofPatientsatIncreasedRiskofChronic KidneyDisease256 Table139 StagesofChronicKidneyDisease: ClinicalPresentations257 Table140 SimplifiedClassificationofChronicKidneyDiseasebyDiagnosis 257 Table141 CluestotheDiagnosisofChronicKidneyDiseaseFromthe PatientsHistory 258 Table142 LaboratoryEvaluationofPatientsWithChronicKidneyDisease 259 Table143 StagesandClinicalFeaturesofDiabeticKidneyDisease 259 Table144 StagesandClinicalFeaturesofNondiabeticKidneyDisease 260 Table145 StagesandClinicalFeaturesofDiseasesintheKidneyTransplant 260 Table146 TreatmentstoSlowtheProgressionofChronicKidneyDisease inAdults 261 Table147 TraditionalRiskFactorsforChronicKidneyDiseaseandAssociated Interventions 262 Table148 AdditionalClinicalInterventionsforAdultsWithGFR (cid: 2)60mL/min/1. 73m2 263 Table149 ClinicalEvaluationofElderlyIndividualsWithGFRof 6089mL/min/1. 73m2 263 Table150 EvaluationofStudiesofPrevalence 268 Table151 DiagnosticTestEvaluation 269 Table152 EvaluationofClinicalAssociations 270 Table153 EvaluationofStudiesofPrognosis 271 Table154 LiteratureSearchandReviewbyTopic 273 Table155 FormatforGuidelines 277 Figures Figure1 EvidenceModelforStagesintheInitiationandProgressionof ChronicKidneyDiseaseandTherapeuticInterventions 6 Figure2 IncidenceandPrevalenceofEnd-StageRenalDiseaseintheUS24 Figure3 EvidenceModelforStagesintheInitiationandProgressionof CardiovascularDiseaseandTherapeuticInterventions 26 Figure4 KidneyFunctionDeclineinChronicKidneyDisease 32 Figure5 CreatinineDistribution: USPopulationAge(cid: 1)20bySex 36 Figure6 CardiovascularMortalityintheGeneralPopulation(NCHS)and inESRDTreatedbyDialysis(USRDS) 39 Figure7 PrevalenceofAlbuminuriaandHighBloodPressure(%)inUS AdultsAge(cid: 1)20Years, NHANESIII, 19881994 46 Figure8 DistributionofAlbumin-to-CreatinineRatioinUSMenand Women, Age(cid: 1)20Years: NHANESIII, 1988-1994 49 Figure9 GFRvs. Age 56 Figure10 PercentilesofGFRRegressedonAge(NHANESIII) 57 potassium/DOQI NationalKidneyFoundation xiii Figure11 LevelofGFRatInitiationofReplacementTherapy(USRDS) 63 Figure12 RelationshipofCreatinineClearanceandSerumCreatinineWith glomerular filtration rate(InulinClearance)inPatientsWithGlomerularDisease 85 Figure13 EstimatesofGFRvs. MeasuredGFRAmongMDRDStudyBaseline Cohort 87 Figure14 AccuracyofDifferentEstimatesofGFRinAdults 88 Figure15 PrevalenceofPatientsbyNumberofAbnormalitiesbyLevelof glomerular filtration rate(NHANESIII) 123 Figure16 ProportionofPatientsbyNumberofAbnormalitiesbyLevelof glomerular filtration rate(NHANESIII) 124 Figure17 RelationshipBetweenBloodPressureandProgressionofDiabetic KidneyDisease128 Figure18 RelationshipBetweenMeanArterialBloodPressureand GFRDecline 128 Figure19 RelationshipBetweenSystolicBloodPressureandGraftSurvival 129 Figure20 Mortalityvs. SystolicBloodPressureinHemodialysisPatients 130 Figure21 PrevalenceofHighBloodPressurebyLevelofGFRinthe MDRDStudy 131 Figure22 PrevalenceofHighBloodPressurebyLevelofGFR, Adjustedto Age60Years(NHANESIII) 132 Figure23 PrevalenceofElevatedSerumCreatininebyJNCVIBlood PressureCategoryandSelf-ReportedTreatmentWith Anti-HypertensiveMedications(NHANESIII) 132 Figure24 EstimatedNumberofIndividualsWithElevatedSerumCreatinine byJNC(cid: 2)nVIBloodPressureCategoryandSelf-ReportedTreatment WithAnti-HypertensiveMedications(NHANESIII) 133 Figure25 AnemiaWork-UpforPatientsWithChronicKidneyDisease 136 Figure26 BloodHemoglobinPercentilesbyGFRAdjustedtoAge60 (NHANESIII)140 Figure27 AdjustedPrevalenceinAdultsofLowHemoglobinbyGFR (NHANESIII)141 Figure28 HemoglobinPercentilesbyGFR 141 Figure29 PrevalenceofLowHemoglobinbyGFRCategory 142 Figure30 AssociationofDietaryIntakeandGFR 151 Figure31 SerumAlbuminPercentilesbyGFRAdjustedtoAge 154 Figure32 AssociationofSerumAlbuminandGFR 155 Figure33 AssociationofSerumTransferrinandGFR 156 Figure34 AssociationofSerumCholesterolandGFR 158 Figure35 AssociationofBodyCompositionandGFR 161 Figure36 ScatterplotofiPTHvs. glomerular filtration rate169 Figure37 iPTHPercentilesbyGFR 170 Figure38 PrevalenceofHighiPTHbyGFRCategory 170 xiv NationalKidneyFoundation potassium/DOQI Figure39 SerumCalciumLevels(AdjustedforAlbumin)vs. glomerular filtration rate 172 Figure40 PrevalenceofHypocalcemia(AdjustedforAlbumin)vs. glomerular filtration rate 172 Figure41 SerumPhosphorusLevelsvs. glomerular filtration rate(NHANESIII) 175 Figure42 PrevalenceofLowCalciumandHighPhosphatebyGFRCategory 175 Figure43 Calcium-PhosphorusProductPercentilesbyGFR(NHANESIII) 176 Figure44 KidneyFunction(glomerular filtration rate)andOddsofHavingSymptomsAffecting QualityofLifeandWell-Being 190 Figure45 AdjustedPrevalenceofPhysicalInabilitytoWalkbyGFR Category(NHANESIII) 191 Figure46 AdjustedPrevalenceofPhysicalInabilitytoLiftbyGFR Category(NHANESIII) 191 Figure47 GFRSlopesintheModificationofDietinRenalDiseaseStudy 199 Figure48 CompositePlotofReciprocalSerumCreatininevs.",
    "word_count": 580,
    "char_count": 10495,
    "sentence_count": 18,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 2,
      "total_chunks": 77,
      "position": "3/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "proteinuria",
        "potassium",
        "calcium",
        "magnesium"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 3,
    "text": "TimeinSix PatientsWithChronicKidneyDisease 201 Figure49 PlotofReciprocalofPlasmaCreatinine(1/P )inaPatient203 creatinine Figure50 ComparisonofGFRDeclineBetweenDietGroupsinthe ModificationofDietinRenalDiseaseStudy204 Figure51 CardiovascularMortalityWithDiabetes 234 Figure52 MicroalbuminuriaandCardiovascularMorbidityWithType 2Diabetes 235 Figure53 GFRandRelativeRiskforDeath 244 Figure54 ProteinuriaandRelativeRiskforCardiovascularDisease 246 Figure55 ProteinuriaandRelativeRiskforCVDDeath 247 Figure56 ProteinuriaandRelativeRiskforDeath 247 Figure57 EvaluationofProteinuriainPatientsNotKnowntoHave KidneyDisease256 potassium/DOQI NationalKidneyFoundation xv ACRONYMS AND ABBREVIATIONS AASK AfricanAmericanStudyofKidneyDiseaseandHypertension ABPM Ambulatorybloodpressuremonitoring ACE-inhibitor Angiotensinconvertingenzymeinhibitor ADA AmericanDiabetesAssociation AFT Autonomicfunctiontesting albumin Albumin ASCVD Atheroscleroticcardiovasculardisease American Society of Nephrology AmericanSocietyofNephrology AST AmericanSocietyofTransplantation ASTP AmericanSocietyofTransplantPhysicians AV Arterio-venous BAP Bonealkalinephosphatase BDI BeckDepressionInventory BEE Basalenergyexpenditure body mass index Bodymassindex blood pressure Bloodpressure BPI Bloodpressureindex BSA Bodysurfacearea blood urea nitrogen Bloodureanitrogen coronary artery disease Coronaryarterydisease CCD Clinicalcardiovasculardisease C Creatinineclearance creatinine CDI CognitiveDepressionIndex CES-D CenterforEpidemiologicalStudies-Depression CGequation Cockcroft-Gaultequation potassium/DOQI NationalKidneyFoundation xvii CHD Coronaryheartdisease congestive heart failure Congestiveheartfailure C Inulinclearance in chronic kidney disease Chronickidneydisease COOP DartmouthCOOPClinicalImprovementSystem COX2 Cyclo-oxygenasetype2 CPG Clinicalpracticeguideline CPM Clinicalperformancemeasure CQI Continuousqualityimprovementprograms creatinine Creatinine chronic renal failure Chronicrenalfailure computed tomography Computedtomography C Clearanceofcreatinineduetotubularsecretion TSCr C Ureaclearance Urea cardiovascular disease Cardiovasculardisease D Day(s) DBP Diastolicbloodpressure DCCT DiabetesControlandComplicationsTrial DEI Dietaryenergyintake DEXA Dualenergyx-rayabsorptiometry(bonedensitometry) diabetes mellitus Diabetesmellitus DMI Type1diabetesmellitus DMII Type2diabetesmellitus DMMS DialysisMorbidityandMortalityStudy DMSA Dimercaptosuccinicacid DOQI DialysisOutcomesQualityInitiative DPI Dietaryproteinintake diethylenetriamine pentaacetic acid scan Diethylenetriaminepentaaceticacid DUKE DukeHealthProfile DUSOI DukeSeverityofIllness E Extra-renalcreatinineeliminationrate creatinine European Dialysis and Transplant Association Ethylenediaminetetraaceticacid EDX Electrodiagnosis EEG Electroencephalogram EMG Electromyography end-stage renal disease End-stagerenaldisease Exp Exponent focal segmental glomerulosclerosis Focalsegmentalglomerulosclerosis G Creatininegenerationrate creatinine glomerular filtration rate Glomerularfiltrationrate glomerulonephritis Glomerulonephritis HBP Highbloodpressure xviii NationalKidneyFoundation potassium/DOQI HCFA HealthCareFinancingAdministration(currentlyCentersfor MedicareandMedicaidServices, CMS) hemodialysis Hemodialysis HDFP HypertensionDetectionandFollow-UpProgram HDL Highdensitylipoprotein Hgb Hemoglobin HI HealthIndex HIV Humanimmunodeficiencyvirus HLA Humanleukocyteantigen HOPE HeartOutcomesPreventionEvaluation HOT HypertensionOptimalTrial heart rate Hour(s) heart rate Heartrate hypertension Hypertension ICD-9 InternationalClassificationofDiseases, 9threvision ICTP TypeIcollagencrosslinkedtelopeptides IDDM Insulindependentdiabetesmellitus IDNT IrbesartaninDiabeticNephropathyTrial IEQ IllnessEffectsQuestionnaire IHD Ischemicheartdisease IN Interstitialnephritis IOM InstituteofMedicine intact parathyroid hormone Intactparathyroidhormone IRMA Intraretinalmicrovascularabnormalities intravenous pyelogram Intravenouspyelography JNC-VI SixthreportoftheJointNationalCommitteeforthePrevention, Detection, Evaluation, andTreatmentofHighBloodPressure potassium/DOQI KidneyDiseaseOutcomesQualityInitiative KDQOL KidneyDiseaseQualityofLife KPS KarnofskyPerformanceScale Krt/V Renalureaclearancedividedbyvolumeofdistribution urea dialysis adequacy measure Ureaclearancedividedbyvolumeofdistribution urea LDL Lowdensitylipoprotein LMW Lowmolecularweight LV Leftventricle LVH Leftventricularhypertrophy mercaptoacetyltriglycine scan Mercaptoacetyltriglycine MAP Meanarterialpressure Max Maximum MCD Medullarycysticdisease MCS SF-36MentalComponentSummary MDRDStudy ModificationofDietinRenalDiseaseStudy potassium/DOQI NationalKidneyFoundation xix myocardial infarction Myocardialinfarction Min Minute(s) Min Minimum MNT Medicalnutritiontherapy Mo Month(s) MR Magneticresonance magnetic resonance imaging Magneticresonanceimaging MSP MultidimensionalScaleofPerceivedSocialSupport N Numberofsubjectsinsubgroup N Numberofsubjectsinsampleorpopulation sodium Notapplicable NAE Normalurinaryalbuminexcretion NAG N-acetyl-(cid: 1)-D-glucosaminidase NCEP NationalCholesterolEducationProgram NCHS NationalCenterforHealthStatistics NCV Nerveconductionvelocity ND Nodata NHANESIII ThirdNationalHealthandNutritionExaminationSurvey NIDDM Non-insulindependentdiabetesmellitus NIH NationalInstitutesofHealth NK Naturalkiller National Kidney Foundation NationalKidneyFoundation No. Number NPNA Normalizedproteinnitrogenappearance NS Non-significant nonsteroidal anti-inflammatory drug Non-steroidalanti-inflammatorydrug PARADE Proteinuria, Albuminuria, RiskAssessment, Detection, and Elimination P Plasmaorserumcreatinineconcentration creatinine PCS SF-36PhysicalComponentSummary peritoneal dialysis Peritonealdialysis PEM Protein-energymalnutrition PICP ProcollagentypeIcarboxy-terminalpropeptides P Plasmainulin in polycystic kidney disease Polycystickidneydisease PN Pyelonephritis PNA Proteinequivalentoftotalnitrogenappearance parathyroid hormone Parathyroidhormone peripheral vascular disease Peripheralvasculardisease QST Quantitativesensorytesting QWB QualityofWell-beingScale xx NationalKidneyFoundation potassium/DOQI red blood cell Redbloodcell RBP Retinolbindingprotein RDA Recommendeddietaryallowance RENAAL ReductionofEndpointsinNon-InsulinDependentDiabetes MellituswiththeAngiotensinIIAntagonistLosartan RHIE RandHealthInsuranceExperiment RPA RenalPhysiciansAssociation respiratory rate Relativerisk SAS-SR SocialAdjustmentScaleSelf-Report SBP Systolicbloodpressure SBW Standardbodyweight SCL90R SymptomChecklist-90R S Serumcreatinineconcentration creatinine SD Standarddeviation SDS-PAGE Sodiumdodecylsulfate-polyacrylamidegelelectrophoresis SE Standarderror SF-36 RANDMedicalOutcomesStudy36-ItemHealthSurvey SGA Subjectiveglobalassessment SIP SicknessImpactProfile SLE Systemiclupuserythematosus SLS SatisfactionwithLifeScale SMBG Self-monitoringofbloodglucose Sn Sensitivity Sp Specificity STAI StateTraitAnxietyInventory SUN Serumureanitrogen TOD Targetorgandamage TS Tubularcreatininesecretionrate creatinine UAC Urinealbuminconcentration U Urinealbumin-to-creatinineratio albumin/creatinine U Urinecreatinineconcentration creatinine U Urineinulinconcentration in UKPDS UnitedKingdomProspectiveDiabetesStudy UNA Ureanitrogenappearance ultrasound UnitedStates USRDS UnitedStatesRenalDataSystem UUN Urineureanitrogen V Urineflowrate V Volumeofdistributionofurea Urea white blood cell Whitebloodcell potassium/DOQI NationalKidneyFoundation xxi WHO WorldHealthOrganization Wk Week(s) Yr Year(s) (cid: 1)-2-magnesium (cid: 1)-2-Microglobulin (cid: 3) Difference/change xxii NationalKidneyFoundation potassium/DOQI Foreword From its rudimentary beginnings in the 1960s, through its widespread and increasing availabilitytothepresent, dialysishasprovidedlifesavingreplacementtherapyformillionsofindividualswithend-stagerenaldisease(end-stage renal disease). Paralleladvancesinunderstandingthecourseofprogressivekidneydiseaseanditscomplicationshaveresultedinthe developmentofinterventionsthatcanslowtheprogressionandamelioratethecomplicationsofchronickidneydisease. Thus, whiledialysishasmadeitpossibletoprolongthe livesofpatientswithESRD, todayitisalsopossibletoretardthecourseofprogression ofkidneydisease, totreataccompanyingcomorbidityearlier, andtoimprovetheoutcomes and quality of life of all individuals afflicted with Kidney disease, well before replacementtherapybecomesnecessary. Yet, theapplicationoftheseadvancesremains inconsistent, resultinginvariationsinclinicalpracticeand, sadly, inavoidabledifferences inpatientoutcomes.",
    "word_count": 575,
    "char_count": 8583,
    "sentence_count": 5,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 3,
      "total_chunks": 77,
      "position": "4/77",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal failure",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "urea",
        "sodium",
        "potassium"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 4,
    "text": "Yet, theapplicationoftheseadvancesremains inconsistent, resultinginvariationsinclinicalpracticeand, sadly, inavoidabledifferences inpatientoutcomes. Inkeepingwithitslongstandingcommitmenttoimprovingthequalityofcaredeliveredtoallpatientswithkidneydiseaseandthefirmconvictionthatsubstantialimprove- ments in the quality and outcomes of their care are achievable, the National Kidney Foundation (National Kidney Foundation) launched in 1995 the Dialysis Outcomes Quality Initiative (DOQI), supportedbyaneducationalgrantfromAmgen, Inc. , todevelopclinicalpracticeguidelinesfordialysispatientsandhealthcareproviders. Sincetheirpublicationin1997, the DOQIguidelineshavehadasignificantandmeasurableimpactonthecareandoutcomes ofdialysispatients. Thefrequencywithwhichtheycontinuetobecitedintheliterature andserveasthefocusofnationalandinternationalsymposiaisbutapartialmeasureof their impact. The DOQI guidelines have also been translated into more than a dozen languages; selectedcomponentsoftheguidelineshavebeenadoptedinvariouscountries acrosstheworld; and theyhaveprovidedthebasisfor clinicalperformancemeasures developed and put into effect by the Health Care Financing Administration (recently renamedtheCenterforMedicareandMedicaidServices)intheUnitedStates. In the course of development of DOQI it became evident that in order to further improve Dialysis outcomes, it is necessary to improve the health status of those who reach ESRDand thattherein existsan even greateropportunity toimprove outcomes potassium/DOQI NationalKidneyFoundation FOREWORD xxiii forallindividualswithkidneydisease, fromearliestkidneydamagethroughthevarious stagesofprogressiontokidneyfailure, whenreplacementtherapybecomesnecessary. ItwasonthisbasisthatintheFallof1999, theBoardofDirectorsoftheNKFapproved aproposaltomovetheclinicalpracticeguidelineinitiativeintoanewphase, inwhich itsscopewouldbeenlargedtoencompasstheentirespectrumofkidneydisease, when earlyinterventionandappropriatemeasurescanpreventthelossofkidneyfunctionin some, slowtheprogressionofthediseaseinmanyothers, andameliorateorgandysfunctionandcomorbidconditionsinthosewhoprogresstokidneyfailureandESRD. This enlargedscopeincreasesthepotentialimpactofimprovingoutcomesofcarefromthe hundredsofthousandsondialysistothemillionsofindividualswithkidneydiseasewho mayneverrequiredialysis. Toreflecttheseexpandedgoals, thereferencetoDialysis inDOQIwaschangedtodisease, andthenewinitiativewastermedKidneyDisease OutcomesQualityInitiative(potassium/DOQITM). Theobjectives ofK/DOQI areambitious andthe challengesare considerable. As a first and essential step it was decided to adhere to the guiding principles that were instrumentalinthesuccessofDOQI. Thefirstoftheseprincipleswasthatthedevelopment of guidelines would be scientifically rigorous and based on a critical appraisal of the available evidence. The second principle was that the participants involved in developingtheguidelineswouldbemultidisciplinary. Thiswasespeciallycrucialbecause thebroadernatureofthenewguidelineswillrequiretheiradoptionacrossseveralspecialtiesanddisciplines. ThethirdprinciplewasthattheWorkGroupschargedwithdevelopingtheguidelineswouldbethefinalauthorityontheircontent, subjecttotherequirements that they be evidence-based whenever possible, and that the rationale and evidentiarybasisofeachguidelinewouldbeexplicit. Byvestingdecision-makingauthority in highly regarded experts from multiple disciplines, the likelihood of developing clinicallyapplicableandsoundguidelinesisincreased. Finally, theguidelinedevelopment process would be open to general review, in order to allow the chain of reasoning underlyingeachguidelinetoundergopeerreviewanddebatepriortopublishing. Itwas believedthatsuchabroad-basedreviewprocesswouldpromoteawideconsensusand supportoftheguidelinesamonghealthcareprofessionals, providers, managers, organizations, andrecipients. ToprovideaunifyingfocustoK/DOQIitwasdecidedthatitscenterpiecewouldbe asetofclinicalpracticeguidelinesontheevaluation, classification, andstratificationof chronickidneydisease(chronic kidney disease). Thisinitialsetofguidelineswillprovideastandardized terminologyfortheevaluationandclassificationofkidneydisease; thepropermonitoring ofkidneyfunctionfrominitialinjurytoendstage; alogicalapproachtostratificationof Kidney disease by risk factors and comorbid conditions; and consequently a basis for continuouscareandtherapythroughoutthecourseofchronickidneydisease. Eventually, potassium/DOQIwillincludeinterventionalguidelines. Someofthesearecurrentlyunderdevelopment, basedonthestagingandclassificationdevelopedbytheseinitialCKDguidelines. We are proud to present this first set and centerpiece of potassium/DOQI guidelines. The WorkGroupappointedtodeveloptheguidelinesscreenedover18, 000potentiallyrelexxiv FOREWORD NationalKidneyFoundation potassium/DOQI vantarticles; over1, 100weresubjectedtopreliminaryreviewandover350werethen selectedforformalstructuredreviewofcontentandmethodology. Whileconsiderable efforthasgoneintothedevelopmentoftheguidelinesduringthepast24months, and greatattentionhasbeenpaidtodetailandscientificrigor, itisonlytheirincorporation intoclinicalpracticethatwillassuretheirapplicabilityandpracticalutility. Weaskforyoursupportintheimplementationoftheseguidelines. Itishopedthat implementationplansdevelopedbytheAdvisoryBoardwillassurethesameacceptance of potassium/DOQI by the broader spectrum of professionals who provide primary care for kidneydiseaseasthatwhichDOQIreceivedfromthosewhoprovidedialysiscare. OnbehalfoftheNKF, wewouldliketoacknowledgetheimmenseeffortandcontributionsof thosewho havemade theseguidelines possible. In particular, we wishto before mealsknowledgethefollowing: themembersoftheWorkGroupandEvidenceReviewTeam chargedwithdevelopingtheguidelines, withoutwhosetirelesseffortandcommitment thisfirstsetofK/DOQIguidelineswouldnothavebeenpossible; themembersofthe SupportGroup, whoseinputatmonthlyconferencecallswasinstrumentalinresolving the problems encountered over the 24 months it has taken to reach this stage; the members ofthe potassium/DOQI AdvisoryBoard, whoseinsights and guidancewere essential inbroadeningtheapplicabilityoftheguidelines; Amgen, Inc. , whichhadthevisionand foresighttoappreciatethemeritsofthisinitiativeandprovidethefundsnecessaryfor its development; and the National Kidney Foundation staff assigned to potassium/DOQI, who worked so diligently in attending to the innumerable details that needed attention at every stage of guideline developmentandinmeetingournearimpossibledeadlines. AspecialdebtofgratitudegoestoAndrewS. Levey, MD, ChairoftheWorkGroup, for his leadership, intellectual rigor, innumerable hours of dedication, and invaluable expertiseinsynthesizingtheguidelines; andtoJosephLau, MD, DirectoroftheEvidence ReviewTeam, forprovidingcrucialmethodologicalrigorandstaffsupportindeveloping theevidentiarybasisoftheguidelines. Inavoluntaryandmultidisciplinaryundertakingofsuchmagnitude, numerousothers havemadevaluablecontributionstotheseguidelinesbutcannotbeindividuallyacknowledgedhere. Toeachandeveryoneofthemweextendoursincerestappreciation. GarabedEknoyan, MD potassium/DOQICo-Chair NathanW. Levin, MD potassium/DOQICo-Chair potassium/DOQI NationalKidneyFoundation FOREWORD xxv PART 1. EXECUTIVE SUMMARY INTRODUCTION: CHRONIC Kidney DISEASE AS A PUBLIC HEALTH PROBLEM Chronickidneydiseaseisaworldwidepublichealthproblem. IntheUnitedStates, there isarisingincidenceandprevalenceofkidneyfailure, withpooroutcomesandhighcost. Thereisanevenhigherprevalenceofearlierstagesofchronickidneydisease. Increasingevidence, accruedinthepastdecades, indicatesthattheadverseoutcomes ofchronickidneydisease, suchaskidneyfailure, cardiovasculardisease, andpremature death, can be prevented or delayed. Earlier stages of chronic Kidney disease can be detectedthroughlaboratorytesting. Treatmentofearlierstagesofchronickidneydisease iseffectiveinslowingtheprogressiontowardkidneyfailure. Initiationoftreatmentfor cardiovascularriskfactorsatearlierstagesofchronickidneydiseaseshouldbeeffective in reducing cardiovascular disease events both before and after the onset of Kidney failure. Unfortunately, chronickidneydiseaseisunder-diagnosedandunder-treatedin theUnitedStates, resultinginlostopportunitiesforprevention. Onereasonisthelack ofagreement onadefinitionand classificationofstages intheprogression ofchronic kidneydisease. Aclinicallyapplicableclassificationwouldbebasedonlaboratoryevaluationoftheseverityofkidneydisease, associationoflevelofkidneyfunctionwithcomplications, andstratificationofrisksforlossofkidneyfunctionanddevelopmentofcardiovasculardisease. CHARGE TO THE potassium/DOQI WORK GROUP ON CHRONIC Kidney DISEASE In2000, theNationalKidneyFoundation(National Kidney Foundation)KidneyDiseaseOutcomeQualityInitiative(potassium/DOQI)AdvisoryBoardapproveddevelopmentofclinicalpracticeguidelinesto definechronickidneydiseaseandtoclassifystagesintheprogressionofchronickidney disease. TheWorkGroupchargedwithdevelopingtheguidelinesconsistedofexperts innephrology, pediatricnephrology, epidemiology, laboratorymedicine, nutrition, social work, gerontology, and family medicine. An EvidenceReview Team, consistingof nephrologistsandmethodologists, wasresponsibleforassemblingtheevidence. Thegoals adoptedbytheWorkGrouparelistedinTable1. Definingchronickidneydiseaseandclassifyingthestagesofseveritywouldprovide a common language for communication among providers, patients and their families, investigators, and policy-makers and a framework for developing a public health approachtoaffectcareandimproveoutcomesofchronickidneydisease. Auniformterminologywouldpermit: 1. More reliable estimates ofthe prevalence of earlier stages ofdisease and of the populationatincreasedriskfordevelopmentofchronickidneydisease 2. Recommendationsforlaboratorytestingtodetectearlierstagesandprogression tolaterstages potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 1 3. Associationsofstageswithclinicalmanifestationsofdisease 4. Evaluationoffactorsassociatedwithahighriskofprogressionfromonestageto thenextorofdevelopmentofotheradverseoutcomes 5.",
    "word_count": 600,
    "char_count": 10102,
    "sentence_count": 56,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 4,
      "total_chunks": 77,
      "position": "5/77",
      "content_type": "recommendation",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "kidney failure",
        "potassium",
        "nutrition",
        "dialysis",
        "cardiovascular disease",
        "guideline",
        "classification"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 5,
    "text": "Recommendationsforlaboratorytestingtodetectearlierstagesandprogression tolaterstages potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 1 3. Associationsofstageswithclinicalmanifestationsofdisease 4. Evaluationoffactorsassociatedwithahighriskofprogressionfromonestageto thenextorofdevelopmentofotheradverseoutcomes 5. Evaluationoftreatmentstoslowprogressionorpreventotheradverseoutcomes. Clinicalpracticeguidelines, clinicalperformancemeasures, andcontinuousquality improvementeffortscouldthenbedirectedtostagesofchronickidneydisease. The WorkGroup did notspecifically addressevaluation and treatmentfor chronic kidneydisease. However, thisguidelinecontainsbriefreferencetodiagnosisandclinical interventionsandcanserveasaroadmap, linkingotherclinicalpracticeguidelines andpointingoutwhereotherguidelinesneedtobedeveloped. Eventually, potassium/DOQIwill includeinterventionalguidelines. Thefirstthreeofthese, onbonedisease, dyslipidemia, andbloodpressuremanagementarecurrentlyunderdevelopment. Otherguidelineson cardiovasculardiseaseindialysispatientsandkidneybiopsywillbeinitiatedintheWinter of2001. Thisreportcontainsasummaryofbackgroundinformationavailableatthetimethe WorkGroupbeganitsdeliberations, the15guidelinesandtheaccompanyingrationale, suggestions for clinical performance measures, a clinical approach to chronic Kidney disease using these guidelines, and appendices todescribe methods for the review of evidence. The guidelines are based on a systematic review of the literature and the consensusoftheWorkGroup. TheguidelineshavebeenreviewedbytheK/DOQIAdvisoryBoard, alargenumberofprofessionalorganizationsandsocieties, selectedexperts, andinterestedmembersofthepublicandhavebeenapprovedbytheBoardofDirectors oftheNKF. FRAMEWORK The Work Group defined chronic Kidney disease to include conditions that affect the Kidney, with the potential to cause either progressive loss of Kidney function or complications resulting from decreased Kidney function. Chronic Kidney disease was 2 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI thus defined as the presence of Kidney damage or decreased level of Kidney function forthreemonthsormore, irrespectiveofdiagnosis. Thetargetpopulationincludesindividualswithchronickidneydiseaseoratincreased riskofdevelopingchronickidneydisease. Themajorityoftopicsfocusonadults(age (cid: 1)18 years). Many of the same principles apply to children as well. In particular, the classificationofstagesofdiseaseandprinciplesofdiagnostictestingaresimilar. AsubcommitteeoftheWorkGroupexaminedissuesrelatedtochildrenandparticipatedin development of the first six guidelines of the present document. However, there are sufficientdifferencesbetweenadultsandchildrenintheassociationofGFRwithsigns and symptoms of uremia and in stratification of risk for adverse outcomes that these latterissuesareaddressedonlyforadults. Aseparatesetofguidelinesforchildrenwill havetobedevelopedbyalaterWorkGroup. Thetargetaudienceincludesawiderangeofindividuals: thosewhohaveorareat increased risk of developing chronic Kidney disease (the target population) and their families; health care professionals caring for the target population; manufacturers of instruments and diagnostic laboratories performing measurements of Kidney function; agenciesandinstitutionsplanning, providingorpayingforthehealthcareneedsofthe targetpopulation; andinvestigatorsstudyingchronickidneydisease. There will be only brief reference to clinical interventions, sufficient to provide a basis forother clinical practiceguidelines relevantto the evaluationand management ofchronickidneydisease. SubsequentK/DOQIclinicalpracticeguidelineswillbebased ontheframeworkdevelopedhere. DEFINITION OF CHRONIC Kidney DISEASE TheWorkGroupdevelopedthefollowingoperationaldefinitionofchronickidneydisease(Table2). potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 3 Classification of Chronic Kidney Disease Table3showstheclassificationofstagesofchronickidneydisease, includingthepopulationatincreasedriskofdevelopingchronickidneydisease, andactionstopreventthe developmentofchronickidneydiseaseandtoimproveoutcomesineachstage. Why Kidney? ThewordKidneyisofMiddleEnglishoriginandisimmediatelyunderstoodbypatients, theirfamilies, providers, healthcareprofessionals, andthelaypublicofnativeEnglish speakers. Ontheotherhand, renalandnephrology, derivedfromLatinandGreek roots, respectively, commonlyrequireinterpretationandexplanation. TheWorkGroup andtheNKFarecommittedtocommunicatinginlanguagethatcanbewidelyunderstood, hence the preferential use of Kidney throughout these guidelines. The term EndStage Renal Disease (end-stage renal disease) has been retained because of its administrative usage in theUnitedStatesreferringtopatientstreatedbydialysisortransplantation, irrespective oftheirlevelofkidneyfunction. Why Develop a New Classification? Currently, thereisnouniformclassificationofthestagesofchronickidneydisease. A reviewoftextbooksandjournalarticlesclearlydemonstratesambiguityandoverlapin themeaningofcurrentterms. TheWorkGroupconcludedthatuniformdefinitionsof terms and stages would improve communication between patients and providers, enhancepubliceducation, andpromotedisseminationofresearchresults. Inaddition, it wasbelievedthatuniformdefinitionswouldenhanceconductofclinicalresearch. Why Base a New Classification System on Severity of Disease? Adverseoutcomesofkidneydiseasearebasedonthelevelofkidneyfunctionandrisk of loss of function in the future. Chronic Kidney disease tends to worsen over time. 4 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI Therefore, theriskofadverseoutcomesincreasesovertimewithdiseaseseverity. Many disciplinesinmedicine, includingrelatedspecialtiesofhypertension, cardiovasculardisease, Diabetes, andtransplantation, haveadoptedclassificationsystemsbasedonseverity toguideclinicalinterventions, research, andprofessionalandpubliceducation. Sucha modelisessentialforanypublichealthapproachtodisease. Why Classify Severity as the Level of glomerular filtration rate? Thelevelofglomerularfiltrationrate(glomerular filtration rate)iswidelyacceptedasthebestoverallmeasure of Kidney function in health and disease. Providers and patients are familiar with the conceptthatthekidneyislikeafilter. GFRisthebestmeasureofthekidneysability tofilterblood. Inaddition, expressingthelevelofkidneyfunctiononacontinuousscale allowsdevelopmentofpatientandpubliceducationprogramsthatencourageindividuals toKnowyournumber! The term glomerular filtration rate is not intuitively evident to anyone. Rather, it is a learned term, which allows the ultimate expression of the complex functions of the Kidney in one single numerical expression. Conversely, numbers are an intuitive concept and easily understandablebyeveryone. Itisfortunatethenthatoncethetermglomerular filtration rateislearned, theexpressionKnowyournumber! becomesintuitiveandeasilyunderstood. Why Include an Action Plan? Action is necessary to improve outcomes, which is the ultimate goal of the National Kidney Foundation. No clinicalpracticeguideline, irrespectiveoftherigorofitsdevelopment, canaccomplish itsintendedimprovementinoutcomewithoutanimplementationplan. Thishasbeen thechargeoftheAdvisoryBoard. Theprocesshasbeensetinmotioninparallelwith thatofdevelopmentoftheguidelines. PREVALENCE OF CHRONIC Kidney DISEASE IN THE UNITED STATES Usingthedefinitionandstagesofchronickidneydisease, theWorkGroupwasableto provideroughestimatesoftheprevalenceofeachstageinadultsfromtheThirdNational HealthandNutritionExaminationSurvey(NHANESIII)(Table4). Methodsforestimating potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 5 Fig 1. Evidence model for stages in the initiation and progression of chronic Kidney disease, andtherapeuticinterventions. Shadedellipsesrepresentstagesofchronickidneydisease; unshadedellipsesrepresentpotentialantecedentsorconsequencesofCKD. Thickarrowsbetweenellipsesrepresentfactorsassociatedwithinitiationandprogressionofdiseasethatcanbeaffectedordetectedbyinterventions: susceptibilityfactors (black); initiation factors (dark gray); progression factors (light gray); and end-stage factors (white). Interventions for each stage are given beneath the stage. Individuals who appear normalshould be screened foCKD risk factors. Individualsknown to be at increased risk for chronic kidney disease should be screened for chronic kidney disease. Modified and reprinted with permission.",
    "word_count": 600,
    "char_count": 8451,
    "sentence_count": 72,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 5,
      "total_chunks": 77,
      "position": "6/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "end-stage renal disease",
        "potassium",
        "classification"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 6,
    "text": "Modified and reprinted with permission. 3 prevalencearedetailedinPart10, Appendix2. Theprevalenceofchronickidneydisease inchildrenistoolowtoprovideaccurateestimatesofprevalenceofeachstagebased ondatafromNHANESIII. FUTURE DIRECTIONS The framework that has been adopted can be used to develop an evidence model of thecourseofchronickidneydisease(Fig1). Itisanticipatedthatclinicalpracticeguidelinesforinterventionstoreduceadverseoutcomesinpatientswithchronickidneydis- easecanbebasedonthismodel. Thislineoflogicallowsfortheultimateconstructionofalistofmodifiableriskfactors ateachstageofchronickidneydisease, asshowninTable5. REVIEW OF EVIDENCE TheguidelinesdevelopedbytheWorkGrouparebasedonasystematicreviewofthe literature using an approach based on the procedure outlined by the Agency for Healthcare Research and Quality (formerly the Agency for Health Care Policy and Research) with modifications appropriate to the goals. An Evidence Review Team was appointed by the National Kidney Foundation to collaborate with the Work Group to conduct a systematic reviewoftheliteratureonwhichtobasetheguidelines. Adetailedexplanationofthese methodsisprovidedinPart10, Appendices1and2; Table6providesabrieflistingof thestepsinvolvedinthisapproach. 6 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 7 8 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI Auniformformatforsummarizingthestrengthofevidencehasbeendevelopedusing fourdimensions: studysize, applicability, results, andmethodologicalquality. Anexample of an evidence table is shown in the above table. Within each table, studies are ordered first by methodologicalquality (best to worst), then byapplicability (most to least), andthenbystudysize(largesttosmallest). Detailedevidencetablesareonfile attheNationalKidneyFoundation. Applicability Applicability(alsoknownasgeneralizabilityorexternalvalidity)addressestheissueof whetherthestudypopulationissufficientlybroadsothattheresultscanbegeneralized tothepopulationofinterestatlarge. Thestudypopulationistypicallydefinedbythe inclusionandexclusioncriteria. Thetargetpopulationwasdefinedtoincludepatients withchronickidneydiseaseandthoseatincreasedriskofchronickidneydisease, except wherenoted. Adesignationforapplicabilitywasassignedtoeacharticle, accordingto a three-level scale. In making this assessment, sociodemographic characteristics were considered, aswerethestatedcausesofchronickidneydiseaseandpriortreatments. glomerular filtration rate Range Forallstudies, therangeofGFR(orcreatinineclearanceC )isrepresentedgraphically creatinine whenavailable(seetableabove). ThemeanormedianGFRisrepresentedbyavertical line, with a horizontal bar showing a range that includes approximately 95% of study participants. Studies without a vertical or horizontal line did not provide data on the mean/medianorrange, respectively. WhenGFRorC measurementsarenotavailable, creatinine serumcreatininelevelsarelistedastext. Results Resultsarerepresentedbyprevalencelevels, proportions(percents)forcategoricalvariables, meanlevelsforcontinuousvariables, andassociationsbetweenstudymeasures. Symbolsindicatethetypeandsignificanceofassociationsbetweenstudymeasures: potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 9 Thespecificmeaningsofthesesymbolsareexplainedinthefootnotesoftableswhere they appear. Some informative studies reported only single point estimates of study measures (eg, mean data) rather than associations. Where data on associations were limited, evidencetablesprovidethesepointestimates. Studiesthatprovidedataonassociations and studies that provide only point estimates are listed and ranked separately, withshadingusedtodistinguishthem(asinthetable, ExampleofFormatforEvidence Tables). Quality Methodologicalquality(orinternalvalidity)referstothedesign, conduct, andreporting oftheclinicalstudy. Becausestudieswithavarietyoftypesofdesignwereevaluated, athree-levelclassificationofstudyqualitywasdevised: Strength of Evidence Eachrationalestatementhasbeengradedaccordingthelevelofevidenceonwhichit isbased. 10 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI GUIDELINE STATEMENTS Guidelinestatementsaregroupedintofourparts, correspondingtothefourgoalsofthe CKDWorkGroup. GuidelinestatementsarereproducedintheExecutiveSummary. The readerisreferredtospecificpagesforrationale, evidencetablesandreferences. DEFINITION AND CLASSIFICATION OF STAGES OF CHRONIC Kidney DISEASE (PART 4, p. 43) Chronickidneydiseaseisamajorpublichealthproblem. Improvingoutcomesforpeople withchronickidneydiseaserequiresacoordinatedworldwideapproachtoprevention ofadverseoutcomesthroughdefiningthediseaseanditsoutcomes, estimatingdisease prevalence, identifyingearlierstagesofdiseaseandantecedentriskfactors, anddetection andtreatmentforpopulationsatincreasedriskforadverseoutcomes. ThegoalofPart 4 is to create an operational definition and classification of stages of chronic Kidney diseaseandprovideestimatesofdiseaseprevalencebystage, todevelopabroadoverview ofaclinicalactionplanforevaluationandmanagementofeachstageofchronickidney disease, andtodefineindividualsatincreasedriskfordevelopingchronickidneydisease. Studies of disease prevalence were evaluated as described in Appendix 1, Table 147. DatafromNHANESIIIwereusedtodevelopestimatesofdiseaseprevalenceinadults asdescribedinAppendix2. GUIDELINE 1. DefinitionandStagesofChronicKidneyDisease (p. 43) Adverseoutcomesofchronickidneydiseasecanoftenbepreventedordelayedthroughearly detection and treatment. Earlier stages of chronic Kidney diseasecan be detected through routinelaboratorymeasurements. Thepresenceofchronickidneydiseaseshouldbeestablished, basedonpresenceof kidneydamageandlevelofkidneyfunction(glomerularfiltrationrateglomerular filtration rate), irrespective ofdiagnosis. Amongpatientswithchronickidneydisease, thestageofdiseaseshouldbeassigned potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 11 based on the level of Kidney function, irrespective of diagnosis, according to the potassium/DOQICKDclassification: GUIDELINE 2. EvaluationandTreatment(p. 66) Theevaluationandtreatmentofpatientswithchronickidneydiseaserequiresunderstanding ofseparatebutrelatedconceptsofdiagnosis, comorbidconditions, severityofdisease, complicationsofdisease, andrisksforlossofkidneyfunctionandcardiovasculardisease. Patientswithchronickidneydiseaseshouldbeevaluatedtodetermine: Diagnosis(typeofkidneydisease); Comorbidconditions; Severity, assessedbylevelofkidneyfunction; Complications, relatedtolevelofkidneyfunction; Riskforlossofkidneyfunction; Riskforcardiovasculardisease. Treatmentofchronickidneydiseaseshouldinclude: Specifictherapy, basedondiagnosis; Evaluationandmanagementofcomorbidconditions; Slowingthelossofkidneyfunction; Preventionandtreatmentofcardiovasculardisease; Preventionandtreatmentofcomplicationsofdecreasedkidneyfunction; Preparationforkidneyfailureandkidneyreplacementtherapy; Replacementofkidneyfunctionbydialysisandtransplantation, ifsignsandsymptoms ofuremiaarepresent. A clinical action plan should be developed for each patient, based on the stage of diseaseasdefinedbytheK/DOQICKDclassification(seetableonpage13). 12 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI Reviewofmedicationsshouldbeperformedatallvisitsforthefollowing: Dosageadjustmentbasedonlevelofkidneyfunction; Detectionofpotentiallyadverseeffectsonkidneyfunctionorcomplicationsofchronic kidneydisease; Detectionofdruginteractions; and Therapeuticdrugmonitoring, ifpossible. Self-managementbehaviorsshouldbeincorporatedintothetreatmentplanatallstages ofchronickidneydisease. Patientswithchronickidneydiseaseshouldbereferredtoaspecialistforconsultation andco-managementiftheclinicalactionplancannotbeprepared, theprescribedevaluationof thepatient cannotbecarried out, or therecommendedtreatment cannotbe carriedout. Ingeneral, patientswithGFR(cid: 1)30mL/min/1. 73m2shouldbereferredto anephrologist. GUIDELINE 3. IndividualsatIncreasedRiskofChronicKidney Disease(p. 75) SomeindividualswithoutkidneydamageandwithnormalorelevatedGFRareatincreasedriskfordevelopmentofchronickidneydisease. Allindividualsshouldbeassessed, aspartofroutinehealthencounters, todetermine whethertheyareatincreasedriskofdevelopingchronickidneydisease, basedon clinicalandsociodemographicfactors. Individualsatincreasedriskofdevelopingchronickidneydiseaseshouldundergo testingformarkersofkidneydamageandtoestimatethelevelofGFR. Individualsfoundtohavechronickidneydiseaseshouldbeevaluatedandtreated asspecifiedinGuideline2. Individualsatincreasedrisk, butfoundnottohavechronickidneydisease, should beadvisedtofollowaprogramofriskfactorreduction, ifappropriate, andundergo repeatperiodicevaluation. potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 13 EVALUATION OF LABORATORY MEASUREMENTS FOR CLINICAL ASSESSMENT OF Kidney DISEASE (PART 5, p. 81) ThedefinitionandstagingofchronickidneydiseasedependsontheassessmentofGFR, proteinuria, andothermarkersofkidneydisease. ThegoalsofPart5aretoevaluatethe accuracy of prediction equations to estimate the level of glomerular filtration rate from serum Creatinine, theaccuracyofratiosofprotein-to-creatinineconcentrationinuntimed(spot)Urine samples to assess Protein excretion rate, and the utility of markers of Kidney damage otherthanproteinuria. AsdescribedinAppendix1, Table151, theWorkGroupevaluated studiesaccordingtoacceptedmethodsforevaluationofdiagnostictests. Toprovidea more comprehensive review, the Work Group attempted to integrate the systematic reviewofspecificquestionswithexistingguidelinesandrecommendations. GUIDELINE 4. EstimationofGFR(p. 81) EstimatesofGFRarethebestoverallindicesofthelevelofkidneyfunction. ThelevelofGFRshouldbeestimatedfrompredictionequationsthattakeintoaccount the serum Creatinine concentration and some or all of the following variables: age, gender, raceandbodysize. ThefollowingequationsprovideusefulestimatesofGFR: Inadults, theMDRDStudyandCockcroft-Gaultequations; Inchildren, theSchwartzandCounahan-Barrattequations. Theserumcreatinineconcentrationaloneshouldnotbeusedtoassessthelevelofkidney function.",
    "word_count": 599,
    "char_count": 10165,
    "sentence_count": 74,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 6,
      "total_chunks": 77,
      "position": "7/77",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "creatinine",
        "potassium",
        "serum creatinine",
        "guideline",
        "classification"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 7,
    "text": "ThefollowingequationsprovideusefulestimatesofGFR: Inadults, theMDRDStudyandCockcroft-Gaultequations; Inchildren, theSchwartzandCounahan-Barrattequations. Theserumcreatinineconcentrationaloneshouldnotbeusedtoassessthelevelofkidney function. ClinicallaboratoriesshouldreportanestimateofGFRusingapredictionequation, in additiontoreportingtheserumcreatininemeasurement. Autoanalyzermanufacturersandclinicallaboratoriesshouldcalibrateserumcreatinine assaysusinganinternationalstandard. Measurementofcreatinineclearanceusingtimed(forexample, 24-hour)urinecollectionsdoesnotimprovetheestimateofGFRoverthatprovidedbypredictionequations. A24-hoururinesampleprovidesusefulinformationfor: Estimation of glomerular filtration rate in individuals with exceptional dietary intake (vegetarian diet, creatinesupplements)ormusclemass(amputation, malnutrition, musclewasting); Assessmentofdietandnutritionalstatus; Needtostartdialysis. GUIDELINE 5. AssessmentofProteinuria(p. 100) Normal individuals usually excrete very small amounts of Protein in the Urine. Persistently increasedproteinexcretionisusuallyamarkerofkidneydamage. Theexcretionofspecific typesofprotein, suchasalbuminorlowmolecularweightglobulins, dependsonthetypeof kidneydiseasethatispresent. Increasedexcretionofalbuminisasensitivemarkerforchronic kidneydiseaseduetodiabetes, glomerulardisease, andhypertension. Increasedexcretion of Low molecular weight globulins is a sensitive marker for some types of tubulointerstitial disease. Inthisguideline, thetermproteinuriareferstoincreasedurinaryexcretionofalbumin, otherspecific proteins, or totalprotein; albuminuria refers specificallyto increased urinaryexcretionofalbumin. Microalbuminuriareferstoalbuminexcretionabovethenormalrangebutbelowthelevelofdetectionbytestsfortotalprotein. Guidelinesfordetection 14 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI andmonitoringofproteinuriainadultsandchildrendifferbecauseofdifferencesintheprevalenceandtypeofchronickidneydisease. GuidelinesforAdultsandChildren: Undermostcircumstances, untimed(spot)urinesamplesshouldbeusedtodetectand monitorproteinuriainchildrenandadults. Itisusuallynotnecessarytoobtainatimedurinecollection(overnightor24-hour)for theseevaluationsineitherchildrenoradults. First morning specimens are preferred, but random specimens are acceptable if first morningspecimensarenotavailable. Inmostcases, screeningwithurinedipsticksisacceptablefordetectingproteinuria: Standardurinedipsticksareacceptablefordetectingincreasedtotalurineprotein. Albumin-specificdipsticksareacceptablefordetectingalbuminuria. Patients with a positive dipstick test (1(cid: 1) or greater) should undergo confirmation of proteinuriabyaquantitativemeasurement(Protein-to-creatinineratiooralbumin-to-creatinineratio)within3months. Patientswithtwoormorepositivequantitativeteststemporallyspacedby1to2weeks shouldbediagnosedashavingpersistentproteinuriaandundergofurtherevaluation andmanagementforchronickidneydiseaseasstatedinGuideline2. Monitoring proteinuria in patients with chronic Kidney disease should be performed usingquantitativemeasurements. SpecificGuidelinesforAdults: Whenscreeningadultsatincreasedriskforchronickidneydisease, albuminshouldbe measuredinaspoturinesampleusingeither: Albumin-specificdipstick; Albumin-to-creatinineratio. Whenmonitoringproteinuriainadultswithchronickidneydisease, theprotein-to-creatinineratioinspoturinesamplesshouldbemeasuredusing: Albumin-to-creatinineratio; Total Protein-to-Creatinine ratio is acceptable if albumin-to-Creatinine ratio is High ((cid: 2)500to1, 000mg/g). SpecificGuidelinesforChildrenWithoutDiabetes: Whenscreeningchildrenforchronickidneydisease, totalurineproteinshouldbemeasuredinaspoturinesampleusingeither: Standardurinedipstick; Totalprotein-to-creatinineratio. Orthostatic proteinuria must be excluded by repeat measurement on a first morning specimeniftheinitialfindingofproteinuriawasobtainedonarandomspecimen. Whenmonitoringproteinuriainchildrenwithchronickidneydisease, thetotalproteinto-creatinineratioshouldbemeasuredinspoturinespecimens. SpecificGuidelinesforChildrenWithDiabetes: Screeningandmonitoringofpost-pubertalchildrenwithdiabetesof5ormoreyears ofdurationshouldfollowtheguidelinesforadults. Screeningandmonitoringotherchildrenwithdiabetesshouldfollowtheguidelinesfor childrenwithoutdiabetes. potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 15 GUIDELINE 6. MarkersofChronicKidneyDiseaseOtherThan Proteinuria(p. 112) Markersofkidneydamageinadditiontoproteinuriaincludeabnormalitiesintheurinesedimentandabnormalitiesonimagingstudies. Constellationsofmarkersdefineclinicalpresentationsforsome typesofchronickidney disease. Newmarkersareneeded todetectkidney damagethatoccurspriortoareductioninGFRinothertypesofchronickidneydiseases. Urinesedimentexaminationordipstickforredbloodcellsandwhitebloodcellsshould beperformedinpatientswithchronickidneydiseaseandinindividualsatincreased riskofdevelopingchronickidneydisease. Imaging studies of the kidneys should be performed in patients with chronic Kidney diseaseandinselectedindividualsatincreasedriskofdevelopingchronickidneydisease. Althoughseveralnovelurinarymarkers(suchastubularorlow-molecularweightproteins andspecificmononuclearcells)showpromiseoffutureutility, theyshouldnotbeused forclinicaldecision-makingatpresent. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH COMPLICATIONS IN ADULTS (PART 6, p. 123) Many of the complications of chronic Kidney disease can be prevented or delayed by earlydetectionandtreatment. ThegoalofPart6istoreviewtheassociationofthelevel ofGFRwithcomplicationsofchronickidneydiseasetodeterminethestageofchronic Estimatedprevalenceofselectedcomplications, bycategoryofestimatedGFR, among participants age (cid: 1)20 years in NHANES III, 1988 through 1994. These estimates are notadjustedforage, themeanofwhichis33yearshigheratanestimatedGFRof15 to29mL/min/1. 73m2thanthatatanestimatedGFR(cid: 1)90mL/min/1. 73m2. 16 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI Estimated distribution of the number of complications shown in figure by category of estimatedGFRamongparticipantsage(cid: 1)20yearsinNHANESIII, 1988through1994. Theseestimatesarenotadjustedforage, themeanofwhichis33yearshigheratan estimatedGFRof15to29mL/min/1. 73m2thanthatatanestimatedGFRof(cid: 1)90mL/ min/1. 73m2. kidneydiseasewhencomplicationsappear. AsdescribedinAppendix1, Table152, the WorkGroupsearchedforcross-sectionalstudiesthatrelatedmanifestationsofcomplications and the level of Kidney function. Data from NHANES III were also analyzed, as describedinAppendix2. Because of different manifestations of complications of chronic Kidney disease in children, especiallyingrowthanddevelopment, theWorkGrouplimitedthescopeof thereviewofevidencetoadults. AseparateWorkGroupwillneedtoaddressthisissue inchildren. The Work Group did not attempt to review the evidence on the evaluation and managementofcomplicationsofchronickidneydisease. Thisisthesubjectofpastand forthcoming clinicalpractice guidelines by theNational Kidney Foundationand other groups, whicharereferencedinthetext. Representativefindingsareshownbystageofchronickidneydiseaseinthefigures aboveandbelow, showingahigherprevalenceofeachcomplicationatlowerGFR, and alargermeannumberofcomplicationsper personandhigherprevalenceofmultiple complicationsatlowerGFR. Theseandotherfindingssupporttheclassificationofstages ofchronickidneydiseaseandarediscussedindetailinGuidelines7through12. potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 17 GUIDELINE 7. AssociationofLevelofGFRWithHypertension (p. 124) Hypertension is both a cause and a complication of chronic Kidney disease. As a complication, Hypertension may develop early during the course of chronic Kidney diseaseandisassociatedwithadverseoutcomesinparticular, fasterlossofkidneyfunction anddevelopmentofcardiovasculardisease. Bloodpressureshouldbecloselymonitoredinallpatientswithchronickidneydisease. Treatmentofhighbloodpressureinchronickidneydiseaseshouldincludespecification oftargetbloodpressurelevels, nonpharmacologictherapy, andspecificantihypertensive agents for the prevention of progression of Kidney disease (Guideline 13) and developmentofcardiovasculardisease(Guideline15). GUIDELINE 8. AssociationofLevelofGFRWithAnemia(p. 136) Anemiausuallydevelopsduringthecourseofchronickidneydiseaseandmaybeassociated withadverseoutcomes. PatientswithGFR(cid: 1)60mL/min/1. 73m2shouldbeevaluatedforanemia. Theevaluation shouldincludemeasurementofhemoglobinlevel. Anemiainchronickidneydiseaseshouldbeevaluatedandtreated(seeK/DOQIClinical PracticeGuidelinesforAnemiaofChronicKidneyDisease, Guidelines14). GUIDELINE 9. AssociationofLevelofGFRWithNutritionalStatus (p. 145) Proteinenergymalnutritiondevelopsduringthecourseofchronickidneydiseaseandisassociatedwithadverseoutcomes. Lowproteinandcalorieintakeisanimportantcauseofmalnutritioninchronickidneydisease. PatientswithGFR(cid: 1)60mL/min/1. 73m2shouldundergoassessmentofdietaryprotein andenergyintakeandnutritionalstatus(seeK/DOQIClinicalPracticeGuidelinesfor NutritioninChronicRenalFailure, Guidelines23and26). Patientswithdecreaseddietaryintakeormalnutritionshouldundergodietarymodification, counselingandeducation, orspecializednutritiontherapy(seeK/DOQIClinical PracticeGuidelinesforNutritioninChronicRenalFailure, Guidelines24and25). GUIDELINE 10. BoneDiseaseandDisordersofCalciumand PhosphorusMetabolism(p. 163) Bonediseaseanddisordersofcalciumandphosphorusmetabolismdevelopduringthecourse ofchronickidneydiseaseandareassociatedwithadverseoutcomes. Patients withGFR (cid: 1)60 milliliters per minute/1. 73m2 should beevaluated for bonedisease and disordersofcalciumandphosphorusmetabolism. Patientswithbonediseaseanddisordersofbonemetabolismshouldbeevaluatedand treated(seeforthcomingK/DOQIClinicalPracticeGuidelinesonBoneMetabolismand DiseaseinChronicKidneyDisease). GUIDELINE 11. Neuropathy(p. 180) Neuropathydevelopsduringthecourseofchronickidneydiseaseandmaybecomesymptomatic. Patients with chronic Kidney disease should be periodically assessed for central and 18 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI peripheralneurologicinvolvementbyelicitingsymptomsandsignsduringroutineoffice visitsorexams. Specializedlaboratorytestingforneuropathyinpatientswithchronickidneydisease isindicatedonlyinthepresenceofsymptoms. GUIDELINE 12. AssociationofLevelofGFRWithIndicesof FunctioningandWell-Being(p. 186) Impairmentsindomainsoffunctioningandwell-beingdevelopduringthecourseofchronic Kidney diseaseand areassociated withadverse outcomes. Impaired functioningand wellbeingmayberelatedtosociodemographicfactors, conditionscausingchronickidneydisease, complicationsofkidneydisease, orpossiblydirectlyduetoreducedGFR. PatientswithGFR(cid: 1)60mL/min/1. 73m2shouldundergoregularassessmentforimpairmentoffunctioningandwell-being: Toestablishabaselineandmonitorchangesinfunctioningandwell-beingovertime; Toassesstheeffectofinterventionsonfunctioningandwell-being. STRATIFICATION OF RISK FOR PROGRESSION OF Kidney DISEASE AND DEVELOPMENT OF CARDIOVASCULAR DISEASE (PART 7, p. 197) The major outcomes of chronic Kidney diseaseare loss of Kidney function, leading to complicationsandkidneyfailure, anddevelopmentofcardiovasculardisease.",
    "word_count": 580,
    "char_count": 11269,
    "sentence_count": 92,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 7,
      "total_chunks": 77,
      "position": "8/77",
      "section": "ThefollowingequationsprovideusefulestimatesofGFR:",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "diet",
        "malnutrition",
        "cardiovascular disease"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 8,
    "text": "Thegoals of Part 7 are to define risk factors for progression of chronic Kidney disease and to determine whether chronic Kidney disease is a risk factor for cardiovascular disease. Becauseofthewell-knownassociationofcardiovasculardiseaseanddiabetes, theWork Groupconsideredpatientswithchronickidneydiseaseduetodiabetesseparatelyfrom patientswithchronickidneydiseaseduetoothercauses. AsdescribedinAppendix1, Table153, theWorkGroupsearchedprimarilyforlongitudinalstudiesthatrelatedrisk factors to loss of Kidney function (Guideline 13) and that related proteinuria and decreasedGFRtocardiovasculardisease(Guidelines14and15). Itwasbeyondthescope oftheWorkGrouptoundertakeasystematicreviewofstudiesoftreatment. However, existingguidelines andrecommendations werereviewed, as wereselected studies, to providefurtherevidenceofefficacyoftreatment. GUIDELINE 13. FactorsAssociatedWithLossofKidneyFunctionin ChronicKidneyDisease(p. 197) The level of Kidney function tends to decline progressively over time in most patients with chronickidneydiseases. TherateofGFRdeclineshouldbeassessedinpatientswithchronickidneydiseaseto: Predicttheintervaluntiltheonsetofkidneyfailure; AssesstheeffectofinterventionstoslowtheGFRdecline. Amongpatientswithchronickidneydisease, therateofGFRdeclineshouldbeestimated by: ComputingtheGFRdeclinefrompastandongoingmeasurementsofserumcreatinine; AscertainingriskfactorsforfasterversusslowerGFRdecline, includingtype(diagnosis)ofkidneydiseaseandnonmodifiableandmodifiablefactors. potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 19 Interventions to slow the progression of Kidney disease should be considered in all patientswithchronickidneydisease. Interventionsthathavebeenproventobeeffectiveinclude: (1) Strictglucosecontrolindiabetes; (2) Strictbloodpressurecontrol; (3) Angiotensin-convertingenzymeinhibitionorangiotensin-2receptorblockade. Interventionsthathavebeenstudied, buttheresultsofwhichareinconclusive, include: (1) Dietaryproteinrestriction; (2) Lipid-loweringtherapy; (3) Partialcorrectionofanemia. AttemptsshouldbemadetopreventandcorrectacutedeclineinGFR. Frequentcauses ofacutedeclineinGFRinclude: Volumedepletion; Intravenousradiographiccontrast; Selectedantimicrobialagents(forexample, aminoglycosidesandamphotericinB); Nonsteroidalanti-inflammatoryagents; includingcyclo-oxygenasetype2inhibitors; Angiotensin-convertingenzymeinhibitionandangiotensin-2receptorblockers; Cyclosporineandtacrolimus; Obstructionoftheurinarytract. Measurements of serumcreatinine for estimation of glomerular filtration rate shouldbe obtained at least yearlyinpatientswithchronickidneydiseaseandmoreofteninpatientswith: glomerular filtration rate(cid: 1)60mL/min/1. 73m2; FastGFRdeclineinthepast((cid: 1)4mL/min/1. 73m2peryear); Riskfactorsforfasterprogression; Ongoingtreatmenttoslowprogression; ExposuretoriskfactorsforacuteGFRdecline. GUIDELINE 14. AssociationofChronicKidneyDiseaseWithDiabetic Complications(p. 230) Theriskofcardiovasculardisease, retinopathy, andotherdiabeticcomplicationsishigherin patientswithdiabetickidneydiseasethanindiabeticpatientswithoutkidneydisease. Prevention, detection, evaluation, andtreatmentofdiabeticcomplicationsinpatients withchronickidneydiseaseshouldfollowpublishedguidelinesandpositionstatements. Guidelinesregardingangiotensin-convertingenzymeinhibitorsorangiotensin-receptor blockersandstrictbloodpressurecontrolareparticularlyimportantsincetheseagents maypreventordelaysomeoftheadverseoutcomesofbothkidneyandcardiovascular disease. Application of published guidelines to diabetic patients with chronic Kidney disease shouldtakeintoaccounttheirhigher-riskstatusfordiabeticcomplications. GUIDELINE 15. AssociationofChronicKidneyDiseaseWith CardiovascularDisease(p. 238) Patientswithchronickidneydisease, irrespectiveofdiagnosis, areatincreasedriskofcardiovasculardisease(cardiovascular disease), includingcoronaryheartdisease, cerebrovasculardisease, peripheral vascular disease, and Heart failure. Both traditional and chronic Kidney diseaserelated(nontraditional)CVDriskfactorsmaycontributetothisincreasedrisk. 20 Part1. ExecutiveSummary NationalKidneyFoundation potassium/DOQI Allpatientswithchronickidneydiseaseshouldbeconsideredinthehighestriskgroup forcardiovasculardisease, irrespectiveoflevelsoftraditionalCVDriskfactors. AllpatientswithchronickidneydiseaseshouldundergoassessmentofCVDriskfactors, including: MeasurementoftraditionalCVDriskfactorsinallpatients; Individualdecision-makingregardingmeasurementofselectedchronic kidney disease-relatedcardiovascular disease riskfactorsinsomepatients. RecommendationsforCVDriskfactorreductionshouldtakeintoaccountthehighestriskstatusofpatientswithchronickidneydisease. potassium/DOQI NationalKidneyFoundation Part1. ExecutiveSummary 21 PART 2. BACKGROUND National Kidney Foundation Kidney DISEASE OUTCOMES QUALITY INITIATIVE (potassium/DOQI) SincetheirpublicationintheFallof1997, theNationalKidneyFoundation(National Kidney Foundation)Dialysis OutcomeQualityInitiative(DOQI)Guidelineshavebecomeanintegralpartofnephrologypracticethroughoutthiscountryandinmanypartsoftheworld. ItiswidelyacknowledgedthattheDOQI Guidelineshavehadanimpactinimprovingquality ofcareand outcomesofpatientstreatedbydialysis. IntheFallof1999, theNKFdecidedtofocus itsattentiononthemillionsofpeoplewithearlierstagesofchronickidneydisease, who through early diagnosis and treatment, could possibly avoid the progression of their diseasetodevelopmentofkidneyfailureandotheradverseoutcomes. Thegoalofthis newinitiative, theKidneyDiseaseOutcomesQualityInitiative(potassium/DOQI), istoimprove the quality of care and outcomes of all individuals with Kidney disease by developing clinical practice guidelines for the management of patients in earlier stages of Kidney disease. Thisguideline, ChronicKidneyDisease: Evaluation, ClassificationandStratification, willserveasthefoundationforfutureguidelinesbystandardizingthedefinition and classification of stages of chronic Kidney disease, laboratory evaluation of Kidney disease, associationofthelevelofkidneyfunctionwithcomplications, andstratification ofriskforadverseoutcomesofkidneydisease. Futureguidelineswillfocusondiagnosis andtreatmentofcomplicationsofearlierstagesofkidneydisease, amelioratingitscomplications, retardingtheprogressionofthedisease, reducingthemorbidityandmortality of cardiovascular disease, and reducing the morbidity and mortality of Kidney failure. Theultimateobjectivesaretoimprovethequalityofcareandoutcomesofallindividuals withkidneydiseaseandtoreducetheriskofdevelopingkidneydisease. THE PROBLEM Chronickidneydiseaseisaworldwidepublichealthproblem. IntheUnitedStates, there isarisingincidenceandprevalenceofkidneyfailure, withpooroutcomesandhighcost. The incidence and prevalence of end-stage renal disease (end-stage renal disease) have doubled in the past 10 years and are expected to continue to rise steadily in the future (Fig 2). Data fromthe2000AnnualDataReportoftheUSRenalDataSystem(USRDS)documentsthe incidenceofESRDin1998ofmorethan85, 000, or308permillionindividualsperyear atrisk. ThepointprevalenceofESRDonDecember31, 1998wasmorethan320, 000, or 1, 160 per million population, of whom 72% were treated by Dialysis and 28% had functioningkidneytransplants. Despiteadvancesindialysisandtransplantation, theprognosisofkidneyfailureremainsbleak. TheUSRDSreportsmorethan63, 000deathsofpatientswithESRDin1998, andanannualmortalityrateofdialysispatientsinexcessof20%. Expectedremaining lifetimes of patients treated by Dialysis were far shorter than the age-matched general population, varying(dependingongenderandrace)from7. 1to11. 5yearsforpatients aged40to44years, andfrom2. 7to3. 9yearsforpatientsaged60to64years. Morbidity potassium/DOQI NationalKidneyFoundation Part2. Background 23 Fig2. Incidenceandprevalenceofend-stagerenaldiseaseintheUnitedStates. Incident patientsreferstonewcasesduringtheyear. Pointprevalentpatientsreferstopatients aliveonDecember31stoftheyear. Solidverticallinesrepresentcompletedatafor1998 and expected data for 2000. Projections for future years are based on extrapolation ofregressionequations. R2forregressionequationsisgiven. DatafromUSRDS2000 AnnualDataReport. 4 ofkidneyfailureisalsohigh. Themeannumberofcomorbidconditionsindialysispatients isapproximately4perpatient, themeannumberofhospitaldaysperyearisapproximately15, andself-reportedqualityoflifeisfarlowerthanthegeneralpopulation. Total Medicare and non-Medicare costs for end-stage renal disease treatment in 1998 were 12. 0 billion and 4. 7billion, respectively. Thereisanevenhigherprevalenceofearlierstagesofchronic kidneydisease. Mortality, morbidity, hospitalizations, qualityoflife, andcostsforcaring forpatientswithearlierstagesofchronickidneydiseasehavenotbeensystematically studied. Historically, theevaluationandmanagementofchronickidneydiseasehasfocused on diagnosis and treatment of specific Kidney diseases, and Dialysis or transplantation forkidneyfailure. Increasingevidence, accruedinthepastdecades, indicatesthatthe adverseoutcomesofchronickidneydiseasecanbepreventedordelayedthroughinterventionsduringearlierstagesofchronickidneydisease, irrespectiveofthecause. Unfortunately, chronickidneydiseaseisunder-diagnosedandunder-treatedintheUnited States. Thisleadstolostopportunitiesforpreventionofcomplicationsandworseoutcomesforpatientswithchronickidneydisease. STRATEGIES FOR EARLY DETECTION AND INTERVENTION Earlierstagesofkidneydiseasecanbedetectedthroughlaboratorytesting. Measurement of serum Creatinine and estimation of glomerular filtration rate can identify patients with reduced Kidney function. Measurementofurinaryalbuminexcretioncanidentifysome, butnotall, patientswithkidneydamage. Screeningasymptomaticindividualsatincreasedriskcould allowearlierdetectionofchronickidneydisease. Currently, theUSPreventiveHealthServicesTaskForcedoesnotrecommendurinaly24 Part2. Background NationalKidneyFoundation potassium/DOQI sisormeasurementofserumcreatinineinotherwisehealthyadults. Untilrecently, recommendationsforscreeningforchronickidneydiseaseinadultswerelargelyfocusedon patientswithhypertension. ArecentanalysisoftheNHANESIIIdatabaseindicatedthat only70%ofindividualsintheUnitedStateswithelevatedserumcreatininehadhypertension. 5 More recent guidelines by the National Kidney FoundationProteinuria, Albuminuria, Risk Assessment, Detection, andElimination(PARADE)6, 7andtheAmericanDiabetesAssociation8recommendperiodicevaluationofallindividualsatincreasedriskforkidneydiseaseandthose with Diabetes for albuminuria.",
    "word_count": 588,
    "char_count": 10517,
    "sentence_count": 80,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 8,
      "total_chunks": 77,
      "position": "9/77",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "serum creatinine"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 9,
    "text": "5 More recent guidelines by the National Kidney FoundationProteinuria, Albuminuria, Risk Assessment, Detection, andElimination(PARADE)6, 7andtheAmericanDiabetesAssociation8recommendperiodicevaluationofallindividualsatincreasedriskforkidneydiseaseandthose with Diabetes for albuminuria. Appropriate measurement and interpretation of Urine albumin and serum Creatinine in all individuals with hypertension and Diabetes could identifyalargenumberofpatientswithearlierstagesofchronickidneydisease. However, it is likely that evaluation programs targeting only individuals with hypertension and Diabetes will miss a large number of individuals with other causes of chronic Kidney disease. Testing criteria could be expanded beyond just Diabetes or hypertension, as recommendedintheNKF-PARADEpositionpaper. Therapeuticinterventionsatearlierstagesofchronickidneydiseaseareeffectivein slowingtheprogressionofchronickidneydisease. Themajortherapeuticstrategiesthat havebeentestedincludestrictbloodglucosecontrolindiabetes, strictbloodpressure control, angiotensin-convertingenzyme(ACE)inhibitorsandangiotensin-receptorblockers, anddietaryproteinrestriction. Thestudyofkidneydiseasesinthetransplantpopulation has longfocused on prevention andtreatment of allograft rejection. Thus far, no large-scaleclinicaltrialsofkidneytransplantrecipientshaveevaluatedtherapiesthatare effectiveinslowingprogressionofdiseasesinnativekidneys. However, withinthepast fewyears, observationalstudieshavedemonstratedthatnon-immunologicalfactors, such asproteinuriaandhigherbloodpressure, appeartoberiskfactorsindiseasesoftransplantedaswellasnativekidneys. Conceivably, treatmentofCVDriskfactorsinearlierstagesofchronickidneydisease couldreduceadverseoutcomesofcardiovasculardiseasebeforeandafterdevelopment ofkidneyfailure. However, fewpatientswithchronickidneydiseasehavebeenincluded inpopulation-basedepidemiologicalstudiesofcardiovasculardiseaseorlong-term, randomizedclinicaltrials. Therefore, theNKFTaskForceonCardiovascularDiseasedevelopedanevidencemodelforcardiovasculardiseaseinchronickidneydisease(Fig3)and developedcriteriaforextrapolationofevidenceontheefficacyofrisk-factorreduction therapiesfromthegeneralpopulationtopatientswithchronickidneydisease. Ingeneral, theTaskForceconcludedthatmostinterventionsthatareeffectiveinthegeneralpopulationshouldalsobeappliedtopatientswithchronickidneydisease. TheNKFhasinitiated twootherK/DOQIWorkGroupsthataredevelopingclinicalpracticeguidelinesforthe evaluation and management of specific cardiovascular disease risk factors in defined targetpopulationswithchronickidneydisease. Thesewillbeavailableinthenearfuture. Inaddition, otherprofessionalorganizationsarefocusingonotherriskfactorsorother targetpopulations. potassium/DOQI NationalKidneyFoundation Part2. Background 25 Fig 3. Evidence model for stages in the initiation and progression of cardiovascular disease, andtherapeuticinterventions. Shadedellipsesrepresentstagesofcardiovasculardisease; unshadedellipsesrepresentpotentialantecedentsorconsequencesofCVD. Thickarrowsbetweenellipsesrepresentfactorsassociatedwithinitiationandprogressionofdiseasethatcanbeaffectedordetectedbyinterventions: susceptibilityfactors (black); initiation factors (dark gray); progression factors (light gray); and end-stage factors (white). Interventions for each stage are given beneath the stage. Individuals whoappearnormalshouldbescreenedforCVDriskfactors. Individualsknowntobe at increased risk for cardiovascular disease should be screened for cardiovascular disease. Modified and reprinted with permission. 9 OVERVIEW OF CURRENT STATUS OF TREATMENT FOR CHRONIC Kidney DISEASE It is difficult to evaluate the current status of treatment for chronic Kidney disease. A systematicsearchyieldedfewguidelinesfordiagnosisandmanagementofearlierstages of chronic Kidney disease (Table 7). While the USRDS is charged with compiling and reportingdataonincidence, prevalence, outcomes, andcostofdialysisandtransplantation, patientswithearlierstagesofchronickidneydiseasearenotsystematicallytracked byanypublichealthagencyintheUnitedStates. Inaddition, standardsofcarehavenot beendefinedinauniversallyacceptedformat. Therefore, thereisnoongoingeffortto ascertain adherence to standards for care or outcomes for patients with earlier stages of chronic Kidney disease. The National Institute for Diabetes, Digestive and Kidney DiseaseisbeginningaprospectivecohortstudyofpatientswithdecreasedGFRtodeterminefactorsthatareassociatedwithadverseoutcomesofchronickidneydisease. However, evenintheabsenceofsuchstudies, thereissubstantialevidenceofunder-diagnosisandunder-treatment. AnalysisofdatafromNHANESIIIontheadequacyofdrugtreatmentofhypertension inpatientswithelevatedserumcreatininerevealedthatonly75%ofpatientswithhypertensionandelevatedserumcreatininehadreceivedtreatment. 5However, only11%had theirbloodpressurereducedto(cid: 1)130/85mmHg, thelevelrecommendedbytheSixth Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of Hypertension (JNC VI), and the National Kidney Foundation to slow the progression of 26 Part2. Background NationalKidneyFoundation potassium/DOQI chronic Kidney disease. Only 27% had their Blood Hypertension reduced to (cid: 1)140/90 mm Hg, thelevelrecommendedbyJNC-VItopreventcardiovasculardiseaseinindividuals withoutpre-existingtargetorgandamage. Inanotherstudy, hospitalrecordsfromMedicarebeneficiariesinGeorgiawereanalyzedforadequacyofdiagnosisandACEinhibitortreatmentofdiabeticandhypertensive Kidney disease. 10 Among patients with Diabetes, Urine Protein was measured in only 63%. Among those with proteinuria, ACE-inhibitors were prescribed in only 33% and thefinding wasrecorded inthedischarge summaryinonly 8%. Serum creatininewas measuredin97%ofdiabeticpatients. Amongthosewithelevatedserumcreatinine, ACEinhibitorswere prescribedin only32%and thefindingwas reportedin thedischarge summary in only 10%. Among nondiabetic patients with hypertension, tests for Urine potassium/DOQI NationalKidneyFoundation Part2. Background 27 proteinwereperformedinonly59%. Amongthosewithproteinuria, ACE-inhibitorswere prescribedinonly13%andthefindingwasrecordedinthedischargesummaryinonly 13%. Serumcreatininewasmeasuredin91%ofnondiabetichypertensivepatients. Among thosewithelevatedserumcreatinine, ACE-inhibitorswereprescribedinonly26%and thefindingwasrecordedinthedischargesummaryinonly11%. Thus, neitherelderly diabeticnorhypertensivepatients, whoareatincreasedriskforchronickidneydisease, wereadequatelyevaluatedortreatedwithprovenagents. DatafromthesecondphaseofUSRDSDialysisMorbidityandMortalityStudy(DMMS Wave 2) was analyzed for adequacy of preparation for initiation of Dialysis. 11 Among patientsbeginninghemodialysis, 52%ofpatientshadsevereanemia(hematocrit(cid: 1)28%), 54%didnothaveapermanentvascularaccess(temporarycatheterfor60daysofinitiation ofdialysis), 39%werereferredtoanephrologistlate(lessthan3monthspriortoinitiation of Dialysis), and24% initiated Dialysis atvery Low levels ofkidney function (estimated glomerular filtration rate(cid: 1)5mL/min/1. 73m2). Amongpatientsbeginningperitonealdialysis, 42%hadsevere anemia, 27%were referredto anephrologist late, and 19%initiated Dialysis withvery lowlevelsofkidneyfunction. Thesearebutafewexamplesfromaliteraturerepletewithevidenceofinadequate diagnosisandtreatmentofearlierstagesofchronickidneydisease, eventhoughappropriateinterventionshavebeenshowntoimproveoutcomes. Overall, thesefindingssuggest thatdiagnosisandtreatmentinthecommunityfallfarshortofthefewrecommended guidelinesthathavebeendeveloped. 28 Part2. Background NationalKidneyFoundation potassium/DOQI PART 3. CHRONIC Kidney DISEASE AS A PUBLIC HEALTH PROBLEM Thepurposeofthissectionistoreviewthegeneralstateofknowledgeatthestartof theWorkGroup. Thisreviewwillprovideadetailedframeworkforthequestionsthe WorkGroupchosetoask(Table8). PUBLIC HEALTH APPROACH TO CHRONIC Kidney DISEASE Solutionstopublichealthproblemsrequirestrategiesforpreventionofadverseoutcomes of disease. Prevention requires a clear understanding of prevalence and outcomes of disease, earlierstagesofdisease, antecedentriskfactors, andappropriatetreatmentsfor populationsatrisk. Thereisaspectrumofriskforadverseoutcomes, rangingfromvery highriskinthosewiththedisease, tohighriskinthosewithriskfactorsfordeveloping thedisease, tolowriskforthosewithoutthediseaseoritsriskfactors. Thepopulation asawholeincludesmanymoreindividualsatlowriskthanathighrisk. Publichealth measuresaddressingchronicdiseasesincludestrategiestopreventadverseoutcomesin individualsatveryhigh riskandhighrisk, aswellaswidespread adoptionoflife-style modificationstoreducetheaverageriskprofileofthepopulation. Withregardtoriskstratificationforadverseoutcomesfromchronickidneydisease, patientswithchronickidneydiseasewouldbeincludedintheveryhighriskgroup. Individuals without chronic Kidney disease, but with risk factors for chronic Kidney disease(CKDriskfactors), wouldconstitutethehighriskgroup. Individualswithout chronickidneydiseaseorCKDriskfactorswouldconstitutethelowriskgroup. Most chronic Kidney diseases tend to progress and worsen over time. The risk of adverseoutcomesinchronickidneydiseasecanbefurtherstratifiedbytheseverityof diseaseandrateofprogression. Therefore, formostpatients, theriskofadverseoutcomes tendstoincreaseovertime. ThemajortaskoftheWorkGroupwastodevelopAClinicalActionPlanan approachtochronic kidneydiseasethatrelates stagesofseverityof chronickidney diseasetostrategiesforpreventionandtreatmentofadverseoutcomes.",
    "word_count": 575,
    "char_count": 9536,
    "sentence_count": 69,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 9,
      "total_chunks": 77,
      "position": "10/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "hematocrit",
        "serum creatinine",
        "dialysis",
        "anemia"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 10,
    "text": "The risk of adverseoutcomesinchronickidneydiseasecanbefurtherstratifiedbytheseverityof diseaseandrateofprogression. Therefore, formostpatients, theriskofadverseoutcomes tendstoincreaseovertime. ThemajortaskoftheWorkGroupwastodevelopAClinicalActionPlanan approachtochronic kidneydiseasethatrelates stagesofseverityof chronickidney diseasetostrategiesforpreventionandtreatmentofadverseoutcomes. To accomplish this task it was first necessary to outline the conceptual approach, includingoperationaldefinitionsofchronickidneydiseaseandthestagesofseverityof chronickidneydisease; determinationoftheprevalenceofchronickidneydisease; issues intheevaluationandmanagementofvarioustypesofchronickidneydisease; definition of individuals at increased risk of chronic Kidney disease; definition of outcomes of chronickidneydisease; associationofcomplicationsofchronickidneydiseasewithdecreasedkidneyfunction; modalitiesofkidneyreplacementtherapy; andanapproachto chronickidneydiseaseusingtheguidelines. STAGES OF SEVERITY OF CHRONIC Kidney DISEASE TheUSRDSprovidesreliablenationwidedataregardingtheincidence, prevalence, treatmentpatterns, outcomes, andcostoftheend-stagerenaldisease, themostseverestage ofchronickidneydisease. Therearenouniformdefinitionsofearlierstagesofkidney potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 29 disease, nor is there reliable information on the prevalence, treatment patterns, outcomes, andcost of theseearlier stages, nor information onhow many peoplechoose toforegodialysisandtransplantationdespitekidneyfailure. Riskfactorsforthedevelopmentofchronickidneydiseasehavenotbeenwelldescribed, andthereisnoreliable estimateofthesizeofthepopulationatrisk. Thissectionintroducestherationalefor developingadefinitionofchronickidneydiseaseandclassificationofstagesofseverity; riskfactors foradverseoutcomes ofchronickidney disease; the relationshipbetween disease severity and rate of progression as risks for adverse outcomes; the definitions andstages definedby theWork Group; and laboratorytests forthe detectionof each stage. 30 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI Rationale for Developing a Definition of Chronic Kidney Disease and Classification of Stages of Severity Defining chronic Kidney disease and classifying the stages of severity would provide a common language for communication among providers, patients and their families, investigators, and policy-makers, and a framework for developing a public health approachtoaffectcareandimproveoutcomesofchronickidneydisease. Auniformterminologywouldpermit: 1. More reliable estimates ofthe prevalence of earlier stages ofdisease and of the populationatincreasedriskfordevelopmentofchronickidneydisease; 2. Recommendationsforlaboratorytestingtodetectearlierstagesandprogression tolaterstages; 3. Associationsofstageswithclinicalmanifestationsofdisease; 4. Evaluationoffactorsassociatedwithahighriskofprogressionfromonestageto thenextorofdevelopmentofotheradverseoutcomes; 5. Evaluationoftreatmentstoslowprogressionorpreventotheradverseoutcomes. Clinicalpracticeguidelines, clinicalperformancemeasures, andcontinuousquality improvementeffortscouldthenbedirectedtostagesofchronickidneydisease. Definingchronickidneydiseaseandstagesofseverityrequirescategorizationof continuousmeasuresofmarkersofkidneydamageandlevelofkidneyfunction. Identifyingthestageofchronickidneydiseaseinanindividualisnotasubstitutefordiagnosis ofthetypeofkidneydiseaseortheaccurateassessmentofthelevelofkidneyfunction inthat individual. However, recognitionofthe stageof chronickidneydisease would facilitateapplicationofguidelines, performancemeasures, andqualityimprovementefforts. Inotherfieldsofmedicine, classificationsofstagesofseverityofillnesshavebeen adoptedwithapparentsuccess, suchastheNewYorkHeartAssociationclassification of Heart disease. Within nephrology and related disciplines, classifications of disease severityhavebeendevelopedthatarebasedoncategorizationofcontinuousmeasures ofdiseaseseverity. Forexample, theJointNationalCommitteeforthePrevention, Detection, EvaluationandTreatmentofHighBloodPressurehasdefinedstagesofhypertension basedonbloodpressurelevel. TheNationalCholesterolEducationProgramhasdefined stagesofhypercholesterolemiabasedonserumcholesterollevel. Diabetickidneydisease isclassifiedaccordingtothemagnitudeofalbuminuria. Criteriaforenrollmentintothe MedicareESRDProgramandlistingforcadaverickidneytransplantationarebased, in part, onthelevelofserumcreatinine. Theseclassificationshavefacilitatedepidemiologicalstudies, clinicaltrials, andapplicationofclinicalpracticeguidelines. Risk Factors for Adverse Outcomes of Chronic Kidney Disease Ariskfactorisdefinedasanattributethatisassociatedwithincreasedriskofanoutcome. Inprinciple, therearefourkindsofriskfactorsforadverseoutcomesofchronickidney potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 31 diseasewhichweredefinedbytheWorkGroupasCKDriskfactors(Table9). This guidelineconcernsitselfprimarilywithidentifyingsusceptibilityandinitiationfactorsto defineindividualsathighriskofdevelopingchronickidneydisease, andwithprogression factors, todefineindividualsathighriskofworseningkidneydamageandsubsequent lossofkidneyfunction. Relationship Between Disease Severity and Rate of Progression as Risks for Adverse Outcomes Inprinciple, onemaydistinguishbetweentheseverityofdiseaseandtheriskforadverse outcomesofdisease. Theseverityofdiseasecanbedeterminedfrommeasurementsof leveloforganfunction, complicationsinotherorgansystems, morbidity(symptomsand clinicalfindings), andimpairmentinoverallfunctionandwell-being. Ingeneral, therisk foradverseoutcomesisrelatedtotheseverityofdisease. Inaddition, theriskforadverse outcomes is also dependent on the rate of progression to a more severe stage or the rateofregressiontoalessseverestage. For the case ofchronic Kidney disease, these concepts canbe illustrated by Fig 4. Fig4. Kidneyfunctiondeclineinchronickidneydisease. Seetext. 32 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI The vertical axis shows the level of Kidney function. The horizontal axis shows time overanintervalofseveralyears. Thehorizontaldottedlinecorrespondstothelevelof Kidney function at the onset of Kidney failure. The declines in Kidney function in 4 individual patients (A through D) are illustrated as diagonal lines. At the discovery of chronickidneydisease(t ), patientsAandBshareidenticallevelsofkidneyfunction, 0 asdopatientsCandD, buttheleveloffunctionislowerinpatientsCandDthanfor patientsAandB. PatientsAandChaveidenticalratesofdeclineinkidneyfunction, as dopatientsBandD, buttherateofdeclineisfasterinpatientsBandDthaninpatients AandC. PatientD, withthelowerinitiallevelofkidneyfunctionandthefasterrateof decline in Kidney function, reaches Kidney failure first (t ). Patient B, with the higher 1 initiallevelofkidneyfunctionbutfasterrateofdecline, andpatientC, withthelower initial level of Kidney function and slower rate of decline, reach Kidney failure at the sametime(t ). PatientA, withthehigherinitiallevelofkidneyfunctionandtheslower 2 rateofdeclineinkidneyfunction, hasnotreachedkidneyfailurebytheendoffollowup(t ). Figure4illustratesthattheriskofdevelopingkidneyfailuredependsbothon 2 thelevelofkidneyfunctionatthediscoveryofchronickidneydiseaseandtherateof declineinkidneyfunction. Theobjectoftherapyforchronickidneydiseasewouldbe todetectkidneydiseaseatahigherlevelofkidneyfunction(openarrow)andtoreduce therateofdeclineinkidneyfunctionthereafter(filledarrows), therebyreducingadverse outcomesofchronickidneydisease. Operational Definition of Chronic Kidney Disease and Stages OneofthefirsttasksoftheWorkGroupwastodefinechronickidneydisease, irrespective of the specific pathological features of the disease. For this definition, the Work Groupusedacombinationofthepresenceofkidneydamageandlevelofkidneyfunction. Definition and Detection of Kidney Damage Chronickidneydamageisdefinedasstructuralabnormalitiesofthekidneythatcanlead todecreasedkidneyfunction. Thelevelofglomerularfiltrationrate(glomerular filtration rate)isaccepted asthebestmeasureofoverallkidneyfunctioninhealthanddisease. Pathologicstudies showthatsubstantial kidneydamagecanbesustainedwithout decreasedGFR. Micropuncturestudiesinanimalmodelsofchronickidneydiseaseshowthatthemaintenance ofnormalGFRdespitekidneydamageisduetoanadaptiveincreaseinglomerularcapillary Blood flow and Hypertension in response to decreased ultrafiltration coefficient and reducednumberofnephrons. Markers of Kidney damage vary depending on the type of Kidney disease and may includeabnormalitiesinthecompositionofthebloodorurineorabnormalitiesinimaging tests, withorwithoutdecreasedGFR. Forexample, albuminuriaiswidelyacceptedas a marker of glomerular damage, and the excretion of even small amounts of albumin (microalbuminuria) is the earliest manifestation of diabetic Kidney disease. In large amounts, albumin excretion can readily be detected by tests of total Urine Protein, whereasdetectionofminimalamountsrequiresspecific, sensitiveassays.",
    "word_count": 573,
    "char_count": 9056,
    "sentence_count": 61,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 10,
      "total_chunks": 77,
      "position": "11/77",
      "content_type": "definition",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "ultrafiltration",
        "classification"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 11,
    "text": "In large amounts, albumin excretion can readily be detected by tests of total Urine Protein, whereasdetectionofminimalamountsrequiresspecific, sensitiveassays. One of the major obstacles to detection of Kidney damage using measurements of Urine albumin or total Protein is the necessity for collection of a timed Urine sample. potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 33 Recently, manyinvestigatorshaveprovidedevidencethattheratioofconcentrationsof albumin-to-creatinineortotalprotein-to-creatinineinaspoturinesampleaccuratelyreflectstheexcretionratesofalbuminortotalproteinintimedurinesamples. Oneofthe questions posed by the Work Group was: Do spot Urine albumin-to-Creatinine ratio andtotalprotein-to-creatinineratioprovideaccuratemeasuresofurinealbuminand proteinexcretionrates, respectively? Inadditiontoitsimportanceasa markerofkidneydamage, albuminuriaisalsoan importantprognosticfactorfortheprogressionofkidneydiseaseanddevelopmentof cardiovasculardisease. TheNKFissuedapositionpaperin1999ontheevaluationand managementofadultswithalbuminuria. Theinitiative, knownasProteinuria, Albuminuria, RiskAssessment, Detection, and Elimination(PARADE), emphasizesfindings relatedtoproteinuriaasariskfactorforcardiovasculardisease, proteinuriaasamediator andmarkerofprogressivekidneydisease, andpersistentmassiveproteinuriaastheincitingfactorthatleadstothenephroticsyndrome. 6Anaccompanyingreportontheevaluationandmanagementofproteinuriaandnephroticsyndromeinchildrenwasissuedin 2000. 7TheCKDWorkGrouphasusedtherecommendationsofPARADEindeveloping itsrecommendationsforlaboratorytestingandevaluationofproteinuriaandalbuminuria. Otherexamplesofmarkersofdamageinchronickidneydiseaseincludeabnormalities inthe urinesedimentandabnormalities onimagingstudies ofthekidney. Oneofthe questionsposedbytheWorkGroupwas: Areotherurinarymarkersofkidneydamage applicableforclinicalpractice? Hypertension was not defined as a marker of Kidney damage because High Blood Hypertension has other causes. The relationship between Hypertension and kidneydiseaseiscomplex, ashighblood pressureisbothacauseandaconsequence ofkidneydisease. Throughouttheguideline, theWorkGrouphasprovidedinformation on Hypertension, including the prevalence of Hypertension at stages of chronickidneydisease, andtheroleofhighbloodpressureasariskfactorforlossof kidneyfunction. Definition and Detection of Decreased glomerular filtration rate and Relationship With Age Asarule, kidneyfailureduetochronickidneydiseaseisprecededbyastageofvariable lengthduringwhichGFRisdecreased. GFRisaffectedbyanumberoffactorsinaddition tokidneydisease, andnotallindividualswithdecreasedGFRhavechronickidneydisease. Mild reduction in glomerular filtration rate was defined as chronic Kidney disease only in the presence of kidneydamage(Stage2). However, becauseoftheriskofcomplications, moderate(Stage 3) to severe (Stage 4) reduction in glomerular filtration rate and Kidney failure (Stage 5) were defined as chronickidneydisease, irrespectiveofthepresenceofkidneydamage. Otherthankidney disease, the most important factor affecting glomerular filtration rate is age. glomerular filtration rate rises during infancy and declinesduringaging. Therefore, mildreductioninGFRmaybenormalattheextremes of age and, in the absence of Kidney damage, is not considered to be chronic Kidney disease. A clinical action plan based on the level of glomerular filtration rate requires knowledge of ageassociated normal values. One of the questions posed by the Work Group was: What arenormalvaluesofGFRduringgrowthandaging? 34 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI Unfortunately, measurementofGFRisinconvenient, andinmoststudies, asinclinical practice, thelevelofkidneyfunctionisestimatedfromtheserumcreatinineconcentration. ThisisdifficultbecauseavarietyoffactorsotherthanGFR, includingage, gender, race, and body size, affect the serum Creatinine concentration. To circumvent these limitations, mostclinical textsrecommendmeasuringcreatinine clearancetoestimate thelevelofGFR. However, asindicatedpreviously, collectionofatimedurinespecimen canbedifficult. OneofthequestionsposedbytheWorkGroupwas: Areestimatesof GFRbasedonpredictionequationsincorporatingserumcreatinineaswellasthese otherfactorsmoreaccuratethanestimatesofGFRbasedonserumcreatininealone ormeasurementofcreatinineclearance? Definition and Detection of Kidney Failure Mosttextsdefinekidneyfailureasseverereductioninkidneyfunctionthatisnotcompatiblewithlife, becauseitsattendantcomplicationsbecomeincreasingrisksformortality. Individualsatthisstagehavebeensaidtohaveend-stagerenaldisease(end-stage renal disease)because they require Dialysis or transplantation to sustain life. Since 1972, the Medicare end-stage renal disease Program has borne 80% of the costs of Dialysis and transplantation for approximately 93% of patients in the United States, allowing near universal access to treatment for Kidney failure. Indeed, treatment with Dialysis or transplantation has become almost synonymous with the diagnosis of chronic Kidney failure. Such a definition of Kidney failurehasobviousoperationalandadministrativeadvantages. However, itlacksprecision. First, patients who have Kidney failure may survive for variable periods of time withouttreatmentbydialysisortransplantation. Second, somesignsandsymptomsof kidneyfailureappearathigherlevelsofkidneyfunctionthatarecompatiblewithlong survival. Third, somehaveadvocatedearlyinitiationofdialysisorpre-emptivekidneytransplantationpriortotheonsetofkidneyfailure. Fourth, manypatientslivingwith dialysisorakidneytransplantfindthephraseend-stagethreateningandmisleading. Thus, it would be preferable to define Kidney failure as a combination of signs and symptomsofuremiaandaspecificlevelofkidneyfunction. Oneofthequestionsposed bytheWorkGroupwas: Isitpossibletoidentifythelevelofkidneyfunctioncorrespondingtothestageofkidneyfailure? PREVALENCE OF CHRONIC Kidney DISEASE As described earlier, the USRDS tracks the prevalence of Kidney failure in the United States. OneofthequestionsposedbytheWorkGroupwas: Whatistheprevalenceof earlier stages of chronic Kidney disease, based on the definitions and methods for measurementdiscussedabove? Prevalence of Kidney Damage GuidelinesbytheAmericanAcademyofPediatriciansrecommendscreeningschool-age childrenforproteinuriausingtheurinedipstick. Therefore, alargenumberofstudies havebeenconductedtoestimatetheprevalenceofproteinuriainchildren. Oneofthe questions posed by theWork Group was: What is theprevalence of dipstick-positive proteinuriainchildren? Ontheotherhand, fewerstudieshavedeterminedthenormal potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 35 rangeofproteinuriainchildren. AnotherquestionaskedbytheWorkGroupwas: What isthenormalvalueforproteinuriainchildren? Incontrast, currentguidelinesbytheUSPreventiveHealthServicesTaskForcedo notsuggestroutinescreeningofadultsforproteinuria. Datafromtwocommunity-based screeningprograms, theFraminghamStudy12andtheOkinawaStudy, 13demonstratean approximately10%prevalenceofdipstick-positiveproteinuriainadults. Theprevalence washigherinolderthanyoungerindividualsandhigherinwomenthanmen. However, thereareseriouslimitationstothesestudies. First, theurinedipstickisnotsensitiveto smallamountsofalbumin, andthusthesestudieswouldnothavedetectedmostpatients withmicroalbuminuria. Second, neithertimedurinecollectionsnorprotein-to-Creatinine ratiosweremeasured, andthusthedipsticktestresultwasaffectedbythestateofdiuresis inadditiontothemagnitudeofproteinuria. Furthermore, atleastsomeoftheindividuals inthesestudieswithproteinuriaalsohadreducedkidneyfunction. Thus, theyprovide only a rough guide to the likelyprevalence of individuals with Kidney damage due to chronickidneydisease. AnotherquestionposedbytheWorkGroupwas: Whatisthe prevalenceofelevatedurinealbumin-to-creatinineratioinadults; andinsubgroups definedbyageandlevelofGFR? Prevalence of Decreased glomerular filtration rate A 1998 report from the third cycle of the National Health and Nutrition Examination Survey(NHANESIII), conductedfrom1988to1994, estimatedthat6. 2millionindividuals overage12yearshadreducedkidneyfunction, definedasaserumcreatinineconcentration(cid: 1)1. 5mg/dL1(Fig5). Thisrepresentsanalmost30-foldhigherprevalenceofreduced kidneyfunctioncomparedtotheprevalenceofESRDduringthesameinterval. Thissame reportestimatedthattherewere2. 5millionindividualswithserumcreatinine(cid: 1)1. 7mg/ dLand800, 000individualswithserumcreatinine(cid: 1)2. 0mg/dL. Becauseofdifferences Fig5. Creatininedistribution: USpopulationage(cid: 1)20bysex, NHANESIII, 19881994, N(cid: 1)15, 600. 36 Part3.",
    "word_count": 599,
    "char_count": 8659,
    "sentence_count": 70,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 11,
      "total_chunks": 77,
      "position": "12/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "end-stage renal disease",
        "albuminuria",
        "creatinine",
        "potassium",
        "serum creatinine",
        "nutrition",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 12,
    "text": "5millionindividualswithserumcreatinine(cid: 1)1. 7mg/ dLand800, 000individualswithserumcreatinine(cid: 1)2. 0mg/dL. Becauseofdifferences Fig5. Creatininedistribution: USpopulationage(cid: 1)20bysex, NHANESIII, 19881994, N(cid: 1)15, 600. 36 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI in Creatinine generation, the prevalence of elevated serum Creatinine varied by age, gender, andethnicity, withahigherprevalenceinoldercomparedtoyoungerindividuals, in men compared to women, and in non-Hispanic blacks compared to non-Hispanic whitesorMexican-Americans. Asdiscussedlaterinthisreport, theseapparentlyminor elevationsinserumcreatininemaywellreflectsubstantialdecreasesinGFR, especially intheelderly. Thissuggeststhatthenumberofindividualswithreducedkidneyfunction, definedasreducedGFR, maybemuchhigherthantheseestimatesbasedonincreased serumcreatininelevels. OneofthequestionsposedbytheWorkGroupwas: Whatis theprevalenceofdecreasedGFRinthegeneralpopulationandinsubgroupsdefined byage? EVALUATION AND MANAGEMENT OF CHRONIC Kidney DISEASE Diagnosisofchronickidneydiseaseisbasedprimarilyonetiologicandpathologicclassification. Refinementsinserologictestsandintroductionofpercutaneousbiopsytechnique have led to increasingly sophisticated classifications. Unfortunately, nomenclature has notbeenstandardized, whichhampersthedevelopmentofstrategiesforpreventionand treatment. 14ItisanticipatedthatafutureWorkGroupwilladdresstheroleofkidney biopsy. OneofthetasksoftheWorkGroupwastorecommendaclassificationofthe typesofkidneydiseaseforapplicationoftheseguidelines. Anothertaskwastodescribetheactionsnecessaryforevaluationandmanagement ofchronickidneydisease, irrespectiveofdiagnosis. TheWorkGrouprecommendedthat these tasks be grouped as follows: treatment of comorbid conditions, prevention or slowingthelossofkidneyfunction, preventionandtreatmentofcardiovasculardisease, prevention and treatment of complications of decreased Kidney function, preparation for Kidney failure, and replacement of Kidney function (if necessary and desired) by dialysisandkidneytransplantation. INDIVIDUALS AT INCREASED RISK FOR CHRONIC Kidney DISEASE DatafromtheUSRDSindicatestheincidenceofESRDisdisproportionatelyhighamong olderindividuals, certainethnicminorities, andindividualswithhypertension, Diabetes, andautoimmunediseases. Thissuggeststhatdemographic andclinicalfactorsmaybe riskfactorsforthedevelopmentorprogressionofchronickidneydisease. Inaddition, individualswithafamilyhistoryofkidneydiseaseappeartobeathigherriskofdeveloping kidneydisease. Thisappearstobetrueformosttypesofkidneydiseases, suggestingthe presenceofgenescodingforsusceptibilityfactorsforthedevelopmentorprogression ofkidneydiseaseingeneral, aswellasgenescodingforspecifickidneydiseases, such asautosomaldominantpolycystickidneydiseaseorAlportssyndrome. Finally, patients who have recovered from an episode of acute Kidney failure, whether due to acute tubularnecrosisorotherparenchymaldiseases, mayalsobeatriskofdevelopingchronic kidneydisease. The prevalence of individuals at increased risk for development of chronic Kidney potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 37 diseasehasnotbeenstudiedsystematically. OneofthetasksoftheWorkGroupwas toassemblealistofpotentialCKDriskfactorsandtheprevalenceofindividualswith theseriskfactors. OUTCOMES OF CHRONIC Kidney DISEASE The Work Group considered two major outcomes of chronic Kidney disease: loss of kidneyfunctionleadingtokidneyfailureanddevelopmentofcardiovasculardisease. Of course, Kidney failure isthe most visible outcome of chronickidney disease, and loss ofkidneyfunctionisassociatedwithcomplicationsinvirtuallyeveryorgansystem. Cardiovasculardiseasewasconsideredseparatelybecause: (1)cardiovasculardiseaseevents aremorecommonthankidneyfailureinpatientswithchronickidneydisease; (2)cardiovasculardiseaseinpatientswithchronickidneydiseaseistreatableandpotentiallypre- ventable; and(3)chronickidneydiseaseappearstobeariskfactorforcardiovascular disease. Loss of Kidney Function Anumberofstudieshaveexaminedfactorsassociatedwithmorerapidlossofkidney function in chronic Kidney disease. Some diseases are associated with a faster loss of kidneyfunctionthan others, whilesomepatient factorsareknownto predictafaster lossoffunction, irrespectiveoftheunderlyingdisease. Identificationofriskfactorsfor progressioncanprovideinsightintothemechanismsofprogressivelossofkidneyfunctionaswellasidentificationofpatientsathigherriskforadverseoutcomes. Oneofthe questionsposedbytheWorkGroupwas: Whataretheriskfactorsassociatedwitha morerapidlossofkidneyfunction? Cardiovascular Disease The 1998 Report of the National Kidney Foundation Task Force on Cardiovascular Disease in Chronic Renal Diseasedrewattentiontocardiovasculardiseaseasanoutcomeofchronickidneydisease. 9TheTaskForcerecommendedthatpatientswithchronickidneydiseasebeconsidered in the highest risk group for subsequent cardiovascular disease (cardiovascular disease) events. Theexcessriskofcardiovasculardiseaseisdue, inpart, toahigherprevalenceofconditionsthatarerecognizedasriskfactorsforcardiovasculardiseaseinthegeneralpopula- tion(traditionalCVDriskfactors)andtohemodynamicandmetabolicfactorscharacteristicofchronickidneydisease(chronic kidney disease-relatedCVDriskfactors). Inaddition, theTaskForceemphasizedthehighmortalityfromcardiovasculardisease. Cardiovasculardiseaseistheleadingcauseofdeathinpatientswithkidneyfailure. After adjustingforage, gender, race, anddiagnosisofdiabetes, mortalityfromcardiovascular diseaseisfarhigherinpatientswithkidneyfailurecomparedtothegeneralpopulation. Amongpatients treatedby Dialysis, the riskranges from500-fold higherin individuals aged2535to5-foldhigherinindividualsaged(cid: 1)85years(Fig6). Excessmortalityalso appeared higher in Kidney transplant recipients, despite the preferential selection of patientswithoutcardiovasculardiseasefortransplantation. One of the questions posed by the Work Group was: Is chronic Kidney disease a 38 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI Fig6. Cardiovascularmortalityinthegeneralpopulation(NCHS)andinESRDtreated bydialysis(USRDS). CVDmortalitydefinedbydeathduetoarrhythmias, cardiomyopathy, cardiacarrest, myocardialinfarction, atheroscleroticheartdisease, andpulmonary edemainthegeneralpopulation(datafromNCHSmultiplecausemortalitydatafiles, ICD-9codes402, 404, 410414, and425429, 1993)comparedtoESRDtreatedby Dialysis (data from USRDS special data request HCFA form 2746, field numbers 23, 2629, and31, 19941996). Reprintedwithpermission. 9 riskfactorforthedevelopmentofcardiovasculardisease? Becauseofthewell-known associationofcardiovasculardiseaseanddiabetes, itseemedreasonablethattheanalysis shoulddistinguishpatientswithdiabetesfromothercausesofchronickidneydisease. Amongpatientswithdiabetes, theWorkGroupsummarizedinformationrelatedtothe associationofchronickidneydiseaseanddiabeticcomplications. Amongpatientswith othercausesofkidneydisease, theWorkGroupsummarizedinformationrelatedtothe associationofchronickidneydiseaseandcardiovasculardisease. COMPLICATIONS OF DECREASED glomerular filtration rate Decreased glomerular filtration rate is associated with complications in virtually all organ systems. These complicationsaremanifestedfirstbyhighbloodpressureandabnormalitiesinlaboratory testsandthenbysymptomsandabnormalitiesinphysicalexamination. Ingeneral, the severity of complications worsens as level of glomerular filtration rate declines, although the actual levels ofGFRwhere thecomplicationsfirstappear andthenworsenvary dependingonthe complication. Amongthemostimportantcomplicationsarehighbloodpressure, anemia, malnutrition, bone disease, neuropathy, and decreased overall functioning and wellbeing. At very Low levels of glomerular filtration rate, these complications are common and collectively knownasuremiaortheuremicsyndrome. Thepathogenesisofthesecomplications potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 39 variesamongorgansystemsandisoftencomplex. Inmanycases, earlytreatmentcan preventoramelioratecomplications. SincesignsandsymptomsofkidneyfailureappearandincreaseinseverityasGFR declines, it should be possible to identify levels of glomerular filtration rate that are associated with the appearanceofparticularsignsandsymptoms. OneofthequestionsposedbytheWork Group was: What is the level of glomerular filtration rate at the onset of Hypertension, anemia, malnutrition, bonedisease, neuropathy, anddecreasedoverallfunctioningandwellbeing? Kidney REPLACEMENT THERAPY: Dialysis AND TRANSPLANTATION Dialysis and transplantation are effective, although not optimal, therapies for Kidney failure. Theagingofthepopulationandtherisingprevalenceofdiseasescausingchronic kidneydisease, suchashypertensionanddiabetes, suggestthatkidneyfailurewillbea growing publichealth problemin thefuture and thatdialysis andtransplantation will becomemorewidelyusedintheUnitedStatesandaroundtheworld. Thesetherapies requireintensiveresources; therefore, measurestoincreasetheefficiencyofthesetreatmentswillbenecessary. Itwillbenecessarytoimprovethepreparationofpatientsfor kidneyreplacementtherapy, aswellastoimprovetheefficacyofdialysisandtransplantation. Preparation for Kidney Replacement Therapy Much of the morbidity of Kidney failure is due to complications that arise during the stage of decreased glomerular filtration rate. Many studies have shown a relationship between severity of complicationsbeforekidneyreplacementtherapyandoutcomes.",
    "word_count": 600,
    "char_count": 9507,
    "sentence_count": 65,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 12,
      "total_chunks": 77,
      "position": "13/77",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "creatinine",
        "potassium",
        "serum creatinine",
        "malnutrition",
        "dialysis",
        "kidney transplant"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 13,
    "text": "Many studies have shown a relationship between severity of complicationsbeforekidneyreplacementtherapyandoutcomes. 15Possibly, improved treatmentduringthestageofdecreasedGFRwouldleadtoimprovedoutcomesofkidney replacementtherapy. Inaddition, theonsetofkidneyfailureisusuallyassociatedwithseverepsychosocial stress. Stressderivesfromthefearofcomplications, fromtreatment, fromlimitationsof functioningandwellbeing, andfromreducedlifeexpectancy. Ateamapproachtothe managementofpatientsisusuallyrequired, includingphysicians, nurses, dietitians, social workers, pharmacists, andphysical, occupational, andvocationalrehabilitationprofessionalsaswellaspatientsfamilies. Patienteducationmustbeginfarinadvanceinorder topreparepatientstocopewiththeirillnessandthedemandsoftheirtreatmentaswell as possible. Clinical practice guidelines are being developed by the Renal Physicians Associationtoaddresspreparationforkidneyreplacementtherapy. Dialysis and Transplantation The past decade has seen dramatic improvements in Dialysis and transplantation. Advances in basic science and technology are needed to pave the way for continuing improvement. Eachadvancewillrequirecarefulclinicalstudytoassessitsefficacy, effectiveness, andefficiency. Asdiscussedearlier, National Kidney Foundation-DOQIclinicalpracticeguidelineswere restricted primarily to the care of patients with Kidney failure treated by Dialysis. The 40 Part3. PublicHealthProblem NationalKidneyFoundation potassium/DOQI original DOQI guidelines have now been updated and published under the potassium/DOQI banner. 16NewguidelinesareunderdevelopmentbytheNKFandotherorganizations toaddressotheraspectsofdialysiscareandthecareofpatientstreatedbykidneytransplantation. APPROACH TO CHRONIC Kidney DISEASE USING THESE GUIDELINES Finally, theWorkGroupattemptedtointegratetheclassificationsofstages, types(diagnosis), andclinicalpresentationsofchronickidneydiseasepresentedinthisguideline. The results provide a simplified approachto common clinical problems in chronic Kidney disease, includingscreening, differentialdiagnosis, utilityofproteinuriaindiagnosisand treatment, estimating and slowing progression, cardiovascular disease risk assessment andreduction, clinicalevaluationofadultswithdecreasedGFR, anddecreasedGFRand chronickidneydiseaseintheelderly. potassium/DOQI NationalKidneyFoundation Part3. PublicHealthProblem 41 PART 4. DEFINITION AND CLASSIFICATION OF STAGES OF CHRONIC Kidney DISEASE Chronickidneydiseaseisamajorpublichealthproblem. Improvingoutcomesforpeople withchronickidneydiseaserequiresacoordinatedworldwideapproachtoprevention ofadverseoutcomesthroughdefiningthediseaseanditsoutcomes, estimatingdisease prevalence, identifyingearlierstagesofdiseaseandantecedentriskfactors, anddetection andtreatmentforpopulationsatincreasedriskforadverseoutcomes. ThegoalofPart 4 is to create an operational definition and classification of stages of chronic Kidney diseaseandprovideestimatesofdiseaseprevalencebystage, todevelopabroadoverview ofaclinicalactionplanforevaluationandmanagementofeachstageofchronickidney disease, andtodefineindividualsatincreasedriskfordevelopingchronickidneydisease. Studies of disease prevalence were evaluated as described in Appendix 1, Table 150. DatafromNHANESIIIwereusedtodevelopestimatesofdiseaseprevalenceinadults asdescribedinAppendix2. GUIDELINE 1. DEFINITION AND STAGES OF CHRONIC Kidney DISEASE Adverse outcomes of chronic Kidney disease can often be prevented or delayed throughearlydetectionandtreatment. Earlierstagesofchronickidneydiseasecanbe detectedthroughroutinelaboratorymeasurements. Thepresenceofchronickidneydiseaseshouldbeestablished, basedonpresence ofkidneydamageandlevelofkidneyfunction(glomerularfiltrationrateglomerular filtration rate), irrespectiveofdiagnosis. Amongpatients withchronic kidneydisease, the stageof diseaseshouldbe assignedbasedonthelevelofkidneyfunction, irrespectiveofdiagnosis, according totheK/DOQICKDclassification(Table10). BACKGROUND Chronickidneydiseaseisamajorpublichealthproblem. Adverseoutcomesofchronic kidneydisease canbepreventedthrough earlydetectionandtreatment. Earlierstages ofchronickidneydiseasecanbedetectedthroughroutinelaboratorymeasurements. The USRDS provides reliable nationwidedata regarding the incidence, prevalence, treatmentpatterns, outcomes, andcostofkidneyfailuretreatedbydialysisandtransplantation, themostseverestageofchronickidneydisease. Thisguidelineprovidesadefinitionofchronickidneydiseaseaswellasdefinitionsandestimatesofprevalenceofearlier stagesofkidneydisease. Chronic Kidney disease is defined according to the presence or absence of Kidney damageandlevelofkidneyfunctionirrespectiveofthetypeofkidneydisease(diagnosis). Amongindividualswithchronickidneydisease, thestagesaredefinedbasedonthe levelofkidneyfunction. Identifyingthepresenceandstageof chronickidneydisease inanindividualisnotasubstituteforaccurateassessmentofthecauseofkidneydisease, potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 43 extentofkidneydamage, levelofkidneyfunction, comorbidconditions, complications ofdecreasedkidneyfunction, orrisksforlossofkidneyfunctionorcardiovasculardisease in that patient. Defining stages of chronic Kidney disease requires categorization of continuous measures of Kidney function, and the cut-off levels between stages are inherentlyarbitrary. Nonetheless, stagingofchronickidneydiseasewillfacilitateapplicationofclinicalpracticeguidelines, clinicalperformancemeasuresandqualityimprovementeffortstotheevaluation, andmanagementofchronickidneydisease. RATIONALE Definition and Classification Definitionofchronickidneydisease(O). ChronickidneydiseasehasbeendefinedaccordingtothecriterialistedinTable11. 44 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Stagesofchronickidneydisease(R, O). Amongindividualswithchronickidney disease, thestageisdefinedbythelevelofGFR, withhigherstagesrepresentinglower glomerular filtration rate levels. Table 12 illustrates the classification of individuals based on the presence orabsenceofmarkersofkidneydiseaseandlevelofGFR, accordingtodefinitionand staging of chronic Kidney disease proposed by this guideline. In addition, it includes columnsforthepresenceorabsenceofhighbloodpressure, becauseofthecomplex relationshipofhighbloodpressureandchronickidneydisease. AllindividualswithGFR(cid: 1)60mL/min/1. 73m2for(cid: 1)3monthsareclassifiedashaving chronickidneydisease, irrespectiveofthepresenceorabsenceofkidneydamage. The rationaleforincludingtheseindividualsisthatreductioninkidneyfunctiontothislevel or lower represents loss of half or more of the adult level of normal Kidney function, whichmaybeassociatedwithanumberofcomplications(Part6). Allindividuals withkidney damageare classifiedas havingchronic kidneydisease, irrespectiveofthelevelofGFR. TherationaleforincludingindividualswithGFR(cid: 1)60 milliliters per minute/1. 73 m2 is that glomerular filtration rate may be sustained at normal or increased levels despite substantialkidneydamageandthatpatientswithkidneydamageareatincreasedriskof thetwomajoroutcomesofchronickidneydisease: lossofkidneyfunctionanddevelopmentofcardiovasculardisease(Part7). ThemethodstoestimateGFRandassessmarkersofkidneydamagearenotcompletely sensitiveorspecificindetectingdecreasedGFRandkidneydamage, respectively. Thus, misclassification is possible, and clinicians should carefully consider all aspects of the patientsclinicalpresentationininterpretingtestresultsanddeterminingevaluationand management. Forthedefinitionofchronickidneydisease, theWorkGroupselectedcutofflevelsforGFRandmarkersofkidneydamagethatmaximizespecificity, acknowledgingpotentiallossofsensitivity. Cliniciansshouldbeespeciallycarefulintheevaluation ofindividualswithborderlineabnormalresultsformarkersofkidneydisease, milddecreaseinGFR(60to89mL/min/1. 73m2), highbloodpressure, andofotherindividuals potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 45 atincreasedriskofchronickidneydisease. Riskfactorsforchronickidneydiseaseare discussedinGuideline3. DecreasedGFRwithoutkidneydamage(R, O). IndividualswithGFR60to89 milliliters per minute/1. 73m2withoutkidneydamageareclassifiedasdecreasedGFR. Decreased GFRwithoutrecognizedmarkersofkidneydamageisveryfrequentininfantsandolder adults, andisusuallyconsideredtobenormalforage. Theage-relateddeclineinGFR in adults is accompanied by pathological findings of global glomerular sclerosis and corticalatrophy. TheconsequencesofdecliningGFRwithagehavenotbeencarefully studied. Itisinterestingtospeculatewhethertheincreasingincidenceofend-stagerenal diseaseintheelderlycouldbedue, inpart, toage-associateddeclineinGFR. OthercausesofchronicallydecreasedGFRwithoutkidneydamageinadultsinclude vegetariandiets, unilateralnephrectomy, extracellularfluidvolumedepletion, andsystemicillnessesassociatedwithreducedkidneyperfusion, suchasheartfailureandcirrhosis. ItisnotcertainwhetherindividualswithchronicallydecreasedGFRintherangeof 60to89mL/min/1. 73m2withoutkidneydamageareatincreasedriskforadverseoutcomes, suchastoxicityfromdrugsexcretedbythekidneyoracutekidneyfailure. After muchdiscussionandinputfromexpertreviewers, theWorkGroupconcludedthatthere is insufficient evidence to label individuals with glomerular filtration rate 60 to 89 milliliters per minute/1. 73 m2, but withoutmarkersofkidneydamage, ashavingchronickidneydisease. Inclinicalpractice, itmaybedifficulttodeterminewhetherindividualswithdecreasedGFRhavechronic Fig7. Prevalenceofalbuminuriaandhighbloodpressure(%)inUSadults age(cid: 1)20years, NHANESIII, 19881994. Basedonone-timeassessment ofalbuminuria, bloodpressure, andestimatedGFR. 46 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Kidney disease. Recommendations for a clinical approach to elderly individuals with decreasedGFRisgiveninPart9. Highbloodpressureinchronickidneydiseaseandinindividualswithdecreased glomerular filtration rate without Kidney disease (R). Hypertension is not included in thedefinitionofchronickidneydiseaseoritsstages.",
    "word_count": 591,
    "char_count": 10048,
    "sentence_count": 79,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 13,
      "total_chunks": 77,
      "position": "14/77",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "dialysis",
        "cardiovascular disease",
        "guideline",
        "classification"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 14,
    "text": "Highbloodpressureinchronickidneydiseaseandinindividualswithdecreased glomerular filtration rate without Kidney disease (R). Hypertension is not included in thedefinitionofchronickidneydiseaseoritsstages. However, highbloodpressureis a common cause and consequence of chronic Kidney disease, and as reviewed later, patientswithchronickidneydiseaseandhighbloodpressureareathigherriskofloss ofkidney functionanddevelopment ofcardiovasculardisease. Highblood pressureis alsocommoninolderindividualswithoutchronickidneydiseaseandisassociatedwith accelerated glomerular filtration rate decline with age and more marked pathological abnormalities in the kidneys. Individualswithhighbloodpressureshouldbecarefullyevaluatedforthepresenceofchronickidneydisease, especiallythosewithdecreasedGFR. Prevalence of chronic Kidney disease and level of Kidney function in the generalpopulation(S). Theprevalenceofchronickidneydisease, basedonthedefinitionabove, wasestimatedusingdatafromNHANESIIIandUSRDS(Fig7andTables13 and14). FortheanalysisofNHANESIIIdata, GFRwasestimatedfromserumcreatinine potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 47 concentrationusingapredictionequationderivedfromtheModificationofDietinRenal Disease (MDRD) Study, 17, 18 elevated Urine albumin-to-Creatinine ratio was taken as a markerofchronickidneydisease, andhighbloodpressurewasdefinedasbloodpressure (cid: 1)140/90mmHgortakingmedicationsforhighbloodpressure. Theseparameterswere ascertained on a single occasion. A subgroup of NHANES III participants underwent repeatmeasurementofalbuminuria. Elevatedalbumin-to-creatinineexcretionwaspersistentin61%ofthesubjectswithalbuminuria(n(cid: 1)163). Therefore, theseestimatesof prevalenceshouldbeconsideredasroughapproximationsofthetrueprevalence. The rationalesfortheseassumptionsandcut-offlevelsarediscussedinmoredetailbelow. Kidney DAMAGE Definition (O) Kidneydamageisdefinedasstructuralorfunctionalabnormalitiesofthekidney, initially withoutdecreasedGFR, whichovertimecanleadtodecreasedGFR. Asdescribedearlier, markers of Kidney damage include abnormalities in the composition of the Blood or Urine or abnormalities in imaging tests. This section will emphasize proteinuria as a marker of Kidney damage because it has been studied most thoroughly, including in NHANESIII. Proteinuria as a marker of Kidney damage (R). Proteinuria is an early and sensitive marker of Kidney damage in many types of chronic Kidney disease. Albumin (molecularweightMW(cid: 1)68, 000daltons)isthemostabundanturineproteininmost typesofchronickidneydisease. Lowmolecularweight(LMW)globulinsarethemost abundanturineproteinsinsometypesofchronickidneydisease. Inthisandlaterguidelines, the term proteinuria includes albuminuria, increased urinary excretion of other specific proteins, and increased excretion of total Urine Protein. On the other hand, thetermalbuminuriahasbeenusedonlywhenreferringtoincreasedurinaryalbumin excretion. Older laboratory methods, such as the Urine dipstick or acid precipitation, detectmosturineproteins. Microalbuminuriareferstoexcretionofsmallbutabnormal amountsofalbumin, whichrequiresrecentlydeveloped, moresensitivelaboratorymethodsthatarenowwidelyavailable. Normalproteinexcretion(S, R). Normalmeanvalueforurinealbuminexcretion in adults is approximately 10 magnesium/d. Albumin excretion is increased by physiological variables, suchasuprightposture, exercise, pregnancy, andfever. Normalmeanvalue for Urine total Protein is approximately 50 magnesium/d. Major constituents of normal Urine proteinarealbumin, LMWproteinsfilteredfromtheblood, andproteinsderivedfrom theurinarytract. Inpractice, itisdifficulttocollectatimedurinespecimen. AsdescribedinGuideline 5, the urinary excretion rate for albumin and total Protein can be estimated from the ratioofalbuminortotalproteintocreatinineconcentrationinanuntimed(spot)Urine specimen. Becauseproteinexcretionvariesthroughouttheday, thenormalratiovaries throughouttheday. Theratioinafirstmorningspecimencorrelatesmostcloselywith overnightproteinexcretionrate, whereastheratioinmid-morningspecimenscorrelates 48 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Fig8. Distributionofalbumin-to-creatinineratioinUSmenandwomen, NHANESIII (19881994), age(cid: 1)20. N(cid: 2)14, 836. mostcloselywith24-hourproteinexcretionrate. Creatinineexcretionishigherinnormal men than women; therefore, the values in the general population (Fig 8) and cut-off values for abnormalities in Urine albumin-to-Creatinine ratio are lower for men than women(Table15). Definitionofproteinuriaandalbuminuriainadults(R). Table15showsdefinitionsforproteinuriaandalbuminuria, includinggenderspecificcut-offvaluesformicroalbuminuriaandalbuminuria. Cut-pointsfordefinitionofabnormalurinetotalproteinand potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 49 albuminaresettomaximizespecificity(avoidfalsepositives), thus, theupperlimitof normaltypicallyextendsfarabovethenormalmeanvalue, resultinginlowsensitivity (manyfalsenegatives). Normalalbuminexcretioninchildren(C). Normalvaluesforalbuminexcretion inchildrenarenotwellestablished. Althoughincreasedurinealbuminexcretionreflects glomerularinjurybetterthanotherurinaryproteinsinbothadultsandchildren, many pediatricnephrologistscontinuetomonitorlevelsoftotalproteinratherthanalbumin in patients with proteinuria. Hence, reports of normal albumin rates in children are 50 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI relativelyfewinnumber, andmosthavebeenpublishedinthepast15years. However, aliteraturesearchofarticlesdescribingalbuminexcretioninchildrenrevealedonestudy in1970. Thisoriginalpaper20consideredthebestmeasurementofglomerularintegrity tobealbuminclearancefactoredbycreatinineclearance. Itconcludedthattheratioof theconcentrationof albumintocreatininein spoturinesamplesis themostaccurate method for estimating albumin clearance and provides a better marker of glomerular permeabilitytoalbuminthanthe24-houralbuminexcretionrate. Theresultswereexpressedasmgalbuminpermgcreatinine, butsubsequentpapershaveusedavarietyof methodstoexpressalbuminexcretion, makingcomparisonsbetweenstudiesverydifficult. Tables 16 and 17 give mean values and ranges for albumin excretion rate and potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 51 albumin-to-creatinineratioinchildren(neonatesthroughage20years), andalsoemphasize some of the ways in which published reports have differed. Overall, the values appearsimilartothevaluesobservedforadults. Prevalenceofproteinuriainadults(S). Table18showstheprevalenceofalbuminuriaestimatedfromthealbumin-to-creatinineratioinasinglespoturinecollection in14, 836adultsstudiedinNHANESIII. Basedontheseresults, itisestimatedthatapproximately20. 2millionadults(11. 7%)haveabnormalurinealbuminexcretion. Albuminuriawaspersistentonrepeatevaluationinonly61%ofindividuals; hence, theseprevalenceestimatesbasedonasinglespoturinearelikelyoverestimates, especially formicroalbuminuria. (Appendix2discussesthereproducibilityofdataonalbuminuria andmicroalbuminuria. ) Amongadults, theprevalenceofalbuminuriavariesbyage(Table19)andpresence (Table20)orabsence(Table21)ofdiabetes. Theprevalenceisapproximately30%in adultswithage(cid: 1)70years: 26. 6%withmicroalbuminuriaand3. 7%withalbuminuria. At all ages, the prevalence is higher among individuals with Diabetes. Among individuals withahistoryofdiabetes, theprevalenceofmicroalbuminuriaandalbuminuriais43. 2% and8. 4%, respectively, atage(cid: 1)70years. Amongindividualswithoutahistoryofdiabetes theprevalenceofmicroalbuminuriaandalbuminuriais24. 2%and3. 0%, respectively, at age(cid: 1)70years. 52 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Prevalenceofproteinuriainchildren(C). Prevalenceofproteinuriaislowerin children. Acompilationofstudiesshowsthat1%to10%ofchildrenmayhaveproteinuria oninitialscreeningusingtheurinedipstick, butthat(cid: 1)1%havepersistentproteinuria, asdefinedbypositiveresultsonrepeatedtesting(Table22). Similarly, theprevalence ofincreasedurinealbuminexcretiononinitialscreeningvariesfrom1%to10%(Table 23). PrevalenceofStage1andStage2chronickidneydisease(S). Theproportion ofadultswithGFR(cid: 1)90and6089mL/min/1. 73m2withalbuminuriaisshowninFig 7. AmongUSadults withaGFR(cid: 1)90mL/min/1. 73m2, 9. 2%had anelevatedalbuminto-creatinineratio(including3. 3%withouthypertensionand5. 9%withhypertension). AsshowninTable14, thisgroupcorrespondstoapproximately5. 9%ofallUSadults, or 10. 5 million people in the years 1988 to 1994. On repeat examination, 54% (n (cid: 1) 102)ofasubsamplewithalbuminuriahadapersistentlypositiveresult. Therefore, the prevalence of persistent albuminuria would be 3. 3% of ultrasound adults with glomerular filtration rate (cid: 1)90 mL/ min/1. 73m2, or5. 9million. ThisistheestimatedprevalenceofStage1chronickidney disease. Among adults with glomerular filtration rate 60 to 89 milliliters per minute/1.",
    "word_count": 596,
    "char_count": 8987,
    "sentence_count": 95,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 14,
      "total_chunks": 77,
      "position": "15/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "exercise"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 15,
    "text": "73m2, or5. 9million. ThisistheestimatedprevalenceofStage1chronickidney disease. Among adults with glomerular filtration rate 60 to 89 milliliters per minute/1. 73 m2, the prevalence of albuminuria was 12. 9%, corresponding to 4. 0% of all ultrasound adults, or 7. 1 million people. On repeat examination, 73%ofasubsamplewithalbuminuria(n(cid: 1)44)hadapersistentlypositive test. Therefore, the prevalence of persistent albuminuria would be 3. 0% of ultrasound adults with glomerular filtration rate 6084 milliliters per minute/1. 73 m2, or 5. 3 million. This is the estimated prevalence of Stage2chronickidneydisease. Notethatpersistentalbuminuriaisnottheonlymarkerofkidneydamage. NHANES IIIdidnotascertainothermarkersofkidneydamage, suchasabnormalitiesoftheurine sedimentand abnormalimagingtests; thus, anyestimatebased onNHANESIII datais likelytounderestimatethetrueprevalenceofchronickidneydamage. potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 53 54 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Decreased glomerular filtration rate GFRasanindexofkidneyfunction(R). ThelevelofGFRisacceptedasthebest measureofoverallkidneyfunctioninhealthanddisease. Inprinciple, thelevelofGFR istheproductofthenumberofnephronsandthesinglenephronGFR. Therefore, glomerular filtration rate canbeaffectedbychronickidneydisease, whichreducesthenumberofnephrons, or byhemodynamicfactorsthataffectsinglenephronGFR. Inchronickidneydisease, as innormalindividuals, GFRismodulatedbyhemodynamicfactors. Normal range and variability of glomerular filtration rate (S, R). The normal level of glomerular filtration rate varies accordingtoage, gender, andbodysize. ItisconventionaltoadjustGFRtostandard bodysize(surfaceareaof1. 73m2). Amongnormaladults, theinter-individualcoefficient ofvariation(standarddeviationdividedbythemean)ofGFR(adjustedforbodysurface area)within thenormalpopulation isapproximately15% to20%. 67The normalmean (standard devation) glomerular filtration rate in young adults is approximately 120 to 130 (20 to 25) mL/ min/1. 73m2. ChildrenreachadultvaluesformeanGFRbyapproximatelyage2years (Table24). 68, 69 Figure 9 and Table 25 show the range of glomerular filtration rate in adults according to age, derived fromnormalmenusinginulinclearance. 72Normalvaluesinwomenareassumedtobe 8%loweratallages. 67, 73Afterapproximatelyage20to30years, thenormalmeanvaluefor GFRdeclineswithageinbothmenandwomen, withameandecreaseofapproximately1 milliliters per minute/1. 73m2peryear. Thus, byage70, thenormalmeanvalueisapproximately70 milliliters per minute/1. 73m2. Atallages, therangeofnormalGFRiswide. DatafromNHANESIIIareshowninFigs9and10; theseincludemenandwomen in the general population, including those with chronic Kidney disease. In part, the potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 55 Fig9. GFRversusage. EstimatedGFRpercentilesfortheUSpopulationusingNHANES IIIserumcreatinine, age, sex, andracedata(seePart10, Appendix2)byagecompared toaregressionofinulinclearancemeasurementofGFRonageamong70healthymale participants. (DataabstractedfromDaviesandShock. 72) inclusion of women and individuals with chronic Kidney disease may account for the slightlylowermeanvaluesobservedintheNHANESIIIcomparedtothedatafromnormal meninFig9. FactorsotherthanagealsoaffectGFR. AsshowninTable24, GFRisslightlylower in youngwomen than inyoung men. Thisdifference appears topersist atolder ages. PregnancyhasamajoreffectonGFR, withGFRreachingvaluesof140%ofnormalduring theendofthesecondtrimester. AdditionalfactorsthatmayaffectGFRtoalesserdegreeinclude: transientincreases 56 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Fig 10. Percentiles of estimated glomerular filtration rate regressed on age (NHANES III). glomerular filtration rate estimated fromserumcreatinineusingMDRDStudyequationbasedonage, gender, andrace(see Part10, Appendix3). Age(cid: 1)20, N(cid: 2)15, 600. potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 57 inGFRafterahighproteinmeal, alowerGFRinindividualsfollowingahabituallylow proteindiet, andantihypertensiveagents(effectonGFRvariesbyclassofagent), especiallyinpatientswithchronickidneydisease. DefinitionofdecreasedGFR(R, O). TheWorkGroupdefineddecreasedGFRas (cid: 1)90 milliliters per minute/1. 73 m2. The interpretation of decreased glomerular filtration rate varies depending on age, duration, andthepresenceorabsenceofmarkersofkidneydamage. ThelowerlimitofnormalGFRvarieswithage. Forexample, asshowninTable25, glomerular filtration rate(cid: 1)90mL/min/1. 73m2wouldbeabnormalinayoungadult. Ontheotherhand, a GFRof6089mL/min/1. 73m2couldbenormalfromapproximately8weeksto1year ofageandinolderindividuals. ItispossiblethatGFR30to59mL/min/1. 73m2could alsobenormalinindividualsattheextremesofage, invegetarians, afterunilateralnephrectomy or in an older individual. It is likely that a glomerular filtration rate (cid: 1)30 milliliters per minute/1. 73 m2 is abnormalatallagesotherthanneonates. Forthesereasons, theWorkGroupbasedthe definitionofchronickidneydiseasesolelyonthelevelofGFRonlyinindividualswith glomerular filtration rate(cid: 1)60mL/min/1. 73m2, whereasindividualswithGFR60to89mL/min/1. 73m2were considered to have chronic Kidney disease only if they also had a marker of Kidney damage(seeTable12, p. 45). DecreasedGFRmaybeacuteorchronic. AnacutedecreaseinGFRdoesnotnecessarilyindicatethepresenceofkidneydamage. Forexample, itiswellknownthatabrief periodofmildlydecreasedbloodflowtothekidneysortransientpartialobstructionof theurinarytractmaycausedecreasedGFRwithoutkidneydamage. However, asustained decreaseinbloodfloworprolongedobstructionisoftenassociatedwithkidneydamage. Chronically decreased glomerular filtration rate is more often associated with Kidney damage. The Work Group arbitrarily chose a cut-off value of greater than 3 months for the definition of chronickidneydisease. Asdiscussedearlier, individualswithdecreasedGFRshouldbeevaluatedformarkers ofkidneydamagetodeterminewhethertheyhavechronickidneydiseaseandtodeterminethecauseofreducedkidneyfunction. Evenifthereisnoevidenceofkidneydamage, individualswithchronicallydecreasedGFRmaybeatincreasedriskforadverseoutcomes (forexample, toxicityfromdrugsexcretedbythekidney, andacutekidneyfailureina widevarietyofcircumstances). AssociationoflevelofGFRwithcomplications(S, R, C, O). DecreasedGFRis associated with a wide range of complications in other organ systems, manifested by highbloodpressure, laboratoryabnormalities, andsymptoms. Severityofcomplications worsens as level of glomerular filtration rate declines (Part 6, Guidelines 7 through 12). The Work Group definedcategoriesofdecreasedGFRasmild(Stage2, 60to89mL/min/1. 73m2), moderate(Stage3, 30to59mL/min/1. 73m2), andsevere(Stage4, 15to29mL/min/1. 73m2). Althoughthesedefinitionsarearbitrary, evidencecompiledinlaterguidelinessupports thesebroadcategoriesandcut-offlevels. Prevalence of decreased glomerular filtration rate by age (S). The prevalence of decreased glomerular filtration rate is higher in the elderly (Table 26). Approximately 14. 9 million individuals (cid: 1)70 years 58 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI (74. 5%)ofagehavedecreasedGFR. Asalreadystated, notallindividualswithdecreased glomerular filtration rate have Kidney disease. The prevalence of persistent albuminuria by glomerular filtration rate level and agegrouphavenotbeendetermined, preventinganaccurateestimateoftheprevalence ofchronickidneydiseaseamongtheelderly. The prevalence of decreased glomerular filtration rate is lower in children. The Schwartz formula was usedtoestimateGFRinchildrenaged12to19yearsintheNHANESIIIdatabase.",
    "word_count": 590,
    "char_count": 7741,
    "sentence_count": 97,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 15,
      "total_chunks": 77,
      "position": "16/77",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "albuminuria",
        "potassium"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 16,
    "text": "The prevalence of decreased glomerular filtration rate is lower in children. The Schwartz formula was usedtoestimateGFRinchildrenaged12to19yearsintheNHANESIIIdatabase. The lowest 1% of children had glomerular filtration rate below approximately 100 milliliters per minute/1. 73 m2. Reliable estimatesofprevalenceofcategoriesofdecreasedGFR(mild, moderate, orsevere)in childrenarenotavailablefromNHANESIII. Kidney Failure Definitionofkidneyfailure(R, O). Kidneyfailureisdefinedaseither(1)alevel of glomerular filtration rate to (cid: 1)15 milliliters per minute/1. 73 m2, which is accompanied in most cases by signs and symptomsofuremia, or(2)aneedforinitiationofkidneyreplacementtherapy(Dialysis ortransplantation)fortreatmentforcomplicationsofdecreasedGFR, whichwouldotherwise increase the risk of mortality and morbidity. Some patients may need Dialysis or transplantationatGFR(cid: 1)15mL/min/1. 73m2becauseofsymptomsofuremia. TheWork Group acknowledges that the level of GFRselected for this definition is arbitrary and mayneedtobemodifiedbasedonadvancesinkidneyreplacementtherapy. End-stagerenaldisease(R). End-stagerenaldisease(end-stage renal disease)isanadministrative termintheUnitedStates, basedontheconditionsforpaymentforhealthcarebythe MedicareESRDProgram, specificallythelevelofGFRandtheoccurrenceofsignsand symptomsofkidneyfailurenecessitatinginitiationoftreatmentbyreplacementtherapy. ESRDincludespatientstreatedbydialysisortransplantation, irrespectiveofthelevelof glomerular filtration rate. The potassium/DOQI definition of Kidney failure differs in two important ways from the definitionofESRD. First, notallindividualswithGFR(cid: 1)15mL/min/1. 73m2orwithsigns andsymptomsofkidneyfailurearetreatedbydialysisandtransplantation. Nonetheless, suchindividualsshouldbeconsideredashavingkidneyfailure. Second, amongtreated patients, Kidney transplant recipients have a higher mean level of glomerular filtration rate (usually 30 to 60mL/min/1. 73m2)andbetteraveragehealthoutcomesthandialysispatients. Kidney transplantrecipientsshouldnot beincludedinthedefinitionof kidneyfailure, unless theyhaveGFR(cid: 1)15mL/min/1. 73m2orhaveresumeddialysis. TheWorkGroupanticipatedthatmostkidneytransplantrecipientswouldbeconsideredtohavechronickidneydiseaseaccordingtotheproposedclassification. First, glomerular filtration rate islowerinpatientswithasolitarykidneyandisevenlowerinkidneytransplantrecipients becauseoftoxicityfromimmunosuppressiveagentsusedtopreventandtreatrejection, such as cyclosporine and tacrolimus. Second, biopsy studies demonstrate pathologic damageduetoacuteandchronicrejectioninvirtuallyalltransplantrecipients, evenif serumcreatinineisnormal. However, becausemarkersofkidneydamagearenotsensitive totubulointerstitialorvasculardamage, itislikelythatsomekidneytransplantpatients willhaveGFR(cid: 1)60mL/min/1. 73m2withoutmarkersofkidneydamage. Suchpatients potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 59 wouldnotbeclassifiedashavingchronickidneydiseasebytheproposedclassification. TheWorkGroupwouldconsiderthemtobeatincreasedriskofchronickidneydisease. Thus, allpatientswithakidneytransplantwouldbeconsideredeithertohavechronic kidneydiseaseortobeatincreasedriskofchronickidneydisease. RelationshipofGFRtoothermeasuresofkidneyfunctioninkidneyfailure (S). Anumberofmeasurements, includingGFR, havebeenusedtoquantifythelevel ofkidneyfunctionamongpatientswithkidneyfailure. TheK/DOQINutritioninChronic RenalFailureGuidelines75andPeritonealDialysisAdequacyGuidelinesUpdate200016 recommendthedecisiontoinitiatedialysisinadultsbebasedonacombinationofmeasurementsofkidneyfunction, aswellasnutritionalstatus. Theseguidelinesarereproducedhere: PeritonealDialysisAdequacyGuideline1: WhentoInitiateDialysisdialysis adequacy measure urea Criterion(Opinion) Unless certain conditions are met, patients should be advised to initiate some formofdialysiswhentheweeklyrenalKt/V (Krt/V )fallsbelow2. 0. Thecondiurea urea tionsthatmayindicatedialysisisnotyetnecessaryeventhoughtheweeklyKrt/V urea islessthan2. 0are: 1. Stableorincreasededema-freebodyweight. Supportiveobjectiveparametersfor adequate nutrition include a lean body mass (cid: 2)63%, subjective global assessment scoreindicativeofadequatenutrition, andaserumalbuminconcentrationinexcess ofthelowerlimitforthelab, andstableorrising; and; 2. Nutritionalindicationsfortheinitiationofrenalreplacementtherapyaredetailed in Guideline 27 of the potassium/DOQI Clinical Practice Guidelines on Nutrition in ChronicRenalFailure, partofwhichisreproducedasGuideline2ofthePDAdequacy Guideline. 3. Completeabsenceofclinicalsignsorsymptomsattributabletouremia. AweeklyKrt/V of2. 0approximatesakidneyureaclearanceof7mL/minand urea a Kidney Creatinine clearance that varies between 9 to 14 milliliters per minute/1. 73 m2. Urea clearance should be normalized to total body Water (V) and Creatinine clearance shouldbeexpressedper1. 73m2ofbodysurfacearea. TheGFR, whichisestimated bythearithmeticmeanoftheureaandcreatinineclearance, willbeapproximately 10. 5mL/min/1. 73m2whentheKrt/V isabout2. 0. urea Peritoneal Dialysis Adequacy Guideline 2 and Nutrition in Chronic Renal FailureGuideline27: IndicationsforRenalReplacementTherapy(Opinion) Inpatientswithchronickidneyfailure(e. g. , glomerular filtration rate(cid: 1)1520mL/min)whoarenot undergoingmaintenancedialysis, ifprotein-energymalnutrition(PEM)developsor persists despite vigorous attempts to optimize Protein and energy intake and there isnoapparentcause formalnutritionotherthanlownutrient intake, initiationof maintenancedialysisorarenaltransplantisrecommended. TheCKDWorkGroupsearchedforstudiesofmeasuresofkidneyfunction, dietary 60 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI intake, and nutritional status at the onset of Kidney replacement therapy. The largest and most comprehensive study is the one reported in abstract by the MDRD Study Group. 76Thisstudyincluded88patientswhowerereferredtotheirphysiciansbythe MDRDStudyinvestigatorsforinitiationofdialysisbecauseofsymptomsorfindingsof uremiapriortotheendofthestudy. Prescribedproteinintakeduringthestudywas0. 6 g/kg/d, eitherasfoodorfromfoodandamixtureofessentialaminoacidsandketoacids. The medianinterval from final GFRto initiation of dialysisin the study groupwas 89 days. Becausethesepatientswereparticipatinginaclinicaltrial, themeanlevelofkidney functionandnutritionalstatusmaybehigherthaninpatientsbeginningdialysisinthe generalpopulation. Tables27and28showmeasuresofkidneyfunctionandnutritional statusinthesepatientswithkidneyfailurejustpriortoinitiationofdialysis. Thecomparison of measured glomerular filtration rate to other Kidney function measurements is shown in Table 29. These data show that estimated glomerular filtration rate provides only a rough approximation of other measuresofkidneyfunction. Thisprovidesadditionaljustificationforperformingother measuresofkidneyfunctiontoassesstheneedforkidneyreplacementtherapy, asrecommendedintheK/DOQIPeritonealDialysisGuidelines. 16ItwastheopinionoftheWork GroupthatthesemeasurementsshouldbeobtainedinpatientswithestimatedGFR(cid: 1)15 milliliters per minute/1. 73m2, since, asdescribedbelow, fewpatientsbegindialysisathigherlevels ofGFR. Level of glomerular filtration rate at initiation of replacement therapy (S, C). Clinicians initiate replacementtherapybasedonthelevelofkidneyfunction, presenceofsignsandsymptomsofuremia, theavailabilityoftherapy, andpatientorsurrogatepreferences. There is variability among individuals in the relationship of level of Kidney function to signs potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 61 62 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Fig11. LevelofGFRatinitiationofreplacementtherapy(USRDS). DatafromObrador etal. 77 and symptoms of uremia. Notably, there is variability within and among health care systemsintheavailabilityoftherapy. ThelevelofGFRatthebeginningofdialysishasbeenestimatedinmorethan90, 000 patientsintheUnitedStatesbetween1995and1997, usingdatacollectedontheMedical EvidenceReport(HCFAForm2728)andtheMDRDStudypredictionequation(Fig11). 77 Themean(SD)levelofserumcreatininewas8. 5(3. 8)milligrams per deciliter. Themean(SD)levelof GFRatinitiationoftreatmentwas7. 1(3. 1)milliliters per minute/1. 73m2. Theproportionofpatients initiating dialysiswith a predictedGFR of 10to 15, 5to 10, and (cid: 1)5mL/min/1. 73 m2 was11%, 63%, and24%, respectively; 98%ofpatientsbegandialysiswithpredictedGFR (cid: 2)15mL/min/1. 73m2. Tables 30, 31, and 32 summarize other studies of the level of Kidney function at initiation of Dialysis. Overall, the results of these studies are consistent with the data fromtheMDRDStudy(Table27)andthelargestudyshowninFig11.",
    "word_count": 600,
    "char_count": 8763,
    "sentence_count": 88,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 16,
      "total_chunks": 77,
      "position": "17/77",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "end-stage renal disease",
        "creatinine",
        "urea",
        "potassium",
        "nutrition",
        "energy intake",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 17,
    "text": "Overall, the results of these studies are consistent with the data fromtheMDRDStudy(Table27)andthelargestudyshowninFig11. Factorsassociatedwithlevelofkidneyfunctionatinitiationofdialysis(R). Timingofinitiationofreplacementtherapyvariesbymodality, clinicalcharacteristics, andsociodemographiccharacteristics. Patientswhoreceiveapre-emptivetransplantor whoarestartedonperitonealdialysisbeginreplacementtherapyathighermeanlevels ofGFRthanpatientsstartinghemodialysis. Dialysisisinitiatedathighermeanlevelsof potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 63 GFRamongpatientswhoareolder, orwhohavediabetes, cardiovasculardisease, and othercomorbidconditions. Prevalenceofkidneyfailure(S). Theincidenceandtheprevalenceofreported ESRDhavedoubledinthepast10yearsintheUnitedStates(Fig2). Datafromthe2000 AnnualData Reportofthe USRDSdocumentsthe incidenceof ESRDin1998 ofmore than 85, 000, or 308 per million individuals per year at risk. The point prevalence of ESRDonDecember31, 1998wasmorethan320, 000, or1, 160permillionpopulation, ofwhom72%weretreatedbydialysis(230, 000patients, or835permillionpopulation) and28%hadfunctioningkidneytransplants(90, 000patients, or325per100, 000). The number of individuals with glomerular filtration rate (cid: 1)15 milliliters per minute/1. 73 m2 not on Dialysis has not been estimatedreliably. Theprevalenceofkidneyfailuretreatedbydialysisvariesbyage. OnDecember31, 1998, therewereapproximately75, 000adultsover70yearsofage(97permillion)with Kidney failure treated by Dialysis, compared to approximately 1, 800 children (2. 1 per million). LIMITATIONS Thereareanumberoflimitationstotheproposeddefinitionandclassificationofchronic kidneydisease. TheWorkGroupbelievesthattheselimitationsshouldbeidentified, but doesnotthinkthattheyinvalidatetheproposal. Instead, theselimitationsshouldserve tostimulatefurtherresearchtorefinethedefinitionandclassification. First, asdescribedlaterinGuideline6, theknownmarkersofkidneydamagearenot sensitive, especiallyfortubulointersitialandvasculardiseaseandfordiseasesinthekidney transplant. Thus, the prevalence of chronic Kidney disease may be substantially higher than the Work Group has estimated, and recognition of patients with chronic kidneydiseasemaybelimitedduetomisclassification. Second, asdescribedinGuideline 4, theMDRDStudypredictionequationhasnotbeenvalidatedextensivelyatlevelsof glomerular filtration rate(cid: 1)90mL/min/1. 73m2; thus, itisdifficulttoestimatethelevelofGFRabove90mL/ min/1. 73m2, anditmaybedifficulttodistinguishbetweenStage1andStage2ofchronic 64 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI kidneydisease. Third, asdescribedearlier, thecauseofage-relateddeclineinGFRand highbloodpressureisnotknown. Possibly, itmaybeduetochronickidneydisease. If so, itwouldbemoreappropriatetoclassifyindividualswithGFR60to89mL/min/1. 73 m2withoutapparentmarkersofkidneydamageashavingchronickidneydiseaserather thandecreasedGFR. Fourth, theGFRcut-offvaluesforStages3to5havebeenselected basedonlimiteddatawithrespecttotherelationshipbetweencomplicationsandlevel ofGFR. Furtherstudiesmaypermitrefinementofthesecut-offvalues. Fifth, theassociationoflevelofGFRwithcomplicationsofchronickidneydiseasedoesnotproveacausal relationshipbetween thetwo. Nonetheless, in manycasesthereis adequateevidence ofacausalrelationship, andevenifthereisnot, theassociationsaccuratelydescribethe burdenofillnessassociatedwiththeseverityofchronickidneydisease. Sixth, prevalence estimatesforstagesofchronickidneydiseaseandtheassociationsoflevelofGFRwith complications are based largely on an analysis of data from NHANES III that has not yetbeenpeer-reviewed. However, theWorkGroupbelievesthatAppendix2provides sufficientdetailtoevaluatethemethods. CLINICALAPPLICATIONS Therearealargenumberofclinicalapplicationsoftheproposeddefinitionandstages ofchronickidneydisease. Anoverallapproachtoevaluationandtreatmentofpatients withchronickidneydiseaseisgiveninGuideline2, andrecommendationsforindividuals atincreasedriskofchronickidneydiseasearegiveninGuideline3. Clinicalapplications arealsogivenattheconclusionofeachsubsequentguideline. Finally, additionalrecommendationsforevaluation, diagnosis, andtreatmentofchronickidneydiseasearegiven inPart9. IMPLEMENTATIONISSUES Implementationofanewapproachtothepatient, classificationofseverity, andassessment of risk for chronic Kidney disease will require appropriate professional, patient, andpubliceducationeffort, aswellasadministrativeandregulatorychanges. Professional, Patient, and Public Education Components of the implementation plan, which determined the success of potassium/DOQI, areunderdevelopmentandwillbeappliedtotheseguidelines. Theyinclude: widespread disseminationandeasyaccesstotheguidelines; educationalinteractiveprogramsaimed at health professionals, patients, providers, administrators, manufacturers, and policy makers; informationtoolsandsystemstofacilitateadherence; developmentofclinical performancemeasures; incorporationofguidelinesintocontinuousqualityimprovement programs; development of quality assessment instruments; and update and review of thepertinentliteratureonanongoingbasis. Administrative and Regulatory Changes Revision of Medicare forms and HCFA billing codes will be necessary. For example, classificationofkidneydiseasebytheInternationalClassificationofDisease(9thEdition) (ICD-9) is based on duration (acute versus chronic), diagnosis, clinical presentation, potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 65 markersofdamage, andkidneyfunctionimpairment. TheK/DOQIclassificationproposes thatbothdiagnosisandstage(severity)shouldbeincludedintheclassificationofchronic kidneydisease. Thiswouldfacilitateusingadministrativedatabasesforepidemiological andoutcomessurveys. RESEARCHRECOMMENDATIONS The Workgroup acknowledges that the proposed definition and classification chronic kidneydiseaseandstagesisarbitraryandcanberefinedbyfurtherresearch. ThenormalrangeforGFRwasdefinedusingarelativelysmallnumberofindividuals. Itwouldbeusefultoconductalargecross-sectionalstudyofGFRingeneralpopulation, acrossthefullrangeofage, gender, race, ethnicity, proteinintake, withadjustmentfor otherfactors, includinghighbloodpressure, Diabetes, andotherconditionsthataffect glomerular filtration rate. ThisstudywouldpermitvalidationofpredictionequationsbasedonserumcreatinineorotherfiltrationmarkerswithinthenormalrangeofGFR. The outcomes of individuals with various stages of chronic Kidney disease are not defined. Acohortstudyofpatientswithchronickidneydiseasewouldenabledefinition oftherelationshipbetweenfactorsandoutcomesofstagesofchronickidneydisease. Thiswouldbeparticularlyusefulindefiningtherelationshipsamongstagesofchronic kidneydisease, progressionofchronickidneydisease, initiationandprogressionofcardiovasculardisease, healthserviceutilization, andbarrierstocare. Age-relatedriseinbloodpressureanddeclineinGFRmayberesponsibleforalarge numberofindividualsinStage3(GFR30to59mL/min/1. 73m2). Thereareevenmore individuals with Hypertension and decreased glomerular filtration rate (glomerular filtration rate 60 to 89 milliliters per minute/1. 73 m2), whohavenotbeenclassifiedashavingchronickidneydisease. Itwouldbeuseful to conduct cross-sectional and cohort studies of elderly individuals with normal and abnormal Blood Hypertension and glomerular filtration rate to assess the effect of Hypertension and decreasedGFRinthispopulation. GUIDELINE 2. EVALUATION AND TREATMENT Theevaluationandtreatmentofpatientswithchronickidneydiseaserequiresunderstanding of separate but related concepts of diagnosis, comorbid conditions, severity ofdisease, complicationsofdisease, andrisksforlossofkidneyfunctionandcardiovasculardisease. Patientswithchronickidneydiseaseshouldbeevaluatedtodetermine: Diagnosis(typeofkidneydisease); Comorbidconditions; Severity, assessedbylevelofkidneyfunction; Complications, relatedtolevelofkidneyfunction; Riskforlossofkidneyfunction; Riskforcardiovasculardisease. Treatmentofchronickidneydiseaseshouldinclude: Specifictherapy, basedondiagnosis; 66 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI Evaluationandmanagementofcomorbidconditions; Slowingthelossofkidneyfunction; Preventionandtreatmentofcardiovasculardisease; Preventionandtreatmentofcomplicationsofdecreasedkidneyfunction; Preparationforkidneyfailureandkidneyreplacementtherapy; Replacement of Kidney function by Dialysis and transplantation, if signs and symptomsofuremiaarepresent. Aclinicalactionplanshouldbedevelopedforeachpatient, basedonthestage ofdiseaseasdefinedbytheK/DOQICKDclassification(seeTable33). Reviewofmedicationsshouldbeperformedatallvisitsforthefollowing: Dosageadjustmentbasedonlevelofkidneyfunction; Detectionofpotentiallyadverseeffectsonkidneyfunctionorcomplicationsof chronickidneydisease; Detectionofdruginteractions; Therapeuticdrugmonitoring, ifpossible. Self-managementbehaviorsshouldbeincorporatedintothetreatmentplanatall stagesofchronickidneydisease. Patientswithchronickidneydiseaseshouldbereferredtoaspecialistforconsultationandco-managementiftheclinicalactionplancannotbeprepared, theprescribedevaluationofthepatientcannotbecarriedout, ortherecommendedtreatmentcannotbecarriedout. Ingeneral, patientswithGFR(cid: 1)30mL/min/1. 73m2 shouldbereferredtoanephrologist. BACKGROUND Historically, theevaluationandmanagementofchronickidneydiseasehasfocusedon diagnosis and treatment of specific Kidney diseases and Dialysis or transplantation for Kidney failure. An action plan for patients with chronic Kidney disease also requires interventions during the earlier stages of Kidney disease, irrespective of the cause of kidneydisease. Thisincludesevaluationandmanagementofcomorbidconditions, slowpotassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 67 ingprogressionofkidneydisease, cardiovasculardiseaseriskreduction, preventingand treatingcomplicationsofchronickidneydisease, andpreparationforkidneyreplacement therapy. RATIONALE Diagnosis(R, O). Classificationofthetypeofkidneydiseaseisbasedonpathology andetiology. Asimplifiedclassification, andthedistributionoftypesofkidneydisease leading to end-stage renal disease are given in Table 34. The definitive diagnosis of the type of Kidney diseaseisbasedonbiopsyorimagingstudies. Biopsyandinvasiveimagingprocedures areassociatedwitharisk, albeitusuallysmall, ofseriouscomplications.",
    "word_count": 598,
    "char_count": 10421,
    "sentence_count": 78,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 17,
      "total_chunks": 77,
      "position": "18/77",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "end-stage renal disease",
        "potassium",
        "dialysis",
        "guideline",
        "classification"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 18,
    "text": "The definitive diagnosis of the type of Kidney diseaseisbasedonbiopsyorimagingstudies. Biopsyandinvasiveimagingprocedures areassociatedwitharisk, albeitusuallysmall, ofseriouscomplications. Therefore, these proceduresareoftenavoidedunlessadefinitivediagnosiswouldchangeeitherthetreatmentorprognosis. Inmostpatients, well-definedclinicalpresentationsandcausalfactors provideasufficientbasistoassignadiagnosisofchronickidneydisease. Anapproach todiagnosis, basedonconceptselaboratedoninthisreport, isgiveninPart9. Diabetic Kidney disease is a type of glomerular disease, but it is singled out here becauseitisthelargestsinglecauseofkidneyfailure. Bothtype1andtype2diabetes causechronickidneydisease. Becauseofthehigherprevalenceoftype2diabetes, itis themorecommoncauseofdiabetickidneydisease. Theclinicalfeatures, naturalhistory andtreatmentfordiabetickidneydiseasearewellknownbecauseithasbeenthesubject ofnumerousepidemiologicalstudiesandclinicaltrials. Diabetickidneydiseaseusually follows a characteristic clinical course after the onset of Diabetes, first manifested by microalbuminuria, then clinical proteinuria, hypertension, and declining glomerular filtration rate. Clinical trials have established a number of effective treatments to slow the development and progression of diabetic Kidney disease, including strict glycemic control, angiotensinconvertingenzymeinhibitorsandangiotensinreceptorblockers, bloodpressurecontrol, andperhapsdietaryproteinrestriction. Avarietyofdiseases, includingotherglomerulardiseases, vasculardiseases, tubulointerstitialdiseases, andcysticdiseases, areoftengroupedtogetherunderthelabelnondiabetic Kidney diseases for the purpose of epidemiological studies and clinical trials. Amongst these, hypertensive nephrosclerosis and glomerular diseases are the second andthirdmostcommoncausesofkidneyfailure. Thevariousdiseasesinthisgroupdiffer widely based on history, clinical presentation, risk for progression, and response to treatment. Differentiation among the diseases can be difficult, often requiring Kidney biopsyorinvasiveimagingstudies. Anapproachtodiagnosis, basedonthehistory, and areviewofclinicalpresentationsofchronickidneydisease, aregiveninPart9. Specific therapiesareavailabletoreverseabnormalitiesinstructureandfunctionforsometypes ofchronickidneydisease: forexample, immunosuppressivemedicationsforautoimmune glomerular diseases, antibiotics for urinary tract infections, removal of urinary stones, relief of obstruction, and cessation of toxic drugs. A thorough search for reversible causesofdecreasedkidneyfunctionshouldbecarriedoutineachpatientwithchronic kidneydisease. Kidneydiseaseinthetransplantisprobablythefourthlargestcauseofkidneyfailure. 68 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 69 Bothimmunologicandnon-immunologicfactorsappeartoplayanimportantrole. The mostcommoncausesarechronicrejection, toxicityduetocyclosporineortacrolimus, recurrentdisease, andtransplantglomerulopathy. Inaddition, differentialdiagnosisincludes all the diseases that can occur in the native Kidney. For a variety of reasons, especiallytheeaseandsafetyofkidneybiopsy, thereisgenerallyamuchlowerthreshold forperforminginvasiveprocedurestoestablishadefinitivediagnosisinkidneytransplant recipients. Comorbid conditions (R, O). Patients with chronic Kidney disease have a large number of comorbid conditions. Comorbidity is defined as conditions other than the primarydisease(inthiscase, chronickidneydisease). Complicationsofchronickidney disease, suchashypertension, anemia, malnutrition, bonediseaseandneuropathy, are notconsideredascomorbidconditions. Itisusefultoconsiderthreetypesofcomorbid conditions(Table35). Diseases which cause chronic Kidney disease. Evaluation and management of thesediseasesisimportantforpatientswellbeingandmayimprovethecourseofchronic kidneydisease. Thisisparticularlyimportantforpatientswithdiabetesandhighblood Hypertension, theleadingcausesofchronickidneydiseaseandcardiovasculardiseaseinthe UnitedStates. Unrelateddiseases, whichmayleadtoimpairmentsoffunctioningandwell-being butdonotaffectthecourseofchronickidneydisease. Evaluationandmanagementis importantforpatientshealthandwell-being. Cardiovasculardisease. Cardiovasculardiseaseissingledoutfromamongthepossible comorbid conditions to emphasize its complex relationship with chronic Kidney disease, anditsimportanceasapreventablecauseofmorbidityandmortalityinpatients withchronickidneydisease. Inallcases, managementofcomorbidconditionsmustbeintegratedintotheoverall careofpatientswithchronickidneydisease. Examplesincludeadjustmentofdrugdos70 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI ages, interpretation of symptoms, and minimizing treatment complications, including acutedeclineinkidneyfunction. InpatientswithnormalormildlydecreasedGFR(chronic kidney disease Stages12), integrationofcareforchronickidneydiseaseandthesecomorbidconditions may be relatively simple. However, in patients with moderate to severe reduction in glomerular filtration rate(CKDStages34)andinpatientswithkidneyfailure(CKDStage5), integrationof careiscomplexandrequirescarefulcoordinationamongallproviders. Risk of loss of glomerular filtration rate (R, O). Risk of Kidney failure depends on the level of glomerular filtration rate (severity)atdetectionofkidneydiseaseandtherateoflossofGFRthereafter. Levelof glomerular filtration rate can be improvedby specific treatment in some chronickidney diseases, but not inmostothers. Rateoflossof glomerular filtration rate(progressionofkidneydisease)isaffectedby diagnosisandby modifiableandnonmodifiablepatientfactors. Thesefactorscanbeassessedevenbefore thedeclineinGFR, therebyallowingimplementationofinterventionstoslowprogression whileGFRisstillnormal. SometherapiestopreventorslowthelossofGFRarespecific forthediagnosis, whileothersarenon-specific. Factorsassociatedwithprogressionof kidneydiseasearediscussedinGuideline13. ItisdifficulttoestimatetherateofprogressionuntiltherehasbeenadeclineinGFR. Indiseasescharacterizedbyaquantifiablemarkerofdamageforexample, albuminuria in diabetic Kidney diseaseprogression, stability, or regression can be estimated by changeinthemarker. Formostdiseases, however, quantitativerelationshipsbetween changesinmarkersandprogressionhavenotbeenestablished. Severityofdiseaseandcomplications(R, O). DecreasedGFRisassociatedwith awiderangeofcomplicationsduetodisordersinotherorgansystems, whicharemanifestedbyhypertension, laboratoryabnormalities, andsymptoms. Complicationsdueto disordersin otherorgansystemsare associatedwithworseoutcomes. Earlydetection andtreatmentofcomplicationscanimproveoutcomes. Theprevalenceofcomplications ofchronickidneydiseaseismainlyrelatedtothelevelofGFR. Interpretationofsigns andsymptomsinpatientswithchronickidneydiseaseshouldbeguidedbythelevelof glomerular filtration rate. Kidneyfunctionsotherthan GFRmaybealteredbychronic kidneydisease. These includemaintenanceofthefiltrationbarrierforplasmaproteins(abnormalitiesinclude albuminuriaandproteinuria), reabsorptionorsecretionofwaterorspecificsolutes(abnormalitiesincludetubularsyndromes), andvariousendocrinefunctions(erythropoietin deficiencycausesanemia, parathyroidhormoneexcesscausesbonedisease, andvitamin Ddeficiencycausesbonedisease). Formostchronickidneydiseases, severityinother abnormalitiesoffunctionparallelstheseverityofdecreasedGFR. Preventionandtreatmentofcomplicationsofchronickidneydiseaseincludesspecifictherapiesrelatedto thepathogenesisofcomplicationsforexample, erythropoietinforanemiaandvitamin Dforbonedisease. potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 71 Table36showstheassociationoflevelsofGFRwithcomplicationsofchronickidney disease. PatientswithGFR60to89mL/min/1. 73m2usuallyhavehypertensionandmay havelaboratoryabnormalitiesindicativeofdysfunctioninotherorgansystems, butusuallynosymptoms. PatientswithGFR30to59mL/min/1. 73m2havelaboratoryabnormalitiesinseveralotherorgansystems, butfewsymptoms. PatientswithGFR15to29mL/ min/1. 73m2usuallyhavelaboratoryabnormalitiesinmanyorgansystemsandhavemild symptoms. PatientswithGFR(cid: 1)15mL/min/1. 73m2usuallyhavemanysymptomsand laboratory abnormalities in several organ systems, collectively known as the uremic syndrome. Theassociationofcomplicationsofchronic kidneydiseasewiththelevel ofGFRisdiscussedinPart6, Guidelines7through12. Risk of cardiovascular disease (R, O). Cardiovascular disease may be a cause andcomplicationofchronickidneydisease. Irrespectiveofdiagnosis, theincreasedrisk of cardiovascular disease in individuals with chronic Kidney disease can be attributed to: (1)ahigherprevalenceoftraditionalCVDriskfactors; and(2)riskfactorsrelated to the hemodynamic and metabolic complications of chronic Kidney disease (chronic kidney diseaserelatedornontraditionalCVDriskfactors). Treatmentandpreventionofcardiovascular disease in chronic Kidney disease includes risk factor reduction as well as specific therapiesforcardiovasculardiseaseandshouldbeginasearlyaspossible. CVDriskfactors maybecomemoreprevalentormoresevereasGFRdeclines; therefore, asGFRdeclines, treatmentmustintensify. Cardiovasculardiseaseinchronickidneydiseaseisdiscussed inGuideline15. Kidneyreplacementtherapyforuremia(R, O). Signsandsymptomsofsevere decrease in glomerular filtration rate, collectively, are known as uremia or the uremic syndrome. Replacementtherapy(dialysisandtransplantation)iseffectiveinimprovingthemostserious featuresofuremia, irrespectiveofthetypeofchronickidneydisease. Patientsrequire educationandadvancepreparationtocopewiththestressesofkidneyfailure, tochoose 72 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI amodalityofkidneyreplacementtherapy, andtoundergoevaluationforthatmodality. It is recommended that preparation for Kidney replacement therapy begin when glomerular filtration rate declinesbelow30mL/min/1. 73m2. Allpatientsshouldprobablybeinstructedtopreservesuitableveinsforpossiblefuturevascularaccessconstruction.",
    "word_count": 598,
    "char_count": 10087,
    "sentence_count": 87,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 18,
      "total_chunks": 77,
      "position": "19/77",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "albuminuria",
        "proteinuria",
        "potassium",
        "malnutrition",
        "erythropoietin",
        "anemia",
        "cardiovascular disease"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 19,
    "text": "It is recommended that preparation for Kidney replacement therapy begin when glomerular filtration rate declinesbelow30mL/min/1. 73m2. Allpatientsshouldprobablybeinstructedtopreservesuitableveinsforpossiblefuturevascularaccessconstruction. Theindicationsfor initiationofkidneyreplacementtherapyarebasedonthelevelofkidneyfunctionand presenceofsignsandsymptomsofuremia. Mostindividualsbegindialysisorreceivea kidneytransplantwhenGFRislessthan15mL/min/1. 73m2. Drugprescribinginchronickidneydisease(R). Patientswithchronickidney disease are prescribed a large number of medications. In addition, patients may take othermedications, suchasover-the-countermedications, non-traditionalmedications, vitaminsandsupplements, herbs, anddrugsofabuse. Athoroughreviewofthemedicationlistandallothermedicationsshouldbeconductedateachvisit. Drugdosageshould be adjusted for the level of estimated glomerular filtration rate. Drugs with potentially adverse effects on kidneyfunctionorcomplicationsofdecreasedkidneyfunctionshouldbediscontinued ifpossible. Drug-druginteractionsshouldbeconsidered. Becauseofpossiblealterations involumeofdistribution, proteinbinding, drugelimination, anddrug-druginteractions inchronickidneydisease, therapeuticdrugmonitoringshouldbeperformed, ifpossible. Alargeamountofinformationisavailabletoprovidersintexts, manuals, anddatabases forhandheldcomputers. Interpretationmaybefacilitatedbythesimilaritybetweenthe classificationoflevelsofkidneyfunctionproposedinthisguidelineandtherecommendationsforpharmacokineticstudiesofdrugsin patientswithdecreasedkidneyfunction made by the Food and Drug Administration84 (on the Internet, cder/guidance/1449fnl. pdf). Barrierstoadherenceinchronickidneydisease(R, O). Healthypeoplemake choicesthatcouldultimatelyshortentheirlives, suchassmoking, drinkingoreatingtoo much, notexercising, missingprescribedmedications, andfailingtogetanannualphysical. Thosewithchronichealthconditionsrequiringlifestylechangesandclinician-initiatedvisits aremore likelytobe noncompliant. 85Patients withchronickidney disease liveday-to-daywithsuchachroniccondition. Otherfactorslinkedwithnoncompliance areshowninTable37. 8598 potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 73 Becausetheterminologynoncomplianceornonadherenceoftenleadstoprejudice and negative stereotyping, it is recommended that self-management behaviors besubstituted. 99TheWorkGrouprecommendsassessmentofbarrierstoadherencein allpatientswithchronickidneydiseaseandincorporationofself-managementbehaviors intothetreatmentplanatallstages. Referral to specialists (O). Frequently the primary care provider will make the diagnosis of chronic Kidney disease. Referral to a nephrologist or other specialist for consultationorco-managementshouldbemadeafterdiagnosisunderthefollowingcircumstances: aclinicalactionplancannotbepreparedbasedonthestageofthedisease, the prescribed evaluation of the patient cannot be carried out, or the recommended treatmentcannotbecarriedout. Theseactivitiesmaynotbepossibleeitherbecausethe appropriatetoolsarenotavailableorbecausetheprimarycarephysiciandoesnothave thetimeorinformationneededtodoso. Ingeneral, patientswithGFR(cid: 1)30mL/min/ 1. 73m2(CKDStages45)shouldbereferredtoanephrologist. LIMITATIONS Thisguidelineprovidesaconceptualframeworktotheevaluationandmanagementof chronickidneydisease, butdoesnotprovidesufficientdetailstoguidehealthcareprovidersinthemanagementofindividualpatientswithchronickidneydiseaseorthedesign ofpublicpolicytoimproveoutcomesforthetargetpopulation. Subsequentguidelines will elaborate on the concepts in this guideline, but it is beyond the scope of these guidelinestoprovidespecificinstructionsforevaluationandmanagement. Thiswillbe thetopicofforthcomingK/DOQIguidelinesandguidelinesbyotherorganizations. The ultimategoalistodevelopspecificguidelinesforeachactionateachstageofdisease. CLINICALAPPLICATIONS Almostallaspectsoftheevaluationandmanagementofchronickidneydiseaseintextbooks of nephrology could be re-written to incorporate the stages of chronic Kidney diseaseproposedinthisguideline. Part9providesanapproachtoselectedtopicsusing thisclassification. IMPLEMENTATIONISSUES Developmentofaclinicalactionplanforallpatientswithchronickidneydiseaseisan enormousundertakingthatwillrequirecoordinateeffortofmanygovernmentandnongovernmental organizations. The National Institute of Diabetes, Digestive and Kidney Disease(NIDDK)hasestablishedaNationalKidneyDiseaseEducationProgram. TheNKF is committed to developing an implementation plan for the potassium/DOQI chronic kidney disease guidelines andtoworkingwiththeNIDDKandotherorganizationstodevelopanationalprogram. RESEARCHRECOMMENDATIONS Muchresearchisneededtodefinediagnosticandtherapeuticstrategiestoreduceadverse outcomesof chronickidney diseaseat eachstageof disease. It willalso beimportant 74 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI toassesstheeffectofimplementingtheseguidelinesontheoutcomesofchronickidney disease. GUIDELINE 3. INDIVIDUALS AT INCREASED RISK OF CHRONIC Kidney DISEASE Someindividuals withoutkidney damageandwith normalor elevatedGFRare at increasedriskfordevelopmentofchronickidneydisease. Allindividualsshouldbeassessed, aspartofroutinehealthencounters, todetermine whether they are at increased risk of developing chronic Kidney disease, basedonclinicalandsociodemographicfactors. Individualsatincreasedriskofdevelopingchronickidneydiseaseshouldundergo testingformarkersofkidneydamage, andtoestimatethelevelofGFR. Individualsfoundtohavechronickidneydiseaseshouldbeevaluatedandtreated asspecifiedinGuideline2. Individualsatincreasedrisk, butfoundnottohavechronickidneydisease, should beadvisedtofollowaprogramofriskfactorreduction, ifappropriate, andundergo repeatperiodicevaluation. BACKGROUND Epidemiological studies show an increased risk for chronic Kidney disease, especially kidneyfailure, amongindividualswithcertainclinicalandsociodemographiccharacteristics. This suggests that there are risk factors for chronic Kidney disease. In principle, preventionofadverseoutcomesofchronickidneydiseasecouldbefacilitatedbyevaluatingindividualswithriskfactors, toenableearlierdetection, andbyriskfactorreduction inindividuals withoutchronic kidneydisease, to preventor slowthedevelopment of chronickidneydisease. RATIONALE Definition of Risk Factors (R) Ariskfactorisdefinedasanattributethatisassociatedwithincreasedriskofanoutcome. In principle, the relationship between the risk factor and the outcome may be either causalornon-causal. Causalriskfactorsaredeterminantsoftheoutcome, andsuccessful intervention to reduce exposure to them would improve outcomes. Non-causal risk factorsmaybeassociatedwiththeoutcomethroughconfoundingorreversecausation. Interventions to reduce exposure to non-causal risk factors would not necessarily improveoutcomes. Classificationofriskfactors(R). Ausefulclassificationofriskfactorshasbeen usedincardiovasculardiseaseepidemiology100andisshowninTable38. Risk factors for chronic Kidney disease (R, O). In principle, risk factors for developmentofchronickidneydiseasewouldincludesusceptibilityfactorsandinitiation potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 75 factors. In addition, because it can be difficult to detect the onset of chronic Kidney disease, some risk factors for faster progression may appear to be to susceptibility or initiationfactors(Table39). Notethatprogressionfactorsmaybeassociatedwithprogressioneitherbecauseinitialdamagecannotberesolvedorbecausedamageisongoing. Inaddition, numerousfactorshavebeenshowntobeassociatedwithworseoutcomes in patients with Kidney failure, (such as inadequate Dialysis dose, temporary vascular access, anemia, andlowserumalbuminconcentration). Theseend-stagefactorshave beendiscussedinpreviousK/DOQIguidelinesandarenotrelevantforthisdiscussion. Textbooksandreviewslistalargenumberofpotentialriskfactorsforchronickidney disease. Thedifficultyofdetectingtheearlystagesofchronickidneydiseasemakesit difficulttodeterminewhethertheriskfactorssofaridentifiedrelatemoretosusceptibility, initiation, orprogression. Table40containsapartiallistofclinicalandsociodemographicfactorsthathavebeenimplicatedassusceptibilityorinitiationfactors. ProgressionfactorsarediscussedinmoredetailinGuideline13. Table 41 shows relationships between types of chronic Kidney disease and chronic kidney disease riskfactors. Forsomeofthesefactors(forexample, Diabetes), interventions(likestrict glycemic control) have been proven to lower the risk of developing chronic Kidney disease(CategoryI, Table38). Forotherfactors(forexample, hypertension), interventions(likeantihypertensivetherapy)arelikelytolowertheriskofchronickidneydisease (CategoryII, Table38). Forotherfactors(forexample, autoimmunediseases), modifica76 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI tion of immune responses might lower the risk chronic Kidney disease (Category III, Table38). Anumberofthesefactors(forexample, familyhistory, age, raceandethnicity) arenotmodifiable(CategoryIV, Table38). Prevalenceofindividualswithriskfactorsforchronickidneydisease(R). Theprevalenceofindividualsatincreasedriskfordevelopmentofchronickidneydisease hasnotbeenstudiedsystematically. However, someideaofthemagnitudeoftheproblem canbeobtainedbyreviewingdatafromrecentpublications(Table42). LIMITATIONS Thisguidelineprovidesaconceptualframeworktothedefinition, detection, andevaluation of individuals at increased risk of chronic Kidney disease, but does not provide sufficientdetailstoguidehealthcareprovidersinscreeningindividualsordeveloping potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 77 screeningprograms. Itisbeyondthescopeoftheseguidelinestoprovidespecificinstructionsforscreening. CLINICAL APPLICATIONS UniversalscreeningforchronickidneydiseaseisrecommendedforchildrenintheUnited States, butnotforadults. However, thelistofindividualsatincreasedriskforchronic Kidney disease includes a large fraction of the adult population (Table 42).",
    "word_count": 596,
    "char_count": 10056,
    "sentence_count": 84,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 19,
      "total_chunks": 77,
      "position": "20/77",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney failure",
        "potassium",
        "dialysis",
        "vascular access",
        "anemia",
        "glycemic control",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 20,
    "text": "Itisbeyondthescopeoftheseguidelinestoprovidespecificinstructionsforscreening. CLINICAL APPLICATIONS UniversalscreeningforchronickidneydiseaseisrecommendedforchildrenintheUnited States, butnotforadults. However, thelistofindividualsatincreasedriskforchronic Kidney disease includes a large fraction of the adult population (Table 42). Thus, it is importanttocarefullyconsiderthedefinitionofindividualsatincreasedriskandmethods fortestingthem. Suggestions(basedonopinion)forevaluationofindividualsatincreased riskforchronickidneydiseaseareprovidedinPart9. IMPLEMENTATION ISSUES AND RESEARCH RECOMMENDATIONS Implementation ofthese guidelines willrequire educationof all healthcare providers aboutriskfactorsforchronickidneydiseaseandmethodsoftesting. TheSixthReport oftheJointNationalCommitteeforthePrevention, Evaluation, DetectionandTreatment of Hypertension (JNC-VI) and the American Diabetes Association have issued recommendationsfortheevaluationofpatientswithhighbloodpressureanddiabetes, respectively, forchronickidneydisease. However, asindicatedinTable42, alargenumber of individuals without Hypertension and Diabetes may also be at increased risk. Thus, itwillbeimportanttotestalargerpopulationthancurrentlytargeted, which wouldincreasethecostofhealthcare. The increased health care costs that would follow implementation of a screening programforchronickidneydiseasemaywellrequireamoresolidbaseofevidencethan iscurrentlyavailable. TheWorkGrouprecommendsdevelopmentofaclinicalpractice guidelinefocusedonthisissueinordertodevelopspecificrecommendationsforevaluat78 Part4. DefinitionandClassification NationalKidneyFoundation potassium/DOQI ing adults forchronic Kidney disease. Inthe past, universal screeningwas not recommendedbecauseofthelowprevalenceofchronickidneydiseaseandthelackoftreat- ments to improve outcomes. Data provided in these guidelines suggests that the prevalenceofearlierstagesofchronickidneydiseaseishigherthanpreviouslyknown andthatearlierdetectionandtreatmenttopreventordelaythelossofkidneyfunction anddevelopmentofcardiovasculardiseaseinchronickidneydisease. Ifsufficientinformationisnotavailabletoassessthevalueoftestingindividualsatincreasedrisk, orof universal screening, the Work Group suggests that research on evaluation programs shouldbeconducted. potassium/DOQI NationalKidneyFoundation Part4. DefinitionandClassification 79 PART 5. EVALUATION OF LABORATORY MEASUREMENTS FOR CLINICAL ASSESSMENT OF Kidney DISEASE ThedefinitionandstagingofchronickidneydiseasedependsontheassessmentofGFR, proteinuria, andothermarkersofkidneydisease. ThegoalsofPart5aretoevaluatethe accuracy of prediction equations to estimate the level of glomerular filtration rate from serum Creatinine concentration, theaccuracyofratiosofprotein-to-creatinineinuntimed(spot)Urine samples to assess Protein excretion rate, and the utility of markers of Kidney damage otherthanproteinuria. AsdescribedinAppendix1, Table151, theWorkGroupevaluated studiesaccordingtoacceptedmethodsforevaluationofdiagnostictests. Toprovidea more comprehensive review, the Work Group attempted to integrate the systematic reviewofspecificquestionswithexistingguidelinesandrecommendations. GUIDELINE 4. ESTIMATION OF glomerular filtration rate EstimatesofGFRarethebestoverallindicesofthelevelofkidneyfunction. The level of glomerular filtration rate should be estimated from prediction equations that take into accounttheserumcreatinineconcentrationandsomeorallofthefollowingvariables: age, gender, race, andbodysize. Thefollowingequationsprovideuseful estimatesofGFR: Inadults, theMDRDStudyandCockcroft-Gaultequations Inchildren, theSchwartzandCounahan-Barrattequations. The serum Creatinine concentration alone should not be used to assess the level ofkidneyfunction. ClinicallaboratoriesshouldreportanestimateofGFRusingapredictionequation, inadditiontoreportingtheserumcreatininemeasurement. Autoanalyzermanufacturersandclinicallaboratoriesshouldcalibrateserumcreatinineassaysusinganinternationalstandard. Measurement of Creatinine clearance using timed (for example, 24-hour) Urine collectionsdoesnotimprovetheestimateofGFRoverthatprovidedbyprediction equations. A24-hoururinesampleprovidesusefulinformationfor: Estimation of glomerular filtration rate in individuals with exceptional dietary intake (vegetarian diet, creatine supplements) or muscle mass (amputation, malnutrition, muscle wasting); Assessmentofdietandnutritionalstatus; Needtostartdialysis. BACKGROUND Glomerularfiltrationrate(glomerular filtration rate)providesanexcellentmeasureofthefilteringcapacity ofthekidneys. AlowordecreasingGFRisagoodindexofchronickidneydisease. Since thetotalkidneyGFRisequaltothesumofthefiltrationratesineachofthefunctioning nephrons, thetotalGFRcanbeusedasanindexoffunctioningrenalmass. 111Adecrease in glomerular filtration rate precedes Kidney failure in all forms of progressive Kidney disease. Monitoring potassium/DOQI NationalKidneyFoundation Part5. Evaluation 81 changesinGFRcandelineateprogressionofkidneydisease. ThelevelofGFRisastrong predictorofthetimetoonsetofkidneyfailureaswellastheriskofcomplicationsof chronickidneydisease. Additionally, estimationofGFRinclinicalpracticeallowsproper dosingofdrugsexcretedbyglomerularfiltrationtoavoidpotentialdrugtoxicity. Glomerularfiltrationratecannotbemeasureddirectly. Ifasubstanceinstableconcentrationintheplasmaisphysiologicallyinert, freelyfilteredattheglomerulus, andneither secreted, reabsorbed, synthesized, nor metabolized by the Kidney, theamount of that substancefilteredattheglomerulusisequaltotheamountexcretedintheurine. The fructosepolysaccharideinulinhaseachoftheabovepropertiesandhaslongbeenconsideredanidealsubstancetoestimateGFR. Theamountofinulinfilteredattheglomerulus equalstheGFRmultipliedbytheplasmainulinconcentration: glomerular filtration rate(cid: 1)P. Theamount in of excreted inulin equals the Urine inulin concentration (U ) multiplied by the Urine in flowrate(V, volumeexcretedperunittime). Sincefilteredinulin(cid: 2)excretedinulin: (1)glomerular filtration rate(cid: 1)P (cid: 2)U (cid: 1)V in in U (cid: 1)V (2)glomerular filtration rate(cid: 2) in P in Theterm(U (cid: 1)V)/P isdefinedastheclearanceofinulinandisanaccurateestimate in in ofGFR. Theinulinclearance, inmL/min, referstothatvolumeofplasmaperunittime thatisclearedofinulinbyrenalexcretion. RATIONALE Criterion Standard Inulinclearanceiswidelyregardedasthegoldstandardformeasuringglomerularfiltrationrate. Inulinclearancemeasurementsinhealthy, hydratedyoungadults(adjustedto astandardbodysurfaceareaof1. 73m2)havemeanvaluesof127mL/min/1. 73m2in menand118mL/min/1. 73m2inwomenwithastandarddeviationofapproximately20 milliliters per minute/1. 73 m2. 67 Among adults, numerous studies suggest that glomerular filtration rate is lower at older ages. After age 20 to 30 years, glomerular filtration rate decreases by approximately 1. 0 milliliters per minute/1. 73 m2 per year with substantial inter-individual variation even among healthyindividuals. 112, 113Whetherthisaveragedeclinewithagingisoptimalinterms of predicting the risk of complications of decreased Kidney function and mortality is unknown. Glomerularfiltrationrateintheinfantdiffersquantitativelyfromthatinolderchildren andadults. Duringinfancyandthroughthefirst12to18monthsoflife, GFRincreases withmaturation6971(seeTable23, Guideline1). Inulinclearanceisalsothegoldstandard to measureGFR inchildren, butis particularly difficultin theneonate becauseof the lowerGFRofneonatesandtheirrelativelylargerextracellularfluidcompartment. These factorsextend thestudy timenecessary fortechniques relyingon equilibrationof the markersubstanceandmonitoringofitsplasmadisappearancerate. Additionally, accurate 82 Part5. Evaluation NationalKidneyFoundation potassium/DOQI assessmentoftheurineflowraterequiresbladdercatheterizationininfantsandyoung children. Rationale for Alternative Measures Theclassicmethodofinulinclearancerequiresanintravenousinfusionandtimedurine collectionsoveraperiodofseveralhoursmakingitcostlyandcumbersome. Asaresult a number of alternative measures for estimating glomerular filtration rate have been devised. The urinary clearanceofexogenousradioactivemarkers(125I-iothalamateand99mTc-diethylenetriamine pentaacetic acid scan)provide excellentmeasuresofGFR114butarenotreadilyavailable. Plasmaclearanceofexogenous substancesincludingiohexoland51Cr-EDTAhasbeenusedaswellbutrequireestimates ofbodysize, whichdecreasestheirprecision. Capillaryelectrophoresisallowsformeasurementofnon-radiolabelediothalamateinbloodandurinewithpromisingresults. 115 SerumcystatinChasbeenusedtoestimateGFRbutdataareconflictingastowhether it provides a sufficient improvement to warrant widespread clinical use. 116 The most widely used measures of glomerular filtration rate in clinical practice are based on the 24-hour Creatinine clearanceorserumcreatinineconcentration. Asdiscussedbelow, eachofthesemeasurementsisassociatedwithseriouslimitations. EquationstopredictGFRandcreatinineclearancefromserumcreatininehavebeen testedinalargenumberofstudieswhoseresultsarereviewed. Useofrelevantequations inchildrenandadultshasbeenshowntogivemorevalidestimatesofGFRthanserum creatininealone. Additionally, forthehealthcareprovider, itmaybeeasiertorecognize clinicallyimportantchangesinkidneyfunctionwhendealingwithlargenumbersestimatingaphysiologicallyrelevantparameter(glomerular filtration rate)ratherthansmallnumbers(serumcreatinine)whichareinverselyrelatedtotherelevantparameter.",
    "word_count": 596,
    "char_count": 9464,
    "sentence_count": 72,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 20,
      "total_chunks": 77,
      "position": "21/77",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "potassium",
        "serum creatinine",
        "diet",
        "malnutrition",
        "supplements"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 21,
    "text": "Asdiscussedbelow, eachofthesemeasurementsisassociatedwithseriouslimitations. EquationstopredictGFRandcreatinineclearancefromserumcreatininehavebeen testedinalargenumberofstudieswhoseresultsarereviewed. Useofrelevantequations inchildrenandadultshasbeenshowntogivemorevalidestimatesofGFRthanserum creatininealone. Additionally, forthehealthcareprovider, itmaybeeasiertorecognize clinicallyimportantchangesinkidneyfunctionwhendealingwithlargenumbersestimatingaphysiologicallyrelevantparameter(glomerular filtration rate)ratherthansmallnumbers(serumcreatinine)whichareinverselyrelatedtotherelevantparameter. Accuracy of an Equation in Estimating glomerular filtration rate Combines Its Bias and Precision InchoosingapredictionequationtoestimateGFR, oneshouldconsiderboththebias andprecisionoftheequation-generatedestimates. Biasexpressesthesystematicdeviation from the gold standard measure of glomerular filtration rate. A prediction equation that consistently overestimatesorunderestimatesthegoldstandardmeasureofGFRyieldsabiasedestimate. Anequallyimportantmeasureoftheusefulnessofapredictionequationisameasure ofitsprecision. Precisionexpressesthevariability(ordispersion)ofpredictionequation estimatesaroundthegoldstandardGFRmeasure. Accuracycombinesprecisionandbias. Ausefulmeasureofaccuracyisadescription of percentiles of the distribution of the differences between estimated and measured glomerular filtration rate. Inotherwords, if99%ofthetimeapredictionequationyieldsanestimatewithin 10%ofthemeasuredGFR, itwouldbeaveryaccurateandusefulclinicaltool. Achieving ahighlevelofaccuracyrequiresbothlowbiasandhighprecision. Descriptionofthe percentofestimatesfallingwithin30%and50%aboveorbelowthemeasuredGFRis ausefulmeasureofaccuracy. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 83 Importance of Sample Size Manyofthestudiesreviewedweresmall. Sinceestimatesofaccuracyfromsmallerstudies canbeunreliable, studiespresentedhaveatleast100adultsor50children. Severallarge validationstudiesevaluatingthenewlydevelopedMDRDStudyequationwereconducted recentlyandwereonlyavailableinabstractform. Inordertocapturethesevaluabledata the authors were contacted and asked to analyze their data and provide estimates of accuracyforthisreview. AdditionaldetailsregardingtheevaluationofpredictionequationstoestimateGFRarereviewedinPart10, Appendix3. Strength of Evidence SerumcreatininealoneisnotanaccurateindexofthelevelofGFR(R). The useoftheserumlevelofcreatinineasanindexofGFRrestsonthreeimportantassumptions: (1)creatinineisanidealfiltrationmarkerwhoseclearanceapproximatesGFR; (2) creatinineexcretionrateisconstantamongindividualsandovertime; and(3)measurement of serum Creatinine is accurate and reproducible across clinical laboratories. Although the serum Creatinine concentration can provide a rough index of the level of glomerular filtration rate, noneoftheseassumptionsisstrictlytrue, andnumerousfactorscanleadtoerrors inestimationofthelevelofGFRfromtheserumcreatinineconcentrationalone. Creatinineexcretionbythekidney. Creatinineisfreelyfilteredbytheglomerulus, butisalsosecretedbytheproximaltubule. Hence, theamountofcreatinineexcreted in the Urine is the composite of both the filtered and secreted Creatinine and can be representedbythefollowingequation: (3)U (cid: 1)V(cid: 2)glomerular filtration rate(cid: 1)P (cid: 3)TS creatinine creatinine creatinine whereTS istherateoftubularcreatininesecretion. DividingbyP: creatinine creatinine (4)C (cid: 2)glomerular filtration rate(cid: 3)C creatinine TSCr where C is the clearance of Creatinine due to tubular secretion. Thus, Creatinine TSCr clearancesystematically overestimatesGFR. Thisoverestimationis approximately10% to 40% in normal individuals, but is greater and more unpredictable in patients with chronickidneydisease(Fig12A). FactorsotherthanthelevelofGFRcanalsoinfluence creatininesecretion. Creatininesecretionisinhibitedbysomecommonmedications, for example, cimetidineandtrimethoprim. Inaddition, measurementofcreatinineclearanceisnoteasy. Urinaryclearancemeasurementsrequiretimedurinecollections, whicharedifficulttoobtainandofteninvolve errorsincollection. Furthermore, day-to-dayvariationincreatinineexcretionexists, makingestimationofGFR, evenfromavalid24-hoururinecollection, imprecise. Creatininemetabolism. Theurinarycreatinineexcretionrepresentsthedifference betweencreatininegenerationinthebody(G )andextra-renalcreatinineelimination creatinine (E ): creatinine (5)U (cid: 1)V(cid: 2)G (cid: 4)E creatinine creatinine creatinine 84 Part5. Evaluation NationalKidneyFoundation potassium/DOQI Fig12. RelationshipofcreatinineclearanceandserumcreatininewithGFR(inulinclearance)inpatientswithglomerulardisease. Verticaldashedlinescorrespondtothelower limit of normal for inulin clearance in the authors laboratory (82 milliliters per minute/1. 73 m2). Thehorizontaldashedlineintheleftpanel(A)correspondstothelowerlimitforcreatinine clearance(77mL/min/1. 73m2); andthehorizontaldashedlineintherightpanel(B) correspondstotheupperlimitfortheserumcreatinineconcentration(1. 4mg/dL)inthe authors laboratory. The shaded areas included values for patients in whom glomerular filtration rate is reduced, but Creatinine clearance and serum Creatinine concentration remain normal. DatafromShemeshetal. 117Reprintedwithpermission. 118 Substitutingintoequation3andre-arrangingforP yieldsthefollowing: creatinine G (cid: 4)TS (cid: 4)E (6)P (cid: 2) creatinine creatinine creatinine creatinine glomerular filtration rate ItcanthereforebeinferredthattherelationshipbetweenserumcreatinineandGFR isaffectedbythegenerationandextra-renalexcretionofcreatinine, aswellasthefiltrationandsecretionofcreatininebythekidney. Creatinineismainlyderivedfromthemetabolismofcreatineinmuscle, anditsgenerationisproportionaltothetotalmusclemass. Asaresult, meancreatininegenerationis higherinmenthaninwomen, inyoungerthaninolderindividuals, andinblacksthan inwhites. Thisleadstodifferencesinserumcreatinineconcentrationaccordingtoage, gender, andrace, evenafteradjustingfor glomerular filtration rate. Musclewastingisalsoassociatedwith reduced Creatinine generation resulting in lower serum Creatinine concentration than expected for the level of glomerular filtration rate in malnourished patients with chronic Kidney disease. Creatinine generation is also affected by meat intake to a certain extent, because the processofcookingmeatconvertsavariableportionofcreatinetocreatinine. Therefore, serumcreatinineislowerthanexpectedforthelevelofGFRinpatientsfollowingalow proteindiet. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 85 Though extra-renal Creatinine excretion is minimal in people with normal Kidney function, itisincreasedinpatientswithchronickidneydiseaseduetothedegradation ofcreatininebybacterialovergrowthinthesmallbowel. Asmuchastwo-thirdsoftotal dailycreatinineexcretioncanoccurbyextra-renalcreatinineeliminationinpatientswith severelyreducedkidneyfunction. Asaconsequenceofallthesefactors, urinarycreatinineexcretionislowerinchronic kidneydisease, leadingtosystematicoverestimationofGFRfromserumcreatinine. Figure 12Bshowsthatserumcreatininecanremainlessthan2. 0mg/dLdespitereductionin glomerular filtration rate to as Low as 15 to 20 milliliters per minute/1. 73 m2. Thus, an elevated serum Creatinine is an insensitiveindex ofdecreased glomerular filtration rate. Only 60%of patientswith decreasedGFR hadincreasedserumcreatinine. Statedotherwise, 40%ofindividualswithdecreasedGFRhad aserumcreatininelevelwithinthenormalrangeforthelaboratory. Creatininemeasurement. Inyoungadults, thenormallevelforserumcreatinine concentration is approximately 1. 0 milligrams per deciliter. The traditional assay for measurement of creatinineisthealkalinepicratemethod, whichdetectsnon-creatininechromogensin serum (approximately 0. 2 milligrams per deciliter), as well as Creatinine. Urine does not contain nonCreatinine chromogens, nor are these compounds retained in chronic Kidney disease. Thus, historically, measuredcreatinineclearancehassystematicallyunderestimatedtrue creatinineclearance. Bycoincidence, thedifferencebetweenmeasuredandtruecreatinine clearance is similar in magnitude to the clearance of Creatinine due to tubular secretion. Hence, measuredcreatinineclearancehashistoricallyapproximatedthelevel ofGFR. Modern autoanalyzers use serum Creatinine assays with less interference by noncreatininechromogens(forexample, kineticalkalinepicrateorenzymaticmethods, such astheimidohydrolasemethod). Consequently, normallevelsofserumcreatininearenow lower, resultinginhighervaluesformeasuredcreatinineclearanceandoverestimationof glomerular filtration rate. InordertominimizethisoverestimationofGFR, autoanalyzermanufacturersand clinical laboratories may calibrate the instruments to report higher serum Creatinine values. Thiscalibrationisnotstandardized, leadingtovariationwithinandacrosslaboratories. Variation is proportionately greater at Low serum Creatinine values than at High values. Inadditiontonon-creatininechromogens, othersubstancesmayalsointerferewith serumcreatinineassays. Thesesubstancesincludeketonesandsomemedications, which mayleadtospuriouselevationinserumcreatinineconcentrationandunderestimation ofGFR. Insummary, serumcreatinineisaffectedbythelevelofGFRandbyfactorsindependentofGFR, includingage, gender, race, bodysize, diet, certaindrugs, andlaboratory analyticalmethods(Table43).",
    "word_count": 600,
    "char_count": 9381,
    "sentence_count": 80,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 21,
      "total_chunks": 77,
      "position": "22/77",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "potassium",
        "serum creatinine",
        "diet"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 22,
    "text": "Inadditiontonon-creatininechromogens, othersubstancesmayalsointerferewith serumcreatinineassays. Thesesubstancesincludeketonesandsomemedications, which mayleadtospuriouselevationinserumcreatinineconcentrationandunderestimation ofGFR. Insummary, serumcreatinineisaffectedbythelevelofGFRandbyfactorsindependentofGFR, includingage, gender, race, bodysize, diet, certaindrugs, andlaboratory analyticalmethods(Table43). Therefore, serumcreatinineisnotanaccurateindexof thelevelofkidneyfunction, andthelevelofserumcreatininealoneshouldnotbeused toassessthestageofchronickidneydisease. 86 Part5. Evaluation NationalKidneyFoundation potassium/DOQI EquationsestimatingGFRbasedonserumcreatininearemoreaccurateand precise than estimates of glomerular filtration rate from measurement of serum Creatinine alone (R, C). Many studies have documentedthat Creatinine productionvaries substantially acrosssex, age, andethnicity. 113Equationshavetheadvantageofprovidinganestimate ofGFRwhichempiricallycombinesalloftheseaverageeffectswhileallowingforthe marked differences in Creatinine production between individuals. Figures 13 and 14 showthatequation-basedestimatesperformbetterthanserumcreatininealone. AnumberofequationshavebeendevelopedtopredictGFRdirectlyinadultpatients (Table44)andchildren(Table45). InadditiontoequationswhichdirectlypredictGFR, the mostfrequently used equationfor estimating GFRin adults isthe Cockcroft-Gault equationwhichwasdevelopedforestimatingcreatinineclearancebuthasbeentested Fig13. EstimatesofGFRversusmeasuredGFRamongMDRDStudybaselinecohort. GFRmeasuredasurinaryclearanceof125I-iothalamateandadjustedforbodysurface areain1, 628patients. Estimatesinclude(A)100/S (R2(cid: 5)80. 4%), (B)Cockcroft-Gault creatinine equationstandardizedforbodysurfacearea(R2(cid: 5)84. 2%), and(C)MDRDStudyequation7(R2(cid: 5)90. 3%). R2valuesindicatethepercentageofvarianceoflogGFRaccounted for in the validation sample (n (cid: 5) 558) by equations derived from the development sample(n(cid: 5)1, 070). Reprintedwithpermission. 17 potassium/DOQI NationalKidneyFoundation Part5. Evaluation 87 Fig14. AccuracyofdifferentestimatesofGFRinadults, expressedasthepercentof estimates within 30% and 50% of the measured glomerular filtration rate in the MDRD Study validation sample(n(cid: 5)558). EstimatesdenotedwithCincludeacalibrationcorrectionof0. 69 for 100/serum Creatinine, 0. 84 for Cockcroft-Gault equation, and 0. 81 for 24-hour creatinineclearancetoshowperformanceafterbiasiseliminatedusingamultiplicative correctionfactor. AnalysisofMDRDStudy17datapreparedbyTomGreene, PhD. widelyinitspredictionofGFR. 120, 121Anotherequationdevelopedin1971forestimation ofcreatinineclearancebyJelliffehasbeenusedextensively. 122 Several formulas for estimating glomerular filtration rate in children have been developed as well. The most widely studied of these are the Schwartz71, 123126 and Counahan-Barratt formulae. 127129BothprovideanestimateofGFRbasedonaconstantmultipliedbythechilds heightdividedbyserumcreatinine. ManystudiesevaluateGFRpredictionequationsbutseveralmethodological aspectslimittheabilitytocompareresultsacrossstudies(C). Asystematicreview oftheliteraturerevealsthatthenumberofreferencesevaluatingGFRpredictionmethods isvast((cid: 1)100references). StudiesevaluatingGFRpredictionequationsarelistedinTable 46(Cockcroft-Gaultequation)andTable47(MDRDStudyequation). Thepresentation of validity data here is limited to four equations: the most widely used equations for estimating glomerular filtration rate in the adult (Cockcroft-Gault) and children (Schwartz and CounahanBarratt)aswellasthenewlydevelopedMDRDStudyequations. Techniquestomeasurecreatinine, referencestandardsforGFRandthestatisticsused to estimate accuracy, bias, and precision vary widely in published reports. The most frequentlyusedstatisticisthecorrelationcoefficient, whichhaslittleapplicabilityand cannotbepooledacrossstudies. Whilemostreportsspecifythemethodsusedtomeasure 88 Part5. Evaluation NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part5. Evaluation 89 serumcreatinine, onlyrarelyisitknownhowcloselytheserumcreatinineassayreflects thetruecreatininelevel. Thisseverelylimitstheabilitytocompareorcombinereported results. (Fordetails, seePart10, Appendix3. ) Amongadults, theMDRDStudyequationprovidesaclinicallyusefulestimate ofGFR(uptoapproximately90mL/min/1. 73m2)(S). TheMDRDStudyequation (Table47)hastheadvantagesofhavingbeenderivedbasedon: GFRmeasureddirectlybyurinaryclearanceof125I-Iothalamate; Alargesampleof(cid: 1)500individualswithawiderangeofkidneydiseases; InclusionofbothEuropean-AmericanandAfrican-Americanparticipants; Validatedinalarge(n(cid: 1)500)separategroupofindividualsaspartofitsdevelopment. This equation provides estimates of glomerular filtration rate standardized for body surface area. The abbreviated version is easy to implement since it requires only serum Creatinine, age, sex, andrace. Thecalculationscanbemadeusingavailableweb-basedanddownloadable medical calculators. The abbreviated MDRD Study equation has two equivalent forms (Table48). TheresultsofstudiesreportingequationsforestimatingastandardmeasureofGFR 90 Part5. Evaluation NationalKidneyFoundation potassium/DOQI with at least 100 adult participants and a plot of predicted versus measured glomerular filtration rate are summarizedinTable46(Cockroft-Gaultequation)andTable47(MDRDStudyequation). ThebiasinestimatingGFRusingtheCockcroft-Gaultequationvariedmarkedlyacross studies(from(cid: 4)14%to(cid: 3)25%). Theaccuracymeasuresindicatedthemajority(median of75%)ofestimatedGFRswerewithin30%ofthemeasuredGFR, anaccuracyconsidered sufficient for Good clinical decision-making. The Cockroft-Gault equation does not includebodysize. Somestudieshavestandardizedtheresultsforbodysurfacearea. Other potassium/DOQI NationalKidneyFoundation Part5. Evaluation 91 studies have suggested using lean body mass rather than total weight, especially for obeseindividuals. Table47showssimilardataforseveralformsoftheMDRDStudyequation. Within thevalidationsampleoftheMDRDStudy, theequationdevelopedonanindependent sample of 1, 070 participants performed better than the Cockcroft-Gault equation (Fig 14). Over 90% of the estimates were within 30% of the measured glomerular filtration rate, with only 2% having an error of greater than 50%. The four different variants of the MDRD Study equationperformedsimilarlyusingthesecriteriaforaccuracyinalloftheavailabledata. Thus, theabbreviatedMDRDStudyequationprovidesarigorouslydevelopedequation 92 Part5. Evaluation NationalKidneyFoundation potassium/DOQI for estimating glomerular filtration rate, which may allow for improved prediction of glomerular filtration rate. (See Part 10, Appendix3. ) Table 49 shows serum Creatinine values which can be used to identify individuals withanestimatedGFRof60mL/min/1. 73m2orlessforadultsofdifferentages, genders and ethnicities. All of the values are well below 2. 0 milligrams per deciliter, which corresponds to an estimatedGFRintherangeof2551mL/min/1. 73m2, dependingonage, gender, and ethnicity. Thisequationmaybesuperiortopreviousequationsbutthedataatthispoint arequitelimited. (SeePart10, Appendix3. )Whilethisequationisdifficulttomemorize, itisavailableontheInternet(www. Kidney Disease Outcomes Quality Initiative. org)andcanbereadilyprogrammedorimportedintocalculatorsandlaboratorysystems. Amongchildren, theSchwartzandCounahan-Barrattformulaeprovideclinicallyusefulestimatesof glomerular filtration rate(C). Severalformulaeforestimating GFRinchildren have been developed. Two of these, the Schwartz formula, and the Counahan-Barratt formulasutilizetheproportionalitybetweenGFRandheight/serumcreatinine71, 123129 (Table44). ThedifferencebetweentheconstantscitedintheCounahan-Barrattandthe Schwartzformulahasbeenattributedtotheuseofdifferentassaystomeasurecreatinine. TheCounahan-Barrattformulawasdevelopedusingameasureoftruecreatinineand GFRby51Cr-EDTAplasmaclearance, whiletheoriginalSchwartzformulawasdeveloped usinginulinclearanceandcreatininemeasuredbyamodifiedJaffereaction, whichmay haveoverestimatedtruecreatinine. Tables49and50showtheresultsofstudiesreporting a standard glomerular filtration rate measure, at least 50 pediatric participants, and presenting a plot of predictedversusmeasuredGFR, allowingassessmentoftheaccuracyoftheprediction equationinestimatingGFRasoutlinedabove. While a systematic review of the literature yielded over 40 references examining predictionequationstoestimateGFR, onlyahandfulusedagoldstandardmeasureof potassium/DOQI NationalKidneyFoundation Part5. Evaluation 93 GFRandincludedmorethan50children(Tables50and51). FortheSchwartzformula, moststudiesreported meandifferencesbetweenestimatedandmeasured glomerular filtration rate. These ranged from(cid: 4)0.",
    "word_count": 598,
    "char_count": 8788,
    "sentence_count": 85,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 22,
      "total_chunks": 77,
      "position": "23/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "glomerular filtration rate",
        "creatinine",
        "potassium",
        "serum creatinine",
        "diet"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 23,
    "text": "Evaluation 93 GFRandincludedmorethan50children(Tables50and51). FortheSchwartzformula, moststudiesreported meandifferencesbetweenestimatedandmeasured glomerular filtration rate. These ranged from(cid: 4)0. 4 to10 milliliters per minute/1. 73m2 with SDranging from2 to20 milliliters per minute/1. 73 m2. ThedatasuggestthatthebiasoftheestimateoftheSchwartzformulaincreaseswith decreasingGFR. 168, 172 Studies describing the accuracy of the estimate show that approximately 75% of SchwartzformulaestimatesofGFRarewithin30%ofthemeasuredGFRbyinulinclearance. 124, 170, 171, 176180ComparablestudiesoftheCounahan-Barrattformulashow70%to 86%ofCounahan-Barrattestimatesfallwithin30%ofGFRmeasuredby51Cr-European Dialysis and Transplant Association. Althoughimprecise, theSchwartzandCounahan-BarrattformulaeforestimatingGFR in children are convenient and practical. Bothuse height in the estimate, as height is proportionaltomusclemass. Theconstantsusedintheequationsdiffer, likelyrelated to the different assays to measure Creatinine. For a 5-year-old child who is at median (50thpercentile)heightforage, theserumcreatininecorrespondingtoaGFRof60mL/ min/1. 73m2is1. 0mg/dLusingtheSchwartzformulaand0. 8mg/dLusingtheCounahan94 Part5. Evaluation NationalKidneyFoundation potassium/DOQI Barrattformula. Thisexampleillustratesthatuseofbothformulascanallowforestimation ofkidneyfunction, andevenserumcreatininelevels(cid: 2)1. 0mg/dLcanbeassociatedwith substantiallyimpairedkidneyfunctioninsmallchildrenandadultswhohavelowmuscle massormalnutrition. Creatinine clearance over-estimates glomerular filtration rate; therefore, equations that accuratelyestimatecreatinineclearanceoverestimateGFRwhentruecreatinineis measured(R, S). TheCockcroft-Gaultequation wasdevelopedto predictcreatinine clearanceratherthanGFR. Theequationwasdevelopedinasampleofmenandacorrectionfactorforwomenwasproposed. 121Theequationsaccuracyinpredictingcreatinine clearancefrom24-hoururinehasbeenevaluatedinmanypublications(Table46). Evaluationofthesedataislimitedbytheuseofdifferentassaysandvariablecalibrationwithin creatinineassaysacrosslaboratoriesandovertime. Analogousstatementsapplytostudies oftheSchwartzformulainchildren. ThelargeststudythatevaluatedtheCockcroft-Gaultequationinasinglelaboratory wastheMDRDStudy. Theserumcreatinineassayinthisstudywascalibratedtoapproximate true Creatinine. As a result, the Cockcroft-Gault equation over-estimated glomerular filtration rate by 23%. Many of the studies evaluating the Schwartz formula in children have substituted creatinineclearanceforGFRinassessingitbiasandprecisionindifferentpopulations. ThebiasofSchwartzformulaestimatescomparedtocreatinineclearancesisrelatively small; however, theSchwartzformulahasbeenshowntooverestimateinulinclearance, particularlyinchildrenwithlowGFR. 168, 169, 172AlthoughformulasthatestimatecreatinineclearanceoverestimateGFR, theyprovideanestimatethatisaccurateenoughfor potassium/DOQI NationalKidneyFoundation Part5. Evaluation 95 most clinical purposes and represent a better alternative to assessing Kidney function thanserumcreatininealone. Measuring24-hourcreatinineclearancetoassessGFRisnotmorereliable thanestimatingGFRfromapredictionequation(R). A24-hoururinecollectionis usefulformeasurementoftotalexcretionofnitrogen, electrolytes, andothersubstances. However, theuseof24-hoururinecollectionfortheestimationofGFRhasconsistently beenshowntobenomore, andoftenless, reliablethanserumcreatininebasedequations. A1998review181foundfiveofsixstudiesthatfoundserumcreatininebasedestimates ofGFRtohavealowererrorthanmeasuredcreatinineclearanceinpatientswithkidney disease. Inadditiontocollectionerrors, thisisattributedtodiurnalvariationinGFRand day-to-dayvariationincreatinineexcretion. Inchildren, severalstudieshavecomparedtheaccuracyofpredictionequationsin estimating glomerular filtration rate with24 hour or timed Creatinine clearancestudies. 127, 182186 None of thesestudiesdemonstratedsubstantialimprovementinestimatingcreatinineclearance usinga24-hourortimedurinecollectionovertheuseofeithertheSchwartzorCounahanBarrattpredictionequations. Onerelativelysmallstudy169demonstratedameandifference of7. 0 (cid: 6)17. 8 milliliters per minute/1. 73m2 between24-hour creatinineclearance compared toGFRasmeasuredbyinulinclearance. Anotherdocumented30%of24-hourcreatinine clearancestudiesyieldedestimatesofGFRmorethan30%aboveorbelowGFRmeasured withiothalamateclearance. 184 Important exceptions may be the estimation of glomerular filtration rate in individuals with variation in dietary intake (vegetarian diet, creatine supplements) or muscle mass (amputation, malnutrition, musclewasting), sincethesefactorsarenotspecificallytakenintoaccount in prediction equations. In these situations, collection of a 24-hour Urine sample for measurement of Creatinine clearance, or measurement of clearance of an exogenous filtrationmarker, mayprovidebetterestimatesofGFRthanpredictionequations. Clinical laboratories should provide an estimate of glomerular filtration rate with the results ofserumcreatinineconcentration(O). Laboratoriesthatmeasureserumcreatinine concentrationshouldcalculateGFRusinganequation. Amongadults, theMDRDStudy equation may perform better than the Cockroft-Gault equation but the data are very limited. Amongchildren, theSchwartzformulaprovidesaclinicallyusefulestimateof glomerular filtration rate. Allfourformulasreviewedprovideamarkedimprovementoverserumcreatinine alone. Calculationsbythelaboratory, requiringonlyminimalclinicalinformation, will facilitatetheclinicalinterpretationofkidneyfunction. Theutilizationofequations, some ofwhicharecomplex, ismuchmoreefficientinthecontextofacentralizedlaboratory computersystemthanperformedbyindividualphysicians. Clinicallaboratorieswillneed toworkwithphysiciansandhospitalorhealthcenterinformationsystemadminstrators todetermineanumberofpracticalissues: whichpredictionequation(s)touse; howto obtaintheadditionalinformationrequiredforthepredictionequation; whentoreport estimatedGFR(onlywhenrequested, oreachtimeserumcreatinineismeasured); what additionalinformationtoincludeonthereport(eg, normalvaluesforageandgender, 96 Part5. Evaluation NationalKidneyFoundation potassium/DOQI GFRlevels forK/DOQI CKDStages). The laboratoriesshould mindtheimportance of calibratingtheirserumcreatininetothesamelevelasthelaboratoryinwhichtheequationwasdeveloped. Inthisregard, developmentofinternationalstandardsforcalibration of serum Creatinine assays will be important in allowing for the accurate diagnosis of Stage2chronickidneydisease. EstimationofGFRorcreatinineclearancefromserumcreatinineiscritically dependentoncalibrationoftheserumcreatinineassay(R). Thereissubstantial variationacrosslaboratoriesinthecalibrationofserumcreatinine, withsystematicdifferencesaslargeas0. 2to0. 4mg/dLnotbeinguncommon. Suchdifferencesreflectavery largepercentageoftheserumcreatinineinpatientswithaserumcreatinineof2. 0mg/ dLorless. A1987review187detailed8differentexistingmethodstomeasurecreatinine concentration. For patients with Low muscle mass and serum Creatinine (cid: 1)1. 0 milligrams per deciliter, themorecommonlyusedJaffeandmodifiedJaffereactionmethodssystematicallyoverestimatedcreatinineby20%to80%comparedtohighperformanceliquidchromatography anddilutionmassspectrometrymeasureswhichshouldapproximatetrueCreatinine. An analysis of College of American Pathologists survey data indicates that systematic differencesincalibrationofserumcreatinineassaysaccountsfor85%ofthedifference betweenlaboratoriesinserumcreatinine. Muchofthevariationwaswithinamethodnot justbetweenmethods. Thelaboratoriessurveyedaveraged(cid: 1)13%biasinmeasurementof Creatinine, larger thanany other analyte examined, as well as substantialvariation between laboratories in the bias. In comparison, reproducibility of the serum Creatinine measureswithinalaboratorywasmuchbetter(averagecoefficientofvariation8%). 188 Standardizationoftheassayacrosslaboratoriesiscriticaltotheabilitytodiagnoseand stage chronic Kidney disease. Laboratories should inform clinicians which Creatinine assayisusedintheirlaboratoryandhowitcomparestomeasuresoftrueCreatinine. Onereasonforvariationinthecalibrationofserumcreatininemayhavebeenadesire toprovideacalculated24-hourcreatinineclearancethatisclosertoGFR. Itispreferable toreportestimatesofappropriatelycalibratedtruecreatinine. Theover-estimateofGFR bycreatinineclearancecanthenbecorrectedexplicitlyusingacorrectionfactor. Inthe MDRDStudy, thiscorrectionrequiredmultiplyingthecreatinineclearanceby0. 81. 17 A24-hoururinesampleshouldbecollectedtoaidintheassessmentofnutritionalstatusandtheneedforkidneyreplacementtherapy(O). Thestatements about the limited utility of 24-hour Urine samples in estimating glomerular filtration rate do not apply to otherusesofthisurinecollection. A24hoururinecollectioncanbeusedtoassessurea clearance, weeklyKt/V, creatinineclearance, anddietaryintakeofprotein, Sodium, urea Potassium, and phosphorus. For details on calculations of urea clearance, weekly Kt/ V, anddietaryproteinintakefrom24hoururine, seePart10, Appendix3. Guideline urea 1reviewsrecommendationsfromDOQIguidelinesregardinginitiationofkidneyreplacementtherapy. Guideline9reviewsK/DOQIguidelinesonassessmentofnutritionalstatus. Inprinciple, accuratemeasurementofcreatinineexcretioninatimedurinecollection at a single point in time could be used to improve the estimate of 24-hour excretion potassium/DOQI NationalKidneyFoundation Part5. Evaluation 97 ratesofvarioussolutesfromtheratioofsolute-to-creatinineconcentrationsinuntimed (spot) Urine samples at later times. Alternatively, estimation of Creatinine excretion fromfactorsrelatedtophysiologicvariablesrelatedtocreatininegenerationandextrarenal elimination (such as age, gender, race, body size, and glomerular filtration rate) could also be used to facilitate estimation of solute excretion rates from the ratio of solute-to-Creatinine concentrationinspoturinesamples. Thusfar, theaccuracyofpredictionequationsfor creatinineexcretionhavenotbeenwidelystudied. Bothmethodsmaybelimited, however, byvariationinsoluteexcretionratesduringtheday(asoccurswithureanitrogen inindividualswithnormalkidneyfunction).",
    "word_count": 597,
    "char_count": 10165,
    "sentence_count": 88,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 23,
      "total_chunks": 77,
      "position": "24/77",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "urea",
        "sodium",
        "potassium",
        "phosphorus",
        "serum creatinine",
        "diet"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 24,
    "text": "Thusfar, theaccuracyofpredictionequationsfor creatinineexcretionhavenotbeenwidelystudied. Bothmethodsmaybelimited, however, byvariationinsoluteexcretionratesduringtheday(asoccurswithureanitrogen inindividualswithnormalkidneyfunction). LIMITATIONS Steady State and Average Body Composition Use of serum Creatinine to estimate GFRrelies on the individual being in steady state andtheabilitytoestimatetheaveragerateofproductionofcreatinine. Therefore, estimateswillbeunreliableifthelevelofGFRischanging(suchasacutekidneyfailure), ifmusclemassisunusuallyhighorlow(suchasathletesormalnourishedindividuals, respectively), orifdietarycreatineintakeisunusuallyhighorlow(suchasindividuals consuming creatine supplements or vegetarians, respectively). Methods proposed for estimatingGFRinacutekidneyfailure189wereoutsidethescopeofthisreview. Selected patientsmayrequireclearanceprocedurestomeasure(ratherthanestimate)thelevel ofGFR(Table52). Mild Decrease in glomerular filtration rate UsingpredictionequationstoestimateGFRismuchlesspreciseatthehigherrangeof glomerular filtration rate, suchasCKDStages12. Earlyglomerularinjurymayleadtocompensatoryhypertrophyandhyperfiltrationinlessaffectednephrons, therebymaintainingorincreasingGFR. At the upper range of Kidney function, the role of the Kidney in determining serum creatinineisofcomparablemagnitudetovariationinotherfactorssuchasthemetabolism of creatine in skeletal muscle and ingested meat in the diet. The degree of Creatinine secretion can vary with time, by as much as 10% even within healthy individuals. 111 Additionally, withamilddecreaseinkidneyfunction, onlyaslightincreaseintheserum Creatinine may be seen because of an increase in tubular secretion. Therefore, other markersofearlykidneydamageareneededtoidentifyearlydeclineinkidneyfunction. 98 Part5. Evaluation NationalKidneyFoundation potassium/DOQI Progression of Kidney Disease Measurementofprogressionofkidneydiseaseissubstantiallymoredifficultthandiagnosisofthepresenceofkidneydiseasesinceprogressionofmanyformsofkidneydisease isslow. EstimatesofGFRbasedonserumcreatininewillallowforreliabledetectionof substantialprogression((cid: 1)25%to50%decline). However, substantialchangesinsecretion, generation, and extra-renal metabolism of Creatinine can occur and will lead to falsemeasuresoflowerdegreesofprogression. Itisparticularlydifficulttouseserum Creatinine alone to assess progression of Kidney disease in children, in whom growth andmaturationleadtosubstantialchangesinmusclemass. CLINICALAPPLICATIONS Serumcreatinine-basedestimatesofGFRusingpredictionformulasinadultsandchildren provideabasisforclassificationofchronickidneydiseaseanddetectionofsubstantial progression. Forteenagersandyoungadults, useofbothformulas(SchwartzandMDRD Study)maygivetheclinicianadependablerangeofestimatesofGFR. Incertainclinical situations, clearancemeasuresmaybenecessarytoestimateGFR(Table52). All individuals should be informed about their estimated level of glomerular filtration rate. Individuals withanestimatedGFRbelow60mL/min/1. 73m2areclassifiedashavingchronickidney diseaseandshouldbeeducatedabouttheirdiagnosisandtheimplicationsofdecreased kidneyfunction. Individualswithaserumcreatinineof2. 0mg/dLhavemoderatetoseveredecrease in glomerular filtration rate, regardless of the equation used to estimate glomerular filtration rate. However, these individuals constituteonlyaminorityofindividualswithchronickidneydisease. ReviewoftheliteratureshowedapaucityofdataonthelowerlimitofanormalGFR inelderlypopulations. Therefore, olderindividualswithlowGFRshouldbeassessedfor othermarkersofchronickidneydiseaseincludinghypertensionandproteinuria. When precise measures of glomerular filtration rate are necessary, or when muscle mass may deviate substantiallyfromvaluespredictedbyage, race, sexinadultsorheightinchildren(eg, in malnourishedpatients174, 190193), clearancemeasuresusingexogenousfiltrationmarkers may be necessary. In patients with mild or moderate decreased glomerular filtration rate, post-cimetidine creatinineclearancemaymorecloselyapproximateGFR, ascimetidineblockstubular secretionofcreatinine. 169, 181ThereisagrowingliteratureonusingserumcystatinCto estimateGFR. However, limitedsamplesize, statisticalmethodology, lackofinformation oncystatinCassaycalibration, andconflictingresultsmaketheavailabledatainadequate forrecommendingcystatinCmeasurementforwidespreadclinicalapplication. 116Nonradiolabelediothalamatecanbeusedtodecreasethecostandinconvenienceofmeasur- ingGFR. 194 IMPLEMENTATIONISSUES Development and implementation of international standardization and calibration of serumcreatinineassayswillbeimportantinallowingfortheaccuratediagnosisofmild andmoderatekidneydisease. Theimportanceofaccuratemeasurementofserumcreatipotassium/DOQI NationalKidneyFoundation Part5. Evaluation 99 nineneedstoberecognizedbyclinicalchemistrylaboratoriesandequipmentmanufacturers. RESEARCHRECOMMENDATIONS Estimating glomerular filtration rate Althoughexistingequationsbasedonserumcreatinineprovideanexcellentcost-effective method for estimating glomerular filtration rate, their precision is limited. New methods are needed, particularlyfordetectingmildandmoderatekidneydisease, buttheirvalueintermsof bias, precision, andpracticalityshouldbewelltestedinlargesamplesofsubjectswith andwithoutkidneydisease. Inadults, newmeasureswillhavetoperformsubstantially better than the 12. 1% median difference ((cid: 2)90% of estimates within 30%) from glomerular filtration rate obtainedwithserumcreatinine, age, sex, andraceusingtheMDRDStudyequation. In children, standardizationofcreatininemeasurementacrossstudies, useofgoldstandard GFRmeasuresforreference, andinclusionoflargersamplesofchildrenofdifferentages andethnicitieswillallowrefinementoftheconstantswhichshouldbeusedinestimating GFRinfuturemodificationsoftheCounahan-BarrattorSchwartzformula. While the MDRD Study equation has many advantages, it needs further validation. Inparticular, furtherstudiesshouldfocusonindividualswithdiabetes, milddecreases inkidneyfunctionornormalGFR, Mexican-Americans(whoseaverageserumcreatinine islowerthanCaucasians), andnon-USpopulations. Theextenttowhichaveragingmultipleestimatesimprovesprecisionneedsfurtherstudy. Includingadirectmeasureofbody composition by bioelectric impedance or dual-energy X-ray absorptiometry scanning mayprovidepromisingdirectionsforimprovingonthepredictionofGFRusingserum Creatinine. Definition of Normal glomerular filtration rate Across Ages and Ethnicities ThedefinitionofdecreasedGFRreliesonanunderstandingofthenormalGFRrange. Theamountofdatainhealthyindividualsofdifferentethnicitiesandchildrenislimited. GFRmaydifferacrossethnicgroupsbutdataareverysparse. Itisalsounknowntowhat extentamilddecreaseinGFRamongindividualswithouthypertensionisindicativeor kidneydiseaseornormalaging. Prediction Equations for Creatinine Excretion Itwouldbeusefulinclinicalpracticetobeabletoestimatecreatinineexcretionfrom physiologicvariablesrelatedtocreatininegenerationandextra-renalelimination, such asage, gender, race, bodysize, andGFR. Thismightbedoneincross-sectionalstudies thatmeasuredthesephysiologicvariablesaswellas24-hoururinecreatinineexcretion. This would allow improved estimates of daily excretion of some Urine solutes from measurementsofsolute-to-creatinineratioinspoturinesamples. GUIDELINE 5. ASSESSMENT OF PROTEINURIA Normalindividualsusuallyexcreteverysmallamountsofproteinintheurine. Persistentlyincreasedproteinexcretionisusuallyamarkerofkidneydamage. Theexcretion 100 Part5. Evaluation NationalKidneyFoundation potassium/DOQI ofspecifictypesofprotein, suchasalbuminorlowmolecularweightglobulins, depends onthetypeofkidneydiseasethatispresent. Increasedexcretionofalbuminisasensitive markerforchronickidneydiseaseduetodiabetes, glomerulardisease, andhypertension. Increased excretion of Low molecular weight globulins is a sensitive marker for sometypes oftubulointerstitialdisease. Inthisguideline, theterm proteinuriarefers toincreasedurinaryexcretionofalbumin, otherspecificproteins, ortotalprotein; albuminuriarefersspecificallytoincreasedurinaryexcretionofalbumin. Microalbuminuriareferstoalbuminexcretionabovethenormalrangebutbelowthelevelofdetection bytestsfortotalprotein. Guidelinesfordetectionandmonitoringofproteinuriainadults andchildrendifferbecauseofdifferencesintheprevalenceandtypeofchronickidney disease. GuidelinesforAdultsandChildren Undermostcircumstances, untimed(spot)urinesamplesshouldbeusedtodetect andmonitorproteinuriainchildrenandadults. Itisusuallynotnecessarytoobtainatimedurinecollection(overnightor24-hour) fortheseevaluationsineitherchildrenoradults. First morningspecimens are preferred, butrandom specimens areacceptable if firstmorningspecimensarenotavailable. Inmostcases, screeningwithurinedipsticksisacceptablefordetectingproteinuria: Standardurinedipsticksareacceptablefordetectingincreasedtotalurineprotein. Albumin-specificdipsticksareacceptablefordetectingalbuminuria. Patientswithapositivedipsticktest(1(cid: 3)orgreater)shouldundergoconfirmation ofproteinuriabyaquantitativemeasurement(Protein-to-creatinineratiooralbuminto-creatinineratio)within3months. Patientswithtwoormorepositivequantitativeteststemporallyspacedby1to2 weeksshouldbediagnosedashavingpersistentproteinuriaandundergofurther evaluationandmanagementforchronickidneydiseaseasstatedinGuideline2. Monitoringproteinuriainpatientswithchronickidneydiseaseshouldbeperformed usingquantitativemeasurements. SpecificGuidelinesforAdults Whenscreeningadultsatincreasedriskforchronickidneydisease, albuminshould bemeasuredinaspoturinesampleusingeither: Albumin-specificdipstick; Albumin-to-creatinineratio. When monitoring proteinuria in adults with chronic Kidney disease, the Proteinto-creatinineratioinspoturinesamplesshouldbemeasuredusing: Albumin-to-creatinineratio; Totalprotein-to-creatinineratioisacceptableifalbumin-to-creatinineratioishigh ((cid: 1)500to1, 000mg/g). potassium/DOQI NationalKidneyFoundation Part5. Evaluation 101 SpecificGuidelinesforChildrenWithoutDiabetes Whenscreeningchildrenforchronickidneydisease, totalurineproteinshouldbe measuredinaspoturinesampleusingeither: Standardurinedipstick; Totalprotein-to-creatineratio. Orthostaticproteinuriamustbeexcludedbyrepeatmeasurementonafirstmorning specimeniftheinitialfindingofproteinuriawasobtainedonarandomspecimen. When monitoring proteinuria in children with chronic Kidney disease, the total Protein-to-creatinineratioshouldbemeasuredinspoturinespecimens. SpecificGuidelinesforChildrenWithDiabetes Screening and monitoring of post-pubertal children with Diabetes of 5 or more yearsofdurationshouldfollowtheguidelinesforadults. Screeningandmonitoringotherchildrenwithdiabetesshouldfollowtheguidelines forchildrenwithoutdiabetes. BACKGROUND Themeasurementofurinaryproteinexcretionprovidesasensitivemarkerofmanytypes ofkidneydiseasefromearlytoadvancedstages. Themostpertinentquestionwithrespect toscreeningforproteinuriaiswhetherearlydetectionofkidneydiseaseassociatedwith thisabnormalitywillresultinamoretimelyintroductionoftherapythatmayslowthe courseofdisease? Theanswerisyesatleastforsomechronickidneydiseases. For example, in diabetic Kidney disease, early detection of albuminuria appears to permit effectivetherapyearlyinthecourseofdisease.",
    "word_count": 583,
    "char_count": 11258,
    "sentence_count": 82,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 24,
      "total_chunks": 77,
      "position": "25/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "serum creatinine",
        "diet",
        "supplements"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 25,
    "text": "Themostpertinentquestionwithrespect toscreeningforproteinuriaiswhetherearlydetectionofkidneydiseaseassociatedwith thisabnormalitywillresultinamoretimelyintroductionoftherapythatmayslowthe courseofdisease? Theanswerisyesatleastforsomechronickidneydiseases. For example, in diabetic Kidney disease, early detection of albuminuria appears to permit effectivetherapyearlyinthecourseofdisease. The American Diabetes Association8 and the National Kidney Foundation-PARADE6, 7 have recommended assessment of proteinuria to detect chronic Kidney disease. These recommendations largelyagreeinthemethodsforassessmentofproteinuria. Thepurposeofthisguideline is to review the rationale for methods of assessment of proteinuria and to determine whetherdetectionandmonitoringofproteinuriausinguntimed(spot)urinesamples is as accurate as using timed (overnight or 24-hour) Urine specimens. Algorithms for screeningandevaluationofproteinuriainasymptomatic, healthyindividualsandinpatients at increased risk for chronic Kidney disease recommended by National Kidney Foundation-PARADE are giveninPart9. RATIONALE Criterion Standard Itisimportanttoconsiderthetimingofurinespecimensandthemethodsfordetection of Urine proteins. Although the basic concepts of measuring and interpreting urinary proteinexcretionhavechangedlittleoverseveraldecades, cliniciansmustnowdecide whether simple qualitative or more cumbersome quantitative tests are necessary and whetheralbuminortotalproteinshouldbemeasured. Inclinicalpractice, mostscreening (qualitative)methodsuseacommercialdipstick, whichmeasurestotalproteinoralbumin. Thesedipsticks, whichareofcoursesimpletouse, usuallyaffordhighspecificity; ie, theyhaverelativelyfewfalsepositiveresults, therebycreatingapracticaladvantage 102 Part5. Evaluation NationalKidneyFoundation potassium/DOQI fortheclinician. However, theyaffordlowsensitivity; ie, theymayfailtodetectsome formsofkidneydiseaseduringtheearlystages, whenthelevelofproteinuriaisbelow thesensitivityoftheteststripused. Timedurinecollectionsversusuntimed(spot)urinesamples. Whenscreening tests are positive, measurement of Protein excretion in a 24-hour collection has beenthe longstandinggold standardforthe quantitativeevaluation ofproteinuria. However, inrecentyearssomestudieshaveadvocatedthatthemeasurementofprotein excretionshouldbedoneonanovernightspecimen. Therationaleformeasuringproteinuriaintimedovernighturinecollectionsratherthan24-hourspecimensrelatestothelack ofconsistencywhenhourlyproteinexcretionratesareexaminedinthesameindividualat differenttimesduringtheday. Thisinconsistencyresultsfromvaryinglevelsofactivity andpossiblyotherfactorsthatarenotwelldocumented. Thehighintra-individualvariabilitythatensuesmakesserialcomparisonsinindividualpatientsverydifficultunlessmulti- ple measurements are taken. This problem is particularly troublesome for individuals withorthostaticproteinuriawhomayexcretemorethan1gofproteinduringwaking hours, butlessthan100mgduringsleep. Indeed, evaluationforpostural(orthostatic) proteinuriarequirescomparisonofameasurementofproteinexcretioninanovernight (recumbent)collectiontoadaytime(upright)collection. Analternative methodforquantitativeevaluation ofproteinuriais measurementof theratioofproteinoralbumintocreatinineinanuntimedspoturinespecimen. These ratioscorrectforvariationsinurinaryconcentrationduetohydrationandprovideamore convenientmethodofassessingproteinandalbuminexcretionthanthatinvolvedwith timedurinecollections. Theissuetobeexploredinthissectioniswhetherthisincreased level of convenience can be achieved without a reduced level of precision. Based on thereviewofevidenceaccumulatedoverthreedecades, theWorkGroupproposesthat the time has come to forego the traditional timed Urine collections and adopt the use of spot Urine measurements that compare the concentration of Protein to the concentrationofcreatinine. Totalprotein versusalbumin. Theassessment ofprotein excretionin theurine canbeaccomplishedbyseveraldifferenttechniques. Inadditiontostandardmethods ofmeasuringtotalprotein, therearenowmultipleversionsofimmunoassayscapableof detectingalbuminlevelsatconcentrationspresentinthemajorityofnormalpeople. In general, theliteraturedoesnotprovidesubstantialinformationconcerningtherelative meritsofmeasuringtotalproteinversusalbumintodetectandmonitorkidneydamage. Differentguidelinesforchildrenandadultsreflectdifferencesintheprevalenceofspecifictypesofchronickidneydisease. Strength of Evidence Rationale for ADULTS and CHILDREN This section will describe the rationale for using spot Urine samples to estimate proteinexcretionindividualsofallages, timingofurinesamples, anddipstickforquantitativeassessment. Thetwosubsequentsectionswillreviewdataforadultsandchildren separately. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 103 Rationale for Using Spot Urine Samples Collection of a timed Urine sample is inconvenient and may be associated witherrors(R, O). Twenty-four-hoururinecollectionsmaybeassociatedwithsignificantcollectionerrors, largelyduetoimpropertimingandmissedsamples, leadingtoovercollectionsandunder-collections. Timedovernightcollectionsorshortertimeddaytime collectionsmayreducetheinconvenienceofa24-hourcollection, butarestillassociated withcollectionerrors. Inaddition, errorsduetoincompletebladderemptyingarerelativelymoreimportantinshortercollectionintervals. Concentrationofproteininaspoturinesampleprovidesaroughindexof theproteinexcretionrate, butisalsoaffectedbyhydration(R, C). Theconcentrationofproteinintheurineisaffectedbyurinevolumeaswellasproteinexcretionrate. Urinevolumeisdependentprimarilyonthestateofhydration. Forexample, inapatient withurineproteinexcretionof500mgperdaytheproteinconcentrationmayvaryfrom 100mg/dL(2(cid: 3)onthedipstick)inapatientwithurinevolumeof500mL/dto20mg/ dL(traceonthedipstick)inapatientwithurinevolumeof2500mL/day. Despitethis, thereisaroughcorrelationbetweenproteinconcentrationinaspoturinesampleand proteinexcretionrate(Tables53, 54, and55). 104 Part5. Evaluation NationalKidneyFoundation potassium/DOQI Urineprotein-to-Creatinine andalbumin-to-Creatinine ratiosprovide accurateestimatesoftheurinaryproteinandalbuminexcretionrate, andarenot affectedbyhydration(R, C). Severalstudieshaveaddressedtherelationshipsbetween totalexcretionofproteinoralbuminandtheratioofeithertocreatinineinpatientsof allages(Tables56, 57, 58, and59). Sinceurineproteinsandcreatininearehighlysoluble inwater, theywillundergosimilar, ifnotidentical, dilutioninurine. Inprinciple, ifthe excretion of Creatinine is relatively constant throughout the day, and similar among individuals, thentheratioofprotein-to-creatinineinanuntimedsamplewouldreflectthe excretionofprotein. Althoughcreatinineexcretionvariesamongindividualsaccordingto age, gender, race, andbody size, the results fromthese studiesin adultsand children demonstrateastrongcorrelationbetweenthesemeasures. Rationale for Timing of Sample Collection A firstmorning urinespecimen is preferred, but randomurine specimens areacceptableiffirstmorningurinespecimensarenotavailable(R, O). Afirst morning Urine specimen is preferred because it correlates best with 24-hour Protein excretionandisrequiredforthediagnosisoforthostaticproteinuria. Inchildren, orthopotassium/DOQI NationalKidneyFoundation Part5. Evaluation 105 staticproteinuriamustbeexcludedbyafirstmorningurineproteinmeasurementifthe initialfindingofproteinuriawasobtainedonarandomspecimenduringtheday. Otherwise, for ease and consistency of collection, a random Urine specimen for Protein or albumintocreatinineratioisacceptableifafirst-morningurinespecimenisnotavailable. ThisrecommendationisconsistentwiththerecommendationsbytheAmericanDiabetes Association8andbytheNKFPARADE, 6, 7whichrecommendafirst-morningsample, but acceptarandomsampleifafirst-morningspecimenisnotavailable. Table 60 compares the advantages and disadvantages of the various modalities of collecting Urine for evaluating Kidney function. For all procedures, identical methods 106 Part5. Evaluation NationalKidneyFoundation potassium/DOQI are utilized in the laboratory. The differences among these protocols balance ease of collectionofsampleswiththeneedtocollecturinetoreflectkidneyfunctionoverthe courseofthedayorovernight. Rationale for Measurement Methods Screeningforproteinuriawithurinedipsticksisacceptable. Confirmation ofproteinuriashouldbeperformedusingquantitativemeasurements(R, O). Standardurinedipsticksdetecttotalproteinaboveaconcentrationof10to20mg/dL. The reagent peripheral arterial disease contains a colorimetric pHindicator dye which changes color when potassium/DOQI NationalKidneyFoundation Part5. Evaluation 107 boundbynegativelychargedserumproteins, includingalbuminandmostglobulins. The standardurinedipstickisinsensitiveforlowconcentrationsofalbuminthatmayoccur inpatientswithmicroalbuminuria. Inaddition, thestandarddipstickisalsoinsensitive topositivelychargedserumproteins, suchassomeimmunoglobulinlightchains. Albumin-specificdipsticksdetectalbuminaboveaconcentrationof3to4mg/dLand areusefulfordetectionofmicroalbuminuria. ConsistentwithrecommendationsbyADAandNKF-PARADE, theWorkGrouprecommendedscreeningusingeitherstandardoralbumin-specificdipsticks, orprotein-to-creatinineoralbumin-to-creatinineratio. Screeningwithadipstickforproteinuriaoralbuminuria is often a satisfactory first approach to evaluation of Kidney disease; however, clinicians need to be cognizant of causes of false positive and more importantly false negativeresults(Table61), andinbothinstancesrepeatanalysesofurinewithquantitativetotalproteinoralbuminandcreatinineanalysesarestronglyadvisedwhenaresult maybeinconsistentwiththeclinicalevaluation. Specialcareshouldbetakentoavoid falsenegativeresultswhichmaydelayimplementationoftreatmentearlyinthecourse ofkidneydisease. Monitoring proteinuria in patients with chronic Kidney disease should be performedusingquantitativemeasurements(O). Changesinproteinuriaprovide importantprognosticinformation. Increasingproteinuriaisassociatedwithahigherrisk of loss of Kidney function. Decreasing proteinuria, either spontaneously or after treatment, isassociatedwithalowerriskoflossofkidneyfunction. Quantitativemeasurementsprovideamoreaccurateassessmentofchangesinproteinuria.",
    "word_count": 591,
    "char_count": 10219,
    "sentence_count": 74,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 25,
      "total_chunks": 77,
      "position": "26/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "monitoring"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 26,
    "text": "Changesinproteinuriaprovide importantprognosticinformation. Increasingproteinuriaisassociatedwithahigherrisk of loss of Kidney function. Decreasing proteinuria, either spontaneously or after treatment, isassociatedwithalowerriskoflossofkidneyfunction. Quantitativemeasurementsprovideamoreaccurateassessmentofchangesinproteinuria. Rationale for Type of Protein: ADULTS Inadults, itispreferabletoassessproteinuriaasalbumin, because: Albuminuria is a more sensitive marker than total Protein for chronic Kidney disease due to Diabetes, hypertension, and glomerular diseases (R). 108 Part5. Evaluation NationalKidneyFoundation potassium/DOQI Inadults, themostcommontypesofchronickidneydiseaseareduetodiabetes, hypertension, andglomerulardiseases. Inpatientswithdiabetesmellitus, therehasbeennearly auniformadoptionofalbuminasthecriterionstandardinevaluatingkidneydamage. Thus, for this disease the same standards have been adopted for adults and children. Preliminarydatasuggestthatelevatedalbuminexcretionisalsoamarkerofkidneydamageinadultswithhypertension. Proteinuriain glomerulardiseasesisprimarilydueto increasedalbuminexcretion. Therefore, theWorkGroupconcludedthatalbuminshould bemeasuredtodetectandmonitorkidneydamageinadults. Theinterpretationofalbuminuriainkidneytransplantrecipientsismorecomplicated thaninotherpatientswithchronickidneydisease. First, dependingontheintervalsince transplantation, thepatientsnativekidneysmaystillexcretesmallamountsofprotein, whichmaybesufficienttocauseapositivetestforalbumin. Second, themaincauses of damage in Kidney transplant, rejection or toxicity from immunosuppressive drugs, arenotcharacterizedbyproteinuria. However, diabetickidneydiseaseistheunderlying causeforalargefractionofkidneytransplantpatients, whichmayrecurinthetransplant. Moreover, hypertensionisverycommonaftertransplantationandisstronglyassociated withamorerapidlossofkidneyfunctionintransplantpatients. Finally, recurrentglomerulardiseasemayoccuraftertransplantationandisassociatedwithagreaterriskofgraft loss. Albuminuriais a bettermarker than totalurine Protein ofkidney damagedue to Diabetes, hypertension, andglomerulardisease. Forthesereasons, theWorkGrouprecommends testing and monitoring for albuminuria, rather than total Protein, in Kidney transplantrecipients, aswellasinpatientswithothercausesofchronickidneydisease. Thecostortechnicaldifficultyofmeasuringalbuminmayexceedthatformeasuring totalprotein. Itisacceptabletomeasuretotalprotein-to-creatinineratioasanindexof proteinuriainadultswhenalbumin-to-creatinineratioissubstantiallyelevated(eg, (cid: 1)500 to1, 000 magnesium/g). However, thereis noreliable methodto convertratios ofalbumin-tocreatininetototalprotein-to-creatinineorviceversa. Rationale for Type of Protein: CHILDREN WITHOUT Diabetes In children without Diabetes, it is preferable to assess proteinuria as total Protein, because: Totalproteindetectsalbumin, whichusuallyispresentinlargequantities inglomerulardiseasesofchildhood(R). Totalproteindetectslowmolecularweightproteinswhicharepresentin othertypesofchronickidneydisease(non-glomerulardiseases)inchildhood(R). The prevalence of chronic Kidney damage due to Diabetes and hypertension is far lower in children than in adults. In contrast, the prevalence of Kidney disease due to urinarytractabnormalitiesandcongenitaltubulardisordersisfarmorecommoninchildren than in adults. 219 These latter diseases may be characterized by Low molecular weight proteinuria, which would be detected by tests for total Urine Protein, but not bytestsforalbumin. Therefore, theWorkGrouprecommendsthattotalurineprotein potassium/DOQI NationalKidneyFoundation Part5. Evaluation 109 shouldbemeasuredtodetectandmonitorkidneydamageinmostchildren, oneexceptionbeingchildrenwithdiabetesmellitus. Rationale for Type of Protein: CHILDREN WITH Diabetes Inpost-pubertalchildrenwithdurationofdiabetesgreaterthan5years, it ispreferabletoassessproteinuriaasalbuminbecause: Albuminuria is a more sensitive marker than total Protein for chronic kidneydiseaseduetodiabetes(R). In other children with Diabetes, it is preferable to assess proteinuria as totalproteinbecause: Totalproteindetectsalbumin, whichusuallyispresentinlargequantities inglomerulardiseasesofchildhood(R). Totalproteindetectslowmolecularweightproteinswhicharepresentin othertypesofchronickidneydisease(non-glomerulardiseases)inchildhood(R). Theriskofdiabetickidneydiseaseinchildrenishigherinpost-pubertalchildrenwith durationofdiabetesgreaterthan5yearsthaninotherdiabeticchildren. Forthesereasons, the American Diabetes Association recommends screening these children for chronic Kidney disease, using the same algorithm as for adults. Other diabetic children are screenedusingthesamealgorithmsasforotherchildren. LIMITATIONS Themainlimitationsofassessmentofproteinuriaasamarkerofchronickidneydisease is potential misclassification of individuals due variability of levels of total Protein or albumin in an individual over time and the extent to which conditions at the time of testing may obscure the true level. Excretion of total Protein or albumin in the Urine arehighlyvariableinindividualswithorwithoutkidneydisease. Moststudiessuggest that the standard deviation is about 40% to 50% of the mean. Examples of conditions that affect Protein excretion other than Kidney disease include activity, urinary tract infection, diet, andmenstruation. Attemptstoavoidthesepitfallsincludecarefuldefinitionofeventsthatshouldprecludetheinterpretationofabnormalresultsandconsidera- tionofrepeatstudieswhenabnormalresultsareobtained. Someauthorshaveadvocated thatmultiple(upto5)specimensbeobtainedinordertoobtainareliableresult. 42The WorkGroupdoesnotbelievethatsuchanapproachisfeasibleinmostinstances. However, theWorkGroupacknowledgestheneedtorepeatabnormaltests, especiallylow levels of total Protein or albumin and the necessity to carefully consider the clinical settingininterpretationofurineproteinmeasurements. Alimitationofthisguidelineistheuseofcorrelationcoefficients, ratherthanmore detailedassessmentsofprecisionandbias, toassesstheaccuracyofspoturinemeasurements of Protein-to-Creatinine ratios as a measure of Protein excretion rates. In most cases, datawerenotavailabletocharacterizetheprecisionandbias. Inaddition, other thandistinguishingnormalfromabnormal, theexactlevelofproteinuriaisnotusually requiredforclinicaldecision-making. Inmostcircumstances, aroughapproximation 110 Part5. Evaluation NationalKidneyFoundation potassium/DOQI of thelevel of proteinuria orchanges over timeare sufficient. Thus, the Work Group concludesthattheuniformlyhighcorrelationcoefficientsaresufficientlystrongevidence towarranttheconclusionspresentedhere. CLINICALAPPLICATIONS General considerations for adults and children The identification of persistent proteinuria or albuminuria in patients of all ages has importancewhenconsideringdiagnosis, prognosis, andtherapeuticoptions. Therelative easewithwhichproteinuriacanbeassessedandmonitoredallowsclinicianstoidentify individuals with completely asymptomatic forms of progressive Kidney disease during theearlystagesoftheirdisease. Suchpatientsmaybenefitfromsubsequentchangesin managementthatforestallorpreventadditionalkidneyproblems. Proteinuria is a key finding in the differential diagnosis of chronic Kidney disease. The relationship between the level of proteinuria and the type (diagnosis) of chronic kidneydiseaseisreviewedinGuideline6andinPart9. Proteinuriaisakeyprognosticfindinginchronickidneydisease. Theprognosisof patientswithavarietyofkidneydisordersoftencorrelateswiththeirlevelofandpersistenceofproteinuriaovertimeevenwhenothervariablesarecontrolled. Thisisimportant because of the obvious therapeutic implications for patients who are in the High riskcategorythatischaracterizedbypersistent, heavyproteinuria. Therelationshipbetweenthelevelofproteinuriaandriskforlossofkidneyfunctionisconsideredfurther inGuideline13. Finally, themostimportantclinicalapplicationofdefiningpatientswithproteinuria ispotentiallybeneficialtherapy. Manylinesofevidencenowindicatethatmedications that reduce proteinuria may provide significant long term benefits for patients with chronickidneydisease. Specific considerations for children The optimal frequency and timing of Urine screening for proteinuria in children have notbeenwellestablished. Atoneendofthespectrum, thegovernmentsofsomecountrieshavemandatedthatsuchscreeningbedoneonallschoolchildreneveryyear. In Japan, forexample, thishasbeeninplaceforover25years. 220Incontrast, theAmerican AcademyofPediatricsrecommendsthatsuchscreeningbedoneontwooccasionsduring childhoodonce before starting school and then again during adolescence.",
    "word_count": 599,
    "char_count": 8667,
    "sentence_count": 65,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 26,
      "total_chunks": 77,
      "position": "27/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "diet",
        "kidney transplant",
        "screening"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 27,
    "text": "Atoneendofthespectrum, thegovernmentsofsomecountrieshavemandatedthatsuchscreeningbedoneonallschoolchildreneveryyear. In Japan, forexample, thishasbeeninplaceforover25years. 220Incontrast, theAmerican AcademyofPediatricsrecommendsthatsuchscreeningbedoneontwooccasionsduring childhoodonce before starting school and then again during adolescence. 221 Some authorsevenconsiderthistobeexcessiveandhaveproposedthaturinalysisscreening belimitedtoasinglefirstmorningdipstickdoneatschoolentryageinallasymptomatic children. 222 Therecommendationsdescribedinthissectionforchildrenareconsistentwithother recentpublicationsfromtheNationalKidneyFoundationPARADE6, 7andtheAmerican DiabetesAssociation. 223Itshouldbenoted, however, thattheADApositionstatement drawsattentiontothefactthatmicrovasculardiseasemayoccurinprepubertalchildren andthatclinicaljudgmentshouldbeexercisedwhenindividualizingtheserecommendations. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 111 IMPLEMENTATIONISSUES Theimplementationoftheguidelinesinthissectionwillencounteratleasttwopotential obstacles. Thefirstisthewidelyheldbeliefthat24-hoururinecollectionsprovidethe onlyaccuratemethodofmeasuringproteinoralbuminexcretion. Thisevenappliesto somepediatricianswhocontinuetorequest24-hoururinestudiesinsmallchildrendespitethehighdegreeofdifficultyinvolved. Thesecondpotentialprobleminvolvestheadoptionofurineproteinmeasurements factoredbyurinecreatinine. Thisapproachhasbeendevelopedtosomeextentforurine calcium-to-creatininemeasurements, butmanyphysiciansarenotawareoftheaccuracy and validity of Protein-to-Creatinine ratios. Many clinical laboratories may not report ratiosofanalytestocreatinine. Asignificantamountofeducationwillbenecessaryto implementthisapproach. Alessobviousimplementationissuerelatestomeasuringalbuminratherthantotal proteinintheurinespecimens. Assaysforalbuminmaynotbeasavailableasthosefor total Protein in some smaller communities. In such instances, the use of a spot Urine andexpressionoftheurineprotein-to-creatinineratioisstillpreferabletothe24-hour collection. RESEARCHRECOMMENDATIONS Evaluatenovelapproachestomeasuringurineandbloodabnormalitieswhichmaypredateandpossiblypredictproteinuria/albuminuria. Examplesincludeelevatedlevelsof (cid: 3)-microglobulinandothertubularproteinsintheurineofdiabeticpatients. Additional 2 effortsshouldbeinstitutedtoidentifyconstituents presentinbloodand/orurinethat indicatenormalkidneyfunctionwithhighspecificity. Itwouldbeusefultoconductprospectivetrialsofthelong-termefficacyofantihypertensivemedicationsthatreducealbumin/proteinexcretioninkidneydisease. Thesestudiesshould incorporatebetterprocedures toexaminethe efficacyof sustainingkidney function in advanced Kidney disease and in reducing the incidence of cardiovascular diseaseinpatientswithkidneydisease. 224227 Itwouldalsobeusefultodeterminetherelationshipsbetweenfactorsthatmayaffect albumin/proteinexcretionandalsoincreasetheriskofmacrovasculardisease(eg, glucoseintolerance/diabetesmellitus, risingbloodpressure, elevatedlipidlevels, andobesity)andprogressivekidneyfailure. 228, 229 GUIDELINE 6. MARKERS OF CHRONIC Kidney DISEASE OTHER THAN PROTEINURIA Markers of Kidney damage in addition to proteinuria include abnormalities in the urinesedimentandabnormalitiesonimagingstudies. Constellationsofmarkersdefine clinicalpresentationsforsometypesofchronickidneydisease. Newmarkersareneeded todetectkidneydamagethatoccurspriortoareductioninGFRinothertypesofchronic kidneydiseases. Urinesedimentexaminationordipstickforredbloodcellsandwhitebloodcells 112 Part5. Evaluation NationalKidneyFoundation potassium/DOQI shouldbeperformedinpatientswithchronickidneydiseaseandinindividualsat increasedriskofdevelopingchronickidneydisease. Imagingstudiesofthekidneysshouldbeperformedinpatientswithchronickidney diseaseandinselectedindividualsatincreasedriskofdevelopingchronickidney disease. Althoughseveralnovelurinarymarkers(suchastubularorlow-molecularweight proteinsandspecificmononuclearcells)showpromiseoffutureutility, theyshould notbeusedforclinicaldecision-makingatpresent. BACKGROUND Abnormalurinaryexcretionofalbuminandtotalprotein(Guideline5)isahighlysensitive indicatorofglomerulardisease. Theresultsofurinesedimentexaminationandofimaging studiesofthekidney, however, canalsosuggestothertypesofchronickidneydiseases, includingvascular, tubulointerstitial, andcysticdiseasesofthekidney. Inaddition, proteinsotherthanalbuminintheurinemayindicatetubulointerstitialinjury. Atpresent, therearenoclinicallyprovenmarkersspecificfortubulointerstitialorvasculardiseases ofthekidney. Thepurposeofthisguidelineistoreview: abnormalitiesofurinesediment andabnormalitiesofimagingstudiesassociatedwithkidneydamage; therelationships oftheseabnormalitiestoclinicalpresentationsofkidneydisease; andpossiblenewmarkersofkidneydamage. RATIONALE Insomespecifictypesofchronickidneydisease, abnormalitiesotherthanproteinuria arepresentpriortoreductioninGFR. Ingeneral, urinalysisandultrasoundofthekidneys are helpful non-invasivetests to detect Kidney damage. Inaddition, these assessments providecluestothetype(diagnosis)ofchronickidneydisease. Abnormalities of the Urinary Sediment Examinationoftheurinarysediment, especiallyinconjunctionwithassessmentofproteinuria, isusefulinthedetectionofchronickidneydiseaseandintheidentificationof thetypeofkidneydisease. Urinarysedimentexaminationisrecommendedinpatients with chronic Kidney disease and should beconsidered in individuals at increased risk ofdevelopingchronickidneydisease. Cellsmayoriginatefromthekidneysorfromelsewhereintheurinarytract, including theexternalgenitalia. Castsformonlyinthekidneysandresultfromgelationwithinthe tubules of Tamm-Horsfall Protein, a High molecular weight glycoprotein derived from theepithelialsurfaceofthedistalnephron. Castsentrapmaterialcontainedwithinthe tubularlumenatthetimeofcastformation, includingcells, cellulardebris, crystals, fat, and filtered proteins. Gelation of Tamm-Horsfall glycoprotein is enhanced in concentratedurineandatacidicpHlevels. Examinationoftheurinarysedimentforcastsrequires carefulpreparation. Afreshfirstmorningspecimenisoptimal, andrepeatedexaminationmaybenecessary. Thepresenceofformedelementsintheurinarysedimentmayindicateglomerular, tubulointerstitial, orvascularkidneydisease. Significantnumbersoferythrocytes, leukopotassium/DOQI NationalKidneyFoundation Part5. Evaluation 113 cytes, orcellularcastsinurinarysedimentsuggestthepresenceofacuteorchronickidney disease requiring further work-up. The differential diagnosis for persistent hematuria, for example, is quite broad, including glomerulonephritis, tubulointerstitial nephritis, vasculardiseases, andurologicdisorders. Therefore, aswithproteinuria, specificdiagnosisrequirescorrelationofurinalysisfindingswithotherclinicalmarkers. Thepresence ofredbloodcellcastsstronglysuggestsglomerulonephritisasthesourceofhematuria. Dysmorphicredbloodcellsmayalsoindicateaglomerulardisease. Pyuria(leukocyturia)especially in the context of leukocyte castsmay be seen in tubulointerstitial nephritis, oralongwithhematuriainvariousformsofglomerulonephritis. Urinaryeosinophilshavebeenspecificallyassociatedwithallergictubulointerstitialnephritis. Examinationofasingleurinarysedimentmaybeadequateinmostcases. However, thefinding ofanegativeurinarysedimentinpatientsconsideredtobeathighriskforchronickidney diseaseshouldleadtoarepeatexaminationofthesediment. Table62providesabrief guidetotheinterpretationofproteinuriaandabnormalitiesinurinesediment. Urinedipsticksincludereagentpadsthataresensitiveforthedetectionofredblood cells (hemoglobin), neutrophils andeosinophils (leukocyteesterase), andbacteria (nitrites). Thus, urinesedimentexaminationisgenerallynotnecessaryfordetectionofthese 114 Part5. Evaluation NationalKidneyFoundation potassium/DOQI formedelements. However, dipstickscannotdetecttubularepithelialcells, fat, orcasts intheurine. Inaddition, urinedipstickscannotdetectcrystals, fungi, orparasites. Urine sedimentexaminationisnecessaryfordetectionoftheseabnormalities. Thechoiceof urinesedimentexaminationversusdipstickdependsonthetypeofkidneydiseasethat isbeingconsidered. Imaging Studies Abnormalresultsonimagingstudiessuggesteitherurologicorintrinsickidneydiseases. Imagingstudiesarerecommendedinpatientswithchronickidneydiseaseandinpatients atincreasedriskofdevelopingchronickidneydiseaseduetourinarytractstones, infections, obstruction, vesico-ureteralreflux, orpolycystickidneydisease. Hydronephrosis on ultrasound examination may be found in patients with urinary tractobstructionorwithvesico-ureteralreflux. Thepresenceofcystsmanifestedeither asmultiplediscretemacroscopiccystsorasbilaterallyenlargedechogenickidneyssuggests autosomal dominant or recessive polycystic Kidney disease. Increased cortical echoes are a nonspecific but sensitive indicator of glomerular, interstitial, or vascular diseases. Imaging studies employing iodinated contrast agents can cause acute Kidney damageandmaypresentsignificantriskstosomepatientswithdecreasedkidneyfunction. Thebenefitsofsuchstudiesmustbeweighedagainstpotentialrisks. Baselineimagingstudieswillbeappropriateinmanypatients. Theappropriatenessandfrequencyof follow-up studies will vary from case to case. Table 63 provides a brief overview of possibleinterpretationsofabnormalitiesonimagingstudiesofthekidney. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 115 Clinical Presentations of Kidney Disease Someconstellationsofabnormalitiesinbloodandurinetestsorimagingstudiescomprise specificclinicalpresentationsofkidneydisease. Thesepresentationsareoftennotdefinedpreciselyintextbooksandreviewarticles. Themajorfeaturesaredescribedbelow. Table64definesthesepresentationsaccordingtolevelofGFR, markersofkidneydisease (urineproteinexcretion, urinesedimentexamination, imagingstudies), andotherclinical features. DecreasedGFRandkidneyfailurearemarkersofmoreseverekidneydisease (CKDStages2through5). TheotherpresentationscanoccurwithoutdecreasedGFR (CKDStage1)andcanthereforeserveasmarkersofkidneydisease. Table65describes themostfrequentpresentationsforeachtypeofchronickidneydisease. DecreasedGFRandkidneyfailure. Eithercanbeacuteorchronicdependingon duration, andduetoanytype(diagnosis)ofkidneydisease. Nephriticandnephroticsyndromes. Nephriticsyndrome(formerlynephritis, alsotermedacuteglomerulonephritis)isanoutdatedterm, characterizedbyhematuria with red Blood cell casts, hypertension, and Edema, with or without decreased glomerular filtration rate. Nephroticsyndrome(formerlynephrosis)isdefinedastotalurineproteinexcretion in excess of 3, 500 magnesium/d (equivalent to a total Protein-to-Creatinine ratio greater than 116 Part5. Evaluation NationalKidneyFoundation potassium/DOQI approximately3, 000mg/g), reducedserumalbuminconcentration, andedema, withor withoutdecreasedGFR. Bothsyndromesindicatethepresenceofaglomerulardisease. TubularSyndromes. Therearedisordersresultingfromabnormaltubulehandling ofwaterorsolutes, withoutdecreasedGFR. Theyincludediversedisorderssuchasrenal tubularacidosis, nephrogenicdiabetesinsipidus, hyporeninemichypoaldosteronismand otherpotassiumsecretorydefects, renalglycosuria, renalphosphaturia, renalaminoaciduria, andmanyothers. Thesesyndromesoftenindicateatubularinterstitialdisease. Kidneydiseasewithurinarytractsymptoms. Mostkidneydiseasesareasymptomatic, but in some tubulointerstitial diseases symptoms are associated with the kidneys orlowerurinarytract. Themostcommoncausesincludeurinarytractinfections, obstruction, andstones. Asymptomaticurinalysisabnormalities. AbnormalitiesinurinaryproteinexcretionorinurinarysedimentwithoutdecreasedGFRorurinarytractsymptoms. Principal abnormalitiesincludehematuriawithredbloodcellcasts(duetoglomerulardiseases), pyuria with white Blood cell casts, renal tubular cells, coarse granular casts, or nonnephroticproteinuria. Asymptomaticradiologicabnormalities. Theseincludestructuralabnormalities potassium/DOQI NationalKidneyFoundation Part5. Evaluation 117 ofthekidneyobservedonimagingstudies, withoutdecreasedGFR, urinarytractsymptoms, orabnormalurinalysis. Highbloodpressureduetokidneydisease. Sustainedelevationofarterialblood pressureastheresultofdiseaseoftheparenchymaormajorvesselsofthekidney, with or without decreased glomerular filtration rate, but usually with either urinary abnormalities or radiologic abnormalities. Largevesseldiseases(unilateralorbilateral)areincludedaschronickidney diseases.",
    "word_count": 585,
    "char_count": 12417,
    "sentence_count": 107,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 27,
      "total_chunks": 77,
      "position": "28/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "nephritis",
        "albuminuria",
        "proteinuria",
        "creatinine",
        "potassium",
        "calcium",
        "magnesium",
        "hemoglobin"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 28,
    "text": "Sustainedelevationofarterialblood pressureastheresultofdiseaseoftheparenchymaormajorvesselsofthekidney, with or without decreased glomerular filtration rate, but usually with either urinary abnormalities or radiologic abnormalities. Largevesseldiseases(unilateralorbilateral)areincludedaschronickidney diseases. Strength of Evidence: New Urinary Markers Increasedurinaryexcretionofsomelowmolecularweight(LMW)proteins and N-acetyl-(cid: 3)-D-glucosaminidase (NAG) are key diagnostic indicators in a numberofspecifictubulardiseasesandmayidentifypatientsathigherrisk of glomerular filtration rate decline in other Kidney diseases (Tables 66, 67, 68, and 69) (C). Low molecularweightproteinuriaisadefiningfeatureinseveraluncommondiseasesofthe Kidney (Dents disease, autosomal dominant and cystinotic Fanconi syndrome, Lowe syndrome, Chineseherbsnephropathy). 231Theurinaryexcretionofretinol-bindingprotein (RBP), but not albumin, increases with the presence of Kidney scarring in reflux nephropathyinchildren. 232IncreasedurinaryexcretionratesoftheLMWproteinRBP andthetubularinjurymarkerNAGarefoundinmanypatientswithtypeIdiabetes, even intheabsenceofalbuminuria. 38, 42Excretionofthesemarkersappearstocorrelatewith the degree of glycemic control in some studies, 38, 42 but not in others. 233 In children withtypeIdiabetes andnormalalbuminexcretion, thepresence ofabnormalurinary NAG excretion at baseline indicates increased risk of developing microalbuminuria within5years(19. 5%versus0%, P(cid: 2)0. 05). 234Inelderlypatientswithtype2diabetes, individualswho developedmacrovascular diseaseafter 7years offollow-up tendedto havehigherbaselineNAGurinaryexcretionrates(P(cid: 2)0. 07). 233Elevatedurinaryexcretionof(cid: 3)-2-microglobulin((cid: 1)500ng/min)atbaselinepredicteddeteriorationofkidney functionoverameanfollow-upperiodofmorethan4yearsinadultpatientswithmembranousnephropathy. 235Inadultandpediatricpatientswithavarietyofkidneydiseases (focalsegmentalglomerularsclerosis, membranousnephropathy, membranoproliferative glomerulonephritis), a pattern of verylow molecular weight proteinuria by Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) was associated with a higherrateofdevelopmentofdecreasedkidneyfunctionatfollow-upthanwasapattern ofLowmolecularweightproteinuria(50%versus12. 5%; P(cid: 2)0. 0001). 236Inadultand pediatric patients with IgA nephropathy and normal Kidney function at baseline, the presenceofalowmolecularweightpatternofproteinuriabySDS-PAGEatpresentation was associated with anapproximately 4-fold increase in their riskof developing a decreasedGFRafter6yearsoffollow-up. 237 Urinaryexcretionofmononuclearcellsmayreflectthepresenceand/ordegreeofglomerularinjuryinsomeglomerulardiseases, includingdiabeticnephropathyandIgAnephropathy(Table70)(C). Inchildrenwithvariouskidney diseases, semiquantitativeevaluationofurinarypodocyteexcretioncorrelatedwiththe severityofmesangialproliferation, extracapillaryproliferation, tubulointerstitialchanges, 118 Part5. Evaluation NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part5. Evaluation 119 andproteinuria. 239InpediatricpatientswithHenoch-SchonleinnephritisorIgAnephropathyfollowedfor12months, thepatientswithresolutionofpodocyturiahadthegreatest resolution of acute inflammatory changes in their biopsies. 240 In adult patients with biopsy-provenIgAnephropathy, theextentofactivecrescentscorrelatedstronglywith thenumberofCD14(cid: 3)cells(macrophages)andCD56(cid: 3)cells(NKcells)inurinarysediment. 241 Inadultpatientswitheitherclinicallystablesystemiclupuserythematosus(SLE)nephritis(WHOclassesIIIa, b, IVb, c)orclinicallyactiveSLEnephritis(WHOclassesIVb, c), only the patients with active disease showed evidence of podocyturia. 242 In adult patientswithtype2diabetes, podocyteswerepresentintheurineof53%ofmicroalbuminuricsubjectsand80%ofmacroalbuminuricsubjects, butinnoneofthenormoalbuminuricsubjects. Treatmentwithanangiotensin-convertingenzymeinhibitor(ACE-inhibitor)reducedbothurinaryalbuminexcretionandpodocyturia. 243 LIMITATIONS The findings of hematuria, pyuria, and casts on urinalysis, or of cystic or echogenic kidneysonultrasound, arewellestablishedasindicatorsofvariouschronickidneydiseases. In the proper setting, these findings are sensitive markers for the presence of chronic Kidney disease, although they may not suggest a specific diagnosis. Since the novel markers described above (eg, Low molecular weight proteinuria, mononuclear cyturia)haveonlybeencorrelatedwithvariouschronickidneydiseasesinafewstudies to date, their application in clinical practice has not been established. In particular, inasmuchasthesemarkersmaycorrelatestronglywithproteinuria, itisnotcertainthat they can yet be considered independent indicators of disease or predictors of risk of diseaseprogression. CLINICALAPPLICATIONS In patients known to have chronic Kidney disease on the basis of a decreased glomerular filtration rate, urinalysisandimagingstudiesmayyieldimportantdiagnosticinformation. Forexample, thefindingofredbloodcellcastsintheurineindicatesahighlikelihoodofaproliferative 120 Part5. Evaluation NationalKidneyFoundation potassium/DOQI glomerulonephritis. This finding would lead to a serological work-up and probably a kidneybiopsy. Thefindingofdiffusenephrocalcinosisandnephrolithiasisonultrasound inapatientwithdecreasedGFRcouldsuggestthepossiblediagnosisofhyperoxaluria, leadingtospecificbloodtests. Inpatientsnotpreviouslyknowntohavechronickidneydiseasebutpresentingwith symptomssuggestiveofkidneydisease(eg, Edema, hematuria, orflankpain), examinationoftheurinarysedimentmayconfirmthepresenceofkidneydisease. Abnormalities in the sediment will be present in a large proportion of patients with chronic Kidney disease. On ultrasound examination, the presence of a Kidney stone and findings of obstruction may help to explain acute flank Pain. Radiologic assessment may help to clarifyotheraspectsofthenatureofthekidneyinvolvement. Forexample, bilateralsmall echogenickidneysinapatientpresentingwithnewlydetecteddecreasedkidneyfunction cansuggestachronicratherthananacuteprocess. Examination of the urinary sediment may lead to the detection of Kidney disease inpatientspresentingforevaluationofsymptomsrelatedtootherorgansystems. The evaluationoftheurineinpatientswithsignsofvasculitisorwithcarcinomasmayresult indetectionofassociatedkidneydisease. Findingssuggestiveofkidneydiseasemaybe expectedtooccurfrequentlyintheevaluationofindividualspresentingwithhypertension, especiallyyoungerindividuals. InselectedindividualswithanormalGFR, butknowntobeatriskofchronickidney disease, markersmayserveasscreeningtests. Forexample, apatientatriskonthebasis of a positive family history of polycystic Kidney disease should undergo a screening kidneyultrasoundoneormoretimesbeforeadulthoood. SeeGuideline3. Applicationofthenewerurinarymarkers(mononuclearcellsandspecificproteins such as NAG) described herein must await their validation in more extensive clinical studies. RESEARCHRECOMMENDATIONS Novelandexpandedusesofestablishedmethodologies(suchasDopplerorfunctional magnetic resonance imaging)shouldbepursuedinclinicalresearchstudies. Severalnovelurinarymarkersshow promiseofnoninvasivedemonstrationofkidneydamageorpredictionofdiseaseprogression. Noneappearstobereadyatthistimeforwidespreadapplicationinclinicalpractice. Longitudinalandfollow-upstudiesarenecessarytoverifywhetherabnormalNAGand possiblyretinol-bindingproteinexcretioninnormoalbuminuricdiabeticpatientsreliably predictlaterdevelopmentofmicroalbuminuriaanddiabeticnephropathy. Similarstudies areneededtoconfirmwhetherincreased(cid: 3)-2-microglobulinexcretionpredictsdevelopmentofkidneyfailureinpatientswithidiopathicmembranousnephropathy. Longitudinalstudiesofurinaryexcretionofspecificcelltypes(macrophages, NKcells, podocytes) indiabeticnephropathy, Henoch-Schonleinnephropathy, andIgAnephropathyarealso necessaryinordertoconfirmpreliminaryfindingsthatcyturiaisstronglyassociatedwith activityinthesediseases. Preliminaryworkontheurinaryexcretionofpodocyte-specific markerproteinssuchaspodocalyxinandnephrinshouldbevalidatedbyfurtherstudies. potassium/DOQI NationalKidneyFoundation Part5. Evaluation 121 PART 6. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH COMPLICATIONS IN ADULTS Many of the complications of chronic Kidney disease can be prevented or delayed by earlydetectionandtreatment. ThegoalofPart6istoreviewtheassociationofthelevel ofGFRwithcomplicationsofchronickidneydiseasetodeterminethestageofchronic kidneydiseasewhencomplicationsappear. AsdescribedinAppendix1, Table153, the WorkGroupsearchedforcross-sectionalstudiesthatrelatedmanifestationsofcomplications and the level of Kidney function. Data from NHANES III were also analyzed, as describedinAppendix2. Because of different manifestations of complications of chronic Kidney disease in children, especiallyingrowthanddevelopment, theWorkGrouplimitedthescopeof thereviewofevidencetoadults. AseparateWorkGroupwillneedtoaddressthisissue inchildren.",
    "word_count": 589,
    "char_count": 9035,
    "sentence_count": 62,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 28,
      "total_chunks": 77,
      "position": "29/77",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "nephropathy",
        "nephritis",
        "proteinuria",
        "sodium",
        "potassium",
        "edema",
        "glycemic control"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 29,
    "text": "Because of different manifestations of complications of chronic Kidney disease in children, especiallyingrowthanddevelopment, theWorkGrouplimitedthescopeof thereviewofevidencetoadults. AseparateWorkGroupwillneedtoaddressthisissue inchildren. The Work Group did not attempt to review the evidence on the evaluation and managementofcomplicationsofchronickidneydisease. Thisisthesubjectofpastand forthcoming clinicalpractice guidelines by theNational Kidney Foundationand other groups, whicharereferencedinthetext. RepresentativefindingsareshownbystageofchronickidneydiseaseinFigs15and 16. Figure15showsahigherprevalenceofeachcomplicationatlowerGFR. Figure16 Fig 15. Estimated prevalence of selected complications, by category of estimated glomerular filtration rate, amongparticipantsage(cid: 1)20yearsinNHANESIII, 1988to1994. Theseestimates arenotadjustedforage, themeanofwhichis33yearshigheratanestimatedGFRof 15to29mL/min/1. 73m2thanatanestimatedGFRof(cid: 1)90mL/min/1. 73m2. potassium/DOQI NationalKidneyFoundation Part6. Association 123 Fig16. Estimateddistributionofthenumberofcomplications, bycategoryofestimated GFRamongparticipantsage(cid: 1)20yearsinNHANESIII, 1988to1994. Theseestimates arenotadjustedforage, themeanofwhichis33yearshigheratanestimatedGFRof 15to29mL/min/1. 73m2thanatanestimatedGFRof(cid: 1)90mL/min/1. 73m2. shows a larger mean number of complications per person and higher prevalence of multiplecomplicationsatlowerGFR. Theseandotherfindingssupporttheclassification ofstagesofchronickidneydiseaseandarediscussedindetailinGuidelines7through 12. GUIDELINE 7. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH HYPERTENSION Highbloodpressureisbothacauseandacomplicationofchronickidneydisease. Asacomplication, highbloodpressuremaydevelopearlyduringthecourseofchronic Kidney disease and is associated with adverse outcomesin particular, faster loss of kidneyfunctionanddevelopmentofcardiovasculardisease. Blood Hypertension should be closely monitored in all patients with chronic Kidney disease. Treatmentofhighbloodpressureinchronickidneydiseaseshouldincludespecification of target Blood Hypertension levels, nonpharmacologic therapy, and specific antihypertensiveagentsforthepreventionofprogressionofkidneydisease(Guideline13)anddevelopmentofcardiovasculardisease(Guideline15). 124 Part6. Association NationalKidneyFoundation potassium/DOQI BACKGROUND Highbloodpressurecanbeeitheracauseoraconsequenceofchronickidneydisease. Adverseoutcomesofhighbloodpressureinchronickidneydiseaseincludefasterdecline inkidneyfunctionandcardiovasculardisease. Theappropriateevaluationandmanagementof highblood pressureremains amajor componentof thecare ofpatients with chronickidneydisease. Highbloodpressureisawell-recognizedpublichealthproblemintheUnitedStates. BasedonepidemiologicaldatafromtheNationalHighBloodPressureEducationProgram andtheNationalHealthandNutritionExaminationSurveys, theratesofdetection, treatment, andcontrolofhighbloodpressurehaveimproveddramaticallyoverthepastfive decades. Concomitantly, theratesofstroke, myocardialinfarction, andheartfailurehave decreasedbyapproximately15%to40%. 244However, duringthesametime, highblood pressureasacauseofESRDhasincreasedatanannualizedrateof10%forthelastseveral years, andcardiovasculardiseaseistheleadingcauseofdeathinESRD. 4, 245, 246Inpart thismaybeduetoinadequatecontrolofhighbloodpressureinpatientswithchronic kidneydisease. In1998, theNKFpublishedtheReportoftheTaskForceonCardiovascularDisease inChronicRenalDisease. 9OneofthemajorgoalsoftheTaskForcewastoassesscurrent knowledgeabouttheassociationofhighbloodpressureandcardiovasculardiseasein chronickidneydisease. PortionsoftheTaskForceReportarereproducedinthisguideline with permission of the authors. 247, 248 More recently, the National Kidney Foundation published a Report on ManagementofHypertensioninAdultswithRenalDiseasesandDiabetesfromtheExecutiveCommitteesoftheCouncilsonHypertensionandDiabeticKidneyDisease. 249 InJulyof2001, theNKFinitiatedaK/DOQIWorkGroupspecificallytoconducta detailedreviewofevidenceandtodevelopclinicalpracticeguidelinesforthemanagementofbloodpressureinchronickidneydiseasetopreventprogressionofkidneydisease anddevelopmentandprogressionofcardiovasculardiseaseinchronickidneydisease. Thegoalofthisguidelineistoprovideaselectedreviewoftheliteraturerelatinghigh bloodpressuretoadverseoutcomesofchronickidneydiseaseandtodescribetheassociationofthelevelofGFRwithhighbloodpressure, asreportedinNHANESIII. Guideline 13describestherelationshipofhighbloodpressuretoprogressionofkidneydisease. RATIONALE Definition Consensus panels in the United States and other countries have defined hypertension inadultsassystolicbloodpressuregreaterthan140mmHgand/ordiastolicbloodpressuregreaterthan90mmHg. TheSixthReportoftheJointNationalCommitteeforthe Prevention, Detection, EvaluationandTreatmentofHighBloodPressure(JNC-VI)classifiescategoriesofbloodpressurelevelsasshowninTable71. JNC-VIrecommendsagoalbloodpressureof(cid: 1)140/90mmHgforindividualswith highbloodpressurewithoutdiabetes, cardiovasculardisease, orchronickidneydisease. potassium/DOQI NationalKidneyFoundation Part6. Association 125 For individuals with Hypertension and decreased Kidney function, the recommendedgoalis(cid: 1)130/85mmHg. Strength of Evidence Highbloodpressuredevelopsduringthecourseofchronickidneydisease (R). Hypertension is a well-described complication of chronic Kidney disease. The prevalence of Hypertension is approximately 80% in hemodialysis patients and 50% in peritoneal Dialysis patients. 250, 251 In patients with earlier stages of Kidney disease, highbloodpressureisalsohighlyprevalent, varyingwithpatientcharacteristics such as the cause of Kidney disease and level of Kidney function. 252 There are many causesofhighbloodpressureinchronickidneydisease. Theclinicallymoreimportant pathogeneticmechanismsofhighbloodpressurearelistedinTable72. 248 Highbloodpressureisassociatedwithworseoutcomesinchronickidney disease(R). Inthegeneralpopulation, thereisastrong, gradedrelationshipbetween thelevelofbloodpressureandall-causemortalityandfatalandnonfatalcardiovascular disease. Optimallevelsofsystolicanddiastolicbloodpressurearedefinedaslessthan 120and80mmHg, respectively. Amongpatientswithchronickidneydisease, thereis alsosubstantialevidenceofarelationshipbetweenelevatedlevelsofbloodpressureand cardiovascularrisk. Inaddition, highbloodpressureisassociatedwithagreaterrateof decline in Kidney function and risk of development of Kidney failure. However, the optimal level of Blood Hypertension to minimize adverse outcomes for cardiovascular and kidneydiseasehasnotbeenestablished. Progressionofkidneydisease. ThissubjectisreviewedinmoredetailinGuideline 13. Thefollowingrepresentafewofthemanystudiesthatdemonstratetheserelationships. 126 Part6. Association NationalKidneyFoundation potassium/DOQI Diabetickidneydisease. Numerousepidemiologicalstudiesandclinicaltrialshave shown a relationship between the level of Blood Hypertension and faster progression of diabetickidneydisease. Figure17showstherelationshipinoneoftheearliestrandomizedtrials. 253 Nondiabetickidneydiseases. TheModificationofDietinRenalDiseaseStudyshowed asignificantrelationshipbetweentherateofdeclineinGFRandlevelofbloodpressure among patientswith predominantly nondiabetickidney disease. Thisrelationship was affectedbythebaselinelevelofurineprotein(Fig18). 255 Diseasesinthe kidneytransplant. Arelationshipbetweenlevel ofbloodpressure andprogressionofkidneydiseasehasnowbeenshownamongkidneytransplantrecipients. TheCollaborativeTransplantGroupdocumentedthathigherbloodpressureafter kidneytransplantationisassociatedwithmorerapiddevelopmentofgraftfailure256(Fig19). Cardiovasculardiseaseandmortality. Theprevalenceofcardiovasculardisease andrelatedoutcomesinpatientswithdecreasedGFRhasnotbeenevaluatedinlargescaleepidemiologicalstudies, andlittleisknownaboutCVDmortalityandmorbidityin thesepatients. Severalstudieshaveshownahighprevalenceofleftventricularhypertrophy(LVH)inpatientswithdecreasedGFRandpatientsbeginningdialysis. Inonestudy, a higher level of systolic Blood Hypertension, lower level of Kidney function, more severe anemia, andolderagewereindependentlyassociatedwithhigherleftventricularmass index. 257Afewstudieshaveshownarelationshipbetweenhighersystolicbloodpressure andclinical cardiovasculardiseaseevents. 258, 259 Amongdialysispatients, higherblood pressureisclearlyassociatedwithdevelopmentofcardiovasculardisease. Table73shows potassium/DOQI NationalKidneyFoundation Part6. Association 127 Fig17. Relationshipbetweenbloodpressureandprogressionofdiabetickidneydisease. Meanarterial bloodpressure, albuminexcretion rate, andGFRin patientswith type1diabetesrandomlyassignedtoareductioninmeanarterialpressureof10mmHg usingmetoprololat100to400mg/d, hydralazineat50to200mg/d, andfurosemideat 80to500mg/dversusnoantihypertensivetherapy. Solidcirclesrepresentthetreated group. Opencirclesrepresentthecontrolgroup. Verticallinesrepresentstandarderror. StudywasstoppedearlierinthecontrolgroupbecauseoffasterdeclineinGFR. Reprinted withpermission. 253 Fig 18. Relationship between mean arterial Blood Hypertension and glomerular filtration rate decline. Mean glomerular filtration rate decline and achieved follow-up Blood Hypertension in MDRD Study A (patients with baselineGFR25to55mL/min/1. 73m2). Regressionlinesrelatingtheestimatedmean GFRdeclineover3yearstomeanfollow-upMAPforgroupsofpatientsdefinedaccording tobaselineproteinuria. Withineachgroup, a3-slopemodelwasusedwithbreakpoints at92and98mmHg. Reprintedwithpermission. 255 128 Part6. Association NationalKidneyFoundation potassium/DOQI Fig19. Relationshipbetweensystolicbloodpressureandgraftsurvival. Associationof systolicbloodpressureat1yearwithsubsequentgraftsurvivalinrecipientsofcadaveric kidneytransplants. RangesofsystolicbloodpressurevalueinmmHgandnumberof patientsstudiedinthesubgroupsareindicated. Theassociationofsystolicbloodpressure withgraftsurvivalatsevenyearswasstatisticallysignificant(P(cid: 1)0. 0001). Reproduced withpermission. 256 potassium/DOQI NationalKidneyFoundation Part6. Association 129 Fig20. Mortalityversussystolicbloodpressureinhemodialysispatients. DialysisClinic, Inc. prevalentcohort(1992to1996, n(cid: 1)5433). 262Coxregressionanalysisincluding age, race, gender, anddiagnosisasbaselinecovariates, andpredialysisorpostdialysis systolicbloodpressure, albumin, andKt/Vastime-dependentcovariates. Reprintedwith permission. 248 therelationshipbetweenmeanarterialpressureandvariouscardiovasculardiseaseoutcomesinaprospectivecohortofincidentdialysispatients. 260Leftventricularhypertrophyandcongestiveheartfailurewerebothstronglyassociatedwithsubsequentmortality. However, lowerratherthanhigherbloodpressurewasassociatedwithahigherriskof death. The association between level of Blood Hypertension and mortality does not appear to be consistent, with a number of studies reporting either positive or negative associations.",
    "word_count": 595,
    "char_count": 10949,
    "sentence_count": 110,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 29,
      "total_chunks": 77,
      "position": "30/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "anemia",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 30,
    "text": "248Onerecentstudyshowedabimodaldistribution(U-shapedrelationship)with excess risk in hemodialysis patients with normal or Low Blood Hypertension, as well as in patientswithveryhighbloodpressure262(Fig20). Itislikelythatexcessriskinpatients withlowbloodpressurereflectsconfoundingeffectsofunderlyingorpre-existingcardiovasculardiseaseonmortality, whilethetruerelationshipofbloodpressuretomortality isreflectedintheexcessriskinpatientswithveryhighbloodpressureasinthegeneral population. Overall, thesestudiesdemonstratethathighbloodpressureisassociatedwithfaster progressionofchronickidneydisease, developmentofcardiovasculardisease, and, likely, highermortalityinpatientswithchronickidneydisease. Prevalence of Hypertension is related to the level of glomerular filtration rate. Patients with chronic Kidney disease have a High prevalence of Hypertension, evenwhenGFRisonlymildlyreduced(S). Figure21showstherelationshipbetween GFRandprevalenceofhypertensionamong1, 795patientsinthebaselinecohortofthe 130 Part6. Association NationalKidneyFoundation potassium/DOQI Fig21. Prevalenceof highbloodpressureby levelofGFRinthe MDRDStudy. High Blood Hypertension was defined as classification by study investigators based on patient history(includingtheuseofantihypertensivedrugs)andreviewofmedicalrecords. glomerular filtration rate wasmeasuredbyurinaryclearanceof125I-iothalamate. PatientswererankedbyGFR into10groups, eachcontaining179or180patients. Dataarepresentedasmeanvalues (cid: 2)standarderrors. MDRDStudy. 263AtGFRlevelsof60to90mL/min/1. 73m2, theprevalenceofhighblood pressurewasapproximately65%to75%. Inthisstudy, highbloodpressurewasdefinedby patienthistory(includingtheuseofantihypertensivemedications)andmedicalrecords, ratherthanthelevelofbloodpressure. InadditiontoGFRlevel, theprevalenceofhigh bloodpressurewassignificantlygreateramongmenandindividualswithhigherbody massindex, blackrace, andolderage. Figure22showstheprevalenceofhighbloodpressurebylevelofGFRamong15, 600 patientsparticipatingintheNHANESIII. Twolevelsofhighbloodpressurearedepicted: JNCStage1orgreater(systolicbloodpressure(cid: 1)140mmHgordiastolicbloodpressure (cid: 1)90mmHg, ortakingmedicationsforhighbloodpressure); andJNCStage2orgreater (systolicbloodpressure(cid: 1)160mmHgordiastolicbloodpressure(cid: 1)100mmHg). In NHANES III, the approximately 40% prevalence of Hypertension among individualswithGFRofapproximately90mL/min/1. 73m2waslowerthanintheMDRD Study, presumably becausenot all patients with GFRin this range inNHANES III had chronickidneydisease. AmongpatientswithlowerGFR, theprevalenceofhighblood pressureissimilartothatobservedintheMDRDStudy. Notably, theprevalenceofJNC Stage(cid: 1)2highbloodpressureisapproximately20%amongindividualswithGFR15to 30 milliliters per minute/1. 73 m2, which is approximately 2-fold greater than among patients with higherGFR. potassium/DOQI NationalKidneyFoundation Part6. Association 131 Fig22. PrevalenceofhighbloodpressurebylevelofGFR, adjustedtoage60years (NHANESIII). Predictedprevalenceofhighbloodpressureamongadultparticipantsage 20yearsandolderinNHANESIII, 1988to1994. Valuesareadjustedtoage60years usinga polynomialregression. 95% confidenceintervalsare shownat selectedlevels ofestimatedGFR. Hypertension is not optimally controlled in patients with chronic kidneydisease(S). ArecentanalysisoftheNHANESIIIdatabaseassessesthelevelof bloodpressurecontrolamongindividualswithdecreasedkidneyfunction. 5Decreased kidneyfunctionwasdefinedaselevatedserumcreatinine((cid: 1)1. 6mg/dLinmenor(cid: 1)1. 4 magnesium/dLinwomen). An estimated 3% (5. 6 million) of the ultrasound population had elevated serum Creatinine accordingtothisdefinition, andofthese70%hadhighbloodpressure. Amongindividuals withdecreasedkidneyfunctionandhighbloodpressure, 75%receivedtreatment. However, only 11% of individuals with Hypertension and elevated serum Creatinine had Blood Hypertension (cid: 1)130/85 mm Hg, and 27% had Blood Hypertension (cid: 1)140/90. Treated Fig23. PrevalenceofelevatedserumcreatininebyJNC-VIbloodpressurecategoryand self-reportedtreatmentwithanti-hypertensivemedications(NHANESIII). Barsindicate standarderrors. Reprintedwithpermission. 5 132 Part6. Association NationalKidneyFoundation potassium/DOQI Fig 24. Estimated number of individuals with elevated serum Creatinine by JNC-VI bloodpressurecategoryandself-reportedtreatmentwithanti-hypertensivemedications (NHANESIII). Barsindicatestandarderrors. Reprintedwithpermission. 5 individualshadameanbloodpressureof147/77mmHg, with48%prescribedonlyone antihypertensive medication. Thus, it appears that additional efforts will be necessary to lowersystolic bloodpressure. Multi-drugtherapy may benecessary inthe majority ofpatients. Figures 23 and 24 show the prevalence and number of individuals with elevated serumcreatinineamongpatientsreceivingandnotreceivingantihypertensivetherapy, accordingtobloodpressurecategory. ThelargestnumberoftreatedanduntreatedindividualshaveJNCStage1highbloodpressure(140to159/90to99mmHg). Treatmentofhighbloodpressureinchronickidneydiseaseshouldinclude specificationoftargetbloodpressurelevels, nonpharmacologictherapy, and specific antihypertensive agents for the prevention of progression of Kidney disease(Guideline13)anddevelopmentofcardiovasculardiseaseinpatients with chronic Kidney disease (Guideline 15) (R). Specific recommendations for evaluationandmanagementofhighbloodpressureinchronickidneydiseasearebeyond thescopeofthisguideline. Theinvestigationofantihypertensiveagentstopreventor delaytheprogressionofchronickidneydiseaseanddevelopmentofcardiovasculardisease is a rapidly evolving. A number of guidelines and recommendations have been developed. Inaddition, theroleofnon-pharmacologictherapyforthetreatmentofhigh bloodpressure, andasadjunctsinthepreventionandtreatmentofcardiovasculardisease, arealsounderinvestigation. Recommendationsbyothergroupsandrecentstudiesare reviewedinGuidelines13and15. LIMITATIONS UnlikeotherguidelinesinPart6, thisguidelineisnotbasedonasystematicreviewof theliterature. Anotherlimitationisthelackoflarge-scalecohortstudiesandclinicaltrials correlatingbloodpressurelevelstosubsequentlossofGFRandcardiovasculardisease events. Since both chronic Kidney disease and cardiovascular disease are chronic illnesses, observational studies are subject to confounding by survival bias, whereby potassium/DOQI NationalKidneyFoundation Part6. Association 133 patients with more severe risk factors may not have survived to be entered into the study, therebyminimizingtheapparentassociationbetweenriskfactorsandoutcomes. Thus, clinical trials may be required to determine the optimal level of Blood Hypertension to prevent or slow progression of chronic Kidney and development of cardiovascular disease. Amajorlimitationofcross-sectionalstudieshasbeentheabsenceofacleardefinition of chronic Kidney disease. Since many patients with chronic Kidney disease are not detected until late in the course, studies that rely on clinical diagnosis are subject to misclassification. The strong relationship between prevalence of Hypertension andGFRlevelobservedinNHANESIII, irrespectiveofdiagnosisofchronickidneydisease, isespeciallyimportantinconfirmingthelinkbetweendecreasedGFRandhighblood Hypertension. However, cross-sectional studies do not permit determination of the causal relationshipbetweenthesevariables. Thus, theycannotdeterminewhetherhighblood pressureisacauseoracomplicationofchronickidneydisease, orwhetherbothhigh bloodpressureanddecreasedGFRarecausedbyathirdfactor, suchasaging. Nonetheless, the data from both the MDRDStudy and NHANES III show a High prevalence of Hypertension among persons with decreased glomerular filtration rate, justifying the emphasis on monitoringandtreatmentofhighbloodpressureinpatientswithchronickidneydisease. CLINICALAPPLICATIONS Detection, evaluation and management of Hypertension should be the goal for all health care providers for patients with chronic Kidney disease. Providers must be awareoflowerrecommendedtargetlevelsforbloodpressureforpatientswithchronic kidneydisease, specificrecommendationsforclassesofantihypertensiveagents, andthe roleofnonpharmacologictherapy. IMPLEMENTATIONISSUES Measuring Blood Hypertension at routine health encounters is widely recommended and practiced.",
    "word_count": 572,
    "char_count": 8285,
    "sentence_count": 73,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 30,
      "total_chunks": 77,
      "position": "31/77",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "potassium",
        "magnesium",
        "serum creatinine",
        "antihypertensive",
        "hemodialysis",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 31,
    "text": "IMPLEMENTATIONISSUES Measuring Blood Hypertension at routine health encounters is widely recommended and practiced. The large number of individuals with Blood Hypertension above the target goal suggestsanumberofpossibleobstaclestoimplementation, suchas: Limitedaccesstoorutilizationofhealthcareformanypatientswithchronickidney disease Inadequaterecognitionofchronickidneydiseaseinpatientswithhighbloodpressure Inadequate education of patients and providers regarding lower Blood Hypertension goals, specificclassesofantihypertensiveagents, andappropriatenonpharmacologictherapyforpatientswithchronickidneydisease Difficultyinattainingbloodpressurecontrolinpatientswithchronickidneydisease. Thehighprevalenceofearlierstagesofchronickidneydiseaserequiresacoordinated nationaleffortbygovernmentalagenciesandnongovernmentalorganizationstoaddress theseissues. 134 Part6. Association NationalKidneyFoundation potassium/DOQI RESEARCHRECOMMENDATIONS Abroadsetofrecommendationsforresearchonhighbloodpressureinchronickidney disease was developed by the National Kidney Foundation Task Force on Cardiovascular Disease in Chronic RenalDisease. 248 Recommendationsforobservational studiesarereproduced inTable 74andforclinicaltrialsinTable75. potassium/DOQI NationalKidneyFoundation Part6. Association 135 GUIDELINE 8. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH ANEMIA Anemiausuallydevelopsduringthecourseofchronickidneydiseaseandmaybe associatedwithadverseoutcomes. Patients with glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2 should be evaluated for anemia. The evaluationshouldincludemeasurementofhemoglobinlevel. AnemiainchronickidneydiseaseshouldbeevaluatedandtreatedseeK/DOQI ClinicalPracticeGuidelinesforAnemiaofChronicKidneyDisease, Guidelines1 through4, asshowninFig25. BACKGROUND Itiswellestablishedthatanemiadevelopsinthecourseofchronickidneydiseaseand isnearlyuniversalinpatientswithkidneyfailure. 264Thedevelopmentofeffectivetherapeuticoptions, suchaserythropoietintherapy, hasprovidedfortheeffectivetreatment Fig25. Anemiawork-upforpatientswithchronickidneydisease. Modifiedandreproducedwithpermission. 265, 266 136 Part6. Association NationalKidneyFoundation potassium/DOQI ofanemia. AnearlierK/DOQIclinicalpracticeguidelineisdevotedtothistopic265, 266; however, thatguidelinefocusedprimarilyonpatientstreatedbydialysis. Thisguideline addressesanemiaintheearlierstagesofchronickidneydisease. Importantly, pastguidelineshavereliedonserumcreatininelevels(cid: 2)2mg/dLasthe criteriontotestforthepresenceofanemia. TheWorkGrouprecommendsthattheK/ DOQI Anemia guideline be updatedto in corporate estimated glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2totriggertheascertainmentofanemia, ratherthanthepreviouslycitedserumcreatininelevels(Fig25). RATIONALE Definition of Anemia Measuresusedtoassessanemiaanditscausesincludehemoglobin, hematocrit, andiron stores(asmeasureddirectlybybonemarrowbiopsy, orindirectlyasmeasuredbyserum ferritin, transferrinsaturationlevels, andpercentageofhypochromicredbloodcellsor reticulocytes). Erythropoietin levels are less useful as a measure of anemia in chronic Kidney disease, since it is now well established that they are often not appropriately elevateddespitelowhemoglobinlevels. 267271 Measurement of hemoglobin, rather than hematocrit, is the preferred method for assessinganemia. Unfortunately, thisissuehasbeenconfusedduetotheuseofhematocrit in a number of studies. Hematocrit is a derived value, affected by plasma Water, and thussubjecttoimprecisionasadirectmeasureoferythropoiesis. Measurementofhemoglobingivesanabsolutevalueand, unlikehematocrit, isnotaffectedgreatlybyshiftsin plasmawater, asmayoccurwithdiureticsorwithdialysistherapy. Hemoglobinlevels aredirectlyaffectedbylackoferythropoietinproductionfromthekidneyandthusserve asamoreprecisemeasurementoferythropoiesis. Whiledecreasedhemoglobinoftenaccompanieschronickidneydisease, thereisno quantitativedefinitionofanemiainchronickidneydisease, sinceacceptable(normal) hemoglobinlevelshavenotbeendefinedforpatientswithkidneydisease. Instead, anemia is defined according to physiological norms. All patients with chronic Kidney disease whohavehemoglobinlevelslowerthanphysiologicalnormsareconsideredanemic. Thedefinitionofanemiainchronickidneydiseaseisfurthercomplicatedbygender differencesinhemoglobinlevels. Inthenormalpopulation, hemoglobinlevelsvarybetweengendersandalsoasafunctionofmenopausalstatus. TheWorldHealthOrganizationdefinesanemiatobethatlevelofhemoglobinandgender-determinednormalranges withoutreferencetoageormenopausalstatus. 272Thus, formales, anemiaisdefinedas hemoglobinlevel(cid: 1)13. 0g/dL, whileinwomen, anemiaisdefinedashemoglobinlevel (cid: 1)12. 0 grams per deciliter. The WHO is in the process of updating these definitions to expand and refinethem withspecific levelsin pregnantwomen andchildren ofdifferent ages. In most studies of anemia related to the level of Kidney function, these issues have not beentakenintoaccount. The operationaldefinition of anemiain patients withkidney disease hasalso been influencedbyhealthpolicy. Inthepast, nationalreimbursements(suchasMedicareand potassium/DOQI NationalKidneyFoundation Part6. Association 137 MedicaidintheUnitedStates)haverequiredtheattainmentofspecificlevelsofhemoglobinorhematocrit, leadinginvestigatorsandclinicianstodefineanemiarelativetothose regulatorylevels. AsstatedintheEuropeanBestPracticeGuidelinesfortheManagement of Anaemia, 273 it is important to define anemia relative to physiological norms rather thanpaymentrules. Somestudieshavearbitrarilydefinedtheanemiaofkidneydiseaseasahemoglobin levelbelowsomediscretionarylevel(eg, 10g/dL)thatiswellbelowthenormativevalues inthegeneralpopulation. Thelowhemoglobinlevelthatisoftenseeninchronickidney disease should not lead to the acceptanceof lower than normal hemoglobin levels as appropriateinpatientswithchronickidneydisease. Strength of Evidence Anemia develops during the course of chronic Kidney disease (R). Lower hemoglobinmayresultfromthelossoferythropoietinsynthesisinthekidneysand/or thepresenceofinhibitorsoferythropoiesis. Numerousarticlesdocumenttheassociation ofanemiawithkidneyfailureanddescribeitsvariouscauses. 267, 268, 274276Theseverity ofanemiainchronickidneydiseaseisrelatedtothedurationandextentofkidneyfailure. Thelowesthemoglobinlevelsarefoundinanephricpatientsandthosewhocommence dialysisatveryseverelydecreasedlevelsofkidneyfunction. 271, 277, 278 Anemiaisassociatedwithworseoutcomesinchronickidneydisease(R). As yet it is undetermined whether the presence of anemia in chronic Kidney disease directlyworsensprognosisorwhetheritisamarkerfortheseverityofotherillnesses. Definitivestudieshavenotbeenconcluded. Theavailableevidence, consistingoflarge databaseanalysisand populationstudies, clearlyshowthatlow hemoglobinlevelsare associatedwithhigherratesofhospitalizations, cardiovasculardisease, cognitiveimpairment, andotheradversepatientoutcomes, includingmortality. 279284 Erythropoietindeficiencyistheprimarycauseofanemiainchronickidney disease (R). Anemia in patients with chronic Kidney disease is due to a number of factors, themostcommonofwhichisabnormallylowerythropoietinlevels. Othercauses include: functionalorabsoluteirondeficiency, bloodloss(eitheroccultorovert), the presence of uremic inhibitors (eg, parathyroid hormone, spermine, etc), reduced half lifeofcirculatingbloodcells, deficienciesoffolateorVitaminB, orsomecombination 12 ofthese witha deficiencyoferythropoietin. 267269, 274, 275 Patientswith kidneydisease may have concurrent underlying hematological problems such as thalassemia minor, sicklecelldisease, oracquireddiseasessuchasmyelofibrosisoraplasticanemia. Thecausativeroleoferythropoietindeficiencyinanemiaofchronickidneydisease includes: (1)anemiaisresponsivetotreatmentwitherythropoietininallstagesofchronic Kidney disease; and (2) in patients with chronic Kidney disease, circulating levels of erythropoietinarenotsufficienttomaintainhemoglobinwithinthenormalrange. North American (United States and Canada) and European studies have demonstrated these points. 270, 271, 282, 285287 138 Part6. Association NationalKidneyFoundation potassium/DOQI OnsetandseverityofanemiaarerelatedtothelevelofGFR; belowaGFR ofapproximately60mL/min/1. 73m2, thereisahigherprevalenceofanemia (Tables 76 and 77 and Figs 26, 27, 28, and 29) (C, S). Studies reviewed for the purposesofthisguidelineincludethoseofpatientswithchronickidneydiseaseprior todialysis, thosewithkidneytransplants, andthoseondialysis. Thereviewedliteraturespansalmost30yearsofinvestigationanddescribestheclinicalfindingsofresearchersastheyexplore therelationshipsbetweenhemoglobinand Kidney function (Tables 76 and 77). The majority of available data have been derived fromstudiesofsmallsamplesize, mostofwhicharecross-sectionalstudiesorbaseline datafromclinicaltrialsofvariablesizeandrobustness. Thesestudiesarepredominantly ofonlymoderateormodestqualityfromamethodologicalstandpoint. Theconsistencyof theinformationtheyprovideddoes, however, indicateatrendtowardlowerhemoglobin levelsatlowerlevelsofGFRandavariabilityinhemoglobinlevelsacrossGFRlevels. In 12 of the 22 studies reviewed, there was an association between the level of hemoglobinorhematocritandtheselectedmeasureofkidneyfunction. Dataobtained fromtheNHANESIIIanalysis(Fig26)demonstratesanassociationbetweenhemoglobin andlevelofGFRatGFRlevels(cid: 1)90mL/min/1.",
    "word_count": 600,
    "char_count": 9438,
    "sentence_count": 73,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 31,
      "total_chunks": 77,
      "position": "32/77",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "potassium",
        "hemoglobin",
        "hematocrit",
        "parathyroid hormone",
        "ferritin",
        "erythropoietin",
        "anemia"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 32,
    "text": "In 12 of the 22 studies reviewed, there was an association between the level of hemoglobinorhematocritandtheselectedmeasureofkidneyfunction. Dataobtained fromtheNHANESIIIanalysis(Fig26)demonstratesanassociationbetweenhemoglobin andlevelofGFRatGFRlevels(cid: 1)90mL/min/1. 73m2. Whiletheincreaseinprevalence ofanemiaismostnotableinthepopulationstudiedatGFRlevels(cid: 1)60mL/min/1. 73m2, anemiacanbepresentinpatientswithhigherGFRlevels. Duetothesparcityofdata potassium/DOQI NationalKidneyFoundation Part6. Association 139 Fig26. BloodhemoglobinpercentilesbyGFRadjustedtoage60(NHANESIII). Median and5thand95thpercentilesofhemoglobinamongadultparticipantsage20yearsand olderinNHANESIII, 1988to1994. Valuesareadjustedtoage60yearsusingapolynomialquantileregression. TheestimatedGFRforeachindividualdatapointisshownwith aplussign((cid: 3))neartheabscissa. 95%confidenceintervalsatselectedlevelsofestimated GFRaredemarcatedwithtriangles, squares, andcircles. 140 Part6. Association NationalKidneyFoundation potassium/DOQI Fig27. Adjusted prevalenceinadults oflowhemoglobin byGFR(NHANES III). Predictedprevalenceofhemoglobin(cid: 1)11and(cid: 1)13g/dLamongadultparticipantsage20 years and older in NHANES III, 1988 to 1994. Values are adjusted to age 60 years using apolynomial regression. 95% confidenceintervals areshown atselected levels ofestimatedGFR. pointsatvalues(cid: 1)30mL/min/1. 73m2intheNHANESIIIdatabase, theCanadianMulticentreStudy288wasutilizedtodemonstratetrendsinalargecohortofpatientspriorto Dialysis(Fig28). NoteinFig29theincreaseinprevalenceofanemiaatlowerlevelsof glomerular filtration rate, but the existence of up to 20% of patients with anemia at higher, though still abnormal levels of glomerular filtration rate (30 to 44 milliliters per minute/1. 73 m2). Thus, the NHANES III data are consistent with data derived from populations with Kidney disease and lower GFR288 (Figs28and29). PublishedstudiescitedinTables76and77demonstrateavariabilityinthelevelsof Fig28. Hemoglobinpercentiles byGFR. Thesedata arebasedonthe resultsof446 patientsenrolledintheCanadianMulticentreLongitudinalCohortstudyofpatientswith chronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994and 1997. Nopatientwasreceivingerythropoietintherapyatthetimeofenrollment, and nopatienthadanAVfistula. Adaptedandreprintedwithpermission. 288 potassium/DOQI NationalKidneyFoundation Part6. Association 141 Fig29. PrevalenceoflowhemoglobinbyGFRcategory. Thesedataarebasedonthe resultsof446patientsenrolledintheCanadianMulticentreLongitudinalCohortstudyof patientswithchronickidneydisease. Allpatientswerereferredtonephrologistsbetween 1994and1997. Nopatientwasreceivingerythropoitentherapyatthetimeofenrollment, andnopatienthadanAVfistula. Adaptedandreprintedwithpermission. 288 hemoglobinorhematocritateachlevelofkidneyfunction, whetherassessedbyserum creatinineconcentration, creatinineclearance, orGFR. Theseobservationsunderscore theneedtomeasurehemoglobinlevelsineveryindividualwithGFR(cid: 1)60mL/min/1. 73 m2andtoindividualizetheassessmentof anemia. Thepopulation-basedtrendtoward lowerhemoglobinlevelsasGFRfallsdoesnotyieldapredictableprogressionthatcan beappliedtoindividualpatients. Thus, anemiashouldbeconsideredinsomepatients withchronickidneydiseaseandGFR(cid: 2)60mL/min/1. 73m2. Erythropoietinlevelsarenotconsistently associatedwiththelevelofGFR (Table78)(C). Erythropoietinlevelsinpatientswithchronickidneydiseasehavenot been wellcharacterized instudies to dateand donot appear tobe directlyrelated to levelofkidneyfunction. Themajorityofstudieshavebeenperformedinpatientsalready receivingdialysis, thoughsomestudiesdescribetherelationshipoferythropoietinlevels toGFRindiabeticsandinpatientsnotondi! -! alysis. 275, 308, 309 The consistent finding apparent from these studies is that, for any given level of kidneyfunctionandanemia, theerythropoietinlevelsarelowerinindividualswithkidney diseasethaninthosewithanemiabutnormalkidneyfunction. Theinterpretationofthesefindingsisthatpatientswithkidneydisease, ascompared tonormalindividuals, donothaveanappropriateriseinthelevelsoferythropoietenin the presence of anemia; while levels may be higher than non-anemic chronic Kidney diseasepatients, theriseinerythropoietinlevelsisnotcommensuratewiththatseenin 142 Part6. Association NationalKidneyFoundation potassium/DOQI patients with the samedegree of anemia but without kidneydisease. Table 77 shows the paucity of data in this area and the weakness of the association demonstrated by publishedstudiesbetweenerythropoitenlevelsandlevelofkidneyfunction. Measuresofironstores, includingferritinandtransferrinsaturation, are notconsistentlyassociatedwiththelevelofGFR(Tables79and80)(C). Several measuresofironstoreshavebeenstudiedinpatientswithkidneydisease. Mostofthese measures, unlikebonemarrowbiopsy, donotdirectlyquantifytheamountofironavailableforuseinerythrocytesynthesis, relyinginsteadonindirectorsurrogatemeasures. FerritinlevelsinpatientswithreducedGFRmayrepresenttotalbodyironstatus, orthey may simply be markers of inflammation. Given the chronic inflammatory state that maycharacterizechronickidneydisease, ferritinlevelsarenotusefulinmeasuringiron stores, norinpredictingtherelationofhemoglobintokidneyfunction. Transferrin saturation, in combination with serum iron and ferritin levels, may be helpful in diagnosing functional iron deficiencyjust as Low serum ferritin levels are helpfulindiagnosingirondeficiencyanemia. 311, 312However, thereislittlecorrelation ofironmeasurementswithstagesofkidneydisease. LIMITATIONS Thisanalysisislimitedbyalackofdataabouttherelationshipoflevelsofhemoglobin and Kidney function in a truly representative sample of patients with chronic Kidney disease. Many of the published studies describe patients entered into clinical trials or seen bynephrologists. Thereasons forthese differencesare incompletelystudied but notedinconventionaltextsandreviewarticles. 277, 313 potassium/DOQI NationalKidneyFoundation Part6. Association 143 Interestingly, specific subgroups of patients (such as those with polycystic Kidney disease)mayhaveerythropoietinsynthesisthatisbetterpreservedthanothersubgroups (suchasdiabetics). Inthesubgroupofpatientswhohavekidneytransplants, thereare multiplecausesforanemiainadditiontodecreasedkidneyfunction. Theuseofimmunosuppressiveagentsorothermedications, orchronicinflammationduetotransplantrejection, may further confound the assessment of the etiology of declining hemoglobin. However, itisclearthatatgivenlevelsofcompromisedGFR, kidneytransplantpatients dodemonstratereducedlevelsofhemoglobin, consistentwithfindingsinpatientswith nativediseasedkidneys, andwiththosewhohaveimpairedkidneyfunction. 310 Another limitation of the current analysis is the variety (and lack of precision) of methodsbywhichkidneyfunctionwasmeasuredinstudiesthatassessedhemoglobin inpatientswithchronickidneydisease. Methodsusedincluded: measuredGFR(iothalamateorothermethods), calculatedGFR(usingdifferentequations), measuredorcalculatedcreatinineclearance(usingdifferentequations). Itisthereforedifficulttodetermine whetherthevariabilityinhemoglobinatlevels ofkidneyfunctionisduetovariability in measurements of Kidney function or to variability associated with chronic Kidney diseaseitself. Whiletruevariabilitybetweenpatientsisthemorelikelypossibility, the magnitudeofvariabilityisunknown. CLINICALAPPLICATIONS Availabledatapermitthedescriptionofmeanlevelsofhemoglobin(withwidestandard deviations)atdifferentlevelsofGFRandsupportthefollowingrecommendations. Physicianstreatingpatientswithchronickidneydiseaseshould: Followhemoglobinlevelsovertimeinallindividualswithchronickidneydisease andexpectsomedegreeofdeclineovertimeaskidneyfunctionworsens EvaluateanemiainallpatientswithGFR(cid: 1)60mL/min/1. 73m2 Assesstherelationshipofanemiatothepatientssymptomsandfindingsandthe impact ofanemia on the patientscomorbid conditions andother complications ofdecreasedkidneyfunction Asinanemiafromanycause, treatmentsappropriatetotheetiologyoftheanemia (ironorothersupplementdeficiency)shouldbeimplemented. Theissuesoftiming of intervention and specific target of hemoglobin are beyond the scope of this guideline. These recommendations are consistent with published potassium/DOQI Clinical Practice GuidelinesonAnemiaofChronicKidneyDisease. 266Whiletherearenonormal/expected values of hemoglobin at any specific level of glomerular filtration rate, available data suggest that individual patients do trend toward a fall in hemoglobin as Kidney function declines. Thecharacterizationofseverityofanemiaforanyindividualwithchronickidneydisease shouldbemadeinlightofchangesinhemoglobinfrompreviouslevels. Thedeclinein hemoglobinismostlikelyassociatedwithareductioninerythropoietineffectivenessor production, whichaccompaniesthedeclineinGFR. Treatmentandassessmentrecommendationsarebeyondthescopeofthisguideline 144 Part6. Association NationalKidneyFoundation potassium/DOQI but are provided in the potassium/DOQI Clinical Practice Guidelines on Anemia of Chronic Kidney Disease266 and the European Best Practice Guidelines for the Management of AnaemiainPatientswithChronicRenalFailure. 273 RESEARCHRECOMMENDATIONS Clearly, moreinformationisneededonhemoglobinlevelsinchronickidneydiseaseespeciallyinpatientsintheearlystagesofkidneydiseaseandaskidneyfunctiondeclines.",
    "word_count": 581,
    "char_count": 9322,
    "sentence_count": 81,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 32,
      "total_chunks": 77,
      "position": "33/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "potassium",
        "hemoglobin",
        "iron",
        "ferritin",
        "transferrin saturation",
        "dialysis",
        "anemia"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 33,
    "text": "273 RESEARCHRECOMMENDATIONS Clearly, moreinformationisneededonhemoglobinlevelsinchronickidneydiseaseespeciallyinpatientsintheearlystagesofkidneydiseaseandaskidneyfunctiondeclines. Futurestudiesshouldinclude: Evaluationoftherelationshipsbetweenerythropoietinlevels, hemoglobinandiron storesinpatientswithchronickidneydiseaseateachstageofthedisease Descriptionofchangesinthesehematologicalparametersinspecificsubgroups, suchasdiabeticsandpatientswithfailingtransplantgrafts Evaluationoftheimpactoftreatmentofanemiainstagesofkidneydiseaseprior to Dialysis (chronic kidney disease Stages 14) on Kidney function decline, cardiac function, and generalwell-being Economicevaluationsoftherapeuticstrategieswhichincludemaintenanceofhemoglobinversuscorrectionfromlowlevelsatdifferentstagesofchronickidney disease. GUIDELINE 9. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH NUTRITIONAL STATUS Proteinenergymalnutritiondevelopsduringthecourseofchronickidneydiseaseand is associated with adverse outcomes. Low Protein and calorie intake is an important causeofmalnutritioninchronickidneydisease. Patients with glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2 should undergo assessment of dietary Protein and energy intake and nutritional statussee potassium/DOQI Clinical Practice GuidelinesforNutritioninChronicRenalFailure(chronic renal failure), Guidelines23and26: Guideline23. PanelsofNutritionalMeasuresforNondialyzedPatients: ForindividualswithCRF(glomerular filtration rate(cid: 1)20mL/min)Protein-energynutritionalstatusshouldbeevaluatedbyserialmeasurementsofapanelofmarkersincludingatleastonevaluefrom eachofthefollowingclusters: (1) Serumalbumin; (2) Edema-freeactualbodyweight, percentstandard(NHANESII)bodyweight, orsubjectiveglobalassessment(SGA); and (3) Normalizedproteinnitrogenappearance(nPNA)ordietaryinterviewsand diaries. (EvidenceandOpinion) Guideline 26. Intensive Nutritional Counseling for Chronic Renal Failure: The nutritionalstatusofindividualswithCRFshouldbemonitoredatregularintervals. Patientswithdecreaseddietaryintakeormalnutritionshouldundergodietarymodification, counseling, andeducationorspecializednutritiontherapyseeK/DOQI potassium/DOQI NationalKidneyFoundation Part6. Association 145 ClinicalPracticeGuidelinesforNutritioninChronicRenalFailure(chronic renal failure), Guidelines 24and25: Guideline24. DietaryProteinIntakeforNondialyzedPatients: Forindividuals withchronicrenalfailure(glomerular filtration rate(cid: 1)25mL/min)whoarenotundergoingmaintenance Dialysis, theinstitutionofaplannedlow-proteindietproviding0. 60gprotein/kg/d should be considered. For individuals who will not accept such a diet or who are unabletomaintainadequatedietaryenergyintakewithsuchadiet, anintakeofup to0. 75gprotein/kg/dmaybeprescribed. (EvidenceandOpinion). Guideline25. DietaryEnergyIntake(DEI)forNondialyzedPatients: Therecommended DEI for individuals with chronic renalfailure (glomerular filtration rate (cid: 1)25 milliliters per minute) who are not undergoing maintenance Dialysis is 35 kcal/kg/d for those who are younger than60yearsoldand3035kcal/kg/dforindividualswhoare60yearsofage orolder. (EvidenceandOpinion). BACKGROUND Anorexiaisevidencedbydecreaseddietaryproteinintake(DPI)anddecreaseddietary energy intake (DEI), which are hallmarks of Kidney failure (potassium/DOQI Clinical Practice GuidelinesforNutritioninChronicRenalFailure, 75Guideline6). Aslimitationofprotein intake reduces the accumulation of toxic substances derived from the metabolism of Protein, decreasedDPImaybeviewedasadaptiveinpatientswithkidneyfailure. However, decreased DPI is also associated with worsening of indices of nutritional status. Thus, theoveralloutcomeofthisadaptiveprocessmaybetheincreasedprevalenceof proteinenergymalnutrition(PEM)inpatientswithchronickidneydisease. Thestageofchronickidneydiseaseatwhichdecreaseddietarynutrientintakeand associatedPEMbecomeprevalenthasnotbeenadequatelydocumented, dueinpartto thefactthatnosinglemeasureprovidesacompleteoverviewofnutritionalstatus. The optimalmonitoringofprotein-energynutritionalstatusrequiresthecollectiveevaluation ofmultipleparameters(ie, assessmentofvisceralprotein, musclemassorsomaticprotein, bodycomposition). Asaresult, dataforappropriateassessmentofnutritionalstatus inpatients withchronic kidneydisease havenot beenadequately collectedand often theonsetandprogressionofmalnutritionisobscuredbytheprogressivelossofkidney function. ThisguidelineprovidesevidenceontheassociationofthelevelofGFRwith dietaryintakeandnutritionalstatusandprovidesrecommendationsonhowtoapproach thisspecificcomplicationofchronickidneydisease. RATIONALE Markers of Protein-Energy Malnutrition PEMischaracterizedbytheinsidiouslossofbodyfatandsomaticproteinstores, diminishedserumproteinconcentrations, andpoorperformancestatusandfunction. Serum albumin, serumpre-albumin, andserumtransferrinlevelsareusedtomeasurevisceral Protein. Anthropometryanddual-energyx-rayabsorptiometryassesssomaticproteinand 146 Part6. Association NationalKidneyFoundation potassium/DOQI fatstores. Inaddition, Edema-freeweight, bodymassindex(body mass index), andsubjectiveglobal assessment(SGA)arevalidandclinicallyusefultoolsforoverallnutritionalassessment. Serumalbuminconcentration, evenwhenonlyslightlylessthan4. 0g/dL, isoneof themostimportantmarkersofPEMinpatientswithchronickidneydisease. Itisavery reliable indicator of visceral Protein, although its concentration is also affected by its rate of synthesis and catabolism (half-life 20 days), which is altered negatively in the presence of inflammation. 314 The distribution of albumin between extra-cellular and intravascularspacesmaybevariabledependingontheetiologyofkidneydisease, magnitudeofproteinuria, andthestateofextra-cellularfluidvolume. Inchronicallymalnourishedpatients, albumintendstoshiftoutoftheintravascularcompartment. Severalmarkersofvisceralprotein, otherthanalbumin, haveashorterhalf-lifeand may be useful markers of early malnutrition. Among these are serum transferrin (halflife8days)andserumpre-albumin(half-life2days). 315Ironstoresaffectserumtransferrin, whilepre-albuminisexcretedbythekidneysanditsconcentrationcanbefalselyelevated in patients with advanced Kidney disease. All these markers are also affected by the presenceofinflammation. Anthropometry(Edema-freeweight, body mass index, assessmentofarmfatandmuscle)hasbeen usedtoestimatebodycompositionandnutritionaladequacy. Reproducibilityofanthropometry measurements is poor and is dependent upon the skill of the observer. SGA hasbeenproposedasaneasy, useful, andclinicallyvalidmethodfornutritionalassessment. SGAincludessubjectivedata(diseasestate, weightchanges), indicatorsofpoor nutritionalstatus(appetite, foodintake, gastrointestinalsymptoms), andtheclinicaljudgmentoftheclinician. ThelimitationofSGAisitsrelianceonsubjectivedata. Thereare nostudieswhichcorrelateanthropometricmeasurementsorSGAwithclinicaloutcome inpatientswithchronickidneydisease. Serumbicarbonateconcentration(alsomeasuredastotalcarbondioxidecontentor CO ), asameasureofacid-basebalance, hasbeenusedtoassessmalnutritioninchronic 2 kidneydisease. Studiesshowthaturemicacidosiscausesanincreaseinproteindegradation. Correctionofacidosisisaccompaniedbyadecreaseinproteintissuebreakdown. 316 AssessmentofnutrientintakecanbeusefulinidentifyingPEMandseveralmeasures ofdietaryintakehavebeenutilizedinpatientswithchronickidneydisease. Theseinclude measurementofproteinequivalentoftotalnitrogenappearance(PNA)asamarkerof dietary Protein intake, measurement of basal energy expenditure (BEE) as a measure ofdietaryenergyneeds, anddietaryinterviewsordiariesasmarkersofoverallintake. Additionally, totalserumcholesterolcanbeausefulmarkerforenergyintake, butnot forproteinintake. Thechallengefortheclinicianistoappropriatelymonitorthenutritionalindicesin patientswithchronickidneydisease. Whileeachmarkerhasitsownadvantageinterms ofprecisionandpredictability, itisrecommendedthatthesemarkersbeusedinacomplementaryfashiontooptimizeassessmentofpatientswithchronickidneydiseaseandto tailorspecificinterventions. 75 It is also important for the clinician to educate patients about a proper diet, since potassium/DOQI NationalKidneyFoundation Part6. Association 147 hyperphosphatemia, hyperkalemia, andmetabolicacidosismaydevelopduringchronic kidneydisease. Medical Nutrition Therapy and Nutrition Counseling AsofJanuary2002, Medicarewillprovidepaymentformedicalnutritiontherapy(MNT) forpatientswithchronickidneydisease. 317 Medical nutrition therapy involves the assessment of the nutritional status of patientswithacondition, illness, orinjurythatputsthematrisk. Thisincludesreview andanalysisofmedicalanddiethistory, laboratoryvalues, andanthropometricmeasurements. Basedontheassessment, nutritionmodalitiesmostappropriatetomanage theconditionortreattheillnessorinjuryarechosenandincludethefollowing: Diet modification, counseling, andeducation leading tothe developmentof a personaldietplantoachievenutritionalgoalsanddesiredhealthoutcomes. Specialized nutrition therapies including supplementation with medical foods forthoseunabletoobtainadequatenutrientsthroughfoodintakeonly; enteral nutritiondeliveredviatubefeedingintothegastrointestinaltractforthoseunabletoingestordigestfood; andparenteralnutritiondeliveredviaintravenous infusionforthoseunabletoabsorbnutrients. Presently, itisproposedthatpatientswillbeeligibletoreceivereimbursementfor medical nutrition therapy if they have glomerular filtration rate 15 to 50 milliliters per minute/1. 73 m2, or if they have receivedakidneytransplantwithintheprevious6months. Thesecriteriaareroughly equivalenttopatientswithCKDStages34andStage5whodonotyetrequiredialysis. Most patients with chronic kidney disease Stage 5 who are treated by Dialysis are eligible for medical nutritiontherapyfromtheirdialysisproviders. Strength of Evidence PEMdevelopsduringthecourseofchronickidneydisease(R). Whencomparedtothedemographicallyadjustedgeneralpopulation, dialysispatientsexperience greatersignsandsymptomsofwasting, malnutrition, morbidity, andmortality. Itisestimatedthat50%to70%ofdialysispatientssufferfromPEM. 314Abnormalitiesinnutritional markersarecommonandincludedecreasedserumproteins, lowerbodymassasassessed byanthropometricmeasurementsandSGA, anddecreasednutrientintake. Reasonsfor PEMincludedisturbancesinproteinandenergymetabolism, hormonalderangements, anorexia, andnauseaandvomitingrelatedtouremictoxicity. Comorbidconditionssuch asdiabetes, vasculardisease, andsuperimposedinfectionsandinflammationarecontributory. 318 Malnutritionisassociatedwithworseoutcomesinchronickidneydisease (R). Amongmaintenancedialysispatients, PEMhasbeenrecognizedasoneofthemost significantpredictorsofadverseoutcomes. Riskofhospitalizationsandmortalityisinverselycorrelatedtonutritionalmarkers.",
    "word_count": 598,
    "char_count": 10791,
    "sentence_count": 76,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 33,
      "total_chunks": 77,
      "position": "34/77",
      "content_type": "dietary",
      "content_type_confidence": 10,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "renal failure",
        "kidney failure",
        "potassium",
        "nutrition",
        "diet",
        "dietary protein",
        "energy intake"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 34,
    "text": "Reasonsfor PEMincludedisturbancesinproteinandenergymetabolism, hormonalderangements, anorexia, andnauseaandvomitingrelatedtouremictoxicity. Comorbidconditionssuch asdiabetes, vasculardisease, andsuperimposedinfectionsandinflammationarecontributory. 318 Malnutritionisassociatedwithworseoutcomesinchronickidneydisease (R). Amongmaintenancedialysispatients, PEMhasbeenrecognizedasoneofthemost significantpredictorsofadverseoutcomes. Riskofhospitalizationsandmortalityisinverselycorrelatedtonutritionalmarkers. 319Recently, attentionhasfocusedonthecharacteristicsofpatientswithchronickidneydiseaseatthetimetheybeginmaintenance Dialysis. Studieshavesuggestedthatapartfromtheseverityofuremicsymptomsaswell 148 Part6. Association NationalKidneyFoundation potassium/DOQI asthebiochemicalfindingsrelatedtotheextentofmetabolicandhormonalabnormalities, thenutritionalstatusofthepatientattheinitiationofdialysisisaclinicallysignificant riskfactorforsubsequentclinicaloutcomes(morbidityandmortality)ondialysis. 320, 321 Theassociationbetweennutritionintakeorstatusandclinicaloutcomedoesnotprove acausalrelationship. Itispossiblethatcomorbidconditionsindependentlyimpairboth nutritional intake or status and increase morbidity and mortality. In addition studies suggest that a combined state of poor nutritional status and inflammation predispose patientswithchronickidneydiseasetopoorclinicaloutcomes. 322, 323 Low Protein and calorie intake is an important cause of malnutrition in chronickidneydisease(R). Whiletherearepossiblymultiplefactorsthatcontribute to the development of PEM in chronic Kidney disease, Low Protein and calorie intake (decreasedfromusualintake)arecertainlyimportantcontributorsinthiscatabolicprocess. Thisrelationshipisevidentfrommultiplestudies, whichshowastrongrelationship between the amount of dietary intake of nutrients, especially Protein intake, and the stage of malnutrition in patients with chronic Kidney disease. 324, 325 Concentrations of serumalbuminandtransferrin, edemafreeweight, andpercentleanbodymasshaveall beendirectlyrelatedtodietaryproteinintakeinpatientswithchronickidneydisease. The mechanism by which chronic Kidney disease leads to this decline in nutrient intakehasnotbeendefined. Accumulationofuremictoxinsduetolossofkidneyfunction is a potential explanation. Metabolic and hormonal derangements predispose patients with chronic Kidney disease to decreased appetite and dietary nutrient intake. 326, 327 Specific comorbid conditions, such as Diabetes mellitus, cardiovascular disease, and depression, can facilitate the worsening of decreased nutrient intake in patients with chronickidneydisease. Themechanismsassociatedwiththeseconditionsaremultiple and include gastrointestinal abnormalities, decreased appetite, effects of concomitant medicationuse, androleofinflammation. Othercausesofmalnutritioninchronickidneydisease(R). Severalfactors other than Low Protein and calorie intake can also predispose chronic Kidney disease patientstomalnutrition. Theseincludeseveralhormonalandmetabolicderangements relatedtolossofkidneyfunction. Metabolicacidosisiscommonlyseeninchronickidney diseasepatientsandshowntobeassociatedwithincreasedproteincatabolisminthese patients. Specifically, thedegradationoftheessential, branched-chainaminoacidsand muscleproteinisstimulatedduringmetabolicacidosis. Further, metabolicacidosissuppresses albumin synthesis. 328 Worsening Kidney function is also associated with resistancetoinsulin, growthhormoneandinsulin-likegrowthfactor1, allofwhichareknown tobeanabolichormones. Ofnote, theseabnormalitiesaremostprominentinpediatric chronickidneydiseasepatientswithapparentgrowthfailure. 329331 Recentstudiespointtotheincreasedconcentrationsofproinflammatorycytokines andacutephasereactantsinchronickidneydiseasepatients. 323, 332Analysisofthedata fromNHANESIIIdemonstratesincreasingC-reactiveproteinconcentrationsasGFRdecreases. 333 Thus, available evidence suggests a chronic inflammatory state in chronic potassium/DOQI NationalKidneyFoundation Part6. Association 149 kidneydiseasepatients, especiallyforpatientsinStages3to5. Themetabolicandnutritionaleffectsofchronicinflammationaremanyandincludeanorexia, increasedskeletal muscleproteinbreakdown, increasedwholebodyproteincatabolism, cytokine-mediated hypermetabolism, anddisruptionofthegrowthhormoneandIGF-1axisleadingtodecreasedanabolism. 334336Thesefindingssuggestthatchronicinflammationobservedin chronickidneydiseasepatientsisanimportantcausativefactorforpoornutritionalstatus observedinthesepatients. Thelevelofdietaryintakeofproteinandenergyintakeisrelatedtothelevel of glomerular filtration rate; below a glomerular filtration rate of approximately 60 milliliters per minute/1. 73 m2, there is a higher prevalenceofreduceddietaryproteinandenergyintake(Tables81and82and 150 Part6. Association NationalKidneyFoundation potassium/DOQI Fig 30. Association of dietary intake and glomerular filtration rate in the MDRD Study. Mean levels of proteinandenergyintakeasafunctionofGFRbasedon24-hoururinecollectionsand dietdiaries(males, solidlines; females, dashedlines). DatadepictMDRDStudyenrollees notonrestricteddiets. Abbreviation: UNA, ureanitrogenappearance. Reprintedwith permission. 324 Fig 30) (C, S). One of the most significant clinical indicators of Kidney failure is an apparentdecreaseinappetite. Spontaneousdecreaseindietaryproteinandenergyintake canberegardedasanearlyindexofuremia. ThisbeginstooccurwhenGFRfallsbelow 60mL/min/1. 73m2. Asproteinandcalorieintakedecline, markersofnutritionhealth indicateworseningnutritionalstatus. potassium/DOQI Nutrition Guideline 24 recommends consideration of a Protein intake of 0. 60g/kg/dforindividualswithGFR(cid: 1)25mL/min(correspondingapproximatelytoCKD Stages45), butdoesnotaddressrecommendationsforpatientswithhigherGFR. The recommendeddietaryallowance(RDA)ofproteinfornormaladultsis0. 75g/kg/d. The MDRD Study was inconclusive regarding the benefits of Protein restriction on Kidney diseaseprogression(seeCKDGuideline13), buttherewasnoevidenceofabeneficial effectfromDPIhigherthantheRDA. ADPIof0. 75g/kg/dthereforeappearsreasonable forpatientswithCKDStages13(intheabsenceofevidenceofmalnutrition), butdata potassium/DOQI NationalKidneyFoundation Part6. Association 151 are inconclusive, and individualizeddecision-making is advised. Patients withDPI less thanapproximately0. 75g/kg/dshouldhavemoreclosemonitoringofnutritionalstatus. potassium/DOQINutritionGuideline25recommendsage-dependentDEIintakesof30to35 kcal/kg/dforindividualswithGFR(cid: 1)25mL/min(correspondingapproximatelytoCKD Stages45), butdoesnotaddressrecommendationsforpatientswithhigherGFR. The RDAforenergyintakeinnormaladultsdependsonenergyexpenditure. Averageenergy intake in adults in the United States is less than that recommended in the potassium/DOQI NutritionGuideline. TherationaleforhigherDEIinpatientswithGFR(cid: 1)25mL/minis basedonstudiesdemonstratingmoreefficientnitrogenutilizationathigherenergyintakes. ForpatientswithCKDStages13, itwouldbereasonabletorecommendhigher energy intakes only if they have abnormally Low body weight or show other signs of malnutrition. Patients with DPI less than the RDA (0. 75 g/kg/d) should be targeted for frequent follow-uptomonitornutritionalstatusmoreclosely. Somestudiesindicatethatintensive nutritioncounselingmayhelpmaintaincalorieintakeandtopreservemarkersofgood nutritionasGFRdeclines. 299, 324, 325, 337342 The onset and severityof PEM is related to the level ofGFR; below a glomerular filtration rate ofapproximately60mL/min/1. 73m2, thereisahigherprevalenceofimpaired nutritional status (C, S). potassium/DOQI Nutrition Guideline 23 states that Protein-energy nutritionalstatusshouldbeevaluatedbyserialmeasurementsforindividualswithGFR (cid: 1)20mL/min. 75AnupdatedliteraturereviewsupportstherecommendationthatevaluationsofnutritionalstatusshouldbeginwhenGFRfallsbelowapproximately60mL/min/ 1. 73m2. PopulationstudiesshowthatalbuminbeginstodeclineonceGFRreachesthis level. 333Othermarkersofnutritionalstatusatthislevelofkidneyfunctionhavenotbeen aswellstudied. potassium/DOQINutritionGuideline23recommendsapanelofnutritionmeasuresforevaluation of nutrition status in nondialyzed patients which includes serum albumin, body weight, subjectiveglobalassessmentandassessmentofproteinintakethroughnPNAor dietaryinterviews. Othermarkersofnutritionalstatus(eg, serumtotalproteins, serum prealbumin, serum transferrin, serum total bicarbonate, serum total cholesterol, and serumlipids)appeartoberelatedtothelevelofGFR. Thecalculationofstandardbodyweight(SBW)requiresaformulathatuseselbow breadthtodeterminethepatientsframesize. Formanyclinicians, thismeasurementis notfeasible. ThecalculationofhealthyweightrangecanbemadewiththesimplerBody MassIndex(body mass index)formula: Weight(kg) body mass index(cid: 4) Height(m)2 It is recommended that the body mass index of maintenance Dialysis patients be maintained in theupper50thpercentilefornormalindividuals, whichwouldmeanaBMIformenand women no lower than approximately 23. 6 to 24. 0 kg/m2. This recommendation also appearsappropriateforchronickidneydiseasepatientswithsignificantGFRreductions (Stages35)seeK/DOQINutritionGuideline, AppendixVII. 152 Part6.",
    "word_count": 598,
    "char_count": 9211,
    "sentence_count": 82,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 34,
      "total_chunks": 77,
      "position": "35/77",
      "content_type": "dietary",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "bicarbonate",
        "nutrition",
        "malnutrition",
        "nutrient intake",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 35,
    "text": "6 to 24. 0 kg/m2. This recommendation also appearsappropriateforchronickidneydiseasepatientswithsignificantGFRreductions (Stages35)seeK/DOQINutritionGuideline, AppendixVII. 152 Part6. Association NationalKidneyFoundation potassium/DOQI potassium/DOQI Nutrition Guideline 26 recommends monitoring of nutritional status at 1to 3-month intervals in patients with glomerular filtration rate (cid: 1)20 milliliters per minute. It is the opinion of the chronic kidney disease Work Group that this recommendation is appropriate for patients with glomerular filtration rate less than 30ml/min/1. 73m2(CKDStages45)andlessfrequentmonitoring(eg, every6to12 months)maybeacceptableforpatientswithGFR30to60mL/min/1. 73m2(CKDStage 3)ifthereisnoevidenceofmalnutrition. The High prevalence of malnutrition in chronic Kidney disease, the association betweenmalnutritionandclinicaloutcomes, andnewevidencethatnutrientintakebegins to decline at glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2 support the recommendation that nutritional statusshouldbeassessedandmonitoredearlierinthecourseofchronickidneydisease. SerumalbuminlevelislowerinpatientswithdecreasedGFR(Tables83and 84andFigs31and32)(C, S). SerumalbuminisloweratlevelsofGFRbelow60mL/ potassium/DOQI NationalKidneyFoundation Part6. Association 153 min/1. 73m2, indicatingadeclineincirculatingproteinlevelsorserumproteinconcentrations, proteinlossesorinflammation. 324, 325, 338, 340, 341, 348, 349Anacceptablegoallevelfor albuminis(cid: 2)4. 0g/dL(bromcresolgreenmethod). Similarfindingshavebeenreportedforserumtotalproteinsandpre-albumin. SerumtransferrinlevelislowerinpatientswithdecreasedGFR(Table85 andFig33)(C, S). SerumtransferrinisloweratlowerGFRlevels. Thisisevidenced Fig31. SerumalbuminpercentilesbyGFRadjustedtoage. Medianand5thand95th percentiles of serum albumin among adult participants age 20 years and older in NHANES III, 1988 to 1994. Values are adjusted to age 60 years using a polynomial quantileregression. TheestimatedGFRforeachindividualdatapointisshownwitha plusneartheabscissa. 95%confidenceintervalsatselectedlevelsofestimatedGFRare demarcatedwithtriangles, squares, andcircles. 154 Part6. Association NationalKidneyFoundation potassium/DOQI Fig 32. Association of serum albumin and glomerular filtration rate in the MDRD Study. Mean levels of serum albumin and the probability of serum albumin concentrations (cid: 1)3. 8 grams per deciliter as a functionofGFR(males, solidlines; females, dashedlines). Reprintedwithpermission. 324 potassium/DOQI NationalKidneyFoundation Part6. Association 155 Fig33. AssociationofserumtransferrinandGFRintheMDRDStudy. Meanlevelsof serumtransferrinandtheprobabilityofserumtransferrinconcentrations(cid: 1)250mg/dL asafunctionofGFR(males, solidlines; females, dashedlines). Reprintedwithpermission. 324 in patients with chronic Kidney disease, with no sign of inflammation, infection, and withstableironstatus. 324, 325, 338, 340 SerumbicarbonateconcentrationislowerinpatientswithdecreasedGFR (Table 86) (C). As glomerular filtration rate falls to (cid: 1)60 milliliters per minute/1. 73 m2, serum bicarbonate decreases. Lowserumbicarbonateisanindicatorofacidemiaandassociatedwithproteindegradation. Lowserumbicarbonate hasbeencorrelatedtolowserum albumin. 325, 340SeeK/ DOQIClinicalPracticeGuidelinesforNutritioninChronicRenalFailure, Guideline14, TreatmentofLowSerumBicarbonate: 156 Part6. Association NationalKidneyFoundation potassium/DOQI Predialysis or stabilized serum bicarbonate levels should be maintained at or above22(cid: 3)mol/L. 75 Serum cholesterol concentration is lower in patients with decreased glomerular filtration rate (Table87andFig34)(C, S). AsGFRdecreasesto(cid: 1)60mL/min/1. 73m2, serumcholesterolfalls, evenwhencontrollingforinflammationandcomorbidconditions. 324, 325, 338, 339, 341 Bodyweight, bodymassindex, percentagebodyfat, andskinfoldthickness are lower in patients with decreased glomerular filtration rate (Tables 88, 89, 90, and 91 and Fig 35) (C, S). As glomerular filtration rate falls to (cid: 1)50 milliliters per minute/1. 73 m2, measurements of body mass show potassium/DOQI NationalKidneyFoundation Part6. Association 157 Fig34. AssociationofserumcholesterolandGFRintheMDRDStudy. Meanlevelsof serumcholesterolandtheprobabilityofserumcholesterolconcentrations(cid: 1)160mg/dL asafunctionofGFR(males, solidlines; females, dashedlines). Reprintedwithpermission. 324 158 Part6. Association NationalKidneyFoundation potassium/DOQI declines in totalmass, fat, and muscle. Thecorrelations may be strongerin men than women. Assessmentofbodycomposition, especiallywithserialmeasurementscanprovidevaluableinformationconcerninglongtermadequacyofproteinenergynutrition. Changesinbodyweight, body mass index, andbodyfatinpatientswithchronickidneydiseaseand glomerular filtration rate(cid: 2)60mL/min/1. 73m2havenotbeenassessed. 324, 338, 341 LIMITATIONS There are certain limitations to the informationpresented herein. The design of most studiesmeasuringnutritionmarkersinchronickidneydiseaseisbasedondataderived fromcross-sectionalstudies. Thereareveryfewlongitudinalstudiesavailable. Inaddition, there is a lack of uniform collective evaluation of the multiple markers of nutritional statusinpatientswithchronickidneydisease. Althoughitisknownthatdietarynutrient intakedecreaseswithGFR, thereisonlylimitedevidencethatdecreaseddietaryprotein potassium/DOQI NationalKidneyFoundation Part6. Association 159 160 Part6. Association NationalKidneyFoundation potassium/DOQI Fig35. AssociationofbodycompositionandGFRintheMDRDStudy. Meanlevelsof anthropometricmeasuresofnutritionalstatusasafunctionofGFR(males, solidlines; females, dashedlines). Reprintedwithpermission. 324 potassium/DOQI NationalKidneyFoundation Part6. Association 161 intake per se causes poor nutritional status. However, research indicates that when patientsreceiveintensivenutritiontherapyandmonitoringwhiletheGFRisdeclining, nutritionstatuscanbemaintained. 337, 343, 345, 351, 358, 365367 CLINICALAPPLICATIONS Dietaryproteinprescriptioninchronickidneydiseaseiscomplicatedbypotential conflict between goals to slow the progression of Kidney disease and preserve Protein nutritional status. There is insufficient evidence to recommend for or againstroutineprescriptionofdietaryproteinrestrictiontoslowprogression(see Guideline 13). Thus, the RDA for Protein of 0. 75 g/kg/d appears reasonable in patientswithGFR(cid: 2)30mL/min/1. 73m2(CKDStages13). Alowerproteinintake of0. 6g/kg/dcanbeconsideredforpatientswithlowerGFR(Stages4and5)to slowprogressionandminimizeaccumulationofuremictoxins. Individualdecisionmakingisrecommendedafterdiscussionofrisksandbenefits. Maintainingadequateenergyintakeisessentialatallstagesofchronickidneydisease. Assessmentofnutritionalstatusinchronickidneydiseaserequiresmultiplemarkers toassessproteinstatus, fatstores, bodycomposition, anddietaryproteinandenergy intake. Thenutritionalstatusofpatientswithchronickidneydiseaseshouldbemonitored atregularintervals: every1to3monthsforpatientswithGFR(cid: 1)30mL/min/1. 73 m2(CKDStages4and5)andevery6to12monthsforpatientswithGFR30to 59mL/min/1. 73m2(CKDStage3). TheextentofPEMcanbeconsideredasanindicationfortheinitiationofkidney replacement therapy. If PEM develops or persists despite vigorous attempts to optimizeproteinandenergyintake, andthereisnoapparentcauseformalnutrition otherthanlownutrientintake, initiationofmaintenancedialysisorkidneytransplantisrecommended. SeeCKDGuideline1, p. 43. Ingeneral, thisguidelineapplies topatientswithGFR(cid: 1)15mL/min/1. 73m2(CKDStage5)butmayapplytosome patientswithhigherGFRlevels. IMPLEMENTATIONISSUES IntheUnitedStates, implementationofthemedicalnutritiontherapylawforreimbursementthroughMedicarewillallowfortheprovisionofnutritionmonitoringasdescribed intheseguidelines. Studiesshowthatthemosteffectivenutritioninterventionsinpatientswithchronickidneydiseaseinvolvepatienttraininginselfmanagementskillsand frequent, ongoingfeedback, andinterventions withthe nutritionteam. 368371 Medical nutritiontherapyforpatientswithchronickidneydiseasemustthereforeincludeadequatetimefornutritionassessmentandeducationandregular, schedulednutritionappointments. Althoughoccasionallyacareprovider, orotherindividual, maypossesstheexpertise andtimetoconductnutritionalassessment, usedietaryinterviewsandrecordstoassess 162 Part6.",
    "word_count": 599,
    "char_count": 8359,
    "sentence_count": 95,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 35,
      "total_chunks": 77,
      "position": "36/77",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "potassium",
        "bicarbonate",
        "nutrition",
        "malnutrition",
        "monitoring",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 36,
    "text": "Studiesshowthatthemosteffectivenutritioninterventionsinpatientswithchronickidneydiseaseinvolvepatienttraininginselfmanagementskillsand frequent, ongoingfeedback, andinterventions withthe nutritionteam. 368371 Medical nutritiontherapyforpatientswithchronickidneydiseasemustthereforeincludeadequatetimefornutritionassessmentandeducationandregular, schedulednutritionappointments. Althoughoccasionallyacareprovider, orotherindividual, maypossesstheexpertise andtimetoconductnutritionalassessment, usedietaryinterviewsandrecordstoassess 162 Part6. Association NationalKidneyFoundation potassium/DOQI proteinenergyintake, assessbodymuscleandfatstores, interpretbiochemicalmarkers ofnutritionstatusandrelatetodietaryintake, andprovidenutritionaltherapy(develop aplanfornutritionalmanagement, counselthepatientandfamilyonappropriatedietary proteinenergyintake, monitornutritionintake, andprovideencouragementtomaximize dietaryadherence)aregistereddietitian, trainedandexperiencedinCKDnutrition, is bestqualifiedtocarryoutthesetasks. Suchanindividualnotonlyhasundergoneallof the training required to become a registered dietitian, including in many instances a dieteticinternship, buthasalsoreceivedformalorinformaltraininginCKDnutrition. Suchapersonisparticularlyexperiencedinworkingwithpatientswithchronickidney diseaseandthenephrologyteam(seeK/DOQIClinicalPracticeGuidelinesforNutrition inChronicRenalFailure, AppendixIV, RoleoftheRenalDietitian75). Research Recommendations Althoughthedatapresentedhereiniscompelling, moreresearch, especiallyprospective studies evaluating the impact of Kidney disease on nutritional parameters, is needed. Importantly, studies to define the optimal methods to evaluate nutritional status in chronickidneydiseasepatientsarecritical. Prospectivestudiesevaluatingtheimpactof differentlevels ofnutritionalstatuson subsequentoutcomeinchronic kidneydisease patientsshouldalsobeperformed. Finally, prospectivestudiesevaluatingtheimpactof intensive nutritional counseling on nutritional status and possibly clinical outcome in chronickidneydiseasepatientsshouldbecarriedout. GUIDELINE 10. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH BONE DISEASE AND DISORDERS OF CALCIUM AND PHOSPHORUS METABOLISM Bonediseaseanddisordersofcalciumandphosphorusmetabolismdevelopduring thecourseofchronickidneydiseaseandareassociatedwithadverseoutcomes. Patients with glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2 should be evaluated for bone disease anddisordersofcalciumandphosphorusmetabolism. Patientswithbonediseaseanddisordersofbonemetabolismshouldbeevaluated andtreatedseeforthcomingK/DOQIClinicalPracticeGuidelinesonBoneMetabolismandDiseaseinChronicKidneyDisease. BACKGROUND Chronickidneydiseaseisassociatedwitha varietyofbonedisordersanddisordersof calciumandphosphorusmetabolism. Themajordisordersofbonecanbeclassifiedinto those associated with High parathyroid hormone (parathyroid hormone) levels (osteitis fibrosa cystica) andthosewithlowornormalPTHlevels(adynamicbonedisease). Thehallmarklesion ofchronickidneydiseaseisosteitisfibrosa, duetosecondaryhyperparathyroidism. However, with the advent of intensive treatments for secondary hyperparathyroidism, the prevalenceofdisordersassociatedwithlowornormalPTHlevelshasincreased. potassium/DOQI NationalKidneyFoundation Part6. Association 163 Irrespectiveofthecause, bonediseasecanleadtopainandanincreasedincidence of fractures. Abnormal calcium-phosphorus metabolism and hyperparathyroidism can alsoleadtocalcificationofbloodvesselsandpotentiallyanincreasedriskofcardiovascularevents. Thestageofchronickidneydiseaseatwhichbonediseasebeginstodevelophasnot beenwelldocumented, norhasaconsensusbeendevelopedregardingthebestscreening measuresfordetectingearlyabnormalitiesofcalcium-phosphorusmetabolismandbone disease. Theaimofthisguidelineistoprovideevidenceontheassociationoflevelof GFRwithdisordersofcalcium-phosphorusmetabolismandbonediseaseandtoprovide recommendationsonhowtoapproachthiscomplicationofchronickidneydisease. RATIONALE Bone Disease in Chronic Kidney Disease Bonediseaseassociatedwithchronickidneydiseaseiscomposedofanumberofabnormalitiesofbonemineralization. ThemajordisorderscanbeclassifiedintothoseassociatedwithhighboneturnoverandhighPTHlevels(includingosteitisfibrosa, thehallmark lesionofsecondaryhyperparathyroidism, andmixedlesion)andlowboneturnoverand lowor normalPTHlevels(osteomalacia andadynamicbone disease). 372Osteomalacia mayberelatedtovitaminDdeficiency, excessaluminum, ormetabolicacidosis; whereas adynamicbonediseasemayberelatedtoover-suppressionofPTHwithcalcitriol. 372374 Thepathophysiologyofbonediseaseduetosecondaryhyperparathyroidismisrelated toabnormalmineralmetabolism: (1)decreasedkidneyfunctionleadstoreducedphosphorusexcretionandconsequentphosphorusretention; (2)elevatedserumphosphorus can directly suppress calcitriol (dihydroxyvitaminD ) production; (3) reduced Kidney 3 massleadstodecreasedcalcitriolproduction; (4)decreasedcalcitriolproductionwith consequent reduced calcium absorption from the gastrointestinal tract contributes to hypocalcemia, asdoesabnormalcalcium-phosphorusbalanceleadingtoanelevatedcalcium-phosphorus product. 375, 376 Hypocalcemia, reduced calcitriol synthesis, and elevated serum phosphorus levels stimulate the production of parathyroid hormone and the proliferation ofparathyroidcells, 377379resultinginsecondaryhyperparathyroidism. HighPTHlevels stimulateosteoblastsandresultinhighboneturnover. Thehallmarklesionofsecondary hyperparathyroidismis osteitisfibrosa cystica. High boneturnover leadsto irregularly wovenabnormalosteoid, fibrosis, andcystformation, whichresultindecreasedcortical boneandbonestrengthandanincreasedriskoffracture. Low turnover bone disease has two subgroups, osteomalacia and adynamic bone disease. Bothlesions arecharacterizedbya decreaseinboneturnover orremodeling, withareducednumberofosteoclastsandosteoblasts, anddecreasedosteoblasticactivity. In osteomalacia there is an accumulation of unmineralized bone matrix, or increased osteoid volume, which may be caused by vitamin D deficiency or excess aluminum. Adynamicbonediseaseischaracterizedbyreducedbonevolumeandmineralizationand maybeduetoexcessaluminumoroversuppressionofPTHproductionwithcalcitriol. 372 164 Part6. Association NationalKidneyFoundation potassium/DOQI Other Complications of Abnormal Calcium-Phosphorus Metabolism Inadditiontoabnormalitiesinbonemetabolism, abnormalcalcium-phosphorusmetabolism may lead to calciphylaxis or extraosseous calcification of soft tissue and vascular tissue. This complication in its full manifestation has been reported to affect approximately 1% of Dialysis patients. 380 However, in studies of coronary artery calcification usingelectronbeamcomputedtomography, dialysispatientshadcoronarycalcification scoresthatwereseveral-foldhigherthanthoseofpatientswithknowncoronaryartery disease. 381Thepathogenesisremainsunclear, buthyperphosphatemia, hypercalcemia, elevatedcalcium-phosphorusproduct, andincreasedPTHlevelsareprobablecontributors. Markers of Bone Disease and Abnormal Calcium-Phosphorus Metabolism in Chronic Kidney Disease Bonebiopsyfollowingdouble-tetracyclinelabelingisthegoldstandardforthediagnosis ofbonediseaseinchronickidneydiseaseandistheonlymeansofdefinitivelydifferentiatingthem. Fivebonelesionsassociatedwithchronickidneydiseasehavebeenclassified basedonboneformationrate, osteoidarea, andfibrosisonbonebiopsyofpatientswith kidneyfailure372, 382(Table92). Bonebiopsyisnoteasy, nornecessaryinroutineclinicalpractice. Classically, bone resorption can be seen on plain radiographs in cases of advanced osteitis fibrosa, but radiologicalstudies, includingdensitometry, havenotbeenconclusivelyshowntodifferentiatethevarioustypesofbonediseaseassociatedwithkidneyfailure. Bonebiopsyis currentlyrecommendedonlyforpatientswithsymptomaticdiseaseinwhominterventionsarebeingcontemplated(suchasparathyroidectomyordesferoxaminetreatment for elevated aluminum levels)383 or for research of the effectiveness of therapies or alternativediagnostictests. 384Intheabsenceofdirectpathologicstudies, clinicianshave reliedonbiochemicaldatatodeterminetheprobablepresenceof, orassesstheriskfor, boneabnormalities. Lowcalcitriol(dihydroxyvitaminD )andcalciumlevels, andhigh 3 phosphorusandPTHlevels, aretheclassicabnormalitieswhichdevelopwithdecreased potassium/DOQI NationalKidneyFoundation Part6. Association 165 glomerular filtration rate. 385Thebiochemicalstudiesincommonuse areserumphosphorus, calcium, and parathyroid hormone levels. Calcitriol levels can also be measured, but this is not commonly done in clinicalpractice. SerumphosphorusandcalciumlevelsareusedinscreeningforabnormalitiesofmineralmetabolismthatmayleadtoPTHexcess; however, PTHlevelsmay begintoriseevenbeforethereisappreciablehyperphosphatemia. 379Hence, therecommendation to obtain parathyroid hormone levels in the assessment of bone disease in chronic Kidney disease. An ideal serologic marker would be unique to bone and would be well correlated to histologic findings on biopsy. Two markers studied more extensively include parathyroid hormone and bone alkaline phosphatase (bAP). parathyroid hormone secretion is directly correlated with bone turnover, butPTHlevelsarenotreliablycorrelatedwithboneturnoveramongdialysis patients, especiallyinthemiddleranges. 386, 387PTHlevels(cid: 1)65pg/mLwerefoundtobe predictiveofnormalboneorlowturnoverlesions, andPTHlevels(cid: 2)450pg/mLwere predictiveofhighturnoverlesions, butlevelsinbetweendidnothavegoodpredictive value. Overallboneturnovercouldnotbepredictedin30%ofHDand50%ofPDpatients. 387Inanotherstudy, lowturnoverlesionswerenotedinthemajorityofpatients withPTHlevels(cid: 1)100pg/mLandhighturnoverlesionsinthemajorityofpatientswith PTHlevels(cid: 2)200to300pg/mL. 386HighbAPlevelshavebeenassociatedwithhighbone turnoverandlowlevelswithadynamicbonediseaseindialysispatients. Inonestudy, thecombinationofhighbonealkalinephosphataselevelswithhighPTHlevelsincreased the sensitivity of diagnosis of High turnover lesions; conversely, Low levels of both of thesemarkersresultinincreasedsensitivityfordiagnosisoflowturnoverlesions. However, specificcut-offlevelsforbAPhavevariedinthefewstudiesexaminingtherelationshiptobonehistology.",
    "word_count": 598,
    "char_count": 10254,
    "sentence_count": 62,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 36,
      "total_chunks": 77,
      "position": "37/77",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "potassium",
        "calcium",
        "phosphorus",
        "parathyroid hormone",
        "vitamin D",
        "calcitriol",
        "dietitian",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 37,
    "text": "Inonestudy, thecombinationofhighbonealkalinephosphataselevelswithhighPTHlevelsincreased the sensitivity of diagnosis of High turnover lesions; conversely, Low levels of both of thesemarkersresultinincreasedsensitivityfordiagnosisoflowturnoverlesions. However, specificcut-offlevelsforbAPhavevariedinthefewstudiesexaminingtherelationshiptobonehistology. 383 Othermarkersofbonediseasenotyetfullyinvestigatednorinwidespreadclinicaluse includeosteocalcin, (cid: 4)2microglobulin, procollagentypeIcarboxy-terminalpropeptides (PICP), and type I collagen cross linked telopeptides (ICTP), among others. PICP has been correlated with bone formation, and ICTP and osteocalcin been correlated with bone resorption. However, levels of many of these markers are affected by age, diet, liverfunction, andkidneyfunction; thus, interpretationoflevelsisdifficult. 383 Thus, abnormalitiesofbonemineralmetabolismarepresentifthereisanelevated serumphosphorusorPTHlevelorreducedserumcalciumorcalcitriollevel. Giventhe possibilityofanelevatedPTHlevelinthefaceofnormalserumcalciumandphosphorus levels, thediagnosisofearlyabnormalityofmineralmetabolismrequiresmeasurement ofPTHlevels. ExtremeelevationsofserumPTHlevelsaremoreconvincinglyassociated withhighturnoverlesionsthanlowlevelswithlowturnoverlesions. Definitivediagnosis oftypeofbonediseaserequiresbonebiopsy. Strength of Evidence Bonediseaseanddisordersofcalciumandphosphorusmetabolismdevelop duringthecourseofchronickidneydisease(R). Radiologicandhistologicchanges of bone disease can be demonstrated in about 40% and nearly 100%, respectively, of 166 Part6. Association NationalKidneyFoundation potassium/DOQI patientswithseverelydecreasedkidneyfunctionandkidneyfailure. 388, 389However, the abnormalitiesthatleadtobonediseasebegintooccuratearlierstagesofchronickidney disease. ElevatedlevelsofPTHandphosphorus, reducedlevelsofcalcium, andreduced urinary phosphateexcretion havebeen describedamong patientswith glomerular filtration rate(cid: 1)70 mL/ minorlower. 372, 379, 386, 390, 391Histologicchangeshavealsobeenshowntooccuratearlier stagesofchronickidneydisease. Inastudyof176patientswithcreatinineclearances of15to50mL/min, 75%hadimportanthistologicalabnormalities, withthemajority having osteitis fibrosa with or without osteomalacia. 392 In another study of patients with Creatinine clearances of 20 to 59 milliliters per minute, 87% of patients had abnormal bone histology, and the majority had lesions of High bone formation rate associated with hyperparathyroidism. 374 Bonediseaseanddisordersofbonemetabolismareassociatedwithworse outcomesinchronickidneydisease(R). Theconsequencesofabnormalbonemineralmetabolismhavebeenstudiedprimarilyinpatientswithoutkidneydiseaseandin patientswithkidneyfailure. 393, 394Hyperparathyroidismhasbeenassociatedwithabnormal bone histology, bone Pain, and fractures among patients with either primary and secondary hyperparathyroidism, 395397 and Low parathyroid hormone levels have been more recently recognizedtoresultinanincreasedriskofvertebralandpelvicfractures. 398, 399 Calcification of cardiac muscle and coronary vasculature may lead to arrhythmia, leftventriculardysfunction, ischemia, congestiveheartfailure, anddeath. Calciphylaxis results in skin lesions that may become infected or gangrenous, leading to significant morbidityandmortalityamongpatientsondialysis. 380, 394, 400Elevatedphosphorusand calcium-phosphorusproducthasalsobeenlinkedtoincreasedmortalityamongpatients ondialysis. 400, 401Ithasbeenhypothesizedthatelevatedphosphoruslevelsmayhasten thelossofkidneyfunction, possiblyviacalcium-phosphorusprecipitation. 402 In addition, there is some experimental evidence that elevated parathyroid hormone levels may be associatedwithmyocardialdysfunction, andimpairedskeletalmuscle, neurological, and hematopoieticfunction. 393TheimpactofPTHlevelsonmortalityappearsconflicting. Onestudyofdialysispatientsreportedanincreasedriskofdeathamongdialysispatients withlowserumPTHlevels, 400, 403whileanotherstudyofpatientsinanemergencyroom reportedanincreasedriskofdeathamongpatientswithhighPTHlevels. 404 Onsetandseverityofbonediseaseandabnormalitiesofbonemineralmetabolism are related to the level of glomerular filtration rate; below a glomerular filtration rate of approximately 60 mL/ min/1. 73m2, thereisahigherprevalenceofabnormalitiesofbonemetabolism (C, S). PTHlevels areelevatedin patientswithdecreased GFRandlikely arethe earliestmarkerofabnormalbonemineralmetabolism(Tables93and94and Figs 36, 37, and 38) (C, S). The studies relating parathyroid hormone levels to Kidney function date backtothe1960s, withsamplesizesrangingfrom6toover200subjectswithkidney disease. Each of the 23 studies on this topic reviewed for this guideline consistently demonstratedtheexpectedrelationshipofincreasingserumPTHlevelswithdecreasing levels of Kidney function. Further details of these studies are presented in Table 93. potassium/DOQI NationalKidneyFoundation Part6. Association 167 168 Part6. Association NationalKidneyFoundation potassium/DOQI Because of the variety of assays used to measure parathyroid hormone and methods used to estimate levelofkidneyfunction, noattemptwasmadetocombinedatafromdifferentstudies. However, itisevidentandcurrentlyacceptedthattheintactPTHtestprovidesthemost consistentlyreliablemeasureofPTHlevels. Therewerefourseparatestudiesthatexaminedthethresholdcreatinineclearance orGFRlevelsatwhichPTHlevelsbegintorise; thesethresholdlevelsrangedfrom(cid: 1)70 mL/minto(cid: 1)40mL/min. 406, 411, 415, 425Inaddition, analysesofdatafromasinglestudy288 demonstrateaninversecorrelationbetweenlevelofGFRandPTH(Figs36and37)and an increasing prevalence of abnormally elevated parathyroid hormone levels with decreasing glomerular filtration rate (Fig Fig 36. Scatterplot of intact parathyroid hormone versus glomerular filtration rate. These data are based on the results of 446 patientsenrolledintheCanadianMulticentreLongitudinalCohortstudyofpatientswith chronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994and 1997. No patient was receiving erythropoiten therapy at the time of enrollment, and nopatienthadanAVfistula. IntactmoleculePTHassayisreportedinpicamolesper liter, andGFRiscalculatedusingthemodifiedMDRDformula(usingage, race, gender, andserumcreatinine). Adaptedandreprintedwithpermission. 288 potassium/DOQI NationalKidneyFoundation Part6. Association 169 Fig37. iPTHpercentilesbyGFR. Thesedataarebasedontheresultsof446patients enrolledintheCanadianMulticentreLongitudinalCohortstudyofpatientswithchronic Kidney disease. All patients were referred to nephrologists between 1994 and 1997. Nopatientwasreceivingerythropoitentherapyatthetimeofenrollment, andnopatient had an AV fistula. Intact molecule parathyroid hormone assay is reported in pica moles per liter, and GFRiscalculatedusingthemodifiedMDRDformula(usingage, race, gender, andserum Creatinine). DataarepresentedasmedianiPTHand5thand95thpercentiles. Adapted andreprintedwithpermission. 288 Fig38. PrevalenceofhighiPTHbyGFRcategory. Thesedataarebasedontheresults of446patientsenrolledintheCanadianMulticentreLongitudinalCohortstudyofpatients withchronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994 and1997. Nopatientwasreceivingerythropoietintherapyatthetimeofenrollment, andnopatienthadanAVfistula. IntactmoleculePTHassayisreportedinpicomoles per liter, and glomerular filtration rate is calculated using the modified MDRD formula (using age, race, gender, andserumcreatinine). Adaptedandreprintedwithpermission. 288 170 Part6. Association NationalKidneyFoundation potassium/DOQI 38). Therefore, thepreponderanceofdatasupportthatserumPTHlevelsareincreased inpatientswithdecreasedGFR. Consistentwiththeseobservations, fractionalexcretionofphosphorousishigherat lowerGFRs(Table94). Serumcalciumlevelsarefrequently, butnotconsistently, abnormalwithdecreasedGFR(Table95andFigs39and40)(C, S). Thestudiesrelatingserumtotal orionizedcalciumlevelstokidneyfunctiondatebacktothe1960s, withsamplesizes rangingfrom15toover125subjectswithkidneydisease. Thestudieswereconflicting potassium/DOQI NationalKidneyFoundation Part6. Association 171 Fig39. Serumcalciumlevels(adjustedforalbumin)versusGFR. Medianand5thand 95thpercentilesofserumcalcium, adjustedforserumalbumin, amongadultparticipants age20yearsandolderinNHANESIII, 1988to1994. Valuesareadjustedtoage60 years using a polynomial quantile regression. The estimated glomerular filtration rate for each individual datapointisshownwithaplusneartheabscissa. 95%confidenceintervalsatselected levelsofestimatedGFRaredemarcatedwithtriangles, squares, andcircles. Fig40. Prevalenceofhypocalcemia(adjustedforalbumin)versusGFR. Thesedataare basedontheresultsof446patientsenrolledintheCanadianMulticentreLongitudinal Cohortstudyofpatientswithchronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994and1997.",
    "word_count": 599,
    "char_count": 8873,
    "sentence_count": 77,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 37,
      "total_chunks": 77,
      "position": "38/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "potassium",
        "calcium",
        "parathyroid hormone",
        "diet",
        "fistula",
        "bone disease",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 38,
    "text": "The estimated glomerular filtration rate for each individual datapointisshownwithaplusneartheabscissa. 95%confidenceintervalsatselected levelsofestimatedGFRaredemarcatedwithtriangles, squares, andcircles. Fig40. Prevalenceofhypocalcemia(adjustedforalbumin)versusGFR. Thesedataare basedontheresultsof446patientsenrolledintheCanadianMulticentreLongitudinal Cohortstudyofpatientswithchronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994and1997. Nopatientwasreceivingerythropoietintherapy atthetimeofenrollment, andnopatienthadanAVfistula. GFRiscalculatedusingthe modifiedMDRDformula. Hypocalcemiawasdefinedasserumcalciumlevels(adjusted foralbumin)of(cid: 1)8. 5mg/dL. Adaptedandreprintedwithpermission. 288 172 Part6. Association NationalKidneyFoundation potassium/DOQI inthataboutonethird(7/20)didnotdemonstratetheexpectedrelationshipbetween serumcalciumlevelsandkidneyfunction, thatis, theydidnotshowlowerserumcalcium levelsamongpatientswithworsekidneyfunction. Theremainingstudies(13/20)showed thatserumcalciumlevelswerelowerwithlowerlevelsofkidneyfunction. Thesedatadonotconsistentlyshowthatthereisadecreaseincalciumlevelswith decliningkidneyfunction. Thiswasnotasexpectedbasedontheknownpathophysiologyofbonemineralmetabolism. Thestudiesshowingconflictingresultsareofsimilar methodologicalqualityandsamplesize. Insummary, thereisnotaclearrelationshipof thelevelofserumcalciumtothelevelofkidneyfunctionoverawiderangeofkidney functioninthereviewedstudies. Similarly, analysisofdatafromNHANESIIIdoesnotdemonstrateaconvincingrelationship between serum calcium levels (adjusted for albumin) and level of glomerular filtration rate, although fewpatientshadGFRbelow30ml/min/1. 73m2(Fig39). However, analysesofdatafromasinglestudywithalargenumberofindividualswith decreased GFR288 demonstrate lower serum calcium levels and higher prevalence of lower serum calcium levels among individuals with lower glomerular filtration rate, in particular below a GFRof(cid: 1)30mL/min/1. 73m2(Fig40). The combination of the available information regarding pathophysiology of bone disease in chronic Kidney disease and the available evidence reviewed herein would suggestthatserumcalciumlevelsareaffectedbythelevelofkidneyfunction, though abnormalities in serum calcium levels may not become evident until glomerular filtration rate is (cid: 1)30 mL/ min/1. 73m2. SerumphosphoruslevelsareelevatedinpatientswithdecreasedGFR(Table 96andFigs41, 42, and43)(C, S). Therewere21studiesrelatingserumphosphorus levelstokidneyfunctionreviewedforthisguideline. Thesamplesizesrangedfrom15 toover250subjectswithkidneydisease. Fifteenstudiesshowedtheexpectedassociation ofhigherserumphosphoruslevelswithlowerkidneyfunction. Theremaining6studies didnotshowanassociationofkidneyfunctionwithserumphosphoruslevels, although one did find a trend for increasing phosphorus levels when Creatinine clearance was below 50 milliliters per minute. 405 There were four studies that provided sufficient information to determineathresholdlevelofkidneyfunctionatwhichphosphoruslevelsstarttorise. TheapparentthresholdGFRrangedfrom20to50mL/min/1. 73m2. Inaddition, analysesofdatafromasinglestudy288andfromananalysisofdatafrom NHANESIII, demonstrateanincreaseinserumphosphoruslevels(Fig41)andanincreasing prevalence of abnormally elevated serum phosphorus (Fig 42), with lower glomerular filtration rate. Concomitantly, NHANESIII datashowed thatcalcium-phosphorus productand prevalence of elevated calcium phosphorus product were higher in individuals with lower glomerular filtration rate(Fig43). Overall, thesedataconfirmthatserumphosphoruslevelishigherinindividualswith decreasedkidneyfunctionandsuggestthatserumphosphoruslevelsbecomeabnormal insomepatientsatGFRbelowapproximately60mL/min/1. 73m2. potassium/DOQI NationalKidneyFoundation Part6. Association 173 174 Part6. Association NationalKidneyFoundation potassium/DOQI Fig41. SerumphosphoruslevelsversusGFR(NHANESIII). Medianand5thand95th percentilesofserumphosphorus amongadultparticipantsage20years andolderin NHANES III, 1988 to 1994. Values are adjusted to age 60 years using a polynomial quantileregression. TheestimatedGFRforeachindividualdatapointisshownwitha plusneartheabscissa. 95%confidenceintervalsatselectedlevelsofestimatedGFRare demarcatedwithtriangles, squares, andcircles. Fig42. PrevalenceoflowcalciumandhighphosphatebyGFRcategory. Thesedata arebasedontheresultsof446patientsenrolledintheCanadianMulticentreLongitudinal Cohortstudyofpatientswithchronickidneydisease. Allpatientswerereferredtonephrologistsbetween1994and1997. Nopatientwasreceivingerythropoitentherapy atthetimeofenrollment, andnopatienthadanAVfistula. IntactmoleculePTHassay isreportedinpicomolesperliter, andGFRiscalculatedusingthemodifiedMDRDformula (usingage, race, gender, andserumcreatinine). Lowcalciumlevelsaredefinedaslevels 8. 5mg/dL, adjustedforalbumin, andhighphosphatelevelsaredefinedas(cid: 2)4. 5mg/ dL. Adaptedandreprintedwithpermission. 288 potassium/DOQI NationalKidneyFoundation Part6. Association 175 Fig43. Calcium-phosphorusproductpercentilesbyGFR(NHANESIII). Medianand5th and95thpercentilesofserumcalcium-phosphorusproduct, adjustedforserumalbumin, amongadultparticipantsage20yearsandolderinNHANESIII, 1988to1994. Values are adjusted to age 60 years using a polynomial quantile regression. The estimated GFRforeachindividualdatapointisshownwithaplusneartheabscissa. 95%confidence intervals at selected levels of estimated glomerular filtration rate are demarcated with triangles, squares, andcircles. VitaminD levelsaredecreasedamongpatientswithdecreasedGFR(Table 3 97)(C). Therewere14studiesrelatingvitaminD (calcitriol)levelstokidneyfunction 3 reviewedforthisguideline, withsamplesizesrangingfrom39toover200subjectswith kidneydisease. Thirteenofthe14studiesevaluated1, 25dihydroxyvitaminDlevels, three ofthesealsoevaluated24, 25dihydroxyvitaminD(2studies)and/or25hydroxyvitaminD levels(3studies), andonestudyevaluatedonly25hydroxyvitaminDlevels. Eachofthe 13studiesnotedthat1, 25dihydroxyvitaminDlevelswerelowerwithdecreasedkidney function. Thetwostudiesevaluating24, 25dihydroxyvitaminDlevelsnotedlowerlevels with lower Kidney function. The four studies evaluating 25 hydroxyvitamin D levels showedconflictingresults. Thesedata confirmthat 1, 25dihydroxyvitaminD levelsare lowerinpatients with decreasedkidneyfunction. Thereislimitedinformationtosuggestthat24, 25dihydroxyvitaminDlevelsarelowerinpatientswithdecreasedkidneyfunction. Thestudiesdo notprovidedataontheassociationbetweenlevelofkidneyfunctionand25hydroxyvitaminDlevels. Bonehistologyisabnormalinthemajorityofpatientswithkidneyfailure (Table98)(C). Sixarticlesthatrelatedbonebiopsyfindingstolevelofkidneyfunction among patients with chronic Kidney disease not yet on Dialysis were reviewed. The sample sizes ranged from 20 to 176 individuals. The levels of Kidney function ranged from nearly normal (Creatinine clearance of 117 milliliters per minute) to the initiation of Dialysis. Among patients with Kidney failure immediately prior to initiation of Dialysis, 98% to 100% had abnormal bone histology, with the majority of the biopsies showing either 176 Part6. Association NationalKidneyFoundation potassium/DOQI osteitisfibrosaoradynamicbonedisease389, 433(datanotshown). Thestudiesevaluating patientswith varyinglevelsofkidney functiondemonstrated: (1)a directrelationship betweenbonemineralizationandkidneyfunction415, 421; (2)aninverserelationshipbetween Kidney function and bone osteoid/resorption415; or (3) a higher prevalence of abnormalitiesonbonebiopsy(osteomalacia, resorption, osteoid)amongpatientswith reduced kidneyfunction. 392, 419, 434, 435 Intwo studiesof patientswith varyinglevels of kidneyfunctionnotyetreceivingtreatmentwithvitaminDagents, one374with76, the other392 with176 subjects, 75% to85% had significantabnormalities onbone biopsy. Themajorityhadosteitisfibrosa, withorwithoutosteomalacia. Therewere4studiesofbonedensitometryreviewedforthistopic, whichdemonstratedthatbonemineralizationisreducedwithdecreasedkidneyfunction. Onestudy presented the results as a higher prevalence of reduced bone mineral content with decreasedlevelsofkidneyfunction. Otherstudiesnotedareducedbonemineralcontent amongpatientswithdecreasedkidneyfunctioncomparedtocontrols. Thisisinsufficient evidencetomakefirmstatementsregardingtherelationshipbetweenbonedensityand levelofkidneyfunction. potassium/DOQI NationalKidneyFoundation Part6. Association 177 LIMITATIONS Theseguidelinesarelimitedbytheinabilitytoprovideadefinitivequantitativeorsemiquantitativeassessmentoftherelationshipbetweenlevelofkidneyfunctionandmarker ofbonedisease. Thisisinpartduetothelackofcomparabilityofmanyofthestudies giventhediversityofthelaboratoryassaysortestsfortheparticularabnormality. This wasparticularlytrueforPTHandvitaminD (calcitriol)levels, butalsoappliestobone 3 densitometry. Similarly, theinterpretationofbonebiopsiesandradiographictestslikely hasarangeoferror, inthiscaserelatedtointer-observervariability. Inaddition, aswithmostoftheGuidelinesinPart6, theresultsaredifficulttocompare astheyusedifferentmeasuresforkidneyfunction: measuredGFRorcreatinineclearance, estimationequationsforGFRorcreatinineclearance, orsimplyserumcreatinine. 178 Part6. Association NationalKidneyFoundation potassium/DOQI Lastly, manyofthestudiesinvolvedonlyfewpatientswithGFR(cid: 2)60mL/min/1. 73 m2. This leads to the extrapolation of the results from other studies to such patients withvariablelevelsofconfidenceforthevariousmarkers.",
    "word_count": 585,
    "char_count": 9510,
    "sentence_count": 93,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 38,
      "total_chunks": 77,
      "position": "39/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "creatinine",
        "potassium",
        "calcium",
        "phosphorus",
        "calcitriol",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 39,
    "text": "73 m2. This leads to the extrapolation of the results from other studies to such patients withvariablelevelsofconfidenceforthevariousmarkers. CLINICALAPPLICATIONS The data reviewed here suggest that abnormalities of bone/mineral metabolism begin tooccurearlyinkidneydisease; thus, theimplicationsarethat: Indicesofbone/mineralmetabolismshouldbemeasuredwhenthereisindication ofanylevelofkidneydysfunctionparathyroid hormone, phosphorusandionizedcalciumlevels arethemostcommonlyusedbiomarkers. Biomarkersofbone/mineralmetabolismshouldbefollowedlongitudinallyinindividualpatientsasitisexpectedthatabnormalitiesmaydeveloporbecomemore severeaskidneyfunctiondeteriorates. Therearecurrentlynoconvincingdatatosuggestthatthereisbenefittoroutinely obtaining bone biopsies or bone densitometry. Bone biopsy may be indicated if thereissymptomaticdiseaseorifaggressiveinterventionssuchasparathyroidectomyordesferoxaminetherapyarebeingcontemplated. Theapplicationssuggestedabovearebasedonreviewoftheavailableliteraturepresented herein and on opinion. The suggestion to follow the biomarkers over time is based on the hypothesis that a change in some of these biomarkers may occur even when there is no change in glomerular filtration rate. In fact, changes in the biomarkers may provide an earlierindicationofworseningkidneyfunction. Treatment recommendations are beyond the scope of this guideline, and will be addressedelsewhere(seeK/DOQIBoneMetabolismandDiseaseinCKDGuidelines). IMPLEMENTATIONISSUES MedicareatpresentdoesnotcoverpaymentforPTHlevelsforscreeningforhyperparathyroidism among patients with chronic Kidney disease, unless they have a diagnosis specifictohyperparathyroidism. 437Calciumandionizedcalciumtestsarealsonotcovered for the evaluation of patients with chronic Kidney disease, while phosphate and alkalinephosphatetestsarecovered. 437 Clearly, since the evidence shows that there may be elevation in the parathyroid hormone level in thesettingofnormalphosphorusandcalciumlevels, andhighPTHlevelsaredeleterious toboneandnon-osseoustissue, policiesregardingtestingandreimbursementneedto bereassessed. RESEARCHRECOMMENDATIONS Muchoftheavailableinformationregardingabnormalitiesofmineralmetabolismisderivedfromstudiesofpatientswithkidneyfailureorseverelydecreasedkidneyfunction. Clearly, moreinformationisneededontheabnormalitiesofbonemineralmetabolism among patients with earlier stages of chronic Kidney disease. Moreover, research on outcomes related to abnormal mineral metabolism or bone disease is lacking in both patientswithmildly, aswellasseverelydecreasedkidneyfunction. Inadditiontobone potassium/DOQI NationalKidneyFoundation Part6. Association 179 complications, thereisincreasingevidencerelatingabnormalcalcium-phosphorusmetabolismandhyperparathyroidismtovascularcalcificationandcardiovascularcomplica- tions. Therelationshipbetweenlevelsoftheavailablemarkers, andlevelsofkidneyfunction, should be more accurately characterized. In addition, the relationship between such levelsandkidneyfunctionshouldbeseparatelystudiedamongpatientswithadditional risksofbonecomplications, thatis, patientstreatedforprolongedperiodswithcorticosteroidsandtransplantrecipients. Researchshouldalsofocusontheimpactofinterventionsonlevelsofavailablemarkers and outcomes, specifically of interest would be comparing patients cared for by nephrologistswiththosenotunderthecareofnephrologists, patientstreatedforsome specified period of time for hyperparathyroidism compared to those not treated, and patientstreatedwithcorticosteroidscomparedtothosenevertreatedwithsuchdrugs. GUIDELINE 11. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH NEUROPATHY Neuropathydevelopsduringthecourseofchronickidneydiseaseandmaybecome symptomatic. Patients with chronic Kidney disease should be periodically assessed for central and peripheral neurologic involvement by eliciting symptoms and signs during routineofficevisitsorexams. Specializedlaboratorytestingforneuropathyinpatientswithchronickidneydiseaseisindicatedonlyinthepresenceofsymptoms. BACKGROUND Neuropathyisacommoncomplicationofpatientswithkidneyfailure. 438440Neuropathy maybemanifestedasencephalopathy, peripheralpolyneuropathy, autonomicdysfunction, sleepdisorders, and, lesscommonly, peripheralmononeuropathy. Occurrenceof neuropathyisrelatedtothelevelofkidneyfunction, butnotthetypeofkidneydisease. However, therearecertaincausesofchronickidneydiseasethatalsoaffectthecentral and/orperipheralnervoussystem. Theseareamyloidosis, Diabetes, systemiclupuserythematosus, polyarteritisnodosa, andhepaticfailure. 438, 439Inaddition, therearecongenital disordersthataffectboththekidneysandnervoussystem, suchasVonHippelLindau disease, Wilsonsdisease, andFabrysdisease. 438 Thepathophysiologyof uremicneuropathyisnotwellunderstood. Levelsofurea, Creatinine, parathyroid hormone, middlemolecules, andothershavebeencorrelatedwithreduction ofnerveconductionvelocity(NCV)andperipheralmanifestationsofneuropathy. 438, 439 Inadvancedstagesthereisevidenceofhistopathologicaldamagewithaxonaldegenerationandsecondarydemyelinationofperipheralnerves. 438 RATIONALE Markers of Neuropathy Uremicneuropathy mayaffect thecentral, peripheral, or autonomicnervous systems. Earlyuremicencephalopathymaypresentwithfatigue, impairedmemory, orconcentra180 Part6. Association NationalKidneyFoundation potassium/DOQI tion. Withmoreadvanceduremiadelirium, visualhallucinations, disorientation, convulsions, and coma may develop. 438 Generally, uremic polyneuropathy is a symmetrical, mixed sensory and motor polyneuropathy, with distal nerves more severely affected. Patients may complain of pruritus, burning, muscle irritability, cramps, or weakness. 438, 439 Autonomic function abnormalities include impaired Heart rate and Blood pressurevariabilityinresponsetorespiratorycycle, posturalchange, andvalsalva. Signs on examination include muscle atrophy, loss of deep tendon reflexes, poor attention span, impaired abstract thinking, abnormal or absent reflexes (in particular ankle jerk), and impaired sensation (vibratory, light touch Hypertension, and Pain). 438, 439 Latersignsincludemeningismus, myoclonus, andasterixis. 438Electroencephalography (EEG)hasgeneralizedslowing, andbilateralspikeandwavecomplexeshavebeendescribedinupto14%ofpatients, evenintheabsenceofevidentclinicalseizureactivity. 438 EEGmeasuresofsleepalsoaredisturbedindialysispatients. 441CTscanorMRIisnot helpful, though there may be cerebral atrophy. 438, 442444 The most sensitive test for detection of asymptomatic peripheral neuropathy is slowed sensory NCV; although motor NCV is slowed, there is a wide intra-individual day-to-day variation, and these findingsoccurwithmoreadvancedkidneydysfunction. 438, 439, 445 Strength of Evidence Neuropathydevelopsduringthecourseofchronickidneydisease(R). Neuropathyispresentinupto65%ofpatientsattheinitiationofdialysis438, 439; thus, itmust begin to develop during an earlier phase of Kidney disease. Symptoms of peripheral neuropathygenerallydonotpresentunlesstheGFRisunder12to20mL/min, oruremia hasbeenpresentforatleast6months. 438, 439Encephalopathymaybecomeevidentwith less prolonged impairment of Kidney function and can be seen with acute decline in glomerular filtration rate, although the correlation of central nervous system manifestations with level of kidneyfunctionispoor. 438Autonomicneuropathyispresentin20%to80%ofpatients withdiabeticnephropathy, 442, 444in66%ofpatientswithseverelyimpairedkidneyfunction(creatinineclearance(cid: 1)8mL/min), andin50%ofpatientsondialysis. 443 ObjectivefindingsofperipheralneuropathyasevaluatedbyNCVstudiesarepresent in 15%to 85% ofindividuals with decreasedGFR. 446449 Sensory NCVis decreased in over90%ofpatients, whereasmotorNCVisdecreasedinonly40%. 445Amongpatients ondialysis, objectiveevidenceofneuropathyispresentin50%to100%, 440, 446andthe prevalenceappearstoincreasewithdurationofdialysis. 440 Objective evidence of central nervous system (CNS) dysfunction is not uniformly evident. EEGhasbeendescribedtobeminimallyabnormalinasmallpercentageof patients445orasslowedinmostpatients, 450withthedegreeofslowingmorepronounced with more advanced dysfunction. EEG findings have been reported to improve after initiationofdialysisorwithtransplant. 450Testsofcognitivefunctionwereabnormalin allpatientsandweremoreimpairedwithincreasingcreatinine.",
    "word_count": 598,
    "char_count": 8338,
    "sentence_count": 59,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 39,
      "total_chunks": 77,
      "position": "40/77",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "potassium",
        "phosphate",
        "parathyroid hormone",
        "bone disease",
        "pruritus",
        "neuropathy"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 40,
    "text": "EEGhasbeendescribedtobeminimallyabnormalinasmallpercentageof patients445orasslowedinmostpatients, 450withthedegreeofslowingmorepronounced with more advanced dysfunction. EEG findings have been reported to improve after initiationofdialysisorwithtransplant. 450Testsofcognitivefunctionwereabnormalin allpatientsandweremoreimpairedwithincreasingcreatinine. Transplantanddialysis patientshadsomewhatbetter, butnotnormal, scores. 450 Treatment with Dialysis improves the more severe symptoms and findings of CNS potassium/DOQI NationalKidneyFoundation Part6. Association 181 involvement and improves the symptoms of polyneuropathy; however, NCV remains abnormalinupto60%to80%. 440Thesymptomsandfindingsofperipheralneuropathy aredramaticallyimprovedbytransplantation. 438 Neuropathyisassociatedwithworse outcomesinchronickidneydisease (R). Noarticleswerefoundthatspecificallyrelatedthepresenceofneuropathytoother outcomesamongpatientswithchronickidneydisease. However, itisself-evidentthat impairedcognitionandsleep, dysesthesias, andimpairedautonomicfunctionwouldat leastleadtoreducedqualityoflifeandinabilitytofunctionnormally. Iftheneuropathy leadstoskinulcers, thencertainlythiswouldresultinobjectivemorbidityandpotentially mortality. Advancedencephalopathymayresultinseizures, coma, anddeath. 438 Objectivefindingsofneuropathycanbedetectedbeforesymptomsarise(C, R). Severalofthearticlesreviewednotethatthemajorityofpatientswhohaveabnormalitiesintestsofnervoussystemfunctionareasymptomatic. 445, 447, 448However, abnormalitiesaremoreprofoundamongpatientswithsymptoms. 447, 448 OnsetandseverityofneuropathyisassociatedwiththelevelofGFR; there isinsufficientevidencetodefineaspecificthresholdlevelofGFRthatisassociated with an increased prevalence or severity of neuropathy (C). The articles reviewedvariedgreatlyinthelevelsofkidneyfunctionassessed, aswellasinthemeasure ofkidneyfunctionused, assomeusedonlyserumcreatininelevelsandotherusedGFR orcreatinineclearance. Moststudiesdemonstratedarelationshipbetweenkidneyfunctionandtheparticularmarkerofneuropathy. However, severalstudiesonlycompared theparticular markerwith thenormal orreference standardfor thetest orcompared groupeddataonpatientswithkidneydiseasewithcontrolsorpatientsondialysis/transplantwithoutprovidingdataatvariouslevelsofkidneyfunction. Summariesofthestudies reviewedarepresentedinTables99and100. 182 Part6. Association NationalKidneyFoundation potassium/DOQI Nerveconductionvelocity(NCV)isslowerinpatientswithdecreasedGFR (Table 99) (C). There were 6 studies relating NCV to level of Kidney function. The studieshadsamplesizesrangingfrom40to210subjects, with29to72patientswith decreasedkidneyfunctionnotyetondialysis. Allbutone450ofthestudiesshowedthat NCVwasdecreasedbelownormallevelsamongpatientswithdecreasedkidneyfunction. In three of the studies, the correlation between Kidney function level and NCV was significant; intheothertwocorrelationwassuggestedbutlackedstatisticalsignificance. Athresholdlevelof kidneyfunctionforabnormalmotorNCV wasonlymentionedor deduciblefromthreestudies. BelowaGFRof8to13446, 448orserumcreatinineabove 7 to 8 milligrams per deciliter, 445 50% or more patients with decreased Kidney function had abnormal NCV. Thethresholdlevelatwhich50%ormoreofpatientshaveabnormalsensoryNCV velocitywasevaluatedinonlytwostudiesandnotedtobeapproximately8to20mL/ min. 445, 448 ThesedatagenerallyconfirmthatNCVisdecreasedamongpatientswithdecreased Kidney function. The reviewed studies do suggest a correlation between level of glomerular filtration rate and NCV, but they do not offer sufficient information to convincingly demonstrate a thresholdlevelofGFRatwhichNCVbecomesabnormal. MemoryandcognitionareimpairedinpatientswithdecreasedGFR(Table 100)(C). Onlyonestudywasfoundthatevaluatedmemoryandcognitionamongpatients with decreased Kidney function prior to the availability of erythropoietin. 450 In thisstudyof177subjects, ofwhom72haddecreasedkidneyfunctionnotyetondialysis, severalcognitivefunctionswereassessed, includingsustainedattention, selectiveattention, speedofdecision-making, short-termmemory, andmentalmanipulationofsymbols. Eachofthesetestmeasureswassignificantlyloweramongpatientswithdecreasedkidney function, correlated with level of dysfunction, and was improved to varying degrees amongpatientsondialysisandtoagreaterdegreeamongpatientswithakidneytransplant. potassium/DOQI NationalKidneyFoundation Part6. Association 183 AutonomicfunctionisimpairedinpatientswithdecreasedGFR(Table101) (C). Onlythreestudieswerefoundthatobjectivelyevaluatedautonomicfunctionamong patients with kidneydisease. These studies hadbetween 42 and 123subjects and between21 and67patients withdecreasedkidney functionnot yetondialysis. Eachof thesestudiesnotedthatautonomicfunctionwasimpairedinmorethan50%ofpatients withchronickidneydisease; however, onlyoneofthemfoundanassociationbetween levelofkidneyfunctionandmeasuresofautonomicnervefunction. Theresultsofthesestudiescannotbeextrapolatedwithconfidencetothegeneral populationofpatientswithchronickidneydisease, astwowerelimitedtopatientswith diabetes442, 444andthusconfoundedbytheneuropathyascribabletodiabetes, andthe third only had patients with very decreased Kidney function (glomerular filtration rate (cid: 1)8 milliliters per minute) or on Dialysis. 443 Symptomsofneuropathy, includingsleepdisturbances, areincreasedinpatientswithdecreasedGFR(C). Symptomsorclinicalsignsofperipheralneuropathy wereevaluatedormentionedinfourofthesixstudiesofperipheralneuropathyreviewed for this guideline. 445448, 450 The method of ascertaining the presence of symptoms or clinicalfindingswasmentionedinonlyoneofthesestudies447asadetailedneurological examinationwascarriedouttofindevidenceofclinicallymanifestneuropathy. The prevalence of symptoms or clinical findings ranged from 0% to 52%. Individuals with clinicalsymptomshadagreaterreductioninNCVascomparedtothosewithoutsuch symptomsin2studies, 446, 448whereastherewasnosignificantcorrelationbetweenNCV andsymptomsinoneofthestudies. 447Noneofthestudiescommentedonthecorrelation between symptoms and level of Kidney function; however, from a single study it was estimatedthatpatientswithsymptomshadalowermeanlevelofkidneyfunction(glomerular filtration rate (cid: 4)6mL/min)thanpatientswithoutsymptoms(glomerular filtration rate(cid: 4)16mL/min). 446 184 Part6. Association NationalKidneyFoundation potassium/DOQI Thereviewedstudiesdonotoffersufficientinformationtoconvincinglydelineatea progressiveincreaseinprevalenceofsymptomswithdecreasingGFR. LIMITATIONS Severalofthereviewedarticlesincludedpatientswhohadstarteddialysisorreceived akidneytransplant; informationonthesepatientswasusedforbackgroundinformation andcomparison. Morearticlesthanwerereviewedwerefoundwiththeliteraturesearch, butwerenotexhaustivelyreviewedaspreliminaryreviewsuggestedthelackoforinability to extract the necessary information. This may have led to the omission of some articlesthatmayhaveprovidedfurtherinformation. These guidelines are limited by the inability to provide a definitive quantitative or semi-quantitative assessment of the relationshipbetween level of Kidney function and markersofneuropathy. Thisisinpartduetothedearthofstudies, theuseofdifferent measures of Kidney function, the limited presentation of methods, and the failure to presentadequatecorrelationdata. Inparticular, therewasextremelylimitedinformation oncognitivefunctionandsymptomsofneuropathy. Lastly, many of the studies involved only a limited number of patients with mildly tomoderatelydecreasedkidneyfunction, andtwoofthestudieswerelimitedtodiabetics, confoundingtheresultswiththepresenceofdiabeticneuropathy. CLINICALAPPLICATIONS The data reviewed here suggest that symptoms of neuropathy begin to occur at very lowlevelsofGFR. Theinconclusiveevidencepresentedhereinhastheimplicationsthat: Indices of neuropathy are not useful to monitor progression of chronic Kidney disease. Symptoms or indices of neuropathy are evidence of Kidney failure, and may be usefultodetermineneedtoinitiatedialysis. Therearecurrentlynoconvincingdatatosuggestthatthereisbenefittoobtaining nerveconductionstudiesornervebiopsiesinasymptomaticpatients. Theapplicationssuggestedabovearebasedonreviewoftheavailableliteraturepresented herein and opinion based on others reviews of the problem. Treatment and assessmentrecommendationsarebeyondthescopeofthisguideline. IMPLEMENTATIONISSUES Theonlyimplementationissuearisingfromthisguidelineistoprovideeducationregarding the prevalence of neuropathy, and the need to elicit symptoms and signs of this conditionduringroutineofficevisits. RESEARCHRECOMMENDATIONS Muchoftheavailableinformationregardingneuropathyisderivedfromstudiesofpatientswithkidneyfailure. Moreinformationonneuropathyamongpatientswithchronic kidneydiseasewith earlierstagesofchronic kidneydiseasemayprovide othermeans tofollowprogressionofchronickidneydisease. Inaddition, ifneuropathyweretobe morecarefullydescribedandnotedtohaveahighprevalenceinearlierstagesofchronic potassium/DOQI NationalKidneyFoundation Part6. Association 185 kidneydiseaseandarelationshiptokidneyfunction, treatmentstodelayitsprogression couldbeconsidered. Therelationshipbetweensubjectiveandobjectivemeasuresofneuropathy, andlevels ofkidneyfunction, shouldbemoreaccuratelycharacterized. Inaddition, therelationship betweenneuropathyandkidneyfunctionshouldbeseparatelystudiedamongpatients withadditionalrisksofneuropathy, suchasdiabeticsandpatientswithamyloidosis. GUIDELINE 12. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH INDICES OF FUNCTIONING AND WELL-BEING Impairmentsindomainsoffunctioningandwell-beingdevelopduringthecourseof chronickidneydiseaseandareassociatedwithadverseoutcomes.",
    "word_count": 583,
    "char_count": 9705,
    "sentence_count": 71,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 40,
      "total_chunks": 77,
      "position": "41/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "potassium",
        "erythropoietin",
        "dialysis",
        "neuropathy",
        "guideline"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 41,
    "text": "GUIDELINE 12. ASSOCIATION OF LEVEL OF glomerular filtration rate WITH INDICES OF FUNCTIONING AND WELL-BEING Impairmentsindomainsoffunctioningandwell-beingdevelopduringthecourseof chronickidneydiseaseandareassociatedwithadverseoutcomes. Impairedfunctioning andwell-beingmayberelatedtosociodemographicfactors, conditionscausingchronic Kidney disease, complications of Kidney disease, or possibly directly due to reduced glomerular filtration rate. PatientswithGFR(cid: 1)60mL/min/1. 73m2shouldundergoregularassessmentfor impairmentoffunctioningandwell-being: Toestablish abaselineandmonitor changesinfunctioningand well-beingover time Toassesstheeffectofinterventionsonfunctioningandwell-being. BACKGROUND When there is no cure for a chronic illness, an essential healthcare goal must be to maximizequalityoflife. Thepurposeofthisguidelineistoidentifystagesandcomplicationsofkidneydiseasethatplaceadultpatientsatgreaterriskforreducedqualityoflife. This guideline is not intended to cover all the quality of life concerns that apply to children and adolescents, nor is it intended to recommend interventions to improve qualityoflifeinanyagegroup. Forthepurposeofthisguideline, conceptsthatembody pertinent components of quality of life will be referred to as functioning and wellbeing. Recent studies show that the functioning and well-being of individuals with chronic Kidney disease is related to such factors as: late referral and inadequate predialysiscare80; symptoms; effectsofillnessonphysical, psychological, andsocialfunctioning; andsatisfactionwithhealthandcare. 452Complicationsofchronickidneydisease, suchasanemia, malnutrition, bonedisease, neuropathy, andcomorbidconditions, such asdiabetesandcardiovasculardisease, cannegativelyaffectfunctioningandwell-being. Toimprovefunctioningandwell-being, patientsmustbereferredsoonerandcomplicationsandcomorbidconditionsmustbemanagedappropriately. This guideline describes the association between the level of Kidney function and domainsoffunctioningandwell-beinginpatientswithchronickidneydisease. Onemust analyzethefullcontinuumofstagesofchronickidneydiseasetounderstandtherisks forcompromisedfunctioningandwell-being. Armedwiththisknowledge, clinicianscan more quickly identify stages of chronic Kidney disease at which deficits are likely to 186 Part6. Association NationalKidneyFoundation potassium/DOQI occur and develop strategies to treat higher risk patients and ameliorate or eliminate deficitsbeforetheybecomesevereorirreversible. RATIONALE Definitions Healthstatusoutcomesexpertsrecommenddefiningqualityoflifetoincludevariables thathealthprofessionalscanidentify, quantify, andmodify: (1)healthstatus(signsand symptoms, lab values, death); (2) functional status (physical, mental, social, and role functioning), and(3)well-being(energy/Fatigue, Pain, healthperceptions, andsatisfaction). 453, 454Self-reportispreferabletostaffreportsinceoutcomesaredependentonthe livedexperienceandexpectationsoftheindividualpatient. Difficultiesinmeasuringthispoorlyunderstoodconcepthaveledresearchersinthe articles reviewed to study several variables using different methods and instruments (Table102). Useofdifferentinstrumentshasimpededcomparingfindings, interpreting results, anddrawingconclusions. Strength of Evidence Indicesoffunctioningandwell-beingareimpairedinchronickidneydisease (R). Dialysispatientsreportsignificantlymorebodilypain, lowervitality, poorergeneral health, greaterphysical, mental, andsocialdysfunction, andgreaterlimitationsintheir ability to work and participate in activities due to their health and emotions than the USreferencenorm. Atleast25%aredepressed. 455Dialysispatientsexercisecapacityis potassium/DOQI NationalKidneyFoundation Part6. Association 187 significantlyworsethanthatofhealthycontrols. 456Kidneyfailurenegativelyaffectssense ofcontrolandhealthoutlookinthoseondialysis. 457About39%ofthosewhoworked full or part-time 6 months before Dialysis do not continue working when they start Dialysis. 4Elderlypeopleondialysisengageinfewpreviouslyenjoyedactivitiesoutside theirhomesandmanyleavehomeonlyfordialysisbecauseofweakness. 458 Impairment in indices of functioning and well-being are associated with worse outcomes in chronic Kidney disease (R). Impaired functioning and wellbeingin dialysispatients islinked toincreased riskof deathand hospitalizationwhile improvementinscoreshasbeenassociatedwithbetteroutcomes. PatientswithSF-36 PhysicalComponentSummary(PCS)scores(cid: 1)34. 6hada2. 03relativeriskofdyingand a1. 67relativeriskofbeinghospitalized. Each5-pointimprovementinPCSscoreswas associatedwith10%longersurvivaland6%fewerhospitaldays. OntheSF-36, aMental Healthscalescore(cid: 2)52andaMentalComponentSummary(MCS)score(cid: 2)42indicate depression. Each 5-point improvement in the MCS score is associated with 2% fewer hospitaldays. 455 Impairment in functioning and well-being are associated with sociodemographic characteristics(R). Lowincome and loweducation wereassociated with greaterimpairmentsinfunctioningandwell-beinginpatientswithchronickidneydisease. 459 Impairment in functioning and well-being may be due to conditions that causechronickidneydisease(suchasdiabetesorhypertension)orcomplicationsofdecreasedGFR(suchasanemia, malnutrition, bonedisease, orneuropathy)(R). Hypertension, diabeteswithangina, priorcardiacinfarction, 460osteoporosis, bonefractures, 461andmalnutrition462havebeenshowntoimpairfunctioningandwellbeinginthosewithnoknownkidneydisease. Amongveteranswithdiabetes, neuropathy andkidneydiseasehavebeenassociatedwiththegreatestdecreaseinfunctioningand well-being. 463 Anemiahasbeenlinkedtopoorfunctioningandwell-beinginpatientswithseverely decreasedGFRanddialysispatients, andimprovinganemiawitherythropoietinhasbeen linkedtoimprovementinfunctioningandwell-being. 284, 464468 Indicesoffunctioningandwell-beingarerelatedtothelevelofGFR; below a glomerular filtration rate of approximately 60 milliliters per minute/1. 73 m2, there is a higher prevalence of impairmentsinindicesoffunctioningandwell-being(S, C). Datafromcross-sectional studies and baselinedata from longitudinal studies were reviewedto assess the relationshipbetweenlevelofkidneyfunctionandleveloffunctioningandwell-being. Populationsstudiedincludethosewithdecreasedkidneyfunction, includingthosewith functioningtransplants, anddialysispatientswhencomparedwithhealthysubjectsor Kidney transplant recipients. While much of the data on functioning and well-being relatedtooutcomeshavebeenobtainedindialysispatients, thereisconvincingevidence thatabnormalitiesinfunctioningandwell-beingbeginearlierinchronickidneydisease andmaywellberelatedtodecliningGFR. 188 Part6. Association NationalKidneyFoundation potassium/DOQI Symptoms (Table 103 and Fig 44). Reduced Kidney function is associated with increasingsymptomssuchastiringeasily, weakness, lowenergy, cramps, bruising, Bad tastingmouth, hiccoughs, andpoorodorperception. Thisistrueinpatientswithnative kidneydiseaseandthosewithkidneytransplants. Diabeticdialysisandtransplantpatients are more likely to report poor health than Dialysis or transplant patients who do not havediabetes. Physical Functioning (Table 104 and Figs 45 and 46). Decreased glomerular filtration rate in NHANESIIIsubjectsisassociatedwithimpairedwalkingandliftingability. Intransplant recipients, reduced Kidney function is also associated with poorer physical function scores. Inone study ofpatients with decreasedGFR, impairment inphysical function was not significantly related to the level of Kidney function, but physical impairment was8timesworsethaninthegeneralpopulation. Dialysispatientsreportgreaterphysical dysfunctionthantransplant recipientsanddiabeticdialysisandtransplant patientsare morelikelytoreportphysicaldysfunctionthanthosepatientswhodonothavediabetes. Depression(Table105). Reducedkidneyfunctionisassociatedwithpoorerpsychosocialfunctioning, higheranxiety, higherdistress, decreasedsenseofwell-being, higher depression, andnegativehealthperception. Depressedpatientsaremorelikelytoreport poorlifesatisfaction, irrespectiveofkidneyfunction. Dialysispatientsreportsignificantly lowerhappinesswithpersonallifeandlowerpsychosocialfunctioningthantransplant potassium/DOQI NationalKidneyFoundation Part6. Association 189 Fig44. Kidneyfunction (glomerular filtration rate)andoddsof havingsymptomsaffectingquality oflife andwell-beingintheMDRDStudy, controlledforage, gender, race, kidneydiagnosis, education, income, andsmokingstatus. Reprintedwithpermission. 469 190 Part6.",
    "word_count": 600,
    "char_count": 8506,
    "sentence_count": 66,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 41,
      "total_chunks": 77,
      "position": "42/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "potassium",
        "malnutrition",
        "dialysis",
        "kidney transplant",
        "fatigue",
        "neuropathy",
        "quality of life"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 42,
    "text": "Kidneyfunction (glomerular filtration rate)andoddsof havingsymptomsaffectingquality oflife andwell-beingintheMDRDStudy, controlledforage, gender, race, kidneydiagnosis, education, income, andsmokingstatus. Reprintedwithpermission. 469 190 Part6. Association NationalKidneyFoundation potassium/DOQI Fig45. AdjustedprevalenceofphysicalinabilitytowalkbyGFRcategory(NHANES III). Predicted prevalence of physical inability to walk one-quarter mile among adult participantsage20yearsandolderinNHANESIII, 1988to1994. Valuesareadjusted toage60yearsusingapolynomialregression. 95%confidenceintervalsareshownat selectedlevelsofestimatedGFR. Fig46. AdjustedprevalenceofphysicalinabilitytoliftbyGFRcategory(NHANESIII). Predictedprevalenceofphysicalinabilitytolift10poundsamongadultparticipantsage 20yearsandolderinNHANESIII, 1988to1994. Valuesareadjustedtoage60years usinga polynomialregression. 95% confidenceintervalsare shownat selectedlevels ofestimatedGFR. potassium/DOQI NationalKidneyFoundation Part6. Association 191 recipients. InelderlyMexicanAmericans, kidneydiseasehasbeenfoundtobepredictive ofdepressivesymptoms. EmploymentandUsualActivities(Table106). Reducedkidneyfunctionisassociatedwithloweremployment. InthosewithchronickidneydiseaseandGFR(cid: 1)50, the presenceofphysicaldysfunctionissignificantlyrelatedtounemployment, buttheassociation to Kidney function is not significant since physical dysfunction is not uniformly present. Full-time employment is higher for those with decreased glomerular filtration rate (mean serum creatinine5. 4mg/dL, 69%)comparedwiththosewithkidneyfailure(meanserumcreatinine13. 7mg/dL, 12%). Moredialysispatientsreporttheirhealthlimitsworkandother activitiesthanthosewithfunctioningtransplants. Dialysisandtransplantpatientswith diabetesaremorelikelytoreportdifficultyworkingthandialysisandtransplantpatients withoutdiabetes. Social Functioning (Table 107). Reduced Kidney function is associated with reducedsocialactivity, socialfunctioning, andsocialinteraction. Dialysispatientsreport fewer neighborhood acquaintances, social contacts, and worse social well-being than healthyindividualswhiletransplantrecipientsreporthighersocialfunctionandsocial 192 Part6. Association NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part6. Association 193 interaction than those on Dialysis. Diabetics on Dialysis or with transplants are more likelytoreportproblemswithsocialinteractionthannondiabeticpatients. Levelofperceivedsocialsupportinchronickidneydiseaseisnotassociatedwiththelevelofkidney function. LIMITATIONSANDEXCEPTIONS Most study samples were not randomly selected. Medication usage was not reported evenifmedications(eg, anti-depressants)couldaffectoutcomes. Sevenof12studiesdid notprovidefullinformationonpatientdemographics. Threestudiesreporteddifferences betweengroupsofveryunequalsizesandonereportedpercentagesbutdidnotreport whetherobserveddifferenceswerestatisticallysignificant. Historically, therehasbeennogoldstandarddefinitionforqualityoflifeorfunctioningandwell-being. Researchershavestudiedmultiplevariablesusingstandardizedand non-standardizedinstruments. Thus, resultsarenotcomparabletooneanother. 479With lackofinstrumentcomparability, findingsappeartobeconflicting. Manystudieshave examinedtherelationshipsbetweenfunctioningandwell-beingandtreatmentmodalities aftertheonsetofkidneyfailure. FewstudiesofpersonswithdecreasedGFRhaveexaminedtherelationshipbetweenlevelofGFRandfunctioningandwell-being. Threeofthe studiesofindividualswithdecreasedGFRhadsuchseverelyrestrictiveinclusioncriteria forlevelofkidneyfunctionthatfunctioningandwell-beingdeficitswerealreadypresent. Ofthe12 studiesreported, 3reported nomeasureofkidneyfunction and2reported onlyserumcreatinine, alessreliablemeasureofkidneyfunctionthanGFRorcreatinine clearance. Mostofthestudiesreportedonlymeanvaluesforkidneyfunction. Onlythe MDRDStudyandNHANESIIIexaminedfunctioningandwell-beingatawiderangeof levels of Kidney function. Precise statements about how early deficits in domains of functioningandwell-beingoccuraskidneyfunctiondeterioratesrequirethisessential data. Finally, sinceanemiahasbeenshowntolimitfunctioningandwell-being, inadequate anemiamanagementinstudiesconductedpriortothewidespreaduseoferythropoietin couldhaveaffectedoutcomes. Therefore, recentfunctioningandwell-beingoutcomes maynotbecomparabletooutcomesreportedinstudiespriorto1989evenifthesame instrumentswereused. CLINICALAPPLICATIONS TheconfereesattheInstituteofMedicine(IOM)WorkshopAssessingHealthandQuality ofLifeOutcomesinDialysisrecommendedthatESRDproviders: Assessfunctioningandwell-beinginkidneydiseaseusingstandardizedsurveyinstrumentsthatarevalid, reliable, responsivetochanges, easilyinterpretable, and easytouse, suchastheDartmouthCOOPCharts, theDukeHealthProfile/Duke Severity of Illness (DUKE/DUSOI), Medical Outcomes Study 36-Item Short Form (SF-36), ortheKidneyDiseaseQualityofLife(KDQOL). Assesspatientfunctioningandwell-beingearlyinchronickidneydiseasetoestablish a baseline, to maintain or improve health status, and to manage the disease 194 Part6. Association NationalKidneyFoundation potassium/DOQI continuum by linking clinical and health outcomes with functional status outcomes. 454 Datareportedinthereviewedstudiessuggestthatdecreasedkidneyfunctionaffects patientsfunctioningandwell-beingthroughseveraldimensions. Deficitsinfunctioning arereportedbypatientsevenatearlystagesofchronickidneydisease, andpersisteven aftertransplantation. Theimplicationsofthesefindingsare: Cliniciansshouldassessfunctionalstatusandwell-beingassoonaspossibleafter referralinordertoobtainbaselinedataandenableearlyinterventiontoimprove functioningandwell-being. Clinicians should regularly reassess functioning and well-being to ascertain the patientscurrentstatusandtheeffectivenessofinterventionstoimprovefunctioningandwell-being. Reassessmentisneededwhenapatientreportsincreasedfrequency or severity of symptoms, has a new complication of Kidney disease, has an access for Dialysis placed, starts Dialysis, changes modality, or participates in aclinicalorrehabilitationintervention (eg, counseling, peersupport, education, physicaltherapyorindependentexercise, orvocationalrehabilitation). Theserecommendationsarebasedontheopinionsexpressedbytheauthorsofmost of the studies reviewed for this guideline, as well as those of recognized experts in functioningandhealthstatusoutcomesmeasurementwhoattendedtheIOMWorkshop. IMPLEMENTATIONISSUES Researchersmayuseanyofawidearrayofinstrumentstomeasurefunctioningandwellbeing throughout the course of chronic Kidney disease. However, clinicians want to knowwhatinstrumenttouse, whentouseit, andwhoshouldadminister, score, and analyzethedata. Ingeneral, itispracticalforclinicianstouseonlyafewinstruments andtogainexperiencewiththem. Basedontheliteraturereviewedforthisguideline, it appears that any clinician treating patients with decreased glomerular filtration rate can administer the DartmouthCOOPCharts, DUKEHealthProfiles, KidneyDiseaseQualityofLife, orSF36thathavebeenusedwithdialysisandtransplantpatients(Table108). Intheclinical setting ease of use is essential. These surveys are recommended because each has an instructional manual and patients can complete them independently or with limited assistance. To assess specific limitations in functioning and well-being, clinicians can supplementthesegeneralinstrumentswithmorespecificinstrumentsincludingperformance-basedtestsofphysicalfunctioning. RESEARCHRECOMMENDATIONS Research in Dialysis patients has shown that functioning and well-being pre-treatment may predict post-treatment outcomes. Therefore, large-scale longitudinal studies are neededto evaluatetherelationship betweenGFRand alldomainsof functionalstatus andwell-beingthroughoutthecourseofprogressionofkidneydisease. Moreresearch shouldbeundertakenusingtherecommendedstandardizedinstrumentsandtheiroutcomescompared. Wheneverspecificmedicationscouldaffectoutcomes, usageshould potassium/DOQI NationalKidneyFoundation Part6. Association 195 beassessed. Becauseconditionssuchasanemia, bonedisease, cardiovascular, disease, anddiabetescanaffectfunctioningandwell-being, researchersneedtostudywhether appropriate management ofthese conditions improves functioning andwell-being. Finally, researchers need to examine the effectiveness of rehabilitation interventions in earlier stages of chronic Kidney disease. Doing so could provide further scientific evidencefortherelationshipofkidneyfunctionandtreatmentonpatientsriskofdysfunction, hospitalization, and death and increase understanding of what interventions improvefunctioningandwell-beingandreducetheburdenofchronickidneydiseaseon thepatient, hisorherfamily, andsociety. 196 Part6. Association NationalKidneyFoundation potassium/DOQI PART 7. STRATIFICATION OF RISK FOR PROGRESSION OF Kidney DISEASE AND DEVELOPMENT OF CARDIOVASCULAR DISEASE The major outcomes of chronic Kidney diseaseare loss of Kidney function, leading to complicationsandkidneyfailure, anddevelopmentofcardiovasculardisease. Thegoals of Part 7 are to define risk factors for progression of chronic Kidney disease and to determine whether chronic Kidney disease is a risk factor for cardiovascular disease. Becauseofthewell-knownassociationofcardiovasculardiseaseanddiabetes, theWork Groupconsideredpatientswithchronickidneydiseaseduetodiabetesseparatelyfrom patientswithchronickidneydiseaseduetoothercauses.",
    "word_count": 587,
    "char_count": 9424,
    "sentence_count": 77,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 42,
      "total_chunks": 77,
      "position": "43/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "potassium",
        "dialysis",
        "cardiovascular disease",
        "guideline"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 43,
    "text": "Becauseofthewell-knownassociationofcardiovasculardiseaseanddiabetes, theWork Groupconsideredpatientswithchronickidneydiseaseduetodiabetesseparatelyfrom patientswithchronickidneydiseaseduetoothercauses. AsdescribedinAppendix1, Table153, theWorkGroupsearchedprimarilyforlongitudinalstudiesthatrelatedrisk factors to loss of Kidney function (Guideline 13) and that related proteinuria and decreasedGFRtocardiovasculardisease(Guidelines14and15). Itwasbeyondthescope oftheWorkGrouptoundertakeasystematicreviewofstudiesoftreatment. However, existingguidelines andrecommendations werereviewed, as wereselected studies, to providefurtherevidenceofefficacyoftreatment. GUIDELINE 13. FACTORS ASSOCIATED WITH LOSS OF Kidney FUNCTION IN CHRONIC Kidney DISEASE Thelevelofkidneyfunctiontendstodeclineprogressivelyovertimeinmostpatients withchronickidneydiseases. TherateofGFRdeclineshouldbeassessedinpatientswithchronickidneydisease to: Predicttheintervaluntiltheonsetofkidneyfailure; AssesstheeffectofinterventionstoslowtheGFRdecline. Among patients with chronic Kidney disease, the rate of glomerular filtration rate decline should be estimatedby: Computing the glomerular filtration rate decline from past and ongoing measurements of serum Creatinine; Ascertaining risk factors for faster versus slower glomerular filtration rate decline, including type (diagnosis)ofkidneydisease, nonmodifiableandmodifiablefactors. Interventions to slow the progression of Kidney disease should be considered in allpatientswithchronickidneydisease. Interventionsthathavebeenproventobeeffectiveinclude: (1) Strictglucosecontrolindiabetes; (2) Strictbloodpressurecontrol; (3) Angiotensin-converting enzyme inhibition or angiotensin-2 receptor blockade. Interventionsthathavebeenstudied, buttheresultsareinconclusive, include: (1) Dietaryproteinrestriction; potassium/DOQI NationalKidneyFoundation Part7. Stratification 197 (2) Lipid-loweringtherapy; (3) Partialcorrectionofanemia. AttemptsshouldbemadetopreventandcorrectacutedeclineinGFR. Frequent causesofacutedeclineinGFRinclude: Volumedepletion; Intravenousradiographiccontrast; Selectedantimicrobialagents(forexample, aminoglycosidesandamphotericin B); Nonsteroidalanti-inflammatoryagents, includingcyclo-oxygenasetype2inhibitors; Angiotensin-convertingenzymeinhibitionandangiotensin-2receptorblockers; Cyclosporineandtacrolimus; Obstructionoftheurinarytract. Measurements of serum Creatinine for estimation of glomerular filtration rate should be obtained at least yearly in patients with chronic Kidney disease, and more often in patients with: glomerular filtration rate(cid: 1)60mL/min/1. 73m2; FastGFRdeclineinthepast((cid: 1)4mL/min/1. 73m2peryear); Riskfactorsforfasterprogression; Ongoingtreatmenttoslowprogression; ExposuretoriskfactorsforacuteGFRdecline. BACKGROUND Kidneyfunctionprogressivelydeclinesinmostpatientswithchronickidneydiseaseafter sufficient damage has occurred to lower the glomerular estimated glomerular filtration rate (glomerular filtration rate). 480 This progressivedeclinehasbeenattributedtoavarietyofmechanisms, includingfailureto resolvetheinitialinjuryandonsetofself-perpetuatinginjury, ultimatelyleadingtothe typicalpathologicfeaturesoftheend-stagekidneyandkidneyfailure. Althoughthe factors responsible for progression of Kidney disease are not known in each case, a varietyoffactorshavebeenassociatedwithmorerapidprogressionandsometherapies havebeenproventoslowtheprogressionofdisease. Theintentofthisguidelineistoexaminetheliteraturetodeterminefactorsassociated withmorerapidlossofkidneyfunctioninchronickidneydisease. Evidenceprimarily fromlongitudinalstudieswasusedtoformulatethisguideline. Althoughsomeauthors haveperformedameta-analysisofstudies, aquantitativedatasynthesiswasnotperformed forthisGuideline. RATIONALE Definitions of Outcome Measures Progression of Kidney disease is defined as either (1) decline in the level of Kidney function, estimated by measuring glomerular filtration rate, Creatinine clearance or serum Creatinine, in a patientwhohasbeenfollowedlongitudinallywithreliable(andcomparable)assaysof kidneyfunction, or(2)onsetofkidneyfailure, definedbyinitiationofkidneyreplacement 198 Part7. Stratification NationalKidneyFoundation potassium/DOQI therapy, either for symptoms or complications of decreased Kidney function. Kidney replacementtherapyincludeshemodialysis, peritonealdialysisorkidneytransplantation. For consideration of therapy for diabetic Kidney disease, development and worsening ofproteinuriawasalsoincludedinthedefinitionofprogressionofkidneydisease. Strength of Evidence The natural history of most chronic Kidney diseases is that glomerular filtration rate declines progressivelyovertime(Fig47)(R). DatafromtheMDRDStudyduringanaverage 2-yearfollow-upshowthattheaveragerateofdeclineinGFRwasapproximately4mL/ min/yearandwasnotrelatedtothebaselinelevelofGFR. Approximately85%ofpatients had glomerular filtration rate decline during follow-up. The remaining patients experienced improvement orstabilizationofGFR. 480 Otherstudieshaveshownthatcertaintypesofkidneydiseasemayundergocomplete remissioninasubstantialnumberofpatients. Forexample, upto35%ofpatientswith idiopathic membranous nephropathy481 and up to 30% of patients with primary focal segmentalglomerulosclerosis482mayundergoremissionofdisease. Fig47. GFRslopesintheModificationofDietinRenalDiseaseStudy. Thebestlinear unbiased estimates of glomerular filtration rate slope over 3 years in Study A or overall slope in Study B areshownasafunctionofbaselineGFR. Thelower, middleandupperlinesrepresent the10th, 50th(median), and90thpercentilesofthedistributionofGFRslopes, respectively. The glomerular filtration rate slope estimates are not related to baseline glomerular filtration rate, but the variability in slopeestimatesishigherathigherlevelsofbaselineGFR. Reprintedwithpermission. 480 potassium/DOQI NationalKidneyFoundation Part7. Stratification 199 TherateofGFRdeclineisoftenrelativelyconstantovertimeinanindividual patient; however, the rate of glomerular filtration rate decline is highly variable among patients, ranging from slowly progressive over decades, to rapidly progressive over months(Table109andFig48)(R, C). Manystudieshavedemonstratedthattherate ofdeclineinthereciprocalofserumcreatinineconcentration(1/S )appearsconstant creatinine 200 Part7. Stratification NationalKidneyFoundation potassium/DOQI Fig48. Compositeplotofreciprocalserumcreatinineversustimeinsixpatientswith chronickidneydisease. UnitsofreciprocalserumcreatinineconcentrationaredL/magnesium. Verticalaxishasuniformdivisionsof0. 1dL/magnesium. Finalvalueforeachpatientisshown. Abbreviations: PN, pyelonephritis; MCD, medullarycysticdisease; glomerulonephritis, glomerulonephritis. Reprintedwithpermission. 485 over time. 483, 484 One of the earliest such studies is shown in Fig 48. Because of the reciprocalrelationshipbetweenserumcreatinineandGFR, ithasbeenassumedthatthe constantrateofdeclinein1/S wouldreflectaconstantdeclineinGFR. Indeed, studies creatinine have shown that the glomerular filtration rate decline does appear relatively constant over time, although other studies have shown that other continuous relationships (such as the logarithm) ornon-continuous(spline)relationshipsmayfitthedatabetterinsomecases. ThestudiesreviewedforthisguidelineshowawiderangeintherateofGFRdecline amongstudies, aswellasamongindividualpatients(Table109). Themeanrateofdecline inGFRvariedwidely, fromnodeclinetoover12mL/min/1. 73m2peryear. 359, 481, 486500 ThestandarddeviationsofGFRdeclines, expressedasapercentofthemeanGFRdecline, alsovarywidely, fromapproximately25%to150%. TherateofdeclineinGFRcanbeusedtoestimatetheintervaluntiltheonset ofkidneyfailure(Table110)(R). Inprinciple, iftherateofGFRdeclineisconstant over time, then the interval until the onset of Kidney failure could be estimated from potassium/DOQI NationalKidneyFoundation Part7. Stratification 201 thecurrentlevelofGFRandtherateofdeclineinGFR. Anestimateofthetimeuntil kidneyfailurewouldbeusefultofacilitateplanningforkidneyreplacementtherapy, or mayevensuggestthatconcernsaboutkidneyfailuremaybeunwarrantediflifeexpectancyisshort. Table110showsthenumberofyearsuntilGFRdeclinesto15mL/min/ 1. 73m2, calculatedfromthecurrentlevelofGFRandtheestimatedrateofdeclineof glomerular filtration rate. For patients with glomerular filtration rate (cid: 1)60 milliliters per minute/1.",
    "word_count": 579,
    "char_count": 8391,
    "sentence_count": 65,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 43,
      "total_chunks": 77,
      "position": "44/77",
      "content_type": "recommendation",
      "content_type_confidence": 4,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "serum creatinine",
        "guideline"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 44,
    "text": "Table110showsthenumberofyearsuntilGFRdeclinesto15mL/min/ 1. 73m2, calculatedfromthecurrentlevelofGFRandtheestimatedrateofdeclineof glomerular filtration rate. For patients with glomerular filtration rate (cid: 1)60 milliliters per minute/1. 73 m2, the interval until Kidney failure is approximately 10 years or less if the rate of decline is (cid: 1)4 milliliters per minute/1. 73 m2 per year. Thisrateofdeclinecanbeconsideredfast. Although it is difficult to predict the rate of decline in glomerular filtration rate, either of the following two general approaches, or a combination of the two, is recommended: Approach1: ComputetheGFRdeclinefrompastandongoingmeasurements ofserumcreatinine; theGFRdeclineinthepastprovidesaroughestimateof theexpectedGFRdeclineinthefuture(R). Inprinciple, theGFRdeclinecouldbe computedsimplyfromtheslopeoftheregressionlinerelatingestimatedGFRversustime. However, thereareanumberoflimitationstoestimationoftheslopeandextrapolationof therateofdeclinetopredictthetimetodevelopmentofkidneyfailure. Theselimitations arerelatedprincipallytowhethertherateofdeclineistrulyconstantandtheprecision oftheestimateoftherateofdecline. First, most of the studies that demonstrated a constant rate of decline in Kidney functionwereretrospective, includingonlypatientswhohadalreadyprogressedtokidneyfailure. ThefractionofpatientswithdecreasedGFRinwhomthesubsequentdecline inkidneyfunctionisconstantisunknown. Second, evenamongpatientsinwhomtherateappearsconstant, theratemaychange overtime. Inapooledanalysisoffourstudiesof77patientswithanapparentlyconstant rateofdeclineinthereciprocaloftheserumcreatinineconcentration, 32%to51%of patients had a significant change in the slope502 (Fig 49). The changes in slope were judgedtobespontaneous, sincetheydidnotnecessarilyoccuratthetimeofchanges 202 Part7. Stratification NationalKidneyFoundation potassium/DOQI Fig 49. Plot of reciprocal of plasma Creatinine (1/P ) in a patient. (A) Solid line is creatinine singlebestfitregressionline. (B)Solidlinesaretwobestfitregressionlines(spline)with anintersection(breakpoint)at26months(verticaldashedline). Diagonaldashedlines are extrapolationsof the regressionlines to earlierand later times. (C) Calculation of predictionerror. Solidlinesaretwobestfitregressionlines. Thediagonaldashedline isanextrapolationofthefirstregressionlinetothetimewhenthefinalvaluefor1/P creatinine (0. 132dL/magnesium)wasobtained. Theintervalpredictedfromthefirstregressionlinewas 30months(leftverticaldashedline). Theactualintervalwas40months(rightvertical dashedline). Thepredictionerror(differencebetweentheactualandpredictedintervals) was10months(25%oftheactualinterval). Reprintedwithpermission. 502 intherapy. Inthatstudy, thesecondslopewaslesssteepin61%ofcasesandmoresteep in39%ofcases. Themagnitudeofthechangesinslopewasrelativelylargeincomparison tothefirstslope(meanof130%ofthevalueofthefirstslope). Consequently, themean errorin theintervaluntilreaching thefinalserum creatininewasalso relativelylarge, 27%ofthepredictedinterval(Fig49). Similar changes in slope of glomerular filtration rate decline have sometimes been observed in clinical trials, wheretheyhavebeenattributedtotheeffectoftheinterventions(forexample, potassium/DOQI NationalKidneyFoundation Part7. Stratification 203 Fig50. ComparisonofGFRdeclinebetweendietgroupsintheModificationofDietin RenalDiseaseStudy. Estimatedmean((cid: 1)SEM)GFRdeclinefrombaseline(B)toselected follow-uptimes(F)inStudyAareshown. Frombaselineto4monthsoffollow-up, mean GFRdeclinewas1. 6mL/minfasterinthelowproteindietgroup(P(cid: 2)0. 004). From4 monthstotheendoffollow-up, meanGFRdeclinewas1. 1mL/min/month(28%)slower intheusualproteindietgroup(P(cid: 2)0. 009). Frombaselineto3yearsoffollow-up, the projectedmeanGFRdeclinewas1. 2mL/min(10%)lessinthelowproteindietgroup (P(cid: 2)0. 30). AdaptedfromKlahretal315andreprintedwithpermission. 492 Low Protein diet, strict Blood Hypertension control, ACE inhibition). Figure 50 shows data fromMDRDStudyA. GFRdeclinewasfasterinthefirstfourmonthsafterrandomization toalowproteindietandaslowerdeclinethereaftercomparedtopatientsrandomized toausualproteindiet. 492Theauthorshypothesizedthatthegreaterdeclinesoonafter theinterventionwasrelatedtoahypothesizedbeneficialeffectoftheintervention: an initialdecreaseinsinglenephronGFR, followedbyasubsequentslowingintherateof declineinthenumberofnephrons. 503 Third, even if the rate of decline is constant, the precision of the estimate of the slopedependsonanumberofvariables, includingthetruerateofdecline, thenumber ofmeasurementsofkidneyfunction, measurementerror, biologicalvariability, andthe durationoffollow-up. Atleastthreepreviousmeasuresofkidneyfunctionarenecessary (morearebetter)topermitapreciseestimateoftheslope, especiallyiftherateofdecline isslow. 504 Approach2: AscertainfactorsassociatedwithafastorslowGFRdecline; these factors include type (diagnosis) of Kidney disease, nonmodifiable and modifiablefactors(R). Forthisreview, longitudinalstudieswerecompiledtorelate therateofdeclineinkidneyfunctionwiththepotentialassociatedfactors. Observational studiesandinterventionaltrialswereincluded. Theeffectofinterventionsontherate ofprogressionis summarizedinalater section. Thearticlesreviewed werepublished between 1984 and 2000. The studies varied in the levels of Kidney function assessed, 204 Part7. Stratification NationalKidneyFoundation potassium/DOQI samplesizes, andmethodologicalquality. Durationoffollow-upisakeycomponentof studiesofprognosis. Durationoffollow-upbetween1and 3yearsorlessthan 1year isnotedinthetables. The rate of glomerular filtration rate decline is related to the type of Kidney disease; diabetic kidneydisease, glomerulardiseases, polycystickidneydisease, andkidneydisease in transplant recipients are associated with a faster glomerular filtration rate decline than hypertensivekidneydiseaseandtubulointerstitialkidneydiseases(Tables109 and111)(C, R). FewstudiesspecificallyrelatedrateofGFRdeclinetotypeofkidneydisease(Table 111). TheMDRDStudywasthelargest, withasamplesizeof826, whiletheothertwo studieshadbetween138and223subjects. Thesestudiesreportedsomewhatconflicting results. IntheMDRDStudy480andthestudybyMassy, 499polycystickidneydiseasewas associatedwithafasterrateofprogression, whereasinthestudybyHannedouche, 490 polycystickidneydiseasewasassociatedwithaslowerrateofprogression. Massyand Hannedouchebothreportedthatglomerulardiseasewasassociatedwithafasterrateof progressionthantubulointerstitialnephropathy. However, thesetwostudiesshoweda conflictingresultregardingtherateofprogressionassociatedwithhypertensivekidney disease. Thesestudieseitherexcludeddiabetics, orhadaverysmallproportionofpatients withdiabetesinthestudysample. AdditionalinformationregardingdifferentratesofGFRdeclinedependingonunderlyingcauseofkidneydiseasewasextractedfromstudiesofisolatedcausesofkidneydisease or from studies which provided rates of progression for individual causes of Kidney disease. Table 111 shows the reported or estimated rates of glomerular filtration rate decline that were describedfordifferentcausesofkidneydisease. ThedatapresentedinTable111arenoteasilycompared; thestudymethodsvaried (retrospective or prospective, observational, or interventional), different measures of potassium/DOQI NationalKidneyFoundation Part7. Stratification 205 kidneyfunctionwereused, andtheeffectofinterventionsorotherpotentialconfounders cannotbedetermined. Nonetheless, thecrudedatasuggestatrendformorerapidprogression among patients with Diabetes, especially those patients with proteinuria or decreasedGFR, comparedwithothercausesofkidneydisease. Therewasawiderange ofratesofdeclineamongpatientswithnondiabetickidneydisease. DataonratesofGFR decline among Kidney transplant recipients could not be found. However, the Work GroupconcludedthatGFRdeclineisfasterthaninmanyothercausesofchronickidney diseasegiventhatgraftsurvivalratesareapproximately75%at5yearsforlivingdonors and60%at5yearsforcadavericdonors509oranapproximatehalf-lifeuntilgraftfailure forkidneytransplantsofapproximately12and7, respectively. Lossofkidneyfunction fortransplantrecipientsisinfluencedbyepisodesofrejection, useofimmunosuppressive agents, patientgenderandsize, andqualityofthedonorkidney, amongotherfactors. TherateofGFRdeclineisrelatedtosomenonmodifiablepatientcharacteristics, irrespective of the type of Kidney disease; African-American race, lower baseline level of Kidney function, male gender, and older age are associated withafasterGFRdecline(C). Race (Table 112). Six studies addressed the association of race with the rate of GFRdeclineineitherunivariateormultivariateanalyses. Halfreportedafasterrateof progression among blacks; however, onlyone study reported a significant association betweenblackraceandfasterratesofprogressioninmultivariateanalysis. LevelofKidneyFunction(Table113). Twenty-onestudiesaddressedtheassociation of Low baseline level of Kidney function with the rate of glomerular filtration rate decline in either univariateormultivariateanalyses. Themajorityofthestudiesreportedafasterrateof progressionamongindividualswithlowerbaselinekidneyfunction, butaboutonethird reportednoassociation. Nostudiesreportedaslowerrateofprogression. 206 Part7. Stratification NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part7. Stratification 207 Gender(Table114). Eighteenstudiesaddressedtheimpactofgenderontherate ofGFRdeclineineitherunivariateormultivariateanalyses.",
    "word_count": 593,
    "char_count": 9466,
    "sentence_count": 90,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 44,
      "total_chunks": 77,
      "position": "45/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "diet",
        "low protein diet",
        "kidney transplant"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 45,
    "text": "Themajorityofthestudiesreportedafasterrateof progressionamongindividualswithlowerbaselinekidneyfunction, butaboutonethird reportednoassociation. Nostudiesreportedaslowerrateofprogression. 206 Part7. Stratification NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part7. Stratification 207 Gender(Table114). Eighteenstudiesaddressedtheimpactofgenderontherate ofGFRdeclineineitherunivariateormultivariateanalyses. Thedatareporteitherafaster rate of progression or no association with male gender, and a single study reported a fasterrateofprogressionamongfemales. Theevidenceisnotconclusive, butsuggests afasterrateofprogressionamongmen. Age(Table115). Twenty-onestudiesreportedtheassociationofagewiththerate ofGFRdeclineineitherunivariateormultivariateanalyses. Thesedatagenerallysupport either an association of older age with faster rates of glomerular filtration rate decline or no association, exceptamongdiabetics, whereyoungerageatdiagnosisofdiabetesisassociatedwith 208 Part7. Stratification NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part7. Stratification 209 210 Part7. Stratification NationalKidneyFoundation potassium/DOQI afaster rateof GFRdecline. Coupledwiththe factthat theelderly startfrom alower baseline glomerular filtration rate, older individuals with chronic Kidney disease deserve special attention andcloserfollow-up. TherateofGFRdeclineisalsorelatedtomodifiablepatientcharacteristics, irrespective of the type of Kidney disease. Higher level of proteinuria, lower serumalbuminconcentration, higherbloodpressurelevel, poorglycemiccontrol, andsmokingareassociatedwithafasterGFRdecline. Theassociations ofdyslipidemiaandanemiawithfasterGFRdeclineareinconclusive(C). Proteinuria(Table116). Twenty-fourstudiesaddressedtheassociationofproteinuriawiththerateofGFRdeclineinunivariateand/ormultivariateanalysesandshowed conflicting results. Although these data do not unanimously show that proteinuria is associatedwithfasterrateofGFRdeclinewhencontrollingforotherfactors, thestudies withlargersamplesizesandhighermethodologicalqualityandapplicabilitydosupport theassociation. LowSerumAlbumin(Table117). Eightstudiesaddressedtheassociationoflow baseline serum albumin with rate of glomerular filtration rate decline in either univariate or multivariate analyses. TheassociationoflowserumalbuminwithfasterrateofGFRdeclinewasmore consistentlynotedinstudiesofdiabeticpatients. Nostudiesreportedaslowerrateof GFRdeclineassociatedwithlowserumalbumin. potassium/DOQI NationalKidneyFoundation Part7. Stratification 211 BloodPressure (Table118). Twenty-sixstudies relatedbloodpressure levelsto therateofGFRdeclineinunivariateand/ormultivariateanalyses. Thestudiesdiffered inthattheyassessedsystolicbloodpressure, diastolicbloodpressure, ormeanarterial Hypertensiontwo of these or all of these. Most studies reporting multivariate analyses showedasignificantassociationbetweenelevatedbloodpressure, basedonanymeasures ofbloodpressure, andfasterrateofGFRdecline. Therewereonly7studiesthatreported nosignificantassociationbetweenelevatedbloodpressuremeasuresandfasterrateof glomerular filtration rate decline in multivariate analysis. These data, though not unanimous, confirm that elevatedbloodpressureisassociatedwithfasterrateofGFRdeclinewhencontrolling forotherfactors. GlycemicControlinDiabetes(Table119). Thirteenstudiesaddressedtheimpact of poor glycemic control on the rate of glomerular filtration rate decline in univariate and/or multivariate analyses. Therewere6studiesthatreportedinmultivariateanalysesasignificantassociation between poor glycemic control, either an elevated fasting Blood Glucose and/or HgbA levelsandfasterrateofGFRdecline; inoneofthesetheassociationwasnoted 1c only among patients on antihypertensive agents. A similar number of studies showed nosignificantassociationbetweenpoorglycemiccontrolandfasterrateofGFRdeclinein 212 Part7. Stratification NationalKidneyFoundation potassium/DOQI multivariateanalyses. Althoughthesedatadonotunanimouslyshowthatpoorglycemic controlisassociatedwithfasterrateofGFRdeclinewhencontrollingforotherfactors, thestudieswithlargersamplesizesandhighermethodologicalqualityandapplicability dosupporttheassociation. Smoking(Table120). Tenstudiesreportedtheassociationofsmokingontherate ofGFRdeclineinunivariateand/ormultivariateanalyses. Thereviewedstudiesreported conflictingresults. However, thelargesamplesizesandadequatemethodologicalquality and applicability of the studies supporting theassociation of smoking with faster rate of glomerular filtration rate decline provide reasonable evidence that there may be a deleterious effect of smokingonrateofprogression. potassium/DOQI NationalKidneyFoundation Part7. Stratification 213 Dyslipidemia(Table121). Fifteenstudiesaddressedtheassociationofdyslipidemia withtherateofGFRdeclineinunivariateand/ormultivariateanalyses. Thestudiesevaluatedoneormoreofthefollowingfactors: highlevelsoftotalcholesterol, triglycerides, or Low density lipoprotein, and Low levels of High density lipoprotein. The impact of dyslipidemiareportedhereinisbasedonwhetheranyoneofthesefactorswasassociated with a faster rate of progression. There were 7 studies that reported in multivariate analyses a significant association between dyslipidemia and faster rate of progression. Therewere7studiesthatreportednosignificantassociationbetweendyslipidemiaand 214 Part7. Stratification NationalKidneyFoundation potassium/DOQI fasterrateofprogressioninmultivariateanalyses. Thedataarenotsufficienttoconclude thatdyslipidemiaisassociatedwithafasterrateofprogression. Anemia(Table122). SevenstudieswerefoundthatrelatedtherateofGFRdecline to anemiaor hematocrit/hemoglobinlevel. However, mostof thesestudies compared ratesofprogressionbeforeoraftertreatmentwitherythropoietinand/oriron, ortreated versusuntreated, andallperformedonlyunivariateanalyses. Therewasonlyonestudy305 thatalsocomparedrateofGFRdeclinebetweenuntreatedanemic(hematocrit(cid: 1)30%) and non-anemic patients (hematocrit (cid: 2)30%) with chronic Kidney disease. In keeping withtherestofthissectiontheguideline, onlythisonestudywasconsideredforinclusion in an evidence table (Table 122). Of the seven studies, three, including Kuriyama, reported an increased rate of progression among patients with lower hematocrit levels; theremainingstudiesreportednoassociation. Thedataarenotsufficienttoconclude thatanemiaisassociatedwithafasterrateofprogression. Partialcorrectionofanemia isdiscussedinalatersection. potassium/DOQI NationalKidneyFoundation Part7. Stratification 215 Interventions may slow rate of glomerular filtration rate decline in chronic Kidney disease in somecircumstances(R). ItwasbeyondthescopeofthisWorkGrouptoperforma systematic review of the literature on interventions to lower the rate of glomerular filtration rate decline. Thus, thegoalofthissectionwastoreviewpublishedguidelinesandpositionstatements by reputablenational organizations addressingwidely accepted interventions. In addition, meta-analyses of randomized trials or data from selected large randomized trials wereusedtoformulatethisguideline. Detailsofthesourcesofinformationarepresented ineachofthefollowingsections. Strictglycemiccontrolindiabetesslowsthedevelopmentandprogression of chronic Kidney disease (R). The American Diabetes Association (ADA) has set forthaPositionStatementwithguidelinesforthecareofpatientswithdiabetesmellitus (diabetes mellitus), 526withspecificattentiontothecomplicationofkidneydisease, 527basedonthe resultsoftheDiabetesControlandComplicationsTrial(DCCT)528andextensivereview ofotherpublishedresearch. Giventherigorousreviewofthenumerousstudiesbythe ADA, itsmostrecentlyupdatedPositionStatement/ClinicalPracticeRecommendations (2001)werereviewedforthissection. Thegoalsforintensiveglycemiccontrolforthepreventionofcomplicationsofdiabetes, includingnephropathy, aspresentedintheADAguidelines, aresummarizedbelow. The reader should refer to the guideline, available on the internet for comprehensive information(www. Diabetes. org/clinicalrecommendations/caresup1Jan01. htm). 216 Part7. Stratification NationalKidneyFoundation potassium/DOQI Among patients with insulin dependent Diabetes mellitus (IDDM), 80% who have sustained microalbuminuria develop overt nephropathy in 10 to 15 years, and among these, kidneyfailuredevelopsin50%. TheDCCT, aprospectivestudycomparingconventional with intensive treatment of 1, 441 patients with IDDM followed for a mean of 6. 5 years, firmly established the benefit of intensive glycemic control in reducing the occurrence of subclinical and overt nephropathy among patients with IDDM.",
    "word_count": 596,
    "char_count": 8658,
    "sentence_count": 77,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 45,
      "total_chunks": 77,
      "position": "46/77",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "nephropathy",
        "proteinuria",
        "potassium",
        "hematocrit",
        "insulin",
        "antihypertensive",
        "anemia",
        "glycemic control"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 46,
    "text": "528 This trialdemonstratedthattheoccurrenceofnephropathyoritsprogressionisreducedby 40%to60%, dependingonwhethertheoutcomewasmicroalbuminuria(40%), albuminuria(54%), orovertnephropathy(60%). ThedifferencewasobservedwithameanHgbA 1c of7. 2%intheintensivelytreatedversus9%intheconventionallytreatedpatients. The role of strict glycemic control in slowing the progression of diabetic Kidney diseaseislesscertain. AsubgroupofpatientswithintheDCCTwithmicroalbuminuria atbaseline(n(cid: 3)73)showedatrendtowardabeneficialeffect. 528Anotherstudyof70 patients did not reveala benefit. 529 Both of these studies may havebeen too small to detectabeneficialeffect. Amongpatients withnon-insulin dependentDM (NIDDM), 20% to40% ofpatients with microalbuminuria develop overt nephropathy, and among these, Kidney failure potassium/DOQI NationalKidneyFoundation Part7. Stratification 217 218 Part7. Stratification NationalKidneyFoundation potassium/DOQI developsin20%. Threerandomizedtrialsofstrictglycemiccontrolintype2diabetes alsodemonstrateabeneficialeffectofstrictglycemiccontrolonthedevelopmentand progressionofdiabetickidneydisease. The United Kingdom Prospective Diabetes Study (UKPDS 33) compared strict glycemic control to standard therapy in diagnosed patients with type 2 Diabetes. 530 The studyemployedacomplexfactorialdesignincludingdiet, sulfonylureas, metformin, and insulintoachievetargetfastingbloodglucosevaluesof(cid: 1)110versus(cid: 1)270mg/dL. Fasting bloodglucosevaluesroseovertimeinbothgroups; themeanHgbA was11%lowerin 1c theinterventiongroup. Theinterventiongrouphada25%reductioninmicrovascular events, a combined endpoint that included both retinal and Kidney disease. The data suggestedalowerprevalenceofmicroalbuminuriaintheinterventiongroupandareducedincidenceofdecliningkidneyfunction. TheKumamotostudycomparedintensiveinsulintherapytostandardtherapyin110 non-obesepatientswithtype2diabetes, usingaprotocolsimilartotheDCCT. 531Mean achieved HgbA levels were 7. 1 versus 9. 4% in the intervention and control groups, 1c respectively. Theresultsshowedalowerincidenceofthedevelopmentandprogression ofmicroalbuminuria. TheStenoType2Studycomparedanintensivemultifactorinterventiontostandard therapyin160patientswithtype2diabetesandmicroalbuminuria. 532Theintervention includednotonlyintensiveinsulintherapy, butalsostrictbloodpressurecontrol, ACE inhibition, dietaryfatrestriction, exercise, lipid-loweringdrugs, anti-oxidants, andaspirin (inpatientswithcoronaryheartdisease). Therewas73%reductionintheincidenceof clinicalproteinuriaintheinterventiongroup. However, therelativeimportanceofstrict glycemiccontrolandanyoftheotherfactorscannotbedeterminedfromthisstudy. ThemostrecentlyupdatedClinicalPracticeRecommendations(2001)526oftheADA regardingintensiveglycemiccontrolrecommendthefollowingtreatmentgoalsforpatientswithdiabetes(Table123). Thedesiredoutcomeofglycemiccontrolintype1diabetesistolowerHgbA (or 1c anyequivalentmeasureofchronicglycemia)soastoachievemaximumpreventionof complicationswithdueregardforpatientsafety. Toachievethesegoalswithintensive management, thefollowingmaybenecessary: Frequentself-monitoringofbloodglucose(atleastthreeorfourtimesaday); potassium/DOQI NationalKidneyFoundation Part7. Stratification 219 Medicalnutritiontherapy; Educationinself-managementandproblemsolving; Possiblehospitalizationforinitiationoftherapy. Insituationswhereresourceareunavailableorinsufficient, referraltoadiabetes careteamforconsultationand/orcomanagementisrecommended. Type2diabetesisaddressedseparatelyintheADAguidelines: Dailyselfmonitoringofbloodglucoseisespeciallyimportantforpatientstreated withinsulinorsulfonylureastomonitorforandpreventasymptomatichypoglycemia. The optimal frequency of self monitoring of Blood glucose for patients with type 2 diabetesisnotknown, butitshouldbesufficienttofacilitatereachingglucosegoals. Therole ofself-monitoring ofblood glucosein stablediet-treated patientswith type 2diabetesisnotknown. Type2diabetestreatmentmethods shouldemphasizediabetesmanagementas amultipleriskfactorapproachincludingmedicalnutritiontherapy, exercise, weight reduction when indicated, and use of oral glucose-lowering agents and/or insulin, with careful attention given to cardiovascular risk factors, including hypertension, smoking, dyslipidemia, andfamilyhistory. Whethertreatedwithinsulinororalglucose-loweringagents, oracombination, goalsremainthoseoutlinedinthetable. Strictbloodpressurecontrolslowstheprogressionofchronickidneydisease(R). TheSixthReportoftheJointNationalCommitteeonPrevention, Detection, EvaluationandTreatmentofHighBloodPressure(JNC-VI), 245themostrecentlyupdated ADAClinicalPracticeRecommendations(2001), 526theNKFTaskForceonCardiovascular Disease in Chronic Renal Disease, 9 and a report from the National Kidney Foundation Hypertension and DiabetesExecutiveCommitteesWorkingGroup249werereviewedforthissection. This 220 Part7. Stratification NationalKidneyFoundation potassium/DOQI sectionwilldiscussprimarilythetargetbloodpressurelevelforpatientswithchronic kidneydisease, withonlybriefreferencetotheroleofspecificantihypertensiveagents. Angiotensin-convertingenzyme(ACE)inhibitorsandangiotensin-2receptorblockersare discussedinthenextsection. Recommendationsforthegeneralpopulationarebasedonalargebodyofevidence fromobservationalstudiesandclinicaltrialsrelatingbloodpressurelevelstomortality andcardiovasculardisease. Thereisgeneralagreementthatriskstratificationshouldbe usedindecidingwhichpatientswithhighbloodpressureshouldbetreatedandhow intensively245(Table124). Therecommendedgoalofantihypertensivetherapyforpatientsatlowormoderateriskforcomplicationsistomaintainsystolicanddiastolicblood pressureless than140and90 mmHg, respectively. 245 Thesedefinitionsand goalsdo not differ according to age (among adults), gender, or race. Target Blood Hypertension is lowerinyoungerpatientsandrelatedtoage, weightandheight. 533Patientsatgreatest riskforcomplicationsorwhoalreadyhaveevidenceofcardiovasculardiseaseareconsideredfortheearliestandmoreaggressivetreatment. In the general population, the recommended antihypertensive agents are diuretics andbeta-adrenergicblockers, becausetheirefficacyinreducingcardiovascularmortality andmorbidityhasbeenproveninclinicaltrials. Recentstudiesshowequalefficacyof angiotensinconvertingenzymeinhibitors(ACE-inhibitors)andcalciumchannelblockers inthegeneralpopulation. 534, 535Inaddition, alternativetargetbloodpressureandmedicationsmaybepreferredinthosesubgroupsofpatientswithcomorbidconditions. These subgroups include, amongothers, patients with chronic kidneydisease, Diabetes, and cardiovasculardisease. Theknowledgebaseforchronickidneydiseaseissubstantiallysmaller. Large-scale epidemiologicalstudiesofcardiovasculardiseasehaveincludedfewpatientswithchronic kidneydisease, andmostclinicaltrialsofantihypertensiveagentstopreventcardiovasculardiseasehaveexcludedpatientswithdecreasedkidneyfunction. Someoftheimportant randomizedtrialsonthetargetlevelofbloodpressureinpatientswithchronickidney diseaseduetodiabetesandotherdiseasesaresummarizedbelow. TheWorkGroupdid notfindrandomizedtrialsontargetbloodpressurelevelsinkidneytransplantrecipients. potassium/DOQI NationalKidneyFoundation Part7. Stratification 221 Diabetickidneydisease. Thebenefitofbloodpressurecontroltolevelsofapproximately140/90mmHginretardingthedeclineinGFRinpatientswithtype1diabetes was shown years ago. 536 The UKPDS has recently shown that better Blood Hypertension control is also associated with decreased development of microalbuminuria in type 2 Diabetes. 537Therehavebeennolarge-scalestudiescomparingevenlowerlevelsoftarget bloodpressure(strictbloodpressurecontrol)ontheprogressionofdiabetickidney disease. However, asubgroupanalysisoftheHypertensionOptimalTrial(HOT)showed that patients with Diabetes who were randomized to lower levels of Blood Hypertension (diastolicbloodpressureof(cid: 1)90versus(cid: 1)85versus(cid: 1)80mmHg)hadlowermortality and fewercardiovascular disease eventsthan patientswith higher bloodpressure levels. 538Thus, itseemsreasonabletorecommendevenlowertargetbloodpressurelevels forpatientswithdiabetickidneydisease. Nondiabetickidneydiseases. TheMDRDStudyisthelargestcompletedrandomized trial on strict Blood Hypertension on the rate of glomerular filtration rate decline in nondiabetic Kidney disease. Atotalof840patientswererandomizedeithertousualtargetbloodpressure (meanarterialpressure(cid: 1)107mmHg, equivalenttobloodpressure(cid: 1)140/90mmHg) versusalower-than-usualtargetbloodpress(meanarterialpressure(cid: 1)92mmHg, equivalent to Blood Hypertension (cid: 1)125/75 mm Hg). The mean separation between randomized groupswas4to5mmHg. Patientswithhigherlevelsofproteinuriaatbaselinehada greaterbeneficialeffectofthelowbloodpressuregoal. Theinvestigatorsrecommended alowertargetbloodpressureforpatientswithurineproteinexcretionlessthanapproximately 1. 0 g/d. At the time of preparation of these guidelines, the African American StudyofKidneyDiseaseandHypertension(AASK)isnearingcompletion, andadditional informationonthebenefitofstrictbloodpressurecontrolinnondiabetickidneydisease isexpectedinthenearfuture. Basedlargelyonextrapolationfromrecommendationsforthegeneralpopulationand limitedobservationalstudiesandclinicaltrialsinpatientswithchronickidneydisease, theNKFTaskForceonCardiovascularDiseaserecommendedtargetbloodpressurelevels andstrategiesfortreatmentforpatientswithchronickidneydisease(Table125). The 222 Part7. Stratification NationalKidneyFoundation potassium/DOQI Task Force recommendations were meant to serve as a guide to clinicians until more definitiverecommendationsareavailable. A potassium/DOQI Work Group has now been established to develop guidelines for the managementofhighbloodpressureinpatientswithchronickidneydiseasenotrequiring Dialysis. ThegoalsoftheWorkGrouparetodeterminetherecommendedbloodpressure targets, nonpharmacologictherapy, andantihypertensivedrugclassesforvariouscauses ofkidneydisease(includingdiabetes), withadditionalrecommendationsforsubgroups ofpatientsbasedonlevelofkidneyfunction, levelofproteinuria, and, ifavailable, age, gender, andrace, forpreventionofprogressionofkidneydisease, atheroscleroticcardiovasculardisease, andheartfailure(includingLVH). Angiotensin-convertingenzymeinhibitorsandangiotensinreceptorantagonistsslowtheprogressionofchronickidneydisease(R). ForthisGuideline, the SixthReportoftheJointNationalCommitteeonPrevention, Detection, Evaluationand TreatmentofHighBloodPressure(JNC-VI), 245themostrecentlyupdatedADAClinical PracticeRecommendations(2001), 526andresultsofameta-analysisandselectedrandomizedclinicaltrialswerereviewed. Thissectionpresentsanoverviewofthemainpoints of these guidelines and studies. In addition, preliminary results of clinical trials with angiotensinreceptorantagonistsarebrieflydiscussed. Fulldetailoftherecommendations oftheADAandJNC-VIisbeyondthescopeofthiswork, andthereaderisreferredto these sources for complete guidelines (ADA guidelines on diabetic Kidney disease are available on the internet at www. Diabetes. org/clinicalrecommendations/Supplement101/S69. htm). Inadditiontoloweringsystemicbloodpressure, ACE-inhibitorsandangiotensinreceptorantagonistsalsolowerglomerularcapillarybloodpressureandproteinfiltration, whichmaycontributetotheirbeneficialeffectinslowingprogression.",
    "word_count": 594,
    "char_count": 11310,
    "sentence_count": 83,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 46,
      "total_chunks": 77,
      "position": "47/77",
      "content_type": "treatment",
      "content_type_confidence": 8,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney failure",
        "nephropathy",
        "albuminuria",
        "potassium",
        "diuretics",
        "insulin",
        "antihypertensive",
        "dialysis",
        "exercise"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 47,
    "text": "Diabetes. org/clinicalrecommendations/Supplement101/S69. htm). Inadditiontoloweringsystemicbloodpressure, ACE-inhibitorsandangiotensinreceptorantagonistsalsolowerglomerularcapillarybloodpressureandproteinfiltration, whichmaycontributetotheirbeneficialeffectinslowingprogression. 539, 540Theymay also have abeneficial effect in reducingangiotensin II mediated cellproliferation and fibrosis. 540 Diabetickidneydisease. TheADArecommendstheuseofACE-inhibitorsfordiabeticpatientswithanyevidenceofkidneydisease(microalbuminuriaorgreaterdegree ofproteinuria), regardlessofthepresenceofhypertension, intheabsenceofcontraindicationsorcomplications: Manystudieshaveshownthatinhypertensivepatientswithtype1diabetes, ACEinhibitorscanreducethelevelofalbuminuriaandcanreducetherateofprogression of renal disease to a greater degree than other antihypertensive agents that lower bloodpressurebyanequalamount. Otherstudieshaveshownthatthereisabenefit inreducingtheprogressionofmicroalbuminuriainnormotensivepatientswithtype 1diabetesandnormotensiveandhypertensivepatientswithtype2diabetes. ACE-inhibitors may exacerbate hyperkalemia in patients with advanced renal insufficiencyand/orhyporeninemichypoaldosteronism. Inolderpatientswithbilateralrenalarterystenosisandinpatientswithadvancedrenaldiseaseevenwithout renal artery stenosis, ACE-inhibitors may cause a rapid decline in renal function. potassium/DOQI NationalKidneyFoundation Part7. Stratification 223 Coughmayalsooccur. Thisclassofagentsiscontraindicatedinpregnancyandthereforeshouldbeusedwithcautioninwomenofchildbearingpotential. Becauseofthehighproportionofpatientswhoprogressfrommicroalbuminuria toovertnephropathyandsubsequentlytoESRD, useofACE-inhibitorsisrecommended foralltype1patientswithmicroalbuminuria(30299mg/24hr), evenifnormotensive. However, becauseofthemorevariablerateofprogressionfrommicroalbuminuriatoovertnephropathyandESRDinpatientswithtype2diabetes, theuseofACEinhibitorsinnormotensivetype2diabeticpatientsislesswellsubstantiated. Should suchapatientshowprogressionofalbuminuriaordevelophypertension, thenACEinhibitorswouldclearlybeindicated. TheeffectofACE-inhibitorsappearstobeaclass effect, sochoiceofagentmaydependofcostandadherenceissues. Tworandomizedtrialscomparingtheimpactofangiotensinreceptorblockerswith conventionalantihypertensivetreatmentontheprogressionofdiabetickidneydisease haverecentlybeencompleted: IrbesartaninDiabeticNephropathy(IDNT)541andReduction of Endpoints in Non-InsulinDependent Diabetes Mellitus with the Angiotensin II AntagonistLosartan(RENAAL). 542Bothstudiesshowedabeneficialeffectoftheangiotensin-receptorantagonists. ComparisonwithACE-inhibitorsisnotavailabletodate. ItisimportanttonotethatACE-inhibitorshavebeenfoundtohavebeneficialeffects ontotalmortalityandcardiovasculardiseaseindiabeticpatientswithoutchronickidney disease. 543545Althoughmostpatientsinthesestudieswerehypertensive, thebeneficial effectofACE-inhibitortherapyappearedtobeindependentofitsbloodpressurelowering effect. Thus, patientswithdiabetesandhypertensionorchronickidneydiseasebenefit fromACE-inhibitors. IfbloodpressureremainselevatedafterinitiationofanACE-inhibitor, otherantihypertensiveagentsshouldbeprescribedtoachievetargetbloodpressure. Nondiabetickidneydisease. TheJNC-VIrecommendsACEinhibitorsasthedrugof choicefortreatinghypertensionamongsometypesofpatientswithnondiabetickidney disease: The most important action to slow progressive renal disease is to lower Blood pressuretogoal. Allclassesofantihypertensivedrugsareeffective, and, inmostcases, multipleantihypertensivedrugsmaybeneeded. Impressiveresultshavebeenachieved withACE-inhibitorsinpatientswithproteinuriagreaterthan1gramper24hours, and in patients with renal insufficiency. Consequently, patients with hypertension whohaverenalinsufficiencyshouldreceive, unlesscontraindicated, anACE-inhibitor (inmostcases, alongwithadiuretic)tocontrolhypertensionandtoslowprogressive renalfailure. Inpatientswithcreatininelevelof265. 2(cid: 3)mol/L(3mg/dL)orgreater, ACE-inhibitorsshouldbeusedwithcaution. AninitialtransientdecreaseinGFRmayoccurduringthefirst3monthsoftreatment as Blood Hypertension is lowered. If patients are euvolemic and Creatinine rises 88. 4 (cid: 3)mol/L (1 milligrams per deciliter) above baseline levels, Creatinine and Potassium should be remeasured after several days; if they remain persistently elevated, consideration shouldbegiventothediagnosisofrenalarterystenosisandACE-inhibitorsandangio224 Part7. Stratification NationalKidneyFoundation potassium/DOQI tensin II receptor blockers discontinued because these drugs can markedly reduce renalperfusioninpatientswithbilateralrenalarterystenosisorrenalarterystenosis toasolitarykidney. Theserecommendationsarebasedonanumberofrandomizedtrialspublishedover thepastdecade, whichhavebeensummarizedrecentlyinameta-analysisofpatientlevel data. 546Inthatanalysis, dataon1860nondiabeticpatientsincludedin11randomized clinical trials of various ACE-inhibitors were pooled. The results showed better Blood pressurecontrol, lowerurineproteinexcretionandanapproximately30%reductionin the risk of development of Kidney failure and the combined endpoint of doubling of baseline serum Creatinine or Kidney failure in the ACE-inhibitor group. The beneficial effectsofACE-inhibitorstoslowprogressionappearedtobeindependentoftheireffects on Blood Hypertension and proteinuria. The results also showed an incrementally greater beneficialeffect withgreater degreesof proteinuria(cid: 2)0. 5 g/d. The benefitto patients withproteinuria(cid: 1)0. 5g/dwasinconclusive. ArecentreportfromtheAfricanAmerican StudyofKidneyDiseaseandHypertension(AASK)documentsabeneficialeffectofthe ACE-inhibitorramiprilcomparedtothedihydropyridinecalciumchannelblockeramlodipine on the glomerular filtration rate decline in African Americans with nephrosclerosis and decreased glomerular filtration rate. 547Thebeneficialeffectwasmorepronouncedinpatientswithproteinuria(cid: 1)300 magnesium/24hr. TheavailableevidencesuggestsabenefittousingACE-inhibitorstotreathypertension amongproteinuricpatientswithnondiabetickidneydisease. Thebenefitmayextendto patientswithoutproteinuriabutthisisnotestablished. TheuseofACE-inhibitorsmust alwaysbedonewiththeconsiderationthatitmayhaveadetrimentaleffectonGFRin patientswithrenovasculardiseaseorrenalarterystenosis. Furthermore, inkidneytransplantrecipients, ACE-inhibitorsmayexacerbatehyperkalemiacausedbycyclosporineor tacrolimus. Thus, treatmentofpatientswithchronickidneydiseasewithACE-inhibitors requiresknowledgeoftheexpectedbenefitsandrisksoftherapyandcarefulattention tobloodpressure, kidneyfunction, serumelectrolytes, andpossibledruginteractions. TheHOPEStudyalsodemonstratedabeneficialeffectoftheACE-inhibitorramipril on total mortality and cardiovascular disease in nondiabetic patients without chronic kidneydisease, butwithahistoryofcardiovasculardiseaseandonecardiovasculardisease risk factor (including hypertension). 545 The beneficial effect of the ACE-inhibitor appearedtobeindependentofitsbloodpressureloweringeffect. Thus, non-diabeticpatientswithchronickidneydisease(especiallyiftheyhaveproteinuria)orcardiovascular disease benefit from ACE-inhibitors. Ifblood Hypertension remains elevated after initiation ofanACE-inhibitor, otherantihypertensiveagentsshouldbeprescribedtoachievethe targetbloodpressure. Thereisinsufficientevidencetorecommendfororagainstroutineprescriptionofdietaryproteinrestrictionforthepurposeofslowingtheprogression ofchronickidneydisease; individualdecision-makingisrecommended, after discussionofrisksandbenefits(R). TheMDRDStudywasdesignedtodetermine potassium/DOQI NationalKidneyFoundation Part7. Stratification 225 the impact of Protein restriction on rate of glomerular filtration rate decline, however the results of this studywereinconclusive. 503StudyAcomparedalowproteindiet(0. 58g/kg/d)toausual proteindiet(1. 3g/kg/d)amongpatientswithmoderatelydecreasedGFR(25to55mL/ min/1. 73 m2). As described earlier (Fig 50), there was an initial faster glomerular filtration rate decline in thelow-proteindietgroup, followedbyaslowerGFRdeclinethereafter, butnosignificant benefitovera3-yearinterval. StudyBcomparedaverylowproteindiet(0. 28g/kg/d) supplementedwithamixtureofessentialketoacidsandaminoacids(0. 28g/kg/d)toa lowproteindiet(0. 58g/kg/d)inpatientswithseverelydecreasedGFR(13to24mL/ min/1. 73m2). Therewasnoapparentbenefitoftheverylowproteindiet. Therehave beenseveralsecondaryanalysesofthedata, whichprovidefurtherinformationonthe effectivenessoftheseinterventions. 503Specifically, comparisonsofthedistributionsof glomerular filtration rate slopes between randomized groups in Study A were consistent with a beneficial effectofthelowproteindietgroup. Analysesoftheimpactofachievedproteinintake inStudyBrevealeda49%reductioninriskofkidneyfailureordeathforevery0. 2g/ kg lowerachieved total proteinintake. In anotherreport, it wasnoted thata specific ketoacid supplement with a very Low Protein diet may be more beneficial than the supplementwithessentialaminoacidsusedintheMDRDstudy. 548Ameta-analysisoffive randomizedtrialsof1, 413patients, includingMDRDStudyA, showeda30%reductionin kidneyfailureordeathinpatientsrandomizedtothelowproteindietgroup. 549Ametaanalysisofrandomizedanduncontrolledtrialsandobservationalstudiessuggestedthat dietaryproteinrestrictionreducedtherateofdeclineofGFRbyonly0. 53mL/minper year. 550Patientsinthesestudiesdidnotreportedlydevelophypoalbuminemiaorother signsofmalnutrition. However, theyreceivedintensivenutritionalmonitoringandcounseling. It is thus unclear whether such severely restricted Protein diets can be safely prescribedorevenmaintainedintheabsenceoffrequentdietitianinvolvement. TheWorkGroupconcludedthattherewasinsufficientinformationtorecommend fororagainstalowproteindiet(0. 6g/kg/d)forpatientswithchronickidneydisease. Thelackoffirmevidenceregardingitsimpact, andthelogisticandfinancialdifficulties ofprovidingintensivenutritionalintervention, precluderecommendationofalowproteindietinallpatientswithchronickidneydisease. Individualdecision-makingisrecommended, afterdiscussion ofrisks andbenefits. Thisis inagreement with theK/DOQI ClinicalPracticeGuidelinesonNutritioninChronicRenalFailure, 75whichrecommends considerationofalow proteindiet(0. 6g/kg/d)forpatientswithGFR intherangeof CKDStage4and5. Whetherornotthedecisionismadetopursuealowproteindiet, the Work Group re inforces the importance of maintaining a Good nutritional status withadvancingchronickidneydisease, whichgenerallywouldinvolveevaluationand monitoringbyadietician, andrefersthereadertoGuideline9. Thereisinsufficientevidencetorecommendlipid-loweringtherapyforthe purpose of slowing the progression of chronic Kidney disease (R). Some of observational studies have reported that various dyslipidemias are associated with decreasedkidneyfunctioninthegeneralpopulationandinpatientswithchronickidney 226 Part7. Stratification NationalKidneyFoundation potassium/DOQI disease.",
    "word_count": 583,
    "char_count": 10957,
    "sentence_count": 89,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 47,
      "total_chunks": 77,
      "position": "48/77",
      "content_type": "dietary",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "renal function",
        "kidney failure",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "serum creatinine",
        "diet"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 48,
    "text": "Some of observational studies have reported that various dyslipidemias are associated with decreasedkidneyfunctioninthegeneralpopulationandinpatientswithchronickidney 226 Part7. Stratification NationalKidneyFoundation potassium/DOQI disease. 480, 551554 However, it is impossible to determine from these studies whether dyslipidemiascausereduced kidneyfunction, resultfromreducedkidney function, or whetherotherconditionssuchasproteinuriacausebothreducedkidneyfunctionand dyslipidemias. Eachoftheseexplanationsisplausible, andonlyrandomized, controlled trials can adequately test the hypothesis that dyslipidemias cause a decline in Kidney function. Unfortunately, therearenolarge, adequatelypowered, randomized, controlledtrials testingthehypothesisthattreatmentofdyslipidemiapreserveskidneyfunction. However, therehavebeenseveralsmallstudies555566andameta-analysisofthesestudies. 567 Thismeta-analysisincludedprospective, controlledtrialspublishedbeforeJuly1, 1999. Three trials published only in abstract form were included, 555, 556, 566 but one of these studieshassubsequentlybeenpublishedinapeer-reviewedjournal. 566Allpatientswere followedforatleast3months, butinonly5studieswerepatientsfollowedforatleast 1year. Statinswereusedin10studies, gemfibrozilin1study, andprobocolin1study. Altogether, 362patientswithchronickidneydiseasewereincludedinthemeta-analysis. The resultssuggested that therate of declinein glomerular filtration rate wassignificantly lessin patients treatedwithalipid-loweringagentcomparedtoplacebo. 567Nosignificantheterogeneity intreatmenteffectwasdetectedbetweenthestudies. However, thequalityofthestudies wasgenerallylow, andtheirsmallsamplesizesandrelativelyshortdurationoffollowupmakeitdifficulttoconcludethatlipid-loweringtherapiesreducetherateofdecline inGFRinchronickidneydisease. Clearly, adequatelypowered, randomizedcontrolled trialsareneededtodeterminetheroleoflipid-loweringtherapyinretardingtherateof declineinkidneyfunctioninpatientswithchronickidneydisease. Theevaluationand managementofdyslipidemiainpatientswithchronickidneydiseasehasbeenaddressed by the NKFTask Force on Cardiovascular Diseasein Chronic Renal Diseaseand is reviewedbrieflyinGuideline15. Themanagementofdyslipidemiainpatientswithkidney failureisthesubjectofanongoingK/DOQIWorkGroup. Thereisinsufficientevidencetorecommendfororagainstpartialcorrection ofanemiawithrecombinanthumanerythropoietinandor/ironforthepurpose ofslowingtherateofdeclineofGFR(R). Therehavebeenseveralstudiesevaluating theuseoferythropoietinand/orironamongpatientswithchronickidneydiseaseprior toinitiationofdialysis, withtheintentionofdemonstratingeffectivenessinimproving anemiaandlackofharmintermsofincreasingtherateofdeclineofkidneyfunction. Most patients enrolled in these studies had severely reduced Kidney function. These studieshaveshowneithernooveralldifferenceintherateofdeclineofkidneyfunction in treated compared to untreatedgroups297, 304, 306 or compared to pre-treatment rates ofdecline, 568oraslightbenefitintermsofaslowerrateofdeclineofGFRinthetreated group294, 569 and prolongation of time to ESRD569, or reduced proportion of patients whoexperienceddoublingofbaselineserumcreatinineinthetreatedversusuntreated groups. 305 Each of these studies, as well as a study comparing intravenous with oral ironanderythropoietin forthetreatmentof anemiainchronickidney disease, 570also potassium/DOQI NationalKidneyFoundation Part7. Stratification 227 concludedthatnormalizationofhemoglobinorhematocrithadessentiallynoeffecton therateofdeclineofkidneyfunction. Inonestudycomparingintravenousironwithor withouterythropoietininpatientswithlessseverereductioninkidneyfunction(mean serumcreatinineof2. 8mg/dL), theauthorsconcludedthattreatmentofanemiawas associatedwithaslowingoftherateofprogressionofrenalfailurebasedonthefact thattheGFRdeclinepre-treatmentwasfasterthanpost-treatmentinlongtermfollowup. 571However, thisstudyexcludedpatientswhoprogressedtodialysisduringtheinitial studyperiod. Insummary, thereviewedstudiesweregenerallydesignedtodemonstratenodifference/noharmoftreatmentofanemia, primarilyamongpatientswithseverelyreduced kidneyfunction. Theavailableevidencethatpartialcorrectionofanemiawitherythropoietin(andiron)resultsinimprovementintherateofdeclineofGFRisthereforeinconclusive. Further studiesspecifically addressingthe effectsof anemiaand itstreatment on rateofGFRdeclinearenecessarytoclarifythisissue. Theevaluationandmanagement ofanemiashouldbeundertakenasdescribedinGuideline8, andaspreviouslydetailed intheK/DOQIClinicalPracticeGuidelinesonAnemiaofChronicKidneyDisease. 265 GFRdeclinemaybeirregular. AcutedeclineinGFRmaybesuperimposed onchronickidneydisease. RiskfactorsforacutedeclineinGFRinclude(R): Volumedepletion; Intravenousradiographiccontrast; Selectedantimicrobialagents(forexample, aminoglycosidesandamphotericinB); Nonsteroidal anti-inflammatory agents (NSAIDs), including cyclo-oxygenasetype2(COX2)inhibitors; Angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers; Cyclosporineandtacrolimus; Obstructionoftheurinarytract. Selectedreviewarticleswereusedtoformulatethissection. 572, 573 Reducedbloodflowtothekidney, toxicinsult, obstruction, inflammation, orinfection canresultinacutedeteriorationofkidneyfunction. Reducedbloodflowtothekidney andintrinsicdamagetothekidneybecauseofanephrotoxicorischemicinsultarethe mostcommoncausesofacutedeteriorationofGFR. Volumedepletion accountsfor themajority ofcommunity acquiredcases ofacute reductioninthebloodflowtothekidneyandaresultantreductioninGFR. Themost commonprecipitantsofvolumedepletionarevomiting, diarrhea, poorfluidintake, fever, anddiureticuse. Heartfailurecaneffectivelyresultinareductionofbloodflowtothe kidneyduetoreducedcardiacoutput, inthefaceofapparentvolumeoverload. Therisk ofdevelopingacutedeteriorationofkidneyfunctionduetovolumedepletionishighest intheelderly, astheymayalreadyhavecompromisedbloodflowtothekidneysdueto atheroscleroticdisease. 228 Part7. Stratification NationalKidneyFoundation potassium/DOQI Commontoxicinsultsencounteredinclinicalpracticeareradiocontrastdye, aminoglycosideantibiotics, andNSAIDs. Inparticular, thesearelikelytoresultinacutedecline inGFRifthereisanadditionalinsultsuchassepsis, volumedepletion, heartfailure, or treatmentwithACEinhibitors. Toxinscancausekidneyfailureviaanumberofmechanismsincluding(notanexhaustivelist): (1)alterationofkidneybloodflow(NSAIDs, ACE inhibitors, cyclosporine, radiocontrastagents), (2)directtubularinjury(aminoglycosides, radiocontrast, amphotericin B), (3) intratubular obstruction (acyclovir, sulfonamides), (4)allergicinterstitialnephritis(NSAIDs, penicillins, cephalosporins, sulfonamides). The avoidanceofpotentialnephrotoxins, suchasintravenousradiographiccontrast, certain antibiotics, andNSAIDs mustbebasedon anindividualizedassessmentof therisksof acute decline in glomerular filtration rate versus the therapeutic benefits of treatment. For example, in a patientwithdebilitatingarthritis, avoidanceofNSAIDuseshouldbeconsideredinlight ofthebenefitsofreducingpainandimmobility; inapatientwithcoronaryarterydisease, theavoidanceofintravenousradiocontrastshouldbeweighedagainstthepotentialbenefitsofanangioplastyprocedure. Finally, obstruction can cause an acute decline in glomerular filtration rate if there is bilateral ureteral obstruction, unilateralureteralobstructioninapersonwithasinglefunctioningkidney, orobstructionatthelevelofthebladder. Themostcommoncausesofobstructionare prostatichypertrophy, canceroftheprostateorcervix, orretroperitonealdisorders. In addition, kidneystones, Blood, fungalinfection, andbladdermalignancymayresultin obstruction. Unlikewithtoxicinsults, acutedeclineinGFRduetoobstructioniscommonlyseenintheoutpatientsetting. Insummary, therearenumeroussituationsthatmaycauseanacutedeteriorationin the glomerular filtration rate that are potentially avoidable. The clinician should become familiar with the mostcommoncauses, inordertopreventavoidableworseningofthecourseofchronic kidneydisease. LIMITATIONS Theformulationofthisguidelinewaslimitedbyanumberoffactors. Mostnotably, with manyofthestudiestheresultsweredifficulttocompareastheyusedifferentmeasures forkidneyfunction: measuredGFRorcreatinineclearance, estimationequationsforGFR orcreatinineclearance, orsimplyserumcreatinine. Furtherlimitingthecomparability oftheresultsacrossthestudiesisthewidevariationintheselectionofanalytictechniques andpresentationofdata. Amajorlimitationofthisguidelineisitsfailuretoprovideasemi-quantitativeassessment of the relationships between the factors assessed and the outcomes of rate of progressionor riskforkidneyfailure. Thisreviewof thesestudiesdoes notprovidea conclusive answer to the causes underlying the more rapid rate of progression or increasedriskforkidneyfailure. CLINICALAPPLICATIONS Itisimportanttofolloweachindividualsrateofprogression, asthereisawidevariation amongindividualsanddiseasetypesandintheresponsetointerventions. potassium/DOQI NationalKidneyFoundation Part7. Stratification 229 Thereisabroadrangeoffactorsthatareassociatedwithmorerapiddeclineinkidney function, someofwhichareamenabletointerventions. Certain patient groups, defined by either type of Kidney disease, clinical, gender, racial, oragecharacteristics, areatgreaterriskforprogressionofkidneydiseasethis denotestheneedtoincreaseawarenessamongpatientsandprovidersaboutpropercare andtheneedtoinstituteinterventionstoattempttoslowprogression. IMPLEMENTATIONISSUES Patientswithcertaincausesofkidneydisease, andcertainmodifiableandnonmodifiable characteristics, maybeatincreasedriskforfasterratesofGFRdecline. Thereisincreasing evidencethatcertaininterventionscanslowthedeclineinGFRandpreventthedevelopmentofkidneyfailureinbothdiabeticandnondiabeticpatients. Itisthuscriticaltoeducatepatientsandprovidersregardingtheriskfactorsandto facilitateprovidingaggressiveinterventionswhereindicated. Thismayrequirechanging thepoliciesofcareprovidersandpayersregardingfrequencyoffollow-upandpayment formedications. RESEARCHRECOMMENDATIONS It is evident that there is a large amount of data in studies of varying size and quality regardingtheimpactofunderlyingconditions, patientcharacteristics, andinterventions. However, therearecertainfactorswhoseimpacthasnotbeenconclusivelydetermined, suchasdietaryproteinintake, hyperlipidemia, andanemiaandtheirtreatment. Proteinuriaasariskfactordeservesspecialconsideration. Antihypertensiveagents, especially ACE-inhibitorsandangiotensin-receptorblockers, reduceproteinuriaandslowtheprogression of Kidney disease. However, the role of proteinuria per se has not been adequatelystudied. Thereisaneedtodevelopalternativetherapiestoreduceurineprotein. Manyof theconclusions regardingthe impactof factorsunrelated tointervention, suchasage, gender, race, andcauseofkidneydisease, comefromsmallinterventional trials. Similarly, inthecaseoftheimpactofbloodpressurecontrol, conclusionslargely come from the observations that patients with lower Blood pressures have improved outcomes. Inthecaseofcauseofkidneydisease, theconclusionthatcertaincausesare associatedwithfasterratesofprogressioncomefromthecomparisonofstudiesofsingle causes, usingdiversemethodstomeasureorestimateGFR. Anoninterventionalprospectivecohortstudyincludingsufficientnumbersofpatientswithallcausesofkidneydis- ease, undergoingsimilartestingforlevelofkidneyfunction, wouldbeidealtoevaluate the impact of cause of Kidney disease on the rate of decline in glomerular filtration rate. Alternatively, a sufficientlylargeprospectiveinterventionaltrialcouldachieveasimilargoal.",
    "word_count": 599,
    "char_count": 11558,
    "sentence_count": 76,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 48,
      "total_chunks": 77,
      "position": "49/77",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "proteinuria",
        "potassium",
        "ACE inhibitors"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 49,
    "text": "Alternatively, a sufficientlylargeprospectiveinterventionaltrialcouldachieveasimilargoal. GUIDELINE 14. ASSOCIATION OF CHRONIC Kidney DISEASE WITH DIABETIC COMPLICATIONS Theriskofcardiovasculardisease, retinopathy, andotherdiabeticcomplicationsis higherinpatientswithdiabetickidneydiseasethanindiabeticpatientswithoutkidney disease. 230 Part7. Stratification NationalKidneyFoundation potassium/DOQI Prevention, detection, evaluation, andtreatmentofdiabeticcomplicationsinpatientswithchronickidneydiseaseshouldfollowpublishedguidelinesandposition statements. Guidelinesregardingangiotensin-convertingenzymeinhibitorsorangiotensin-receptorblockersandstrictbloodpressurecontrolareparticularlyimportantsince theseagentsmaypreventordelaysomeoftheadverseoutcomesofbothkidney andcardiovasculardisease. Applicationofpublishedguidelinestodiabeticpatientswithchronickidneydisease shouldtakeintoaccounttheirhigher-riskstatusfordiabeticcomplications. BACKGROUND Theonsetofdiabetesischaracterizedbymetabolicandhemodynamicdisturbancesthat increase vascular permeability, raise systemic Blood Hypertension, and alter the regulation ofintracapillarypressure. Inthekidney, thesechangesmayleadtoincreasedtrafficking ofplasmaproteinsacrosstheglomerularmembraneandtotheappearanceofprotein in the Urine. The presence of urinary Protein not only heralds the onset of diabetic Kidney disease, but it may contribute to the glomerular and tubulointerstitial damage thatultimatelyleadstodiabeticglomerulosclerosis. 574Thestrongrelationshipbetween proteinuriaandaconstellationofotherdiabeticcomplicationssupportstheviewthat elevatedurinaryproteinexcretionreflectsageneralizedvasculardisturbancethataffects manyorgans, includingtheeyes, Heart, andnervoussystem. 575 This guideline describes the association of cardiovascular (macrovascular), retinal (microvascular), andother(principallyneuropathic)complicationsofdiabeteswithlevelsofalbumin/proteinintheurine. Ithighlightsthestrongrelationshipbetweenprogressivediabetic kidneydiseaseandthe developmentofotherdiabetic complicationsand emphasizestheimportanceofmonitoringandtreatingdiabeticchronickidneydisease patientsfortheseothercomplications. RATIONALE Microalbuminuriareferstolevelsofurinaryalbuminexcretionbelowthosedetectedby standarddipstickmethodsandmacroalbuminuriareferstohigherlevelsofurinaryalbumin excretion. Microalbuminuria is present when the albumin excretion rate is 30 to 300mg/24hours(20to200(cid: 3)g/min)orthealbumin-to-creatinineratiois30to300mg/ g. 576Proteinuriagenerallyreferstoapositivedipsticktestforproteinortoadailyoutput ofproteinaboveacertaincutpoint, typically(cid: 1)500mg/d. Thus, macroalbuminuriaand proteinuriamayberelativelyequivalentmeasuresofurinaryproteinexcretion(seeGuideline5). Nevertheless, differencesinmethodsofmeasurementandthelackofstandardized definitionsorterminologyoftenmakecomparisonsbetweenstudiesdifficult. Definitions of Diabetic Complications Other Than Chronic Kidney Disease Cardiovasculardisease. Cardiovasculardiseaseisnotaspecificcomplicationof Diabetes per se, since it occurs frequentlyin nondiabetic individuals. Diabetes and an arrayofmetabolicdisordersassociatedwithit, however, increasetheriskofcardiovascupotassium/DOQI NationalKidneyFoundation Part7. Stratification 231 lar disease in diabetic patients and may accelerate the process of atherosclerosis. For thepurposesofthisguideline, cardiovasculardiseasereferstocoronaryheartdisease, cerebrovascular disease, peripheral vascular disease, congestive Heart failure, and left ventricularhypertrophy. TheAmericanDiabetesAssociationprovidesclinicalpractice recommendationsfor screeningand treatmentof cardiovasculardiseasein diabetes526 whichareavailableontheInternet(www. Diabetes. org/Clinicalrecommendations) Thevarietyofmeasuresofcardiovasculardiseaseusedindifferentstudiesmaylimit theinterpretabilityofthefindingsreviewedforthisguideline, althoughthenearlyuniformly positive association suggests this may not be an important limitation. On the otherhand, cardiovasculardiseaseitselfmayincreasethelevelofurinaryalbumin/protein. Thus, theextenttowhichchronicdiabeticglomerulosclerosisisanindependent riskfactorforthedevelopmentofcardiovasculardiseasemaybedifficulttodetermine with certainty, especially in congestive Heart failure, without demonstrating diabetic kidneydamageatthetissuelevel. Retinopathy. Theearliestchangeofdiabeticretinopathythatcanbeseenwiththe ophthalmoscopeistheretinalmicroaneurysm. Otherchangesfoundinnonproliferative retinopathyincluderetinalhemorrhages, hardexudates, cotton-woolspots, intraretinal microvascular abnormalities (IRMA), and venous abnormalities. Growth of abnormal Blood vessels and fibrous tissue that extends from the retinal surface or optic nerve characterizes the proliferative stage of diabetic retinopathy. With experience, these changescanbeidentifiedreadilybydirectophthalmoscopy, preferablythroughdilated pupils. Stereoscopicfundusphotographs, however, produceamorereliableandreproducible assessment of diabetic retinopathy. The Airlie House Classification scheme, or a modification of this scheme, is commonly used to classify the level of retinopathy in epidemiological studies; the more severely involved eye is used for classification. The AmericanDiabetesAssociationprovidesclinicalpracticerecommendationsforscreening andtreatmentofdiabeticretinopathy. 526 Neither the diagnosis nor classification of retinopathy was uniform in the studies reviewedforthisguideline. Somestudiesperformedretinalphotographs(from 2to7 fields, depending on the study) and others relied on ophthalmoscopic examinations throughdilatedpupils. Moreover, retinopathywasgradedbytheAirlieHouseClassification scheme (or a modification of this scheme) in some studies and by less precisely definedclinicalcriteriainothers. Beyondmethodologicalissues, theabsenceofretinopathyinsomesubjectswithelevatedalbuminuria/proteinuriamayreflectthepresenceof nondiabetickidneydisease, particularlyinoldertype2diabeticpatients. Thesefactors undoubtedlycontributed, atleastinpart, tothereportedvariabilityoftheassociation betweenretinopathyandalbuminuria/proteinuria. Neuropathy. Diabeticneuropathyisperhapsoneofthemostdifficultcomplications ofdiabetestomeasure. Although60%to70%ofpeoplewitheithertypeofdiabetesare affected, manyinvestigators inthe past usednon-standardized methodsfor measuring neuropathy. Thelackofstandardizednomenclatureandcriteriafordiabeticneuropathy 232 Part7. Stratification NationalKidneyFoundation potassium/DOQI undoubtedlydiminishedthequalityofthedataavailableforreview. Accordingly, studies examining the relationship between the level of urinary albumin/Protein and diabetic neuropathyoftenyieldedconfusingandconflictingresults. In1988, ajointconferenceoftheAmericanDiabetesAssociationandtheAmerican AcademyofNeurologyadoptedstandardizednomenclatureandcriteriaforthediagnosis ofneuropathyindiabetes. 577Theclassificationwasdividedintosubclinicalandclinical neuropathy(Table126). Subclinicalneuropathyisdefinedasanabnormalelectrodiagnostic test, quantitative sensory threshold, or autonomic function test in the absence of clinicalsignsandsymptoms. Clinicalneuropathyisdefinedasanabnormaltestassociated withclinicalsignsand/orsymptoms. TheAmericanDiabetesAssociationprovidesclinical practicerecommendationsforscreeningandtreatmentofdiabeticneuropathy. 526 Strength of Evidence Giventhenumerousstudiesandgeneralagreementontherelationshipbetweenproteinuria and complications of Diabetes other than chronic Kidney disease, review articles wereusedastheprimarysourceofinformationforthisguideline. Sincereviewsoften reportedtheassociationsqualitatively, individualstudieswereincludedtoprovidequantitativeestimatesoftheassociation. ReferencewasalsomadetoindividualstudiesofnonCaucasianpatients, sincemanyreviewsreportedonlyresultsfromstudiesinCaucasians. Giventhelowrateorabsenceoftype1diabetesinmanynon-Caucasians, theimpact ofethnicity ontherelationshipbetween proteinuriaandother diabeticcomplications was examined only in those with type 2 Diabetes. Selection of individual studies for potassium/DOQI NationalKidneyFoundation Part7. Stratification 233 thisguidelinewasnotsubjecttothesystematicreviewprocessusedinotherK/DOQI guidelinesandisintendedtobeillustrativeratherthancomprehensive. Cardiovasculardiseaseisrelatedtothelevelofproteinuriaoralbuminuria indiabetickidneydisease(Table127andFigs51and52)(R, C). Increasedcardiovascularmortalitywaslinkedwithelevatedurinaryalbuminexcretionintype2diabetes in1984578, 579andwithtype1diabetesin1987. 580ThisassociationwasconfirmedsubseFig 51. Cardiovascular mortality with Diabetes. Relative cardiovascular mortality in type 1 (left panel) and type 2 (right panel) Diabetes according to the level of urinary proteinexcretionintheWHOMultinationalStudyofVascularDiseaseinDiabetes. 597 Deathrateratioswereadjustedforage, durationofdiabetes, systolicbloodpressure, serumcholesterolconcentration, andsmokinghistorybyPoissonregression. 234 Part7. Stratification NationalKidneyFoundation potassium/DOQI Fig52. Microalbuminuriaandcardiovascularmorbiditywithtype2diabetes. Crude association of microalbuminuria and cardiovascular morbidity or mortality in type 2 Diabetes. The results are presented with (total) and without (subtotal) the study that includedsubjectswithclinicalproteinuria. Adaptedandreprintedwithpermission. 586 quentlyinmanystudiesanddescribedinnumerousreviewarticles, 581596anditisreportedindiverseracial/ethnicgroups(Table127). Theassociationbetweendiabetickidneydiseaseandcardiovasculardiseaseisgenerally considered stronger intype 2 than in type 1 Diabetes atall levels of albuminuria/ proteinuria, due in large part to the older age of the type 2 diabetic patients. In the WHOMultinationalStudyofVascularDiseaseinDiabetes, 597however, similarcardiovasculardeathrateswerereportedinthe1, 188patientswithtype1andthe3, 234patients withtype2diabetesfromtencentersworldwide(Fig51). Theseresultsmaybeinfluencedbytheracial/ethnicmixofthesamplecohort, sincesomepopulationsincluded inthecohortwithhighratesoftype2diabetes, suchasthePimaIndians, havelower ratesofcardiovasculardiseasethanCaucasianswithtype2diabetes. 601 Ameta-analysisof11cohortstudiesinvolving2, 138patientswithtype2diabetes586 providescompellingevidencethatevenmodestelevationsofurinaryalbuminexcretion areassociatedwithincreasedcardiovascularrisk.",
    "word_count": 597,
    "char_count": 10349,
    "sentence_count": 74,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 49,
      "total_chunks": 77,
      "position": "50/77",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "albuminuria",
        "proteinuria",
        "potassium",
        "heart failure",
        "neuropathy",
        "retinopathy",
        "guideline",
        "classification"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 50,
    "text": "In the WHOMultinationalStudyofVascularDiseaseinDiabetes, 597however, similarcardiovasculardeathrateswerereportedinthe1, 188patientswithtype1andthe3, 234patients withtype2diabetesfromtencentersworldwide(Fig51). Theseresultsmaybeinfluencedbytheracial/ethnicmixofthesamplecohort, sincesomepopulationsincluded inthecohortwithhighratesoftype2diabetes, suchasthePimaIndians, havelower ratesofcardiovasculardiseasethanCaucasianswithtype2diabetes. 601 Ameta-analysisof11cohortstudiesinvolving2, 138patientswithtype2diabetes586 providescompellingevidencethatevenmodestelevationsofurinaryalbuminexcretion areassociatedwithincreasedcardiovascularrisk. Inthisreview, patientswithmicroalbuminuria had an overall crude odds ratio for cardiovascular morbidity and mortality of 2. 0(95%confidenceinterval, 1. 4to2. 7)comparedtothosewithnormalurinaryalbumin excretion(Fig52). Retinopathyisrelatedtothelevelofproteinuriaoralbuminuriaindiabetic Kidney disease (Table 128) (R, C). Review articles evaluated for this guideline included patients from clinic and population-based studies of type 1 and type 2 diabetes. 581, 585, 590, 591, 595, 602Thesearticlesreflectthewidelyrecognizedpositiveassociation betweenthelevelofalbuminuria/proteinuriaandretinopathyinbothtypesofdiabetes. Discordance between these two diabetic complications, however, occurs frepotassium/DOQI NationalKidneyFoundation Part7. Stratification 235 quently, 603, 604particularlyintype2diabetes, becauseofthecoexistenceofnondiabetic kidneydisease. Nevertheless, theincidenceofproliferativeretinopathyincreasesdramaticallywiththedevelopmentofelevatedurinaryalbumin/proteinexcretion. 605Agreater frequencyofretinopathywithhigherlevelsofurinaryalbumin/proteinexcretionisalso reportedinvariousracial/ethnicgroups(Table128), andtherelationshipmaybestronger insomegroupsthaninothers. 606 Otherdiabeticcomplications(forexample, neuropathy)mayberelatedto thelevelofproteinuriaoralbuminuriaindiabetickidneydisease(R). Lessis knownaboutthestrengthoftheassociationbetweenurinaryalbumin/proteinexcretion andneuropathythanabouttheothercomplicationsoftype1andtype2diabetes. The reviewarticlesevaluatedforthisguidelinecommentbrieflythatsomestudiesfounda relationshipwhereasothersdidnot. 581, 591Muchoftheconfusionisundoubtedlyattributable to non-standardized definitions of diabetic neuropathy. In 1988, consensus was achieved on a standardized classification scheme (vide supra), but there are still few reviews available that comment on the relationship between albuminuria/proteinuria anddiabeticneuropathybythesecriteria. Alargenumberofpublishedguidelinesandpositionstatementsareavailabletoguidethepractitionerintheprevention, detection, evaluationandtreatmentofdiabeticcomplications(Table129). Guidelinesregardingangiotensinconverting-enzymeinhibitorsorangiotensin-receptorblockersandstrictblood pressurecontrolareparticularlyimportantsincetheseagentsmaypreventor delaysomeoftheadverseoutcomesofbothkidneyandcardiovasculardisease (R). LIMITATIONS Dataintheelderlyandinracial/ethnicgroupsotherthannon-Hispanicwhitesaresparse, particularlyinreviewarticles, makingthefindingsreportedinthisguidelinedifficultto extrapolatewithconfidencetotheelderlyandtodifferentpopulationsaroundtheworld. Moreover, after the development of Kidney failure, much of the available data do not differentiatetype1fromtype2diabetes. CLINICALAPPLICATIONS Studies in both type 1617 and type 2618 Diabetes indicate that nearly all of the excess mortalityassociatedwithdiabetesisfoundinthosewithelevatedurinaryalbumin/Protein 236 Part7. Stratification NationalKidneyFoundation potassium/DOQI excretion. Muchoftheexcessmortality, particularlyintype2diabetes, isattributable tocardiovasculardiseaseratherthankidneyfailure, indicatingtheimportanceofidentifyingandtreatingtheothercomplicationsofdiabetesinthesepatientsandtheimportance of close monitoring of proteinuria and Kidney function to identify those at increased risk. Theevidencereviewedtodatesuggeststhattheappearanceofelevatedalbuminuria/ proteinuriaisassociatedwithahigherriskofthenon-kidneycomplicationsofdiabetes evenaspatientsprogresstowardschronickidneydisease. Theassociationbetweenalbuminuria/proteinuriaandcardiovasculardisease, diabeticretinopathy, anddiabeticneuropathy described in this guideline supports the recommendation that patients with diabeticnephropathybecarefullyexaminedforthepresenceofotherdiabeticcomplicationsandthatpropercareforthesecomplicationsbeinitiated. Thisrecommendationis basedonopinionderivedfromareviewoftheavailableevidence. IMPLEMENTATIONISSUES Implementationofcoordinatedpatientmanagementtoaddressthediversityofpotential complicationsisoneofthegreatestchallengesofdiabetescare. Recommendationsrepotassium/DOQI NationalKidneyFoundation Part7. Stratification 237 gardingmanagementofdiet, exercise, glycemia, bloodpressure, lipids, neuropathy, retinopathy, andcardiovasculardiseasemustallbeconsideredinadditiontothoseforkidney disease. Althoughthechallengesforhealthcareprovidersareformidable, theymayseem overwhelming to those with Diabetes. One of the objectives of the National Diabetes EducationProgram, aProgrammanagedjointlybytheNationalInstituteofDiabetesand Digestive and Kidney Diseases and the Centersfor Disease Control and Prevention, is to promote an integrated patient-centered approach to Diabetes care with the goal of reducing the morbidity and mortality associated with Diabetes and its complications (www. ndep. nih. gov). RESEARCHRECOMMENDATIONS Muchoftheunderstandingabouttherelationshipsbetweendiabeticnephropathyand cardiovasculardisease, retinopathy, andneuropathycomesfromstudiesinCaucasians. Yettheepidemicofdiabetesaffectsmanyracial/ethnicgroupsworldwide. Sincerace/ ethnicitymayinfluencenotonlytheriskofdiabetes, buttheseverityandtypeofdiabetic complicationsthatdevelop, furthercharacterizationoftheimpactofdiabetesindifferent populationsisneeded. Furthercharacterizationoftheserelationshipsintheelderlyisalso needed. Moreover, theextenttowhichaggressivetreatmentofdiabeticcomplications modulatestheprogressionofkidneydiseaseneedstobeexamined, sincerecentstudies suggest thatimprovements in thetreatment ofcardiovascular disease inpatients with type2diabeteshavecontributedtoanincreaseindiabetickidneyfailure. 619 GUIDELINE 15. ASSOCIATION OF CHRONIC Kidney DISEASE WITH CARDIOVASCULAR DISEASE Patientswithchronickidneydisease, irrespectiveofdiagnosis, areatincreasedrisk ofcardiovasculardisease(cardiovascular disease), includingcoronaryheartdisease, cerebrovasculardisease, peripheral vascular disease, and Heart failure. Both traditional and chronic kidneydiseaserelated(nontraditional)CVDriskfactorsmaycontributetothisincreased risk. Allpatientswithchronickidneydiseaseshouldbeconsideredinthehighestrisk group for cardiovascular disease, irrespective of levels of traditional cardiovascular disease risk factors. AllpatientswithchronickidneydiseaseshouldundergoassessmentofCVDrisk factors, including: MeasurementoftraditionalCVDriskfactorsinallpatients; Individualdecision-makingregardingmeasurementofselectedchronic kidney disease-related CVDriskfactorsinsomepatients. RecommendationsforCVDriskfactorreductionshouldtakeintoaccounttheHighest-riskstatusofpatientswithchronickidneydisease. BACKGROUND Similartothegeneralpopulation, cardiovasculardiseaseaccountsfor40%to50%ofall deathsintheend-stagerenaldisease(end-stage renal disease)population, andCVDmortalityratesinESRD 238 Part7. Stratification NationalKidneyFoundation potassium/DOQI patientsareapproximately15timeshigherthanthegeneralpopulation. 261Theburden of cardiovascular disease is evident upon the initiation of replacement therapy. Forty percent of patients starting Dialysis already have evidence of coronary Heart disease (CHD)2andonly15%areconsideredtohavenormalleftventricularstructureandfunctionbyechocardiographiccriteria. 620Clearly, manymanifestationsofcardiovasculardiseasearisebeforetheonsetofkidneyfailureandtheneedfordialysisortransplantation. Previously the National Kidney Foundation convened a Task Force to evaluate the epidemicofcardiovasculardiseaseinpatientswithchronickidneydisease. 9Highlighted inthisreportwasthehighmortalityfromcardiovasculardiseaseinpatientswithkidney failure. ThepurposeofthisguidelineistofocusontheCVDriskassociatedwithchronic kidneydisease(excludingpatientstreatedbydialysis). Guideline14addressestheriskof cardiovasculardiseaseinpatientswithdiabetickidneydisease. Therefore, thisguideline focusesontheriskofcardiovasculardiseaseinpatientswithnondiabetickidneydisease, andspecificallytoaddressthequestionwhetherchronickidneydiseaseisariskfactor forthedevelopmentofcardiovasculardisease. Guidelinesfortheevaluationandmanagementofspecific CVDriskfactorsin thispopulationarecurrently beingdevelopedby otherK/DOQIWorkGroups. RATIONALE Definitions For the purposes of this guideline, cardiovascular disease refers to coronary Heart disease, cerebrovasculardisease, peripheralvasculardisease, andcongestiveheartfailure. Leftventricularhypertrophy(LVH)wasnotalwaysincluded, eventhoughitisassociated withchronickidneydiseaseandisariskfactorforclinicalcardiovascularevents. TraditionalriskfactorsarethosevariablesdefinedinthegeneralpopulationthroughprospectivecohortstudiessuchastheFraminghamHeartStudy(Table130). Chronickidney disease(chronic kidney disease)-relatedriskfactorsincludethehemodynamicandmetabolicabnormalitiesassociatedwithchronickidneydiseaseandcomplicationsofdecreasedkidneyfunc- tion. SomeauthorshavesubdividedCKD-relatedriskfactorsinthosefactorsalteredby theuremicstate(forexample, hypertension, dyslipidemia, homocysteine)andfactors thatarecharacteristicoftheuremicstate(forexample, anemia, malnutrition, oxidative stress, andhyperparathyroidism). 621 Strength of Evidence Where possible, data from the National Kidney Foundation Task Force on Cardiovascular Disease in Chronic RenalDisease9hasbeenusedasthesourceofinformationforthisguideline. Giventhe breadth of the topic and the extensive summary by the National Kidney Foundation Task Force, the current Work Group did not feel it was necessary to duplicate their effort. In addition to the Task Force summary, other recent review articles, where necessary, were used as a sourceofinformationforthefollowingrationalestatements. Todeterminetheassociation ofalbuminuriaanddecreasedGFRwithincidentcardiovasculardisease, evidencetables werecompiledafterasystematicreviewoforiginalarticles. potassium/DOQI NationalKidneyFoundation Part7. Stratification 239 Nondiabeticpatientswithchronickidneydiseasehaveanincreasedprevalenceofcardiovasculardiseasecomparedtothegeneralpopulation(R). HighlightedintheNKFTaskForceReportwasthehighprevalenceofcardiovasculardisease in Dialysis patients. 9 Data from the USRDS in 1997 show a 40% prevalence of either coronaryarterydiseaseorcongestiveheartfailureinpatientsstartingdialysis.",
    "word_count": 591,
    "char_count": 10819,
    "sentence_count": 72,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 50,
      "total_chunks": 77,
      "position": "51/77",
      "content_type": "evidence",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "kidney failure",
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "potassium",
        "malnutrition",
        "dialysis",
        "anemia"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 51,
    "text": "HighlightedintheNKFTaskForceReportwasthehighprevalenceofcardiovasculardisease in Dialysis patients. 9 Data from the USRDS in 1997 show a 40% prevalence of either coronaryarterydiseaseorcongestiveheartfailureinpatientsstartingdialysis. 2However, fewstudieshaveexaminedtheprevalenceofcardiovasculardiseaseinarepresentative sample of patients with earlier stages of chronic Kidney disease. In a report from the FraminghamHeartStudy, theprevalenceofvariousmanifestationsofcardiovasculardisease were examined in participants with elevated serum Creatinine (serum Creatinine 1. 5to3. 0mg/dLand1. 4to3. 0mg/dLinmenandwomen, respectively). Inmen, cardiovascular disease prevalencewas17. 9%andinwomen, CVDprevalencewas20. 4%. Thiscontrastswith theCVDprevalencereportedinthesamestudyinmen(13. 9%)andwomen(9. 3%)with normalserumcreatininelevels. 622Inanothercross-sectionalanalysis, theprevalenceof LVHbyechocardiographywas27%, 31%, and45%inpatientswithacreatinineclearance greaterthan50, 25to50, andlessthan25, respectively. 257ThishighprevalenceofLVH contrastswithaprevalenceoflessthan20%inFraminghamHeartStudyparticipants. 623 Cardiovasculardiseaseistheleadingcauseofdeathinnondiabeticpatients withchronickidneydisease(R). Cardiovasculardiseaseistheleadingcauseofdeath inpatientswithchronickidneydisease, regardlessofstageofkidneydisease. Approximately40%ofalldeathsintheUnitedStatesaresecondarytocardiovasculardisease. 624 240 Part7. Stratification NationalKidneyFoundation potassium/DOQI Studiesinvolvingpatientswithkidneydiseasearenotdissimilar. Inanancillaryanalysis oftheHypertensionDetectionandFollow-upProgram(HDFP)involvingnearly11, 000 individuals, 58% of deaths in participants with baseline serum Creatinine (cid: 1)1. 7 milligrams per deciliter weresecondarytocardiovascularcauses. 510IntheBritishRegionalHeartStudycomprising7690menfollowedformorethan14years, greaterthan50%ofalldeathsinsubjects withintheupperdecileofbaselineserumcreatinineweresecondarytocardiovascular causes. 625AlthoughtheHDFPandBritishRegionalHeartStudyanalysesdidnotstratify by Diabetes status, only a minority of subjects was known to be diabetic (16% within theHDFPstudyand(cid: 1)2. 0%withintheBritishRegionalHeartStudy). Cardiovasculardiseasemortalityismorelikelythandevelopmentofkidney failure in nondiabetic patients with chronic Kidney disease (R). Most patients withchronickidneydiseasedonotdevelopkidneyfailure. Theprevalenceofchronic kidneydiseasebystageisshowninTable4. TheestimatedprevalenceofStage3CKD is(cid: 1)30timesgreaterthantheprevalenceofkidneyfailure(Stage5CKD). Althoughno prospectivedataonacohortwithStage3CKDisavailable, indirectlyitisevidentthat mostoftheseindividualsdonotproceedtokidneyfailure, butlikelydiebeforetheonset ofkidneyfailure. Fromthediscussionabove, thecauseofdeathislikelycardiovascular inorigin. FurthersupportivedataisavailablefromtheHDFPandFraminghamanalyses. IntheHDFPtrial, only19%ofdeathswereattributabletokidneyfailureversus58%from cardiovascularcauses. 510IntheFraminghamstudy, 198deathsoccurredinsubjectswith elevated serum Creatinine values. 622 Only 10 of these deaths occurred when patients hadalreadydevelopedESRD(unpublisheddata). NondiabeticpatientswithchronickidneydiseasehaveanincreasedprevalenceoftraditionalCVDriskfactorscomparedtothegeneralpopulation(R). PrevalenceofriskfactorswithdecreasedGFR. Manypatientswithchronickidney diseasehaveahigherprevalenceoftraditionalCVDriskfactorscomparedtothegeneral population. Data from NHANES III (Table 26) clearly illustrate the inverse association betweenolderageandreducedGFR. Usingthesamedataset, theprevalenceofdiabetes andhypertensioninsubjectswithelevatedserumcreatininelevels((cid: 1)1. 6mg/dLinmen and(cid: 1)1. 4mg/dLinwomen)inthisdatabasewasrecentlyreported. Inthiscross-sectional study, 19% of subjects with elevated serum Creatinine were known to have Diabetes mellitus, and70%hadhighbloodpressure. Incontrast, theprevalenceofdiabetesmellitus andhypertensionintheentireNHANESIIIsamplewas4. 8%and22. 8%, respectively. 5 AmoreextensivediscussionontheassociationofhypertensionwithGFRisfoundunder Guideline7. Comparedtothegeneralpopulation, thepercentprevalenceoflipoprotein abnormalitiesinpatientswithchronickidneydiseaseisalsoincreased(Table131). The prevalenceoftobaccouseinpatientswithchronickidneydiseasedoesnotappearto bemarkedlydifferentfromtheprevalenceinthegeneralpopulation. 626 Prevalenceofriskfactorswithproteinuria. Proteinuriaisastrongindependent predictorofGFRdeclineinpatientswithandwithoutdiabetesmellitus. 6Therefore, it isnotsurprisingthatmanyofthesameCVDriskfactorsassociatedwithdecreasedGFR arealsoassociatedwithincreasedurinaryproteinexcretion. Proteinuriaincreaseswith potassium/DOQI NationalKidneyFoundation Part7. Stratification 241 ageandthedurationandseverityofhypertension. 628Inpatientswithessentialhypertension, the combined presence of proteinuria and dyslipidemia is frequent, and greater levelsofurinaryproteincorrelatesignificantlywithgreaterserumlevelsoftotalcholesterol, triglycerides, andlipoprotein(a). ProteinuriaisalsoinverselycorrelatedwithHDL cholesterollevels. 628Thepositivecorrelationbetweenproteinuriaandbloodpressure, totalserumcholesterol, andtriglycerides, andtheinversecorrelationwithHDLcholesterol, have also been reported in a recent analysis of data from the MDRD Study. 629 Theseassociationsremainedpresentevenafteradjustmentforthepresenceofdiabetes. 242 Part7. Stratification NationalKidneyFoundation potassium/DOQI Evidenceforabnormalitiesofthecoagulationsystemwithincreasedfibrinogen, increased vonWillebrandfactor, andreducedplasminogenactivatorinhibitorhavealsobeendescribedinpatientswithelevatedlevelsofurinaryprotein. 630 Nondiabetic patients with chronic Kidney disease have a High prevalence of chronic Kidney disease-related cardiovascular disease risk factors (R). Numerous hemodynamicandmetabolicfactorsassociatedwithchronickidneydiseasehavebeenimplicated aspotentialCVDriskfactors(Table130). TheprevalenceofmanyofthesefactorsincreasesasGFRdeclines. TheinverseassociationbetweenanemiaandGFRisreviewed in Guideline 8. The increased prevalence of abnormalities in parathyroid hormone, and calcium and phosphate metabolism, are reviewed in Guideline 10. The reader is also referred to reviewswhichdiscussfactorssuch ashomocysteine, inflammatorymarkers, thrombogenicfactors, andoxidativestressinmoredetail. 3, 631633 Chronickidneydiseaseisariskfactorforsubsequentcardiovasculardiseaseinindividualswithoutdiabetes(C). Decreased glomerular filtration rate is a risk factor for cardiovascular disease in individuals without Diabetes (Tables 132 and 133 and Fig 53) (C). Reduced glomerular filtration rate identifies potassium/DOQI NationalKidneyFoundation Part7. Stratification 243 Fig53. GFRandrelativeriskfordeath. Wannamethee625: riskisforS (cid: 1)1. 5mg/dL creatinine versusS (cid: 2)1. 3mg/dL. UpperlimitforS wasnotdefined. Culleton622: riskisforS creatinine creatinine creatinine (cid: 1)1. 5mg/dLand(cid: 1)1. 4mg/dLversus(cid: 1)1. 5and(cid: 1)1. 4inmenandwomenrespectively. UpperlimitforS was3. 0mg/dLforbothmenandwomen. Mann637: riskisforS creatinine creatinine (cid: 1)1. 4mg/dLversus(cid: 1)1. 4mg/dL. UpperlimitforS was(cid: 2)2. 3mg/dL. Endpointonthis creatinine figurereferstothecompositeendpointofcardiovasculardeath, myocardial infarction, orstroke. Ruilope634: risk is for S (cid: 2)1. 5 milligrams per deciliter versus (cid: 2)1. 5 milligrams per deciliter. Upper limit for S was 3. 0 milligrams per deciliter. creatinine creatinine Fried640: riskisforS (cid: 1)1. 5mg/dLversusS (cid: 2)0. 9mg/dL. UpperlimitofS wasnot creatinine creatinine creatinine defined. Hemmelgarn642: riskisforS (cid: 2)2. 3mg/dLversus(cid: 2)2. 3mg/dL. Damsgaard643 creatinine (1990), Friedman645 (1991), Matts641 (1993), Shulman510 (1989), Beattie644 (2001), andSchillaci635(2001): datanotprovidedtopresentriskwithconfidenceintervals. individualsatgreaterriskforCVDevents, includingcoronaryheartdisease, cerebrovasculardiseaseandperipheralvasculardisease, anddeath. Theresultsofthesestudiesarenot entirelyconsistent. Someofthisvariabilitymaybeexplainedondifferencesinbaseline demographics, severityofkidneydisease, andtheoverallcardiovascularriskofthestudy sample. Thereisinsufficientevidencetosupportanassociationwithincidentcongestive heartfailure, possiblybecausethenumberofcongestiveheartfailureeventsislow. Proteinuriaisariskfactorforcardiovasculardiseaseinindividualswithout Diabetes (Tables 134, 135, and 136 and Figs 54, 55, and 56) (C). Likewise, proteinuriaisalsoariskfactorforCVDevents, CVDmortality, andall-causemortality. Again, theresultsforallstudiesarenotcompletelyconsistentbuttheweightofevidence isverysupportive. Theidentificationofchronickidneydiseaseasariskfactorforcardiovasculardisease doesnotprovecausation. Atemporalrelationwithchronickidneydiseaseandincident cardiovascular disease has been identified in many of these studies, but other criteria forcausationarelacking, includingconsistencyandbiologicplausibility. Furthermore, althoughadose-responserelationshipwithproteinuriaandcardiovasculardiseasemay exist, sucharelationshipwithreducedGFRhasnotbeenshownconclusively. Analternativehypothesisisthatchronickidneydiseaseisamarkerfortheburdenofexposureto 244 Part7. Stratification NationalKidneyFoundation potassium/DOQI potassium/DOQI NationalKidneyFoundation Part7. Stratification 245 Fig54. Proteinuriaandrelativeriskforcardiovasculardisease. Wherepossible, results presented are from multivariable analyses. Agewall650, Ljungman647: Unadjusted resultsshown. Datanotavailabletocalculateageormultivariableadjustedrisk. 246 Part7. Stratification NationalKidneyFoundation potassium/DOQI Fig55. ProteinuriaandrelativeriskforCVDdeath. Wherepossible, resultspresented arefrommultivariableanalyses. Agewall650: unadjustedresultsshown.",
    "word_count": 598,
    "char_count": 9799,
    "sentence_count": 124,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 51,
      "total_chunks": 77,
      "position": "52/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "creatinine",
        "potassium",
        "calcium",
        "phosphate",
        "parathyroid hormone",
        "serum creatinine",
        "dialysis"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 52,
    "text": "Agewall650, Ljungman647: Unadjusted resultsshown. Datanotavailabletocalculateageormultivariableadjustedrisk. 246 Part7. Stratification NationalKidneyFoundation potassium/DOQI Fig55. ProteinuriaandrelativeriskforCVDdeath. Wherepossible, resultspresented arefrommultivariableanalyses. Agewall650: unadjustedresultsshown. Datanotavailable to calculate age or multivariable adjusted risk. Jager651, Kannel12, Culleton648: some diabetics included, but results shown are adjusted for Diabetes. Grimm228: (a) proteinuriapositiveonce; (b)proteinuriapositivemorethanonceover6yearsoffollowup. Fig56. Proteinuriaandrelativeriskfordeath. Wherepossible, resultspresentedare from multivariableanalyses. Damsgaard643: 4/216subjects excreted morethan 200 (cid: 3)g/minofalbumin. Agewall650: unadjustedresultsshown. Datanotavailabletocalculateageormultivariableadjustedrisk. Jager651, Kannel12, Culleton648: somediabetics included, butresultsshownareadjustedfordiabetes. Grimm228: (a)proteinuriapositive once; (b)proteinuriapositivemorethanonceover6yearsoffollow-up. Miettinen649: Resultsnotshown. Proteinuriapredictedmortalitybutdatawasnotprovidedtocalculate risk. potassium/DOQI NationalKidneyFoundation Part7. Stratification 247 traditionalCVDriskfactors. Therelativecontributionfromkidneydisease-related riskfactorsinthispopulationremainsuncertain. Riskfactorreductionislikelytobeeffectiveinreducingmorbidityandmortality due to cardiovascular disease in patients with chronic Kidney disease (O). Fewpatientswithchronickidneydiseasehavebeenincludedinclinicaltrialswith hardcardiovascularendpoints. Intheabsenceofthishighlevelevidence, extrapolation ofevidencefromclinicaltrialresultsinthegeneralpopulationtopatientswithchronic kidneydiseaseisnecessary. Severallinesofreasoningsupportthisprocess. First, traditionalCVDriskfactorscanbemodifiedinpatientswithchronickidneydisease. Clearly, antihypertensiveagentsareeffectiveinloweringbloodpressure. Lipidparameterscan be improved with dietary and pharmacologic therapy. Smoking cessation programs shouldbenolesseffectiveinpatientswithchronickidneydiseasethaninthegeneral population. Second, adverse effectsofrisk factorreductiondo notappear substantiallygreater inpatientswithchronickidneydiseasethaninthegeneralpopulation. Third, thelifespanofmostpatientswithchronickidneydiseaseoftenexceedsthe durationoftreatmentrequiredforbeneficialeffects. Inthegeneralpopulation, thebeneficialeffectofriskfactorreductiononmorbidityandmortalitybeginstoappearwithin 1to3yearsorlessinhighriskgroups. Forexample, survivalcurvesforhighriskpatients randomizedtolipidloweringtherapyfrequentlydivergefromplacebotreatedpatients within6monthsofthestartoftreatment. Thelife-spanofmostpatientswithchronic kidneydiseaseexceeds1to3years. Treatmentrecommendations arebeyond thescope ofthis guideline. The readeris referredtotheNKFTaskForceReport9forasummaryoftreatmentrecommendations fortraditionalCVDriskfactorsinchronickidneydisease, andtoforthcomingK/DOQI guidelinesonCKD-relatedCVDriskfactors. LIMITATIONS Thevarietyofmeasuresusedtoassesskidneyfunctionhasplacedasignificantlimitation onthiscurrentreview. ThisisparticularlytruefortheassessmentofCVDriskassociated withreducedGFR. AsamarkerforGFR, serumcreatininewasusedinmoststudies. The limitations withserum creatininemeasurements havebeen describedpreviously. Few studies provided data on Creatinine clearance, and no prospective studies provided a more accurate measureof glomerular filtration rate than serum Creatinine. As a result, itwas not possible toquantifytheprevalenceofcardiovasculardiseaseorCVDriskfactorsbystageofkidney disease. Furthermore, theriskforfutureCVDeventscouldnotbedefinedbystageof kidneydisease. AsimilarproblemwasfoundduringtheassessmentofCVDriskassociated withalbuminuria. Olderstudiesuseddipsticksonrandomurines. Somedipsticksmeasuredtotalprotein, whileothersmeasuredalbuminexcretion. Morerecentstudieshave quantifiedalbuminexcretionwithmorestandardizedtechniques. Thevariabilityinurine proteinmeasurementmakescomparisonsbetweenstudiesdifficult. Inaddition, fewstudiesprovidedanalysesstratifiedbydiabetesstatus. Incontrastto 248 Part7. Stratification NationalKidneyFoundation potassium/DOQI theliteratureonCVDriskindiabetickidneydisease, fewgeneralizablestudieshavebeen publishedonCVDriskspecificallyinnondiabeticindividualswithchronickidneydisease. Toouradvantage, manyofthestudiesreviewedincludedlessthan10%diabeticpatients. TheWorkGroupagreedtoextrapolateresultsfromthesemixedsamples, limitingassessmentstoqualitativestatements. CLINICALAPPLICATIONS TraditionalCVDriskfactorsappeartobesharedriskfactorsforbothchronickidney diseaseandcardiovasculardiseaseandthereforeareinhighprevalenceinchronickidney disease. Therefore, itisessentialtodevelopinterdisciplinaryprogramsfordetectionand treatmentoftraditionalriskfactors, emphasizingtheinter-relationshipsamongdiabetes, cardiovasculardisease, andkidneydisease. IMPLEMENTATIONISSUES Physician, allied health, and patient education initiatives are necessary to ensure that patientswith chronickidneydiseaseare recognizedtobe athighrisk forfutureCVD events, irrespectiveofdiagnosis. CoordinatedpatientmanagementsystemswillbenecessarytoappropriatelyrecognizeandmanageCVDriskfactorsinthispatientpopulation. RESEARCHRECOMMENDATIONS A large prospective multi-ethnic cohort study involving patients with Stage 3 and 4 chronickidneydiseaseisnecessarytofurtherexaminetheimpactoftraditionaland kidneydisease-relatedriskfactorsonincidentcardiovasculardisease. Emphasisshould beplacedontherecognitionofpotentiallymodifiableriskfactors. Suchastudycould alsodeterminethetimecourseofcardiovasculardiseaseinthechronickidneydisease population. Apredictiveclinicaltool, usingkidneydiseasestageanddiagnosis, riskfactors, and/ orothervariables, shouldbedevelopedtobetterpredictriskinpatientswithchronic kidneydisease. Standardsforthemeasurementofkidneyfunctionandalbuminuriainobservational andcontrolledtrialsshouldbeestablished. potassium/DOQI NationalKidneyFoundation Part7. Stratification 249 PART 8. RECOMMENDATIONS FOR CLINICAL PERFORMANCE MEASURES Clinicalpracticeguidelines(CPGs)aresystematicallydevelopedstatementsbasedon currentprofessionalknowledgetoassistpractitionerandpatientdecisionsaboutappropriate health care for specific clinical circumstances. As such, guidelines define best clinicalpracticesbasedonavailableevidence. Theirtranslationintoclinicalpracticefor useinspecificclinicalcircumstancesiswhatmakesguidelinesrelevant. Passivedisseminationofguidelineshasproventobeoflimitedclinicalutility. Nonadherencetobestclinicalpractices, asarticulatedinCPGs, hasbeenroutinelyobserved. ThetranslationofCPGsintoclinicalpracticerequiresthedevelopmentofamulti-componentlong-termimplementationplan. Acentralcomponentofsuchaplanisthelinkage ofselected guidelinesto continuousquality improvement(CQI) programsto improve outcomeswithinagivenlocalhealthcaredeliverysystem. CQIeffortsrequiremeasurementtools, bothtoquantifythecurrentprocessofcare andtomonitorthesuccessofchangingpracticepatternsonclinicaloutcomes. Clinical performancemeasures(CPMs)aresuchtools. TherationaleforCPMs, theessentialsteps in their development, and the attributes of well-designed CPMs have been described. 653, 654 ThefirststepinthedevelopmentofCPMsistheprioritizationofCPGs, incollaborationwiththeWorkGroupthatdevelopedtheguidelines. Followingareguidelinestatementsrecommended bytheCKDWork Groupforpotential useinCQI andCPMand examplesofCPMthatcouldbedevelopedfromthem(Table137). Aspecialsubcommittee of the Advisory Board, chaired by Alan S. Kliger, MD, is assessing feasibility and exploringopportunitiesfordevelopingtheserecommendationsforfutureuseasCPMs. PROPOSED CLINICAL PERFORMANCE MEASURES FOR CHRONIC Kidney DISEASE Guideline 2 Preparation for Kidney replacement therapy (Dialysis and transplantation), as well as vascularaccesscare, shouldbeinitiatedwhentheestimatedGFRdeclinesto(cid: 1)30mL/ min/1. 73m2. Guideline 3 Individualsatincreasedriskforchronickidneydiseaseshouldbetestedatthetimeof a health evaluations to determine if they have chronic Kidney disease. These include individualswith: Diabetes; Hypertension; Autoimmunediseases; Systemicinfections; Exposuretodrugsorproceduresassociatedwithacutedeclineinkidneyfunction; Recoveryfromacutekidneyfailure; potassium/DOQI NationalKidneyFoundation Part8. RecommendationsforMeasures 251 Age(cid: 2)60years; Familyhistoryofkidneydisease; Reducedkidneymass(includeskidneydonorsandtransplantrecipients). Measurementsshouldinclude: SerumcreatinineforestimationofGFR; 252 Part8. RecommendationsforMeasures NationalKidneyFoundation potassium/DOQI Assessmentofproteinuria; Urinarysedimentorurinedipstickforredbloodcellsandwhitebloodcells. Guideline 4 EstimatedGFRshouldbetheparameterusedtoevaluatethelevelofkidneyfunction. Guideline 5 Theratioofproteinoralbumintocreatinineinspoturinesamplesshouldbemonitored inallpatientswithchronickidneydisease. Guideline 7 Bloodpressureshouldbemonitoredinallpatientswithchronickidneydisease. Highbloodpressureshouldbeevaluatedandtreatedaccordingtoestablishedguidelines, suchasJNC-VIandADA. Guidelines 812 PatientswithGFR(cid: 1)60mL/min/1. 73m2shouldbeevaluatedandtreatedforcomplicationsofdecreasedGFR. Thisincludesmeasurementof: Anemia(hemoglobin); Nutritionalstatus(dietaryenergyandproteinintake, weight, serumalbumin, serum totalcholesterol); Bonedisease(parathyroidhormone, calcium, phosphorus); Functioningandwell-being(questionnaires). Guideline 13 EstimatedGFRshouldbemonitoredyearlyinpatientswithchronickidneydisease, and morefrequentlyinpatientswith: glomerular filtration rate(cid: 1)60mL/min/1. 73m2 FastGFRdeclineinthepast((cid: 1)4mL/min/1. 73m2) Riskfactorsforfasterprogression Ongoingtreatmenttoslowprogression ExposuretoriskfactorsforacuteGFRdecline. Guideline 14 Individuals with diabetic Kidney disease are at higher risk of diabetic complications, includingretinopathy, cardiovasculardisease, andneuropathy. Theyshouldbeevaluatedandmanagedaccordingtoestablishedguidelines. Guideline 15 Individualswithchronickidneydiseaseareatincreasedriskofcardiovasculardisease. Theyshouldbeconsideredinthehighestriskgroupforevaluationandmanagement accordingtoestablishedguidelines. potassium/DOQI NationalKidneyFoundation Part8. RecommendationsforMeasures 253 PART 9. APPROACH TO CHRONIC Kidney DISEASE USING THESE GUIDELINES INTRODUCTION Theworkgroupexpandedonselectedclinicaltopicsthatwerenotincludedinthescope ofthereviewofevidence, butwhichnonethelessarerelevanttotheimplementationof a clinical action plan for patients with chronic Kidney disease. The clinical approach outlined below is based on guidelines contained within this report; the reader is cautioned that many of the recommendations in this section have not been adequately studiedandthereforerepresenttheopinionofmembersoftheWorkGroup. DETECTION OF CHRONIC Kidney DISEASE Assessment of Risk Allindividualsshouldbeevaluatedduringhealthencounterstodeterminewhetherthey are at increased risk of having or of developing chronic Kidney disease. Guideline 3 lists risk factors for susceptibility to and initiation of chronic Kidney disease (chronic kidney disease risk factors).",
    "word_count": 596,
    "char_count": 11142,
    "sentence_count": 106,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 52,
      "total_chunks": 77,
      "position": "53/77",
      "content_type": "evidence",
      "content_type_confidence": 8,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "creatinine",
        "potassium",
        "calcium",
        "phosphorus",
        "hemoglobin",
        "serum creatinine",
        "dialysis",
        "anemia"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 53,
    "text": "Guideline 3 lists risk factors for susceptibility to and initiation of chronic Kidney disease (chronic kidney disease risk factors). Ascertainment of risk factors through assessment of sociodemographic characteristics, reviewofpastmedicalhistoryandfamilyhistory, andmeasurementof bloodpressurewouldenablethecliniciantodeterminewhetherapatientisatincreased risk. Patientswhoarefoundtobeatincreasedriskshouldbeevaluatedfurther. Clinical Evaluation of Patients at Increased Risk Clinicalevaluationofpatientsatincreasedriskofchronickidneydiseaseincludesassessmentofmarkersofkidneydamage, estimatedGFR, andbloodpressure(Table138). Unfortunately, thesemarkersdonotdetectalltypesofchronickidneydamage. Thus, itmaybedifficulttodetecttheonsetofsometypesofchronickidneydiseaseuntilGFR isdecreased, forexample, hypertensivenephrosclerosisandnoninflammatorytubulointerstitialdiseases. Testing for Proteinuria The algorithms recommended by National Kidney Foundation PARADE distinguish between individuals at increasedforchronickidneydiseaseversusasymptomatic, healthyindividuals. ThesealgorithmshavebeenmodifiedbytheWorkGroupwithinputfrommembersofthePARADE WorkGroup(Fig57). Thealgorithmforadultsandchildrenatincreasedrisk(rightside) beginswithtestingofarandomspoturinesamplewithanalbumin-specificdipstick. Alternatively, testingcouldbeginwithaspoturinesampleforalbumin-to-creatineratio. Thealgorithmforasymptomatichealthyindividuals(leftside)doesnotrequiretesting specificallyforalbumin. Thisalgorithimisusefulforchildrenwithoutdiabetes, inwhom universalscreeningisrecommended. Universalscreeningisnotcurrentlyrecommended foradults. DIFFERENTIAL DIAGNOSIS OF CHRONIC Kidney DISEASE Clinical Presentation Table139showstherelationshipbetweenstagesofchronickidneydiseaseandclinical presentations. DuringthestageAtIncreasedRiskandStage1(KidneyDamage), spepotassium/DOQI NationalKidneyFoundation Part9. Approach 255 Fig57. Evaluationofproteinuriainpatientsnotknowntohavekidneydisease. ModifiedfromNKFPARADE. NKFPARADEdoesnotusegender-specificdefinitionsforabnormalalbumin-to-creatinineratio. Modifiedwithpermission. 6 256 Part9. Approach NationalKidneyFoundation potassium/DOQI cific diseases are associated with specific risk factors and are manifested by specific clinical presentations, although markers for each diagnosis have not been discovered. DuringStages2through4(DecreasedGFR)andStage5(KidneyFailure), differentdiseasesmayhavesimilarclinicalpresentations, althoughmarkersofkidneydamagemay persistandprovidecluestodiagnosis. Simplified Classification of Chronic Kidney Disease Diseasesofthekidneyareclassifiedaccordingtoetiologyandpathology. Asimplified classificationisgiveninTable140. potassium/DOQI NationalKidneyFoundation Part9. Approach 257 Definitivediagnosisoftenrequiresabiopsyofthekidney, whichisassociatedwith arisk, albeitusuallysmall, ofseriouscomplications. Therefore, kidneybiopsyisusually reservedforselectedpatientsinwhomadefinitivediagnosiscanbemadeonlybybiopsy and in whom a definitive diagnosis would result in a change in either treatment or prognosis. Inmostpatients, diagnosisisassignedbasedonrecognitionofwell-defined clinicalpresentationsandcausalfactorsbasedonclinicalevaluation. Clinical Evaluation Chronickidneydiseaseisusuallysilent. Therefore, clinicalassessmentreliesheavilyon laboratoryevaluation anddiagnostic imaging. Nonetheless, a carefulhistory willoften revealcluestothecorrectdiagnosis(Table141). Bloodpressuremeasurementisessential, butotherelementsofthephysicalexaminationareusuallynothelpful, exceptto assess comorbid conditions and complications of decreased glomerular filtration rate. A number of drugs canbeassociatedwithchronickidneydamage, soathoroughreviewofthemedication list (including prescribed medications, over-the-counter medications, nontraditional medications, vitamins andsupplements, herbs, and drugsofabuse)is vital. Moreover, medicationswillrequireadjustmentindosageordiscontinuationbasedonthelevelof glomerular filtration rate. 258 Part9. Approach NationalKidneyFoundation potassium/DOQI Laboratory Evaluation Laboratoryevaluationinallpatientswithchronickidneydiseaseshouldbeperformed (Table142). Guideline 6 provides a guide to interpretation of proteinuria and Urine sediment abnormalitiesandfindingsonimagingstudiesasmarkersofkidneydamageandadefinitionofclinicalpresentations. Basedonthesemeasurements, thecliniciancanusuallydefinetheclinicalpresentation, therebynarrowingthedifferentialdiagnosisandguidingfurtherdiagnosticevaluation, decisionsaboutkidneybiopsy, and, often, decisionsabouttreatmentandprognosis withnoneedforkidneybiopsy. Relationships Among Type and Stage of Kidney Disease and Clinical Presentations Tables143, 144, and145showtherelationshipsbetweenstageofkidneydiseaseand clinical features for diabetic Kidney disease, nondiabetic Kidney diseases, and diseases inthekidneytransplant. potassium/DOQI NationalKidneyFoundation Part9. Approach 259 Utility of Proteinuria in Diagnosis, Prognosis, and Treatment Proteinuriaisakeyfindinginthedifferentialdiagnosisofchronickidneydisease. Proteinuriaisamarkerofdamageindiabetickidneydisease(Table143), inglomerulardiseases occurring in the native Kidney (Table 144), and in transplant glomerular disease and recurrentglomerulardiseaseinthetransplant(Table145). Inthesediseases, themagnitudeofproteinuriaisusually(cid: 1)1, 000mg/g(exceptinearlydiabetickidneydisease), and mayapproachnephroticrange(spoturineprotein-to-creatinineratio(cid: 1)3, 000mg/g). On theotherhand, proteinuriaisusuallymildorabsentinvasculardiseases, tubulointerstitial diseases, andcysticdiseasesinthenativekidneyandinrejectionanddrugtoxicitydue tocyclosporineortacrolimusinthetransplant. Proteinuria is also a key prognostic finding. It is well-known that nephrotic range proteinuria is associated with a wide range of complications, including hypoalbuminemia, Edema, hyperlipidemia, andhypercoagulablestate; fasterprogressionofkidney disease; andprematurecardiovasculardisease. However, itisnowknownthatelevated urineproteinexcretionbelowthenephroticrangeisalsoassociatedwithfasterprogression of Kidney disease and development of cardiovascular disease. Furthermore, the reductioninproteinuriaiscorrelatedwithasubsequentslowerlossofkidneyfunction. Finally, proteinuriaisalsoaguidetotherapy. Thebenefitofantihypertensivetherapy, especially with angiotensin-converting enzyme inhibitors, to slow the progression of kidneydiseaseisgreaterinpatientswithhigherlevelsofproteinuriacomparedtopatients withlowerlevelsofproteinuria. 260 Part9. Approach NationalKidneyFoundation potassium/DOQI Insummary, proteinuriaisnotonlyamarkerofkidneydamage, itisalsoaguideto thedifferentialdiagnosis, prognosis, andtherapyofchronickidneydisease. ESTIMATING AND SLOWING PROGRESSION OF CHRONIC Kidney DISEASE IN ADULTS Guideline13reviewsestimatingdeclineinGFRandtreatmentstoslowtheGFRdecline inadults. Ingeneral, GFRshouldbeestimatedfromserumcreatinineatleastyearlyin patientswithchronickidneydiseaseandmoreofteninpatientswith: glomerular filtration rate(cid: 2)60mL/min/1. 73m2 FastGFRdeclineinthepast((cid: 1)4mL/minperyear) Riskfactorsforfasterprogression Ongoingtreatmenttoslowprogression ExposuretoriskfactorsforacuteGFRdecline. Treatmentstoslowtheprogressionofchronickidneydiseaseinadultsinareshown inTable146. CARDIOVASCULAR DISEASE RISK ASSESSMENT AND REDUCTION Guideline 15 concludes that patients with chronic Kidney disease have a High risk of adverseoutcomesofcardiovasculardiseaseandshouldbeconsideredinthehighestriskgroupforcardiovasculardiseaseriskreduction. However, fewpatientswithchronic kidneydiseasehavebeenincludedinpopulation-basedepidemiologicstudiesofcardiovasculardiseaseorlong-termrandomizedclinicaltrials. TheNKFTaskForceonCardiovascular Disease in Chronic Renal Disease recommended risk factor reduction for traditional risk factors based largely on extrapolation from the general population and evidenceofsafetyandefficacyofinterventionsonriskfactorlevelsinchronickidney disease. ItwastheopinionoftheCVDTaskForceandtheCKDWorkGroupthatextrapolationfromthegeneralpopulationtopatientswithchronickidneydiseaseismostappro- priateforpatientswithhigherlevelsofGFR(Stages1through4)andless(butpossibly still)appropriateforpatientswithkidneyfailure(Stage5). Apartiallistoftraditional potassium/DOQI NationalKidneyFoundation Part9. Approach 261 cardiovasculardiseaseriskfactorsandriskfactorreductionstrategiesthatarepotentially safeandeffectiveforpatientswithchronickidneydiseaseisshowninTable147. CLINICAL EVALUATION OF ADULTS WITH glomerular filtration rate (cid: 2)60 milliliters per minute/ 1. 73 m2 (chronic kidney disease STAGES 35) Guidelines7through12showtheassociationsbetweenlevelofGFRandcomplications ofchronickidneydiseaseinadults. ManycomplicationsbegintooccuratGFR(cid: 2)60mL/ min/1. 73m2. Table148listsadditionalclinicalevaluations(inadditiontotheoneslisted inTables105and142)thatshouldbeperformedinadultswithGFR(cid: 2)60mL/min/1. 73 m2. DECREASED glomerular filtration rate AND CHRONIC Kidney DISEASE IN THE ELDERLY Guideline1definesadecreaseinGFRof60to89mL/min/1. 73m2aschronickidney diseaseonly ifaccompanied bya markerof kidneydamage. GFRdeclines withage in normal individuals; therefore, it can be difficult to distinguish age-related decrease in GFRfromchronickidneydiseaseintheelderly. Othercausesofchronicallydecreased GFRinnormalindividualswithoutchronickidneydiseaseincludeahabituallylowprotein intakeandunilateralnephrectomy. DatafromNHANESIIIsuggestthatalmost75%ofindividuals(cid: 1)70yearsoldmayhave 262 Part9. Approach NationalKidneyFoundation potassium/DOQI glomerular filtration rate(cid: 2)90mL/min/1. 73m2, andalmost25%mayhaveGFR(cid: 2)60mL/min/1. 73m2. The fractionofelderlyindividualswithdecreasedGFRwhotrulyhavechronickidneydisease hasnotbeensystematicallystudied. Moreover, thehealthoutcomesofdecreasedGFR intheelderly, withorwithoutchronickidneydisease, arealsonotknown. ClinicalevaluationofelderlyindividualswithGFRof60to89mL/min/1. 73m2should includeanassessmentforchronickidneydisease(Table149). AdditionalitemsforclinicalevaluationofindividualswithGFR(cid: 2)60mL/min/1. 73m2 arelistedinTable148.",
    "word_count": 584,
    "char_count": 10131,
    "sentence_count": 83,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 53,
      "total_chunks": 77,
      "position": "54/77",
      "content_type": "treatment",
      "content_type_confidence": 7,
      "medical_entities": [
        "chronic kidney disease",
        "glomerular filtration rate",
        "proteinuria",
        "potassium",
        "edema",
        "cardiovascular disease",
        "guideline",
        "classification"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 54,
    "text": "73m2, andalmost25%mayhaveGFR(cid: 2)60mL/min/1. 73m2. The fractionofelderlyindividualswithdecreasedGFRwhotrulyhavechronickidneydisease hasnotbeensystematicallystudied. Moreover, thehealthoutcomesofdecreasedGFR intheelderly, withorwithoutchronickidneydisease, arealsonotknown. ClinicalevaluationofelderlyindividualswithGFRof60to89mL/min/1. 73m2should includeanassessmentforchronickidneydisease(Table149). AdditionalitemsforclinicalevaluationofindividualswithGFR(cid: 2)60mL/min/1. 73m2 arelistedinTable148. ItistheopinionofthemembersoftheWorkGroupthatclinicalinterventionsfor the elderly with chronic Kidney disease should be based on diagnosis (as described above), severityofkidneyfunctionimpairment, andstratificationofriskforprogression potassium/DOQI NationalKidneyFoundation Part9. Approach 263 of Kidney disease and cardiovascular disease. There is a spectrum of risk for adverse outcomes. PatientswithmilddecreasedGFR, lowriskforprogressivedeclineinGFR, andlow riskforcardiovasculardiseasehaveagoodprognosisandmayrequireonlyadjustment ofthedosageofdrugsthatareexcretedbythekidney, monitoringofbloodpressure, avoidance of drugs and pro! -! cedures with risk for acute Kidney failure, and life-style modificationstoreducetheriskofcardiovasculardisease. Consultationwithanephrologist may be necessary to establish the diagnosis and treatment of the type of Kidney disease. Kidneyfunctionshouldbemonitoredatleastyearly. PatientswithmoderatelyorseverelydecreasedGFRorriskfactorsforfasterdecline inGFRorcardiovasculardiseasehaveaworseprognosis. Inadditiontotheinterventions mentionedabove, theyrequireassessmentforcomplicationsofdecreasedGFRanddietaryandpharmacologictherapydirectedatslowingtheprogressionofkidneydisease andamelioratingcardiovascularriskfactorlevels. Consultationand/orco-management withakidneydiseasecareteamisadvisableduringStage3, andreferraltoanephrologist inStage4isrecommended. Kidneyfunctionmayneedtobemonitoredfourtimesper year or more. A multidisciplinary team approach may be necessary to implement and coordinatecare. 264 Part9. Approach NationalKidneyFoundation potassium/DOQI PART 10. APPENDICES APPENDIX 1. METHODS FOR REVIEW OF ARTICLES AIMS Theoverall aimofthe projectwasto developaclassification ofthestages ofchronic kidneydisease, irrespectiveoftheunderlyingcauseofthekidneydisease, andaclinical actionplanfortheevaluationandtreatmentofchronickidneydisease. Thisclassification couldthenbetransformedtoanevidencemodelforfuturedevelopmentofadditional practice guidelines regarding specific diagnostic evaluations and therapeutic interventions(ExecutiveSummary). The Work Group sought to develop an evidence base for the classification and clinicalactionplan, derivedfromasystematicsummaryoftheavailablescientificliteratureon: theevaluationoflaboratorymeasurementsfortheclinicalassessmentofkidney disease; associationofthelevelofkidneyfunctionwithcomplicationsofchronickidney disease; and stratification of the risk for loss of Kidney function and development of cardiovasculardisease. Twoproductsweredevelopedfromthisprocess: asetofclinicalpracticeguidelines regardingtheclassificationandactionplan, whicharecontainedinthisreport; andan evidencereport, whichconsistsofthesummaryoftheliterature. Portionsoftheevidence reportarecontainedinthisreport. TheentireevidencereportisonfilewiththeNational KidneyFoundation. OVERVIEW OF PROCESS Developmentoftheguidelineandevidencereportrequiredmanyconcurrentsteps: FormtheWorkGroupandEvidenceReviewTeamthatwouldberesponsiblefor differentaspectsoftheprocess; Holdmeetingstodiscussprocess, methods, andresults; Developandrefinetopics; Definepopulationofinterest; Createdraftguidelinestatementsandrationales; Createdraftsummarytables; Createdataextractionforms; Createandstandardizequalityassessmentmetrics; Developliteraturesearchstrategies; Performliteraturesearches; Screenabstractsandretrievefullarticles; Reviewliteraturebyprimaryandsecondaryreviewers; Extractdataandperformcriticalappraisaloftheliterature; Tabulatedatafromarticlesintosummariesandcreatesummarygraphics; Writeguidelinestatementsandrationalesbasedonliterature. potassium/DOQI NationalKidneyFoundation Part10. Appendices 265 CREATION OF GROUPS TheCo-ChairsoftheK/DOQIAdvisoryBoardselectedtheWorkGroupChairandDirector of the Evidence Review Team, who then assembled groups to be responsible for the developmentoftheguidelinesandtheevidencereport, respectively. Thesegroupscollaboratedcloselythroughouttheproject. TheWorkGroupconsistedofdomainexperts, includingindividualswithexpertise in nephrology, epidemiology, laboratory medicine, nutrition, social work, pathology, gerontology, and family medicine. In addition, the Work Group had liaison members from the National Institute of Diabetes, Digestive and Kidney Diseases and from the NationalInstituteonAging. Midwaythroughtheproject, attherequestoftheK/DOQI Advisory Board, the Work Group expanded the target population to include children andinvitedadditionalmemberswithexpertiseinpediatricnephrology. Thefirsttaskof theWorkGroupmemberswastodefinetheoveralltopicandgoals, includingspecifying thetargetcondition, targetpopulation, andtargetaudience. Theythenfurtherdeveloped andrefined eachtopic, literaturesearch strategy, anddataextraction form(described below). TheWorkGroupmembersweretheprincipalreviewersoftheliterature, and fromthesedetailedreviewstheysummarizedtheavailableevidenceandtooktheprimary rolesofwritingtheguidelinesandrationalestatements. TheEvidenceReviewTeamconsistedofnephrologists(oneseniornephrologistand threenephrologyfellows)andmethodologistsfromNewEnglandMedicalCenterwith expertiseinsystematicreviewofthemedicalliterature. Theywereresponsibleforcoordinating the project, including coordinating meetings, refinement of goals and topics, creationoftheformatoftheevidencereport, developmentofliteraturesearchstrategies, initialreviewandassessmentofliterature, andcoordinationofallpartners. TheEvidence ReviewTeamalso coordinatedthemethodologicalandanalyticprocess ofthereport, coordinatedthemeetings, anddefinedandstandardizedthemethodologyofperforming literaturesearches, ofdataextraction, andofsummarizingtheevidenceinthereport. Theyperformedliteraturesearches, retrievedandscreenedabstractsandarticles, created formstoextractrelevantdatafromarticles, andtabulatedresults. Throughouttheproject, and especially at meetings, the Evidence Review Team led discussions on systematic review, literaturesearches, dataextraction, assessmentofqualityofarticles, andsummary reporting. Inaddition, amemberoftheEvidenceReviewTeam(BCA)atJohnsHopkins MedicalInstitutionsassistedDr. CoreshinanalysisofNHANESIIIdata. DEVELOPMENT OF TOPICS The goals of the Work Group spanned a diverse group of topics, which would have beentoolargeforacomprehensivereviewoftheliterature. Basedontheirexpertise, members of the Work Group focused on the specific questions listed in Table 8 and employedaselectivereviewofevidence: asummaryofreviewsforestablishedconcepts (reviewoftextbooks, reviews, guidelines, andselectedoriginalarticlesfamiliartothem asdomainexperts)andareviewofprimaryarticlesanddatafornewconcepts. 266 Part10. Appendices NationalKidneyFoundation potassium/DOQI REFINEMENT OF TOPICS AND DEVELOPMENT OF MATERIALS TheWorkGroupandEvidenceReviewTeamdeveloped(a)draftguidelinestatements; (b)draftrationalestatementsthatsummarizedtheexpectedpertinentevidence; (c)mock summarytablescontainingtheexpectedevidence; and(d)dataextractionformsrequestingthedataelementstoberetrievedfromtheprimaryarticlestocompletethetables. The development process included creation of initial mock-ups by the Work Group ChairandEvidenceReviewTeamfollowedbyiterativerefinementbytheWorkGroup members. The refinement process began prior to literature retrieval and continued through the start of reviewing individual articles. The refinement occurred by e-mail, telephone, andin-personcommunicationregularlywithlocalexpertsandwithallexperts duringin-personmeetingsoftheEvidenceReviewTeamandWorkGroupmembers. Dataextractionformsweredesignedtocaptureinformationonvariousaspectsofthe primaryarticles. Formsforalltopicsincludedstudysettinganddemographics, eligibility criteria, causes of Kidney disease, numbers of subjects, study design, study funding source, population category (see below), study quality (based on criteria appropriate for each study design, see below), appropriate selection and definition of measures, results, andsectionsforcommentsandassessmentofbiases. The various steps involved in development of the guideline statements, rationale statements, tables, anddataextractionformswerepilotedononeofthetopics(bone disease)withaWorkGroupmemberatNewEnglandMedicalCenter. Thein-person pilot experience allowed more efficient development and refinement of subsequent formswithWorkGroupmemberslocatedatotherinstitutions. ItalsoprovidedexperienceinthestepsnecessaryfortrainingjuniormembersoftheEvidenceReviewTeam todevelop formsand toefficiently extractrelevant informationfrom primaryarticles. TrainingoftheWorkGroupmemberstoextractdatafromprimaryarticlessubsequently occurredbye-mailaswellasatmeetings. RELEVANCE AND APPROPRIATENESS OF STUDY DESIGNS Throughouttheprocessofrefinementoftopics, thetypesofstudydesignthatwould be relevant and appropriate to answer the questions posed in Table 8 were carefully considered. Classification of Stages Definingthestagesofseveritywasaniterativeprocess, basedonexpertiseoftheWork Groupmembersandsynthesisofevidencedevelopedduringthesystematicreview. After definingthestagesofseverity, itwasnecessarytoestimatetheprevalenceofeachstage (albuminuriaorproteinuriaasamarkerofkidneydamage, decreasedGFR, kidneyfailure) inthegeneralpopulation. Theidealstudydesigntoassessprevalencewouldbeacrosssectionalstudyofpopulationrepresentativeofthegeneralpopulation. Criteriaforevaluation of cross-sectional studies to assess prevalence are listed in Table 150.",
    "word_count": 598,
    "char_count": 9873,
    "sentence_count": 65,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 54,
      "total_chunks": 77,
      "position": "55/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "kidney function",
        "kidney failure",
        "potassium",
        "nutrition",
        "bone disease",
        "cardiovascular disease",
        "guideline",
        "classification"
      ],
      "entity_count": 9
    }
  },
  {
    "chunk_id": 55,
    "text": "After definingthestagesofseverity, itwasnecessarytoestimatetheprevalenceofeachstage (albuminuriaorproteinuriaasamarkerofkidneydamage, decreasedGFR, kidneyfailure) inthegeneralpopulation. Theidealstudydesigntoassessprevalencewouldbeacrosssectionalstudyofpopulationrepresentativeofthegeneralpopulation. Criteriaforevaluation of cross-sectional studies to assess prevalence are listed in Table 150. Data from NHANESIIIwerefortunatelyavailableforsomeoftheseanalyses. ThemethodsforanalysisofdatafromNHANESIIIaredescribedinAppendix2. Inaddition, articlesfromstudies of community screening were included. For these studies, the relevant result is the potassium/DOQI NationalKidneyFoundation Part10. Appendices 267 estimateofprevalence, expressedasapercent, withtheabsolutenumberofindividuals derivedbyextrapolationtotheUSpopulation, wherepossible. Evaluation of Laboratory Tests Evidencewasrequiredtoassesstheperformanceofdiagnostictests(predictionequations for glomerular filtration rate, spot Urine samples for Protein-to-Creatinine and albumin-to-Creatinine ratios, and new urinary markers of Kidney damage) for the evaluation of severity of chronic kidneydisease. Theidealstudydesignfordiagnostictestevaluationwouldbeacrosssectionalstudyofarepresentativesampleofpatientswhoaretestedusingthegold 268 Part10. Appendices NationalKidneyFoundation potassium/DOQI (criterion)standardaswellasthenewertest. CriteriaforevaluationofstudiesofdiagnostictestsarelistedinTable151. 655Forthesestudies, therelevantresultisthemeasure ofperformance(biasandprecision)ofthenewtest. Association of Level of glomerular filtration rate With Complications TheappropriatestudytoassesstheassociationoflevelofGFRwithcomplicationswould be a cross-sectional study of a representative sample of patients with chronic Kidney diseaseinwhomthelevelofkidneyfunctionisrelatedtothepresenceorabsenceor severityofacomplication. Inaddition, baselinedatafromalongitudinalstudywouldbe appropriate. Principlesofcross-sectionalstudiestoassessassociationsaredescribedin potassium/DOQI NationalKidneyFoundation Part10. Appendices 269 Table152. Forsomecomplications, datafromNHANESIIIwereavailable. However, the NHANESIIIdatabaseincludesrelativelyfewpatientswithseverelydecreasedGFR(15 to 29 milliliters per minute/1. 73 m2); therefore, it was also desirable to use cross-sectional studies, baselinedatafromlongitudinalstudies, andcaseseriesofpatientswithdecreasedGFR. DatafrombaselineassessmentsofpatientsenrolledintheCanadianMulticentrecohort studyofpatientswithchronickidneydiseasewereusedforFigures28, 29, 36, 37, 38, 40, and42. 288Datafromall446patientsenrolledfrom1994to1997wereavailable. Studiesthatprovideddataforvariouslevelsofkidneyfunctionwerepreferred; how270 Part10. Appendices NationalKidneyFoundation potassium/DOQI ever, ifdataweresparse, studiesthatprovidedonlythemeanlevelofkidneyfunction wereincluded. MembersoftheWorkGroupprovidedindividualpatientdatathatwere usedforsomeanalyses. Stratification of Risk (Prognosis) Theappropriatestudytoassesstherelationshipofriskfactorstolossofkidneyfunction anddevelopmentofcardiovasculardiseasewouldbealongitudinalstudyofarepresentativesampleofpatientswithchronickidneydiseasewithprospectiveassessmentoffac- torsatbaselineandoutcomesduringfollow-up. Becauseitcanbedifficulttodetermine theonsetofchronickidneydiseaseandcardiovasculardisease, prospectivecohortstudies were preferredto case-control studies or retrospective studies. Clinical trials were included, with the understanding that the selection criteria for the clinical trial may haveleadtoanon-representativecohort. Criteriaforevaluatingstudiesofprognosisare describedinTable153. 656Ofparticularimportanceismultivariableanalysistocontrol forconfoundingbyfactorsotherthanthevariablesofinterest(forexample, confounding byageinstudiesoffactorsrelatedtocardiovasculardiseaseevents). Becauseofthewellpotassium/DOQI NationalKidneyFoundation Part10. Appendices 271 knownassociationbetweendiabetesandcardiovasculardisease, diabeticandnondiabetic patients were considered separately. The association between diabetic Kidney disease andotherdiabeticcomplicationswasevaluatedusingreviewsofcross-sectionalstudies and selected primary articles of cohort studies. The association between nondiabetic kidneydiseaseandcardiovasculardiseasewasevaluatedusingseveralstrategies: reviews and selected primary articles of incidence rates of cardiovascular disease in patients withnondiabetickidneydisease; reviewsandselectedprimaryarticlesofcross-sectional studiesoftheprevalenceofriskfactorlevelsinpatientswithnondiabetickidneydisease; andasystematicsearchforcohortstudiesoftherelationshipbetweenalbuminuriaor proteinuriaanddecreasedGFRwithsubsequentcardiovasculardiseaseeventsinnondiabeticindividuals. LITERATURE SEARCH TheWorkGroupandEvidenceReviewTeamdecidedinadvancethatasystematicprocesswouldbefollowedtoobtaininformationontopicsthatreliedonprimaryarticles. In general, onlyfulljournalarticlesoforiginaldatawereincluded. Reviewarticles, editorials, letters, orabstractswerenotincluded(exceptasnoted). Thoughreportsofformalstudies werepreferred, caseserieswerealsoincluded. Nosystematicprocesswasfollowedto obtaintextbooksandreviewarticles. StudiesfortheliteraturereviewwereidentifiedprimarilythroughMedlinesearches of English language literature conducted between February and June 2000. These searches were supplemented by relevant articles known to the domain experts and reviewers. TheMedlineliteraturesearcheswereconductedtoidentifyclinicalstudiespublished from1966throughthesearchdates. Separatesearchstrategiesweredevelopedforeach topic. Developmentofthesearchstrategieswasaniterativeprocessthatincludedinput fromallmembersoftheWorkGroup. Searchstrategiesweredesignedtoyieldapproximately1, 000to2, 000titleseach. ThetextwordsorMeSHheadingsforalltopicsincluded kidneyorkidneydiseasesorkidneyfunctiontests. Thesearcheswerelimitedtostudies onhumansandpublishedinEnglishandfocusedoneitheradultsorchildren, asrelevant. In general, studies that focusedon hemodialysis or peritoneal Dialysis were excluded. TheMedlinesearchstrategiesareincludedintheEvidenceReport. Medlinesearch resultswerescreened byclinicianson theEvidence ReviewTeam. Potentialpapersforretrievalwereidentifiedfromprintedabstractsandtitles, basedon study population, relevance to topic, and article type. In general, studies with fewer than10subjectswerenotincluded(exceptasnoted). Afterretrieval, eachpaperwas screenedtoverifyrelevanceandappropriatenessforreview, basedprimarilyonstudy designandascertainmentofnecessaryvariables. Somearticleswererelevanttotwoor moretopics. Agoalwassetofapproximately30articlespertopic. Inmanycases, the goalwasexceeded. Domainexpertsmadethefinaldecisionforinclusionorexclusion of articles. All articlesincluded wereabstracted and containedin theevidence tables. 272 Part10. Appendices NationalKidneyFoundation potassium/DOQI Table154detailstheliteraturesearchandreviewforeachtopic. Overall, 18, 153abstracts werescreened, 1, 110articleswerereviewed, andresultswereextractedfrom367articles. FORMAT FOR EVIDENCE TABLES Two types of evidence tables were prepared. Detailed tables contain data from each fieldofthecomponentsofthedataextractionforms. Thesetablesarecontainedinthe evidence report but are not included inthe manuscript. Summary tables describe the strengthofevidenceaccordingtofourdimensions: studysize, applicabilitydepending onthetypeofstudysubjects, results, andmethodologicalquality(seetableonthenext page, Exampleof FormatforEvidenceTables). Withineachtable, studies areordered firstbymethodologicalquality(besttoworst), thenbyapplicability(mosttoleast), and thenbystudysize(largesttosmallest). Study Size Thestudy(sample)sizeisusedasameasureoftheweightoftheevidence. Ingeneral, largestudiesprovidemorepreciseestimatesofprevalenceandassociations. Inaddition, potassium/DOQI NationalKidneyFoundation Part10. Appendices 273 large studies are more likely to be generalizable; however, large size alone does not guarantee applicability. Astudy that enrolled alarge number of selectedpatients may be less generalizable than several smaller studies that included a broad spectrum of patientpopulations. Applicability Applicability(alsoknownasgeneralizabilityorexternalvalidity)addressestheissueof whetherthestudypopulationissufficientlybroadsothattheresultscanbegeneralized tothepopulationofinterestatlarge. Thestudypopulationistypicallydefinedbythe inclusionandexclusioncriteria. Thetargetpopulationwasdefinedtoincludepatients withchronickidneydiseaseandthoseatincreasedriskofchronickidneydisease, except wherenoted. Adesignationforapplicabilitywasassignedtoeacharticle, accordingto a three-level scale. In making this assessment, sociodemographic characteristics were considered, as werethe statedcausesof chronickidney diseaseandprior treatments. Ifastudyisconsideredtobenotfullygeneralizable, reasonsforlackofapplicabilityare reportedinthedetailedtablesonfileattheNKF. glomerular filtration rate Range Forallstudies, therangeofGFR(orcreatinineclearanceC )isrepresentedgraphically creatinine whenavailable. ThemeanormedianGFRisrepresentedbyaverticalline, withahorizontalbarapproximatingthe95%coverageinterval. Studieswithoutaverticalorhorizontal linedidnotprovidedataonthemean/medianorrange, respectively. Whendatawere available, therangewascalculatedas: Range(cid: 1)meanGFR(cid: 2)1. 96(cid: 3)(standarddeviation). Whensufficientdatawerenotavailable, therangewasestimatedfromthefullrange ofGFRlevelsreported, fromthemedianGFR, orfromavailablegraphs. Forstudiesthat reportedcreatinineclearanceinsteadofGFR, themeanandrangeofcreatinineclearance 274 Part10. Appendices NationalKidneyFoundation potassium/DOQI wereusedtoestimateGFR. ForstudiesthatreportedneitherGFRnorcreatinineclearance, themean level ofserum Creatinine ((cid: 2)standarddeviation and/or range)is listed astext(eg, S (cid: 1)3. 4(cid: 2)0. 3mg/dL). creatinine Results In principle, the study design determined the type of results obtained. For studies of prevalence, the result is the percent of individuals with the condition of interest.",
    "word_count": 590,
    "char_count": 10072,
    "sentence_count": 90,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 55,
      "total_chunks": 77,
      "position": "56/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "glomerular filtration rate",
        "creatinine",
        "potassium",
        "dialysis",
        "hemodialysis",
        "peritoneal dialysis",
        "cardiovascular disease",
        "screening"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 56,
    "text": "For studies of prevalence, the result is the percent of individuals with the condition of interest. For diagnostic test evaluation, the result is the strength of association between the new measurement method and the criterion standard. In addition to evaluating the size of correlations and regression coefficients, bias and precision of glomerular filtration rate estimate equations werealsoconsidered. ForstudiesoftheassociationbetweenthelevelofGFRandcomplications, theresultisdirectionandstrengthoftheassociation. Inadditiontoexamining continuousrelationships(correlationsandregressions), theprevalenceofcomplications forlevelsofGFRcorrespondingtostagesofchronickidneydiseasewereestimated. For studiesofprognosis, theresultisthefactorandthedirectionandstrengthoftheassociapotassium/DOQI NationalKidneyFoundation Part10. Appendices 275 tionbetweentheriskfactorandoutcome. Associationswererepresentedaccordingto thefollowingsymbols: Thespecificmeaningofthesymbolsisincludedasafootnoteforeachtable. For studies that provided only single point estimates (such as the mean value) of complications, those values are presented instead of data on association with level of glomerular filtration rate. Studies that reported strength of association of an outcome with glomerular filtration rate are listed andrankedseparatelyfromthosethatsimplyreportedmeanlevels, withshadingused tovisuallydistinguishthem. Quality Methodologicalquality(orinternalvalidity)referstothedesign, conduct, andreporting oftheclinicalstudy. Becausestudieswithavarietyoftypesofdesignwereevaluated, athree-levelclassificationofstudyqualitywasdevised: 276 Part10. Appendices NationalKidneyFoundation potassium/DOQI SUMMARIZING REVIEWS AND SELECTED ORIGINAL ARTICLES WorkGroupmembershadwidelatitudeinsummarizingreviewsandselectedoriginal articles for topics that were determined, a priori, not to require a systemic review of the literature. The use of published or derived tables and figures was encouraged to simplifythepresentation. TRANSLATION OF EVIDENCE TO GUIDELINES Format Thisdocumentcontains15guidelines. TheformatforeachguidelineisoutlinedinTable 155. Each guideline contains one or more specific guideline statements, which are presented as bullets that represent recommendations to the target audience. Each guidelinecontainsbackgroundinformation, whichisgenerallysufficienttointerpretthe guideline. Adiscussionofthebroadconceptsthatframetheguidelinesisprovidedin theprecedingsectionofthisreport. Therationaleforeachguidelinecontainsdefinitions potassium/DOQI NationalKidneyFoundation Part10. Appendices 277 andclassificationsofmarkersofdisease(ifappropriate)followedbyaseriesofspecific rationale statements, each supported by evidence. The guideline concludes with a discussionoflimitationsoftheevidencereviewandabriefdiscussionofclinicalapplications, implementationissuesandresearchrecommendationsregardingthetopic. Strength of Evidence Eachrationalestatementhasbeengradedaccordingthelevelofevidenceonwhichit isbased(seethetable, GradingRationaleStatements). LIMITATIONS OF APPROACH Whiletheliteraturesearcheswereintendedtobecomprehensive, theywerenotexhaustive. Medline was the only database searched, and searches were limited to English languagepublications. Handsearchesofjournalswerenotperformed, andreviewarticles andtextbookchapterswerenotsystematicallysearched. Inaddition, searchstrategies weregenerallyrestrictedtoyieldamaximumofabout2, 000titleseach. Thisapproach requiredtheexclusionofsometopicsfromsearches. However, importantstudiesknown tothedomainexpertsthatweremissed bytheliteraturesearchwereincludedinthe review. In addition, essential studies identified during the review process were also included. Exhaustive literature searches were hampered by limitations in available time and resourcesthatwerejudgedappropriateforthetask. Thesearchstrategiesrequiredto captureeveryarticlethatmayhavehaddataoneachofthequestionsfrequentlyyielded upwardsof10, 000articles. Thedifficultyoffindingallpotentiallyrelevantstudieswas compoundedbythefactthatinmanystudies, theinformationofinterestforthisreport wasasecondaryfindingfortheoriginalstudies. Duetothe widevarietyofmethods ofanalysis, unitsof measurements, definitions ofchronickidneydisease, andmethodsofreportingintheoriginalstudies, itwasoften verydifficulttostandardizethefindingsforthisreport. 278 Part10. Appendices NationalKidneyFoundation potassium/DOQI APPENDIX 2. Kidney FUNCTION AND ASSOCIATED CONDITIONS IN THE UNITED STATES: METHODS AND FINDINGS FROM THE THIRD NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (1988 TO 1994) The Third National Health and Nutrition Examination Survey (NHANES III) data offer thefirstopportunitytostudytheprevalenceandnumberofpeoplewithchronickidney diseaseinanationallyrepresentativesampleoftheUnitedStates. Aninitialanalysisfrom NHANESIIIshowedthattheprevalenceofelevatedserumcreatininewashigheramong non-Hispanicblacksthannon-Hispanicwhitesandamongoldercomparedtoyounger individuals. 1 The present analysis was undertaken to describe the distribution of estimatedglomerularfiltrationrate(glomerular filtration rate)intheUSpopulation. EstimatedGFRwascalculated usinganequationbasedoneachparticipantscreatinine, age, sex, andrace. TheassociationsofestimatedGFRwithage, highbloodpressure, anemia, andothermetabolicand functionalabnormalitiesarealsoexaminedtodisplaytherangeofabnormalitiesassociatedwithdecreasedkidneyfunction. Theprevalenceofmicroalbuminuriaandproteinuria by age, sex, race, and Diabetes are tabulated to show the frequency with which theseabnormalitiesarepresentinthepopulation. METHODS Survey TheNHANESIIIsurvey, conductedduring1988to1994bytheNationalCenterforHealth Statistics (NCHS) of the Centers for Disease Control and Prevention, provides crosssectional, nationallyrepresentativedataonthehealthandnutritionalstatusofthecivilian, non-institutionalizedUSpopulation. 657, 658Non-Hispanicblacks, Mexican-Americans, as well as the elderly and children were deliberately oversampled in this survey. This oversamplingmakesitpossibletoobtainreliableestimatesofthedistributionofcreatinineinthetwolargestminoritygroupsofthecivilian, non-institutionalizedUSpopulation aswellinabroadrangeofagegroups. Standardizedquestionnaireswereadministered inthehome, followedbyadetailedphysicalexaminationataMobileExaminationCenter. Serum Creatinine Serum was collected at the Mobile Examination Center and Creatinine measurements wereperformedbythemodifiedkineticJaffe reaction659usingaHitachi737analyzer (Boehringer Mannheim Corp, Indianapolis, IN) and reported using conventional units (1 milligrams per deciliter (cid: 1) 88. 4 (cid: 1)mol/L). The coefficient of variation for Creatinine determination rangedfrom0. 2%to1. 4%duringthe6yearsofstudy. Dataonphysiologicvariationin creatininewereobtainedinasampleof1, 921participantswhohadarepeatcreatinine measurement. Thepercentdifferencebetweenthetwocreatininemeasurements, amean of17daysapart, hadameanof0. 2%andstandarddeviationof9. 7%. 5 Estimation of glomerular filtration rate EstimationofGFRusinganequationrequiresthatthecalibrationoftheserumcreatinine assaybethesameasthatinthelaboratorywheretheequationwasdeveloped. InNHANES potassium/DOQI NationalKidneyFoundation Part10. Appendices 279 III, serumcreatininewasmeasuredintheWhiteSandsLaboratory, wherequalitycontrol datashowsstablecalibrationovertime. The meanserumcreatininefor20to39-yearoldparticipantswithouthypertensionordiabeteswas1. 14mg/dLformenand0. 91mg/ dLforwomen. CollegeofAmericanPathologistsSurveydata, releasedwithpermission ofbothlaboratories, showthatcreatininevaluesintheWhiteSandslaboratorymeasured during1992to1995usingtheHitachi737instrumentaveraged0. 2to0. 3mg/dLhigher than values in the Cleveland Clinic measured using the Beckman Astra and Synchron instruments. The latter values were similar to the overall mean of all laboratories for Creatinine. TheselowervalueswerealsoclosetoagoldstandardHPLCassayforcreatinineinasmallvalidationstudy. 660Thisconcernleadtoadirectcomparisonofthetwo laboratoriesusingfrozensamplesfrom212ModificationofDietinRenalDisease(MDRD) Study participants and 342 Third National Health and Nutrition Examination Survey (NHANES III) participants which were assayed for serum Creatinine a second time in eachofthestudylaboratoriesduringtheyear2000. 661TheGFRestimatesinthisreport arebasedoncreatininevalueswhichwererecalibratedusingtheseresults. ThiscorrectionresultedinanestimatedmedianGFRvalueof119mL/min/1. 73m2atage20years (5thand95thpercentilesof88and180mL/min/1. 73m2). Thesevaluesarealittlelower than published data on normal glomerular filtration rate among young adults.",
    "word_count": 596,
    "char_count": 8624,
    "sentence_count": 72,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 56,
      "total_chunks": 77,
      "position": "57/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "glomerular filtration rate",
        "kidney function",
        "creatinine",
        "potassium",
        "serum creatinine",
        "nutrition",
        "anemia",
        "guideline"
      ],
      "entity_count": 8
    }
  },
  {
    "chunk_id": 57,
    "text": "661TheGFRestimatesinthisreport arebasedoncreatininevalueswhichwererecalibratedusingtheseresults. ThiscorrectionresultedinanestimatedmedianGFRvalueof119mL/min/1. 73m2atage20years (5thand95thpercentilesof88and180mL/min/1. 73m2). Thesevaluesarealittlelower than published data on normal glomerular filtration rate among young adults. Whether the equations for estimatingGFRrequirefurtherrefinementinthenormalGFRrangeisuncertain, butthe associations observed support the utility of this estimated glomerular filtration rate. Individuals with very lowcreatininevalueshadanestimatedGFRthatwashigherthanphysiologicallyplausible. TheseNHANESparticipantswereassignedaGFRvalueof200mL/min/1. 73m2as an upper limit to avoid undue influence (0. 5% of men, 2. 3% of women, 0. 7% of nonpregnant women). Pregnant women accounted for approximately half of the women with an estimated glomerular filtration rate(cid: 2)200 milliliters per minute/1. 73 m2. Statistics focused on percentiles of the distributiontofurtherdecreasetheinfluenceofsuchoutliers. Proteinuria Arandomspoturinesamplewasobtainedfromeachparticipantaged6yearsandolder, usingaclearcatchtechniqueandsterilecontainers. Urinesampleswereplacedondry ice and shipped overnight to a central laboratory where they were stored at (cid: 4)20(cid: 1)C. Urinary albumin concentration was measured by solid-phase fluorescent immunoassay. 662Urinealbuminwasnotmeasuredinspecimenswhichcontainedbloodorwhich testedpositiveforhemoglobinusingqualitativeteststrips(Multistix). Urinecreatinine concentrationwasmeasuredbythemodifiedkineticrateJaffemethodusingaBeckman SynchronAS/ASTRAanalyzer. Theinter-assaycoefficientsofvariationforlow(1. 0mg/ L)andmedium(15mg/L)urinealbuminqualitycontrolstandardswere16%and10%, respectively. The urinary albumin to urinary Creatinine ratio is reported in magnesium/g. Sex specificcutoffswereusedtodefinemicroalbuminuriaandalbuminuriainasinglespot Urine. Ourestimatesreflecttheprevalenceofalbuminuriabasedonasingleuntimedurine specimenandincludeindividualswithpersistentalbuminuriaandindividualswithinter280 Part10. Appendices NationalKidneyFoundation potassium/DOQI mittentalbuminuria. Repeatmeasurementswereobtainedinasubsetof1, 241NHANES IIIparticipantswithin2monthsoftheinitialexamination. Agreementbetweentheinitial andrepeattestsclassifiedasnormal, micro, andmacroalbuminuriawas91. 2%(kappa 0. 59). Microalbuminuriapersistedinthesecondvisitin57%andmacroalbuminuriawas presentinanother4%ofthe110participantswithmicroalbuminuriaonthefirstexam. Thevariationinpersistencebyagegroupandsexwas: 45%at20to39(n(cid: 1)22), 59% at40to59(n(cid: 1)32), 70%at60to79(n(cid: 1)43), and44%at(cid: 2)80years(n(cid: 1)9), 65% amongmen(n(cid: 1)48), and52%amongwomen(n(cid: 1)62). Among1, 099individualswithout microalbuminuriaatthefirstvisit5%(n(cid: 1)56)hadmicroalbuminuriaoralbuminuriaon thesecondvisit. Biochemistry A 22 analyte biochemistry panel, including serum Creatinine, was performed with a HitachiModel737multi-channelanalyzer(BoehringerMannheimDiagnostics, Indianapolis, IN). Blood Hypertension Bloodpressuremeasurementswereobtainedthreetimesduringthehomeinterviewand anotherthreetimesduringtheexaminationandaveraged. Individualswereclassifiedas hypertensiveiftheyhadameanbloodpressure(cid: 2)140mmHgsystolic, or(cid: 2)90mmHg diastolic, or reported being currently prescribed medication for hypertension treatment. 102 Diabetes Diabeteswasdefinedby historyaswellasbloodglucose values. Theprimaryanalysis stratifiedindividualsbasedonahistoryofdiagnoseddiabetesmellitussincethisinformation was available for nearly all individuals and could be used by physicians for risk stratification. Ancillary analyses examined the impact of using the American Diabetes Association(ADA)criteria663fordiabetesmellitusinthesubsetofindividualswhofasted atleast8hours. Dietary History Dietaryhistorywascollectedusingafoodfrequencyquestionnaire. STATISTICAL ANALYSIS ThecomplexsurveydesignofNHANESIIIincorporatesdifferentialprobabilitiesofselection. Toderivenationalestimates, samplingweightsareusedtoadjustfornon-coverage andnon-response. Allprevalenceestimateswereweightedtorepresentthecivilian, noninstitutionalizedUS populationandtoaccount foroversamplingand non-responseto the household interview and the physical examination. 658 All data analyses were conductedusingSTATAsvycommandsforanalyzingcomplexsurveydesigndatawith49 strata and 98 primary sampling units. 664 A total of 16, 589 participants out of 20, 050 (82. 7%)examinedhadbothbloodpressureandserumcreatininedatawereusedasthe starting sample for all analyses. The missing data rate was higher in older individuals potassium/DOQI NationalKidneyFoundation Part10. Appendices 281 (individuals missing data were 4 years older), among men than women (17. 9% versus 16. 7%), andloweramongMexican-Americansandotherethnicgroups(14%)thanamong non-Hispanicwhites(19%)andnon-Hispanicblacks(18%). Thesedifferenceswereprimarilyduetomissingphlebotomydata. TominimizebiasthecombinedMobileExamination Center and home exam weights were divided by the proportion of participants missing Creatinine data in each of the design age, sex, and race ethnicity strata. This corrects differences in missing data across sampling strata but assumes that data are missingrandomlywithinstrata. Missingdataratesforothercovariatesamongtheseindividualsvariedfrom0%forserumalbuminto4. 3%forurinaryalbumin. Surveyweights werenotfurtheradjustedformissingdatainthesevariables. EstimatedGFRwascalculatedusingtheabbreviatedMDRDStudyequationusingthe correctedserumcreatinine(S, milligrams per deciliter)asfollows: creatinine EstimatedGFR(milliliters per minute/1. 73m2)(cid: 1)186(cid: 3)(S )(cid: 4)1. 154(cid: 3) creatinine (Age)(cid: 4)0. 203(cid: 3)(0. 742iffemale)(cid: 3)(1. 21ifAfricanAmerican) Thisequationisalsoequivalentto: EstimatedGFR(milliliters per minute/1. 73m2)(cid: 1)exp(5. 228(cid: 4)1. 154(cid: 3)ln(S )(cid: 4)0. 203(cid: 3) creatinine ln(Age)(cid: 4)(0. 299iffemale)(cid: 5)(0. 192ifAfricanAmerican) EstimatedGFRwasanalyzedbothasacontinuousmeasureanddividedintoranges asdescribedintheguidelinessummaryofstagesofchronickidneydisease. Continuous Analysis ContinuousanalysisofestimatedGFRusedquantileregressiontoavoidundueinfluence ofoutliers. 664Themedians, aswellas95thand5thpercentilesofeachcovariates(for example, percentilesofbloodhemoglobin), wereregressedonestimatedGFRtoshow howthemiddleandtopandbottomendsofthecovariatedistributionvariedacrossthe rangeofGFR. TheshapeoftheassociationofeachcovariatewithmedianestimatedGFR wasmodeledusingafifthorderpolynomialtoallowfordeviationfromalinearassociation. The regression was further adjusted for age to avoid confounding by age since older individuals have a much lower glomerular filtration rate than younger individuals and older age is also associated with abnormalities in many other covariates. To allow for non-linear associationswithage, ageadjustmentusedafifthorderpolynomial. Theregressionwas thenusedtopredictvaluesacrosstherangeofGFRwhilefixingageto60years. Regressionswereweightedusingthesamplingweightsbutquantileregressiondidnotallow forexplicitincorporationofsurveystrataintocalculationofstandarderrors. Theresults arepresentedingraphicalformatasregressionalongwith95%confidenceintervalsfor selected points in the age-adjusted regression. Regressions include all of the relevant databutthegraphsaredisplayedforestimatedGFRsbetween15and150mL/min/1. 73 m2wheretheresultsaremostmeaningful. Categorical Analysis CategoricalanalysisofestimatedGFRdividedestimatedGFRintofourcategoriesaccordingtotheproposedstagesofchronickidneydisease((cid: 2)90, 60to89, 30to59, and30 282 Part10. Appendices NationalKidneyFoundation potassium/DOQI to15mL/min/1. 73m2). Theprevalenceofabnormalityineachcategorywascalculated fortwocutoffvalues. Forexample, withbloodhemoglobinasthecovariate, thecutoffs were(cid: 3)11g/dLand(cid: 3)13g/dL. Thisshowstheprevalenceofmoreandlesssevereabnormalities. Prevalenceestimateswereageadjustedusinglogisticregressiontoavoidconfounding by age. Logistic regressions incorporating sample weights and the complex surveydesignwerefitseparatelyforeachoutcome(forexampleserumalbumin(cid: 3)3. 4 g/dLcoded as0/1) witha fifthorderpolynomial inGFR tofit non-linearassociations. Themodeladjustedforagebyincludingafifthorderpolynomialinage. Theregression wasthenusedtopredicttheprevalencefora60-year-oldpersonwithallothercovariates unchanged. Bargraphsshowthisageadjustedprevalenceand95%confidenceintervals byestimatedGFR. glomerular filtration rate Estimation in the Canadian Multicentre Cohort ThiscalculationwasmadeusingtheabbreviatedMDRDformulasimilarlytomethodsin NHANES III. Some of the figures label this estimate as milliliters per minute, although it should morecorrectlybelabeledmilliliters per minute/1. 73m2. APPENDIX 3.",
    "word_count": 585,
    "char_count": 8795,
    "sentence_count": 93,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 57,
      "total_chunks": 77,
      "position": "58/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "glomerular filtration rate",
        "proteinuria",
        "creatinine",
        "potassium",
        "magnesium",
        "serum creatinine"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 58,
    "text": "Some of the figures label this estimate as milliliters per minute, although it should morecorrectlybelabeledmilliliters per minute/1. 73m2. APPENDIX 3. METHODOLOGICAL ASPECTS OF EVALUATING EQUATIONS TO PREDICT glomerular filtration rate AND CALCULATIONS USING 24HOUR Urine SAMPLES IMPORTANCE OF SAMPLE SIZE Manyofthestudiesreviewedweresmall. Sinceestimatesofaccuracyfromsmallerstudies canbeunreliable, studiespresentedhaveatleast100adultsor50children. Asmaller samplesizewaspermittedforpediatricstudiesbecauselargepediatricstudiesarerare. Severallarge validationstudiesevaluatingthe newlydevelopedMDRD Studyequation were conducted recently and were only available in abstract form. 162, 165 In order to capturethesevaluabledata, theauthorswerecontactedandaskedtoanalyzetheirdata andprovideestimatesofaccuracyforthisreview. EVALUATION OF BIAS, PRECISION, AND ACCURACY Reviewoftheliteratureshowedgreatheterogeneityinhowtheperformanceofprediction equations was assessed. The mean difference between the actual measured glomerular filtration rate (goldstandard)andtheestimatedGFRbasedonanequationprovidesavalidmeasure ofbias. Themediandifferenceprovidesameasurethatisvalidandlesssusceptibleto influence by outliers. The standard deviation of the difference between the measured andestimatedGFRshouldbereportedasameasureofprecision. Thedifferencefrom thegoldstandardcanalsobeexpressedasarelativedifference, eg, percentdifference fromthemeasuredGFR. Thishastheadvantageofallowingforthedecreasedabsolute precisioninestimatinghighervaluesofGFR. Clinicallythisisrelevant, asthereisless concernaboutthedifferencebetween100and130mL/min/1. 73m2thanbetween30 and60mL/min/1. 73m2. MoststudieshadaplotofthepredictedversusmeasuredGFR, whichprovidedfor potassium/DOQI NationalKidneyFoundation Part10. Appendices 283 acommonbasisforcomparison. Amagnified copyofthegraphwasusedtoestimate theproportionofGFRestimateswithin30%and50%ofthemeasuredGFRbycounting thenumberofpointsoutsideoftheselimits. Theaveragepercentbiasforthestudywas estimatedaswell. Inmoststudiesthishadtobedonebycomparingthepercentdifference between the average estimated and measured glomerular filtration rate since average percent bias at the individuallevelwasrarelyavailable. ANALYSIS AND INTERPRETATION OF DATA Correlation coefficients are frequently cited in the literature on prediction equations. However, theyareinadequateformeasuringthevalidityofamethodinestimatingGFR fortworeasons. Althoughcorrelationcoefficients(r)measuretheassociationbetween predictionequationandmeasuredGFR, thecorrelationcoefficientishighlydependent onthedistributionofGFRsinthestudypopulationselected. Evenpoorestimatescan discriminatebetweenaGFRof20and120veryreliably. Second, correlationmeasures ignore bias and measure relative rather than absolute agreement. For example, in the MDRDStudytheCockroft-GaultequationhadasimilarcorrelationtoGFRastheMDRD Study equation but overestimated glomerular filtration rate by 19%. 17 Analogous studies in children show similarlimitationsinassessingtheutilityofapredictionequationbyvirtueofitscorrelationcoefficient. 124ThecorrelationbetweeninulinclearanceandestimatedGFRbythe Schwartz formula was 0. 905, while in the same study, the standard deviation of the differencebetweenthereferencevalue(C )onthepredictedvaluewas28. 6%, indicating in limitedprecision. Regressionequationsareanothercommonlyusedmeasureofpredictionequations. Regression equations relating an estimate of glomerular filtration rate and the measured glomerular filtration rate provide an estimateofsystematicbias, intherelationshipbetweenthetwovariables, aswellasthe correlationandresidualrootmeanerror, measuresofprecision. However, suchregressionanalyseshavetwodrawbacks. First, ordinaryleastsquareregressiondoesnotallow formeasurementerrorintheX-variable. Asaresult, theregressionequationprovidesa predictionequationconditionaloftheX-valueratherthananunbiasedestimateofthe relationship. Forexample, aregressionofoneGFRmeasureonasecondGFRmeasure, usingthesametechniqueonanotherday, wouldhaveaslopethatissubstantiallylower than1. 0 andan interceptgreaterthan zero. Theimportance ofmeasurement errorin theX-valuesdependsonthecorrelation, whichinturndependsonthestudypopulation. Second, regressionequationscannotbepooledacrossdifferentstudies. Finally, evaluationoftheaccuracyofanyequationforestimatingGFRmustbemadeinanindependent groupfromthegroupinwhichtheequationitselfwasderived. NOTES ON EVALUATION OF MDRD STUDY EQUATION Nopeer-reviewedpublicationsvalidatingtheMDRDStudyequationwereavailable. An analysis of 1, 775 glomerular filtration rate measurements in participants of the African-American Study of KidneyDiseaseandHypertension(AASK)indicatesthattheequationperformssimilarly inthisstudypopulation. 162Accuracywasalsosimilaramong321kidneytransplantrecipi284 Part10. Appendices NationalKidneyFoundation potassium/DOQI ents. 165 Thus, the abbreviated MDRD Study equation provides a rigorously developed equationforestimatingGFR, whichmayallowforimprovedpredictionofGFR. AdirectcomparisonoftheabbreviatedMDRDStudyequationwithotherequations developedinthesamestudythatincludeothervariables(serumureanitrogen, serum albumin, and24-hourcreatinineclearance)showsonlyamarginalimprovementinthe prediction. The median percent difference from glomerular filtration rate was 12. 1% versus 11. 3% for a 6 variableequation, whichincludesserumureanitrogenandalbumin. Exclusionofthese analytes decreases the cost of testing, the susceptibility to bias in calibration of these otheranalytes, andbiasduetoalterationoftheseanalysesbydiseasesotherthankidney disease. This abbreviated equation also predicted glomerular filtration rate better than 24-hour Creatinine clearance, even after bias correction of the Creatinine clearance. While the equation performed well in the AASK study where a substantial number of glomerular filtration rate values in the normalrangewereincluded, theequationwasdevelopedinasamplewithfewindividuals withaGFRgreaterthan90mL/min/1. 73m2. CALCULATIONS USING 24-HOUR Urine SAMPLES Thedailyureaclearance(U (cid: 3)V)/P andcreatinineclearance(U (cid: 3)V)/S can urea urea creatinine creatinine becalculatedfromtheconcentrationsofureaandcreatinineandthevolume(converted to milliliters per minute) of the 24-hour Urine collection. The weekly dialysis adequacy measure is equal to the daily urea ureaclearancemultipliedbyseven(Kt)dividedbytheestimatedtotalbodywater(V). Total body Water can be estimated in adults by the Watson formula665 or the MellitsCheekmethodforchildrenusingmeasuredweightandheight. 16Ifdailyproteinintake isrelativelyconstantandthepatientisinasteadystate, thenurinarynitrogenexcretion isroughlyequaltonitrogenintake. Therefore, usingtheureanitrogenconcentrationin the24-hoururine, proteinintakecanbeestimatedfrom666: Urinarynitrogenexcretion(cid: 1)Urineureanitrogen(cid: 5)nonureanitrogen Nonureanitrogenexcretionisrelativelyconstantat30mg/kgperday. Eachgramof nitrogenisderivedfrom6. 25gramsofprotein. Therefore: Estimatedproteinintake(g/d)(cid: 1)6. 25(cid: 3) (Urineureanitrogen(g/d)(cid: 5)30mg/kg/d(cid: 3)Weight(kg) Forexample, a50-kgwomanwitha24-hoururineureanitrogenexcretionof7ghas anestimatedproteinintake(cid: 1)6. 25(7(cid: 5)1. 5)(cid: 1)53. 1g. These parameters are useful in evaluating the patients nutritional status, need for Dialysis, andprescriptionofdialysisdoseandmodality. 320, 667 potassium/DOQI NationalKidneyFoundation Part10. Appendices 285 PART 11. WORK GROUP MEMBERS THEFOLLOWINGarebriefsketchesthatdescribetheprofessionaltrainingandexperience, particularlyastheyrelatetotheK/DOQICKDClinicalPracticeGuidelines, aswell asprincipalacademicaffiliationsoftheworkgroupmembers. Allworkgroupmembers completedadisclosurestatementcertifyingthatanypotentialconflictofinterestwould notinfluencetheirjudgmentoractionsconcerningtheK/DOQI. ADULT WORK GROUP KlineBolton, MD, FACP, isProfessorofMedicineatUniversityofVirginiainCharlottesville, whereheisChiefoftheDivisionofNephrologyandDirectoroftheNephrology Clinical Research Center, Kidney Center and Renal Operations. He has received specialhonorsfromorganizationsrangingfromtheAmericanSocietyforClinicalInvestigation to the International Society of Nephrology. He has published many articles in journalsrangingfromAmericanJournalofKidneyDiseasesandKidneyInternational to Immunologic Renal Diseases, and contributed to numerous text books, including the Textbook of the Autoimmune Diseases and the Textbook of Nephrology. He is ChairmanoftheRenalPhysiciansAssociationWorkGrouponAppropriatePreparation of Patientsfor Renal ReplacementTherapy.",
    "word_count": 591,
    "char_count": 8589,
    "sentence_count": 76,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 58,
      "total_chunks": 77,
      "position": "59/77",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "glomerular filtration rate",
        "creatinine",
        "urea",
        "potassium",
        "dialysis",
        "dialysis adequacy"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 59,
    "text": "He is ChairmanoftheRenalPhysiciansAssociationWorkGrouponAppropriatePreparation of Patientsfor Renal ReplacementTherapy. His researchinterests are inrefining the epitope(s) involved in causing Goodpastures syndrome, treating glomerulonephritis, anddiseasemanagementofCKDandESRD. JosefCoresh, MD, PhD(WorkGroupCo-Chair), isAssociateProfessorofEpidemiology, Medicine and Biostatistics at Johns Hopkins Bloomberg School of Public Health, Baltimore. HecurrentlyservesontheNationalAnalgesicNephropathyAdvisoryCommittee and is conducting research focussing on cardiovascular and Kidney disease in the Atherosclerosis Risk in Communities Study and the CHOICE Study cohort of Kidney failurepatientsaswellasNHANESdata. Hehasbeenactiveinthefollowingorganizations: theInternationalSocietyofNephrology, theAmericanSocietyofNephrology, theAmericanHeartAssociation, theAmericanStatisticalAssociation, theDeltaOmegaHonorSociety in Public Health (Alpha Chapter), the International Genetic Epidemiology Society, theAmericanSocietyofHumanGenetics, andtheSocietyforEpidemiologicalResearch. DrCoreshdirectsacardiovascularepidemiologytraininggrant, andisanAmericanHeart AssociationEstablishedInvestigator. Bruce Culleton, MD, FRCPC, is Clinical Assistant Professor of Nephrology at the UniversityofCalgaryFoothillsMedicalCenter, Alberta, Canada. Hehasbeenactiveinthe followingorganizations: theAmericanSocietyofNephrology, theInternationalSocietyof Nephrology, theKidneyFoundationofCanada, theCanadianHypertensionSociety, and the Canadian Renal Disease Alliance. In addition to serving on the Medical Advisory BoardforAmgenCanada, DrCulletonisamemberoftheCanadianHypertensionSociety subgrouponthepharmacologicmanagementofhypertension. Recently, hecompleted aResearchFellowshipattheFraminghamHeartStudywherehepursuedhisinterestin cardiovascularepidemiologyinpatientswithkidneydisease. Hehasalsopublishedsevpotassium/DOQI NationalKidneyFoundation Part11. WorkGroupMembers 287 eraljournalarticles, abstracts, andbookchapters intheareaofcardiovasculardisease inpatientswithchronickidneydisease. KathySchiroHarvey, MS, RD, CSR, isChiefRenalDietitianatPugetSoundKidney Centers in Everett, Washington. She is past Chair of the Renal Practice Group of the AmericanDieteticAssociation, andRenalDietitianatProvidenceSt. PeterKidneyCenters, Olympia, Washington, andatNorthwestKidneyCenters, Seattle, Washington. AsBoard CertifiedSpecialistinRenalNutrition, shefocusesontheareasofpre-end-stage renal disease, hemodialysis, andperitonealdialysis. ShecurrentlyservesontheEditorialBoardoftheJournalofRenal Nutrition and is on the Dietitian Advisory Board of Genzyme Therapeutics. Ms Schiro Harvey was the recipient of the Outstanding Service Award of the American Dietetic Association. Talat Alp Ikizler, MD, is Assistant Professor of Medicine at Vanderbilt University Medical Center, and Medical Director of the Vanderbilt University Outpatient Dialysis Unit, Nashville, Tennessee. HeisamemberofseveralsocietiesincludingtheAmerican SocietyofNephrologyandtheInternationalSocietyofNutritionandMetabolisminRenal Disease. His ongoing research projects are focused on nutrition and metabolism in chronickidneyfailurepatients, effectsofinitiationofdialysisonnutritionalparameters, clinicalaspectsofacutekidneyfailure, inflammationinend-stagekidneydiseasepatients, andvascularaccessinchronichemodialysispatients. Hehaspublishedover30papers and5bookchaptersandpresentedmultipleabstracts. DrIkizleristherecipientofseveral grant(federalandpharmaceutical)awardsandisamemberoftheMedicalReviewBoard Network8Inc. andsecondvicepresidentoftheNationalKidneyFoundationofMiddle Tennessee. CyndaAnnJohnson, MD, MBA, isprofessorandheadoftheDepartmentofFamily MedicineattheUniversityofIowa. ShereceivedherbachelorsdegreeinGerman(with honors)andBiologyandPhiBetaKappaatStanfordUniversityandherMDdegreefrom UCLAin1977. ShereturnedforresidencytrainingattheUniversityofKansas, followed byapart-timeteachingfellowshipatUNC. ShecontinuedonthefacultyatKUforthe next19years. ShejoinedtheFamilyMedicinefacultyattheUniversityofIowainOctober 1999asdepartmenthead. SheischairoftheBoardofDirectorsforUniversityofIowa CommunityMedicalServicesandamemberoftheIowaAcademyofFamilyPhysicians BoardofDirectors. DrJohnsonrecentlycompleteda5-yeartermontheAmericanBoard ofFamilyPractice, andwasPresidentoftheBoardin19992000. Shecurrentlyserveson theExecutiveCommitteeoftheAmericanBoardofMedicalSpecialtiesandisamemberof theABMS-ACGMEJointInitiativeonResidentEvaluation. Inaddition, DrJohnsonserves asthefamilymedicinerepresentativeonanumberofotherboardsaddressingsubspecialtyissues. DrJohnsonwasamemberoftheJacobsInstituteofWomensHealthExpert PanelonMenopauseCounseling, whichsubsequentlypublishedGuidelinesforCounselingWomenontheManagementofMenopausein2000. Sheandherhusband, Bruce Johnson, MD, Professor of Internal Medicine at the University of Iowa, are co-authors ofWomensHealthCareHandbook, 2ndedition. DrJohnsonservesonmultipleeditorial boardsandalsoisareviewerforgrantingagencies. Sheisthephysicianrepresentative 288 Part11. WorkGroupMembers NationalKidneyFoundation potassium/DOQI ontheLutheranChurchsnationalTaskForceonHealthandEthicalChallengesinHealth Care. AnnamariaKausz, MD, MS, isAssistantProfessorofMedicineatTuftsUniversity SchoolofMedicine, Boston. ShecompletedherFellowshipinNephrologyandinPediatric Nephrology at the University of Washington Childrens Hospital and Medical Center, Seattle, andreceivedherMastersDegreeinEpidemiologyattheUniversityofWashington School of Public Health. She received a K08 grant to conduct research in the area of chronickidneydisease. DrKauszisapastrecipientoftheAmericanSocietyofTransplant PhysiciansYoungInvestigatorAward. SheservesontheMedicalAdvisoryBoardofAmgen Inc. Paul L. Kimmel, MD, is Professor of Medicine at George Washington University Medical Center, Washington, DC, and Director of the Diabetic Nephropathy and HIV ProgramsattheNationalInstituteofDiabetesandDigestiveandKidneyDiseases, National InstitutesofHealth, Bethesda, Maryland. HehasservedontheEditorialBoardofseveral nephrologyjournals andhaspublishedover 250papers, includingabstracts andbook chapters. Hehasbeenamemberofseveralprofessionalorganizations, scientificsocieties, andacademiccommittees. HiscommitmenttocommunityhealthledhimtoChairthe National Kidney Foundations National Capital Chapters Professional Advisory Board and be a Member of its BoardofDirectors. HeispastDirectorofdialysiscentersinPennsylvaniaandWashington, DC. Dr Kimmel is the recipient of a Medal for Excellence in Research from George WashingtonUniversityMedicalCenterandislistedinWhosWhoinScienceandEngineering. HehasreceivedseveralgrantsfromtheNationalKidneyFoundationandNational InstitutesofHealth. JohnKusek, PhD, istheClinicalTrialsProgramDirectorfortheDivisionofKidney, UrologicandHematologicDiseasesoftheNationalInstituteofDiabetesandDigestive andKidneyDiseases, NationalInstitutesofHealth. Hisinterestsareintheepidemiology ofchronicrenalinsufficiencyandclinicaltrialstopreventprogressionofchronicrenal diseaseandinimprovingsurvivalofhemodialysispatients. Hehasbeeninvolvedwith anumberofclinicaltrialsincludingtheModificationofDietinRenalDisease(MDRD) Study, the African American Study of Kidney Disease and Hypertension (AASK), the Hemodialysis(HEMO)Study, theDialysisAccess(DAC)Consortium, andtheFolicAcid forVascularOutcomeReductioninTransplantation(FAVORIT)Trial. Heisalsoco-project director for a newly initiated prospective cohort study of chronic renal insufficiency. Areasofparticularinterestincluderecruitment, adherence, andqualityoflifefornephrologyclinicaltrials. AndrewS. Levey, MD(WorkGroupChair), isDrGeraldJ. andDorothyR. Friedman ProfessorofMedicineatTuftsUniversitySchoolofMedicineandChiefoftheWilliam B. Schwartz, MDDivision ofNephrologyat NewEngland MedicalCenter, Boston. His researchismainlyintheareasofepidemiologyofchronickidneydiseaseandcardiovasculardiseaseinchronickidneydisease, clinicaltrialstoslowtheprogressionofchronic kidneydisease, clinicalassessmentofkidneyfunction, andassessmentandimprovement ofoutcomesindialysisandtransplantation. DrLeveyiscurrentlyProgramDirectorfor potassium/DOQI NationalKidneyFoundation Part11. WorkGroupMembers 289 anNIDDK-fundedclinicalresearchtrainingprogram, ClinicalTrials, Epidemiologyand OutcomesResearchinNephrology. HeispastChairoftheClinicalScienceCommittee oftheAmericanSocietyofNephrology. HeispastChairoftheNationalKidneyFoundationsTaskForceonCardiovascularDiseaseinChronicRenalDiseaseandwillChaira forthcoming Work Group on Management of Hypertension in Chronic Kidney Disease. DrLeveyistherecipientoftheNationalKidneyFoundationsPresidentAward of1998. Adeera Levin, MD, FRCPC, is Clinical Associate Professor of Nephrology at the UniversityofBritishColumbia, St. PaulsHospital, Vancouver, Canada. Sheiscurrently theDirectorofClinicalResearchandEducationforNephrologyandthePostGraduate Fellowship Director. She is the President of the Canadian Society of Nephrology (20002002)andhasservedontheExecutiveoftheCSNforthelast4years. DrLevin has been a memberof the Scientific Review committee forthe Kidney Foundation of CanadaandservedastheChairoftheMedicalAdvisoryCommitteeforKidneyFoundation of Canada. She is the Director of the BC Provincial Agency, an organization working withthegovernmenttoenhancethecareofpatientswithkidneydisease. Herareaof interestandpublicationsincludeearlykidneydisease, comorbidity, anemia, andother nontraditionalriskfactorsforcardiovasculardisease.",
    "word_count": 582,
    "char_count": 9478,
    "sentence_count": 70,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 59,
      "total_chunks": 77,
      "position": "60/77",
      "content_type": "dietary",
      "content_type_confidence": 5,
      "medical_entities": [
        "chronic kidney disease",
        "end-stage renal disease",
        "nephropathy",
        "potassium",
        "nutrition",
        "dietitian",
        "dialysis",
        "hemodialysis",
        "anemia",
        "adherence"
      ],
      "entity_count": 10
    }
  },
  {
    "chunk_id": 60,
    "text": "She is the Director of the BC Provincial Agency, an organization working withthegovernmenttoenhancethecareofpatientswithkidneydisease. Herareaof interestandpublicationsincludeearlykidneydisease, comorbidity, anemia, andother nontraditionalriskfactorsforcardiovasculardisease. Sheistheprincipalinvestigatoron a number ofmulticenter Canadian studies andhas developed a groupof investigators known as the Canadian Renal Disease Alliance Group. She is active in the following organizations: theAmericanSocietyofNephrology, theInternationalSocietyofNephrology, andtheKidneyFoundationofCanada, aswellaslocallyintheUniversityofBritish Columbia, Research Advisory Committee at St. Pauls Hospital. She is the recipient of theUBCMartinHoffmanAwardforExcellenceinResearchandtheDeanWhitlawaward forOutstandingGrandRounds. SheistheChiefMedicalEditorforaneducationalpublicationaimedatincreasingawarenessofkidneydisease, entitledPROFILES. Sheiscurrently on theeditorial boardof NephrologyDialysis Transplantationand forthe American JournalofKidneyDisease(2001)andreviewsarticlesforPeritonealDialysisInternational, KidneyInternational, JournalofAmericanSocietyofNephrology, andCanadianFamilyPractice. Also, sheservesontheMedicalAdvisoryBoardforAmgenCanada, AmgenUSA, JanssenCilagInternational, OrthoBiotechInc, Canada, andRocheInternational. ShehasreceivedgrantsfromtheKidneyFoundationofCanadatostudycomorbiditiesassociatedwithchronickidneydiseaseand, morerecently, tostudythevariability inthecaredeliveredacrossCanadatopatientswithCKD. Shehasalsoreceivedgrants fromBCHealthResearchFoundation, BCTransplantFoundation, JanssenCilaginternational, OrthoBiotech, Amgen, andGenzymeInc. KennethLloydMinaker, MD, FRCP(C), CSC(GM), UE, isAssociateProfessorof MedicineatHarvardMedicalSchool, Boston, andChieffortheGeriatricMedicineUnit atMassachusettsGeneralHospital. HedirectsMGHSeniorHealth, isCo-Directorofthe ProgramforLifelongHealthMaintenanceatHarvardUniversityHealthServices, isSenior EditorofIntelihealth, HarvardHealthPublications, andisGerontologyEditor, theHarvard HealthLetter. HehasservedasBoardMemberoftheAmericanGeriatricSociety, asEditor 290 Part11. WorkGroupMembers NationalKidneyFoundation potassium/DOQI oftheJournalofGerontology: MedicalSciences, andasDirectorofGreccBrockton/West RoxburyVAMC. Hisresearchinterestsareintheareaofphysiologyofaging, glucose/ insulinphysiology, andsarcopenia. HeisPrincipalInvestigatorofaProgramProjecton thebiomedicalaspectsofaging. HeislistedinWhosWhoinAmericaandBestDoctors inAmerica. HehasreceivedresearchfundsfromAccorInc. forhealthpromotionresearch andfromBioNebraskaInc. forhisworkonGHRHandGLP-1. RobertNelson, MD, PhD, isStaffClinicianattheNationalInstituteofDiabetesand DigestiveandKidneyDiseases, Arizona. HehasservedasScientificReviewerofseveral nephrology journals and has over 90 publications. He is a member of the American SocietyofNephrologyandtheAmericanDiabetesAssociation. Hehaslecturedallover theworldandconsultedfortheNKFConsensusConferenceonProteinuriaAlbuminuria Risk Assessment Detection Elimination (PARADE), Nashville. Dr Nelsons research in diabeticnephropathyhasbeensponsoredbytheNationalInstituteofDiabetesandDigestiveandKidneyDiseasesandbytheAgencyforHealthCarePolicyandResearch. Heis therecipientoftheL. S. GoerkeMemorialAwardfromUCLASchoolofPublicHealth. HelmutRennke, MD, isDirectoroftheRenalPathologyLaboratoryatBrighamand WomensHospitalandaprofessorofPathologyatHarvardMedicalSchool, Boston, and theHarvard-MITDivisionofHealthSciencesandTechnologyatMassachusettsInstitute ofTechnology. Hisresearchareascurrentlyfocusonareasofrenalpathology, including keyclinicalandmorphologicaspectsoffibrillaryglomerulopathyandcollapsingglomerulopathy. He is a noted regional, national, and international lecturer on renal research and renal pathology, and he is a recipient of the Annual Irving M. London Teaching Award, amongothers. HeiswidelypublishedinjournalsincludingtheJournalofCell BiologyaswellastheAmericanJournalofPhysiology, JournaloftheAmericanSociety ofNephrology, JournalofClinicalInvestigation, Endocrinology, andKidneyInternational. Michael Steffes, MD, PhD, is Professor in Laboratory Medicine and Pathology at theUniversityofMinnesota, Minneapolis, andClinicalPathologistatFairviewUniversity MedicalCenter, Minneapolis. Hisresearchareasincludediabetesmellitus, diabeticnephropathy, andcardiovasculardisease. Heparticipatesfromthebaseofthecentrallaboratory for several clinical trials and studies. He has reported receiving several grants to conductresearchondiabetes, itscomplications, andmacrovasculardisease. Beth Witten, MSW, ACSW, LSCSW, is a Kidney disease rehabilitation consultant with Witten and Associates, LLC. She serves as patient education coordinator for the MissouriKidneyProgramCenterforRenalEducationandstaffstheLifeOptionsRehabilitationResourceCenter. MsWittenhaspublishedover20papers, co-authoredachapter onkidneydiseaseintheEncyclopediaofDisabilityandRehabilitation, andmadenumerouspresentationsonrehabilitationtopics. SheservedaspresidentoftheNationalKidney FoundationsCouncilofNephrologySocialWorkersandonseveralaffiliateandnational NKFcommittees. ShehasconsultedonprojectsfortheHealthCareFinancingAdministration, theRehabilitationServicesAdministration, andtheSocialSecurityAdministration. ApastmemberoftheMissouriKidneyProgramAdvisoryCouncil, LifeOptionsRehabilitapotassium/DOQI NationalKidneyFoundation Part11. WorkGroupMembers 291 tion Advisory Council, and the Network 12 Medical Review Board, Ms Witten is the recipientoftheNationalKidneyFoundationsDistinguishedServiceAwardandtheCouncilofNephrologySocialWorkersSpecialRecognition. PEDIATRIC WORK GROUP SusanFurth, MD, PhD, isAssistantProfessorofPediatricsatJohnsHopkinsUniversity School of Medicine, Baltimore. She completed her PhD in Clinical Investigation from JohnsHopkinsUniversitySchoolofHygieneandPublicHealth. DrFurthhasservedas areviewerforseveraljournalsandpublishedover25peer-reviewmanuscriptsandinvited reviews, numerous abstracts, and book chapters. She has received extensive research support from several organizations for her investigations in pediatric nephrology. She isamemberoftheClinicalAffairsCommitteeoftheAmericanSocietyofPediatricNephrologyClinicalScienceCommitteeandasymposiumspeakerattheCongressofthe InternationalSocietyforPediatricNephrologyAssociation. Shehasconductedseminars and lectures, and been interviewed for Reuters Health News On-Line. Dr Furth is the recipientoftheYoungInvestigatorAwardandtheJohnsHopkinsComprehensiveTransplantCenterClinicalResearchAward. RonaldJ. Hogg, MD(PediatricWorkGroupChair), isDirectorofPediatricNephrologyatNorthTexasHospitalforChildrenatMedicalCityandDirectoroftheSouthwest PediatricNephrologyStudyGroup, Texas. HeiscurrentPresidentoftheNationalKidney FoundationofNorthTexasMedicalAdvisoryBoardandmemberoftheNationalKidney Foundation potassium/DOQI Advisory Board. Dr Hogg has published over 94 original papers, book chapters, and invited reviews on children with chronic Kidney failure. He is a memberoftheNephrologySectionoftheAmericanAcademyofPediatrics, theInternationalSocietyofNephrology, andtheAmericanSocietyofNephrology. HeispastChief of the Department of Pediatrics at Baylor University Medical Center, past Director of RenalMicropunctureLaboratoryattheUniversityofTexasHealthCenteratDallas, and pastClinical AssociateProfessorofPediatrics attheUniversityof TexasSouthwestern Medical School. Dr Hogg has reported receiving research grants from Astra Zeneca, Merck, Novartis, Parke-Davis, andPfizer. KevinV. Lemley, MD, PhD, isAssistantProfessorofPediatricsatStanfordUniversity Medical Center and Attending Nephrologist at Lucile S. Packard Childrens Hospital, California. HecompletedhisResearchFellowshipattheUniversityofHeidelberg, Germany, and his Clinical Fellowship at Stanford University. His research interests are in theareaoftheprogressionofglomerulardisease, glomerularpathology, andmechanisms of proteinuria. He has been an active reviewer for several journals and has published over30peer-reviewedarticles. DrLemleyservedontheNationalKidneyFoundations PARADE(Proteinuria, Albuminuria, Risk, Assessment, Detection, andElimination)InitiativeCommitteeandconsultsforFibrogen, Inc. HehasbeenaFellowoftheAlexander vonHumboldtFoundationandisamemberoftheInternationalSocietyofNephrology, theAmericanSocietyofNephrology, theAmericanSocietyofPediatricNephrology, the InternationalPediatricNephologyAssociation, andtheSocietyforPediatricResearch. 292 Part11. WorkGroupMembers NationalKidneyFoundation potassium/DOQI RonaldJ. Portman, MD, isProfessorofPediatricsandDirectoroftheDivisionof Pediatric Nephrology and Hypertension at the University of Texas-Houston Medical School. HecompletedhisFellowshipinPediatricNephrologyatWashingtonUniversity School of Medicine and St. Louis Childrens Hospital. Dr Portman has been an active JournalReviewerandhaspublishedover100papers. Heisfoundingmemberandofficer oftheAmericanAssociationof MedicalChronobiologyandChronotherapeutics. Heis theChairman ofthe ExecutiveCommittee ofthe InternationalPediatric Hypertension AssociationandisanASHClinicalHypertensionSpecialist. HeisamemberoftheAmericanSocietyofNephrology, theSouthwestPediatricNephrologyStudyGroup, theAmericanSocietyofPediatricNephrology, andtheInternationalPediatricNephrologyAssociation. HiscommunityservicehasledhimtoCo-DirectPediatricDialysisCampandbea memberoftheMedicalAdvisoryBoardoftheNationalKidneyFoundationofSoutheast TexasandoftheMedicalReviewBoardofESRDNetwork14ofTexas. Hereportsresearch grantsfromAstraZenica, Pfizer, andNovartis. GeorgeJohnSchwartz, MD, isChiefofPediatricNephrologyandAssociateChair forAcademicAffairsattheUniversityofRochesterSchoolofMedicineandDentistry. He hasrevieweddozensofabstractsandmanuscriptsformanynephrologyandphysiology journalsandis ontheeditorialboards ofSeminarsinNephrology andTheAmerican JournalofPhysiologyandRenalPhysiology. DrSchwartzhaspublishedover170papers, includingarticles, books, abstracts, andlettersinnephrology.",
    "word_count": 590,
    "char_count": 9995,
    "sentence_count": 75,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 60,
      "total_chunks": 77,
      "position": "61/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "kidney failure",
        "albuminuria",
        "proteinuria",
        "potassium",
        "anemia",
        "patient education"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 61,
    "text": "Hereportsresearch grantsfromAstraZenica, Pfizer, andNovartis. GeorgeJohnSchwartz, MD, isChiefofPediatricNephrologyandAssociateChair forAcademicAffairsattheUniversityofRochesterSchoolofMedicineandDentistry. He hasrevieweddozensofabstractsandmanuscriptsformanynephrologyandphysiology journalsandis ontheeditorialboards ofSeminarsinNephrology andTheAmerican JournalofPhysiologyandRenalPhysiology. DrSchwartzhaspublishedover170papers, includingarticles, books, abstracts, andlettersinnephrology. Heisamemberof theAmericanSocietyforClinicalInvestigation, AmericanSocietyofPediatricNephrology, the International Pediatric Nephrology Association, the Society for Pediatric Research, andtheAmericanSocietyofNephrology. HehasreceivedtheAMAPhysicians RecognitionAwardandhasbeenrecognizedasaSpecialistinClinicalHypertensionby theAmericanSocietyofHypertension. potassium/DOQI NationalKidneyFoundation Part11. WorkGroupMembers 293 PART 12. ACKNOWLEDGEMENTS TheworkgroupthankstheNationalKidneyFoundationforsupportandguidanceduring this project. James Smith, Nadine Ferguson, Donna Fingerhut, and Kerry Willis, PhD, wereinstrumentalincoordinatingtheproject. TheK/DOQIChairsandAdvisoryBoard provided constructive criticism that helped shape the project. The potassium/DOQI Support Groupprovidedpracticaladvicetofacilitateimplementation. StefanArmstrong, consultanteditor, providedinvaluableassistanceinpreparingthereport. TheWorkGroupisindebtedtotheEvidenceReviewTeam, whoworkedtirelessly toassembletheevidenceandcreativelytosynthesizetheinformation. TheWorkGroupappreciatesthecarefulreviewofthedraftguidelinesandsuggestions forimprovement byexternal reviewers. Eachcomment wascarefully consideredand, wheneverpossible, suggestionsforchangewereincorporatedintothefinalreport. As aresult, theCKDguidelinesaretheproductoftheWorkGroup, theEvidenceReview Team, theNKF, andallthosewhocontributedtheirefforttomaketheGuidelinesbetter. The following individuals provided written review of the draft guidelines: Hernan Aguirre, MD; SuhailAhmad, MD; PedroAljama, MD; JaneAllen, FNPC; SanfordD. Altman, MD; Theresa M. Ambrose, PhD; Lawrence J. Appel, MD; YoshinoriAraki; Teri Arthur, MSW, CSW, LSW; CarolynL. Atkins, RN, BS, CCTC; JohnAu; GeorgeR. Bailie, PharmD, PhD; GeorgeL. Bakris, MD; VinodK. Bansal, MD; WilliamBarrie, MD; RuthBarry, RN; BruceBecker, MD; StengelBenedide, MD, PhD; JeffreyS. Berns, MD; RichardK. Bernstein, MD, FACE, FACN, CWS; CharlesW. Bishop, PhD; RolandC. Blantz, MD; WendyT. Blouin, RN, BSN, CNN; KlineBolton, MD, FACP; JurgenBommer, MD; PeggyBorum, PhD; James Brandes, MD; DeliaBravo, BSN, RN; EmmanuelBravo, MD; DeborahI. Brommage, MS, RD, CSR; EileenBrophy; JoanneBrown, BSN, RN, CNN, CPHQ; WendyW. Brown, MD; JuanP. Bosch, MD; SallyBurrows-Hudson, MS, RN; JerrilynnD. Burrowes, MS, RD, CDN; CarrieButler; BernardCanaud, MD; ClaudiaCampieri, MD; AnthonyW. Capparelli, MD; FernandoCarrera, MD; JudyCastagnola, RN, MSN; GloriaChaigret, RN, CNN; AliceChan, RD, CSR, LD; James C. M. Chan, MD; AlfredK. Cheung, MD; Michael P. Cinquegroni, MD; NathanielClark, MS, RD, MD; EricCohen, MD; AldoColombi, MD; AnnD. Compton, MSN, RNC; MichaelConrad, MD; Rev. KenCrossman; GerryCurry, RN, BSN, CNN; Jeffrey A. Cutler, MD; LeslieDebaun, RN, MSN; JamesA. Delmez, MD; MaryDenno, MSN, RN, CNN; MariaDeVita, MD; ClaudiaDouglas, MA, CNN, APNC; EarlDunnigan, MD, FACP; CatherineDupre, MD; KathyEdwards, RN; SharonEhlers, MA, RN, CNN, CCTC; Sameiro Faaria, MD; MarkD. Faber, MD; StevenFishbane, MD; MichaelJ. Flanigan, MD; Edward Foote, PharmD; HaroldA. Franch, MD; BlancaRamosFrendo, MD; EugeneFreund, MD, MSPH; Tony Fuccello, MD, PhD; Wendy Funk Schrag, LMSW, ACSW; Suzanne Gagne, RN, CNN; ScottGarland; RichardS. Goldman, MD; DianeGoodwin, DCI; FrankA. Gotch, MD; JohnGraham, IV; JaneH. Greene, RD, CSR, LDN; TomasL. Griebling, MD; Cheryl Grimes, PGDE, DPSN, RGN, ENB; Neil J. Groombridge, RN; Robert A. Gutman, MD; WilliamE. Haley, MD; MorrisHamilton, MD; TamaraHarris, MD, MS; GeorgHasche, MD; potassium/DOQI NationalKidneyFoundation Part12. Acknowledgements 295 Carol M. Headley, RN, MSN; Lee A. Hebert, MD; Mary Jane Helenek, RPN, MS, MBA; Richard N. Hellman; Mary Henderson, RN; Sue High, RN, CNN; Karen Hill, RN, BSN; LeliaHolthus, RN, BS; WalterH. Horl, MD; ThomasH. Hostetter, MD; SusannaS. Itty, RN, CNN; BuneaJivanescu; RosieJones, RN; KamyarKalantar-Zadeh, MD, MPH; Mandip S. Kang, MD; LynetteKartechner, RN; BertramL. Kasiske, MD; DouglasKeith, MD; Carol A. Keller, MPA; GwenA. Kendall, RD, LD; Rita-AnKiely, ACSW, CICSW; MichaelJ. Klag, MD, MPH; JaniceKnouff, RN; RaymondKrediet, MD; EduardoLacson, Jr, MD; CraigB. Langman, MD; SandraLathrop, RD, CDN; JanezLavre, MD; ClaudeLenfant, MD; JenJar Lin, MD, PhD; StanM. Lindenfield, MD; FrancescoLocatelli, MD; KathyLueker, RN, CNN; IainMacdougall, MD; DeniseMafra; LionelU. Mailloux, MD, FACP; DonnaMapes, DNSc, MS; GaryR. Matzke; HannaW. Mawad, MD, FACP; LindaM. McCann, RD, LD, CSR; Sally McCulloch, MSN, RN, CNN; PeterA. McCullough, MD, MPH; PatrickMcGary, MD; Patrick McKenna, MD; MaureenMcKinley, MSW, LCSW, CNSW; KimMeehl, CNN; C. Kenneth Mehrling; IraMeisels, MD; D. Mendelssohn, MD, FRCPC; JudyMennig, RN, CNN; MaureenA. Michael, RN; EdgarR. Miller, III, MD, PhD; WilliamE. Mitch, MD; SteveMontoya, Jr, MD; GabrielMorduchowicz, MD; BruceZ. Morgenstern, MD; DonnaMullen, RN, MSN, ARNP; JosephV. Nally, Jr, MD; JeanM. Nardini, RN, MSN; AndrewS. Narva, MD; Pauline Nelson, RD; Ellen Newman, RN, CNN; Sheila Nulf; Paul M. Palevsky, MD; Thakor G. Patel, MD; GlendaM. Payne, RN; TammyB. Pennington, MS, LDN, RD; RobertA.",
    "word_count": 598,
    "char_count": 5566,
    "sentence_count": 68,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 61,
      "total_chunks": 77,
      "position": "62/77",
      "content_type": "evidence",
      "content_type_confidence": 3,
      "medical_entities": [
        "potassium"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 62,
    "text": "Payne, RN; TammyB. Pennington, MS, LDN, RD; RobertA. Phillips, MD, PhD, FACC; DeloresJ. Phipps, RN, CNN; JeanPirozzi, BS, RN, CNN; LindaPlush, MSN, CNN, CNS/FNP; GeraldinePodgorski, BSN, RN, CNN; potassium. S. Prabhakar, MD; Debra Punch, RN, BS; GopalK. Rangan, MD; SusanM. Reams, RD, CSR, LD; CarlRedding, MSW; DorisRedding; SallyI. Rice, LCSW, DCSW; EdwardJ. Roccella, MD; NoreenK. Rogers; MicheleRoot, CNS; JeromeRossert, MD, PhD; HarryRubenstein, MD; MarkP. Rutkowski, MD; DoriSchatell, MS; SethSchulman, MD; MaryAnnSevick, RN, PhD; GaurangShah, MD; RobertShay, MD; DonaldJ. Sherrard, MD; JamesShinaberger, MD; JeffreyI. Silberzweig; DonaldSilverbergMD, FRCP; ErikSkullerud; DonnaSmolen, RN, BSM; AnnSnyderManson, MSW, CSW, BA; EdwardSondik, PhD; LeslieA. Spry, MD; SusanStark; Theodore I. Steinman, MD; Pam Stephens, RN; D. G. Struggle, MD; Arlene Sukolsky; Timothy J. Swenson, AND, RN, CNN; JudyH. Taylor, MPH, BSN, RN, CNN; BrendanP. Teehan, MD; Carol A. Tindira, RN, MS, CNN; Vicente E. Torres, MD; Walter Tozzi, MSRPN, MBA; AmbroseY. Tsang, MD; ShojiTsujimoto, MD, DMCA; JonahUkiwe, MD; AbiUmra; Yoshie Uyeda, RD; FernandoValderrabano, MD; L. J. Vleming, MD, PhD; SusanVogel, MHA, RN, CNN; MaryAnn Webb; BurkhardWeimer, MD; DebraWellman, RN; NanetteWenger, MD; DavidC. Wheeler, MD, MRCP; JosephD. White; BjornWikstrom, MD; D. Winearls; MarionWinkler, MS, RD, LDN, CNSD; NancyM. Wise, RD, MS; SunYang, MD; Mujdat Yenicesu, MD; JeffZavitz; CarmineZoccali, MD; andAnthonyW. Zydlewski, MD. Organizationsthattookpartinthereviewprocessinclude: AASK; AmericanAssociation of Kidney Patients; American College of PhysiciansAmerican Society of Internal Medicine; American Diabetes Association; American Nephrology Nurses Association; AmericanRegentLaboratories, Inc; AmericanSocietyforParenteralandEnteralNutrition; AmericanSocietyofNephrology; AmgenInc; AssociationfortheAdvancementofMedical 296 Part12. Acknowledgements NationalKidneyFoundation potassium/DOQI Instrumentation; AstraZeneca; Bone Care International; CNNT Executive Committee (National Kidney Foundation); CNSWExecutiveCommittee(National Kidney Foundation); DaVitaDialysisCenter; ESRDNetwork3; ESRDNetwork4; ESRDNetwork6; ESRDNetworkofFlorida, Inc, 7; ESRDNetwork 9/10; end-stage renal disease Network 11; Gambro Healthcare; Indian Health Service; Kaiser Permanente; Minority Outreach Committee (National Kidney Foundation); National Center for Health Statistics; sodiumtionalHeart, Lung, BloodInstitute; NationalInstituteforHealthandMedicalResearch; NationalInstituteofDiabetesandDigestiveandKidneyDisorders; NationalKidneyFoundationSingapore; OrthoBiotech, Inc; RenalCareGroup; RenalPhysiciansAssociation; RocheDiagnosticsCorporation; SatelliteDialysisCenters, Inc; ScribnerKidneyCenter; Sigma-TauPharamaceuticals; TotalRenalCare, Inc. Participationinthereviewdoesnotnecessarilyconstituteendorsementofthecontent ofthereportbytheindividualsortheorganizationorinstitutiontheyrepresent. TheNationalKidneyFoundation, aswellastheWorkGroup, recognizethesupport of Amgen. The National Kidney Foundation is proud to partner with Amgen on this importantinitiative. AsChairoftheWorkGroup, Ipersonallywishtothanktheothermembersofthe Work Group who volunteered their time, effort, wisdom, and humor to this project. Theirwillingnesstothinkaboutthebigpicturewhilesteadfastlyadheringtoaccuracy aboutsmalldetailsisresponsibleforthebreadthanddepthoftheseguidelines. Ihave learned a great deal from them. I would like to give special thanks to the following individuals: JosefCoresh, MD, PhD, Vice-ChairoftheWorkGroup, forhisexpertanalysis oftheNHANESIIIdatabaseandwisecounselaboutthedefinitionandclassificationof chronickidneydisease; RonaldJ. Hogg, MD, ChairofthePediatricWorkGroup, who insistedthatweenlargeourviewpointtoincludetheproblemsofchildren; AdeeraLevin, MD, whovolunteeredanalysisofindividualpatientdatafromherstudyandcoordinated presentationsbytheWorkGrouprepresentatives; EthanBalk, MD, MPH, whotirelessly workedwitheachmemberoftheWorkGrouptodevelopforms, reviewarticles, and synthesizedataintotables; RonaldD. Perrone, MD, myclosecolleagueofmanyyears, whoprovidedadviceonthescopeoftheevidencereviewandsupervisedthenephrology fellowsontheEvidenceReviewTeam; andJosephLau, MD, whosecreativity, practical approach, andhumorhelpedustoovercomeallobstacles. Finally, Iwouldliketothank GarabedEknoyan, MD, whosevision, leadership, andcommitmentguidedmethroughout theprocess. AndrewS. Levey, MD potassium/DOQI NationalKidneyFoundation Part12. Acknowledgements 297 BIBLIOGRAPHY 1. JonesCA, McQuillanGM, KusekJW, EberhardtMS, HermanWH, CoreshJ, SaliveM, JonesCP, AgodoaLY: SerumcreatininelevelsintheUSpopulation: ThirdNationalHealthandNutritionExaminationSurvey. AmJKidneyDis32: 992999, 1998(erratum35: 178, 2000) 2. USRenalDataSystem. USRDS1998AnnualDataReport, NationalInstitutesofHealth, National InstituteofDiabetesandDigestiveandKidneyDiseases. Bethesda, MD, 1998 3. SarnakMJ, LeveyAS: Cardiovasculardiseaseandchronicrenaldisease: Anewparadigm. AmJ KidneyDis35: S117-S131, 2000(suppl1) 4. USRenalDataSystem. USRDS2000AnnualDataReport, NationalInstitutesofHealth, National InstituteofDiabetesandDigestiveandKidneyDiseases. Bethesda, MD, 2000 5. CoreshJ, WeiGL, McQuillanG, BrancatiFL, LeveyAS, JonesC, KlagMJ: Prevalenceofhighblood pressureandelevatedserumcreatininelevelintheUnitedStates: FindingsfromthethirdNational HealthandNutritionExaminationSurvey(19881994). ArchInternMed161: 12071216, 2001 6. KeaneWF, EknoyanG: Proteinuria, albuminuria, risk, assessment, detection, elimination(PARADE): ApositionpaperoftheNationalKidneyFoundation. AmJKidneyDis33: 10041010, 1999 7. HoggRJ, PortmannRJ, MillinerD, LemleyKV, EddyA, IngelfingerJ: Evaluationandmanagement ofproteinuriaandnephroticsyndromeinchildren: Recommendationsfromapediatricnephrology panelestablishedattheNationalKidneyFoundationconferenceonProteinuria, Risk, Assessment, Detection, Elimination(PARADE). Pediatrics105: 12421249, 2000 8. AmericanDiabetesAssociation: ClinicalPracticeRecommendations2001. DiabetesCare24: S69S72, 2001(suppl1) 9. LeveyAS, BetoJA, CoronadoBE, EknoyanG, FoleyRN, KasiskeRL, KlagMJ, MaillouxLU, Manske chloride, MeyerKB, ParfreyPS, PfefferMA, WengerNK, WilsonPW, WrightJTJr: Controllingtheepidemicofcardiovasculardiseaseinchronicrenaldisease: Whatdoweknow? Whatdoweneed tolearn? Wheredowegofromhere? AmJKidneyDisease32: 853905, 1998 10. McClellanWM, KnightDF, KarpH, BrownWW: Earlydetectionandtreatmentofrenaldiseasein hospitalizeddiabeticandhypertensivepatients: Importantdifferencesbetweenpracticeandpublishedguidelines. AmJKidneyDis29: 368375, 1997 11. ObradorGT, RuthazerR, AroraP, KauszAT, PereiraBJ: Prevalenceofandfactorsassociatedwith suboptimalcarebeforeinitiationofdialysisintheUnitedStates. JAmSocNephrol10: 17931800, 1999 12. KannelWB, StampferMJ, CastelliWP, VerterJ: Theprognosticsignificanceofproteinuria: The Framinghamstudy. AmHeartJ108: 13471352, 1984 13. IsekiK, IsekiC, IkemiyaY, FukiyamaK: Riskofdevelopingend-stagerenaldiseaseinacohortof massscreening. KidneyInt49: 800805, 1996 14. PernegerTV, BrancatiFL, WheltonPK, KlagMJ: Studyingthecausesofkidneydiseaseinhumans: Areviewofmethodologicobstaclesandpossiblesolutions. AmJKidneyDis25: 722731, 1995 15. PereiraKI: Optimizationofpre-ESRDcare: Thekeytoimproveddialysisoutcomes. KidneyInt57: 351365, 2000 16. National Kidney Foundation-potassium/DOQIClinicalPracticeGuidelinesforPeritonealDialysisAdequacy: Update2000. AmJ KidneyDis37: S65-S136, 2001(suppl1) 17.",
    "word_count": 598,
    "char_count": 7481,
    "sentence_count": 71,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 62,
      "total_chunks": 77,
      "position": "63/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "end-stage renal disease",
        "albuminuria",
        "proteinuria",
        "potassium",
        "chloride"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 63,
    "text": "AmJKidneyDis25: 722731, 1995 15. PereiraKI: Optimizationofpre-ESRDcare: Thekeytoimproveddialysisoutcomes. KidneyInt57: 351365, 2000 16. National Kidney Foundation-potassium/DOQIClinicalPracticeGuidelinesforPeritonealDialysisAdequacy: Update2000. AmJ KidneyDis37: S65-S136, 2001(suppl1) 17. LeveyAS, BoschJP, LewisJB, GreeneT, RogersN, RothD: Amoreaccuratemethodtoestimate glomerularfiltrationratefromserumcreatinine: Anewpredictionequation. ModificationofDietin RenalDiseaseStudyGroup. AnnInternMed130: 461470, 1999 18. LeveyAS, GreeneT, KusekJW, BeckGJ: Asimplifiedequationtopredictglomerularfiltrationrate fromserumcreatinine. JAmSocNephrol11: A0828, 2000(abstr) 19. WarramJH, GearinG, LaffelL, KrolewskiAS: EffectofdurationoftypeIdiabetesontheprevalence ofstagesofdiabeticnephropathydefinedbyurinaryalbumin/creatinineratio. JAmSocNephrol 7: 930937, 1996 20. BarrattTM, McLainePN, SoothillJF: Albuminexcretionasameasureofglomerulardysfunctionin children. ArchDisChild45: 496501, 1970 21. DaviesAG, PostlethwaiteRJ, PriceDA, BurnJL, HoultonCA, FieldingBA: Urinaryalbuminexcretion onschoolchildren. ArchDisChild59: 625630, 1984 potassium/DOQI NationalKidneyFoundation Bibliography 299 22. BangstadHJ, Dahl-JorgensenK, KjaersgaardP, MevoldK, HanssenKF: Urinaryalbuminexcretion rateandpubertyinnon-diabeticchildrenandadolescents. ActaPaediatr82: 857862, 1993 23. CowellCT, RogersS, SilinkM: Firstmorningurinaryalbuminconcentrationisagoodpredictorof 24-hoururinaryalbuminexcretioninchildrenwithtype1(insulin-dependent)Diabetes. Diabetologia 29: 9799, 1986 24. SalardiS, Cacciari, PascucciMG, GiambiasiE, TacconiM, TazzariR: Microalbuminuriaindiabetic childrenandadolescents. Relationshipwithpubertyandgrowthhormone. ActaPaediatrScand79: 437433, 1990 25. MarshallSM, HackettA, CourtS, ParkinM, AlbertiKG: Albuminexcretioninchildrenandadolescentswithinsulin-dependentdiabetes. DiabetesRes3: 345348, 1986 26. EllisD, BuffoneGJ: Newapproachtoevaluationofproteinuricstates. ClinChem23: 666670, 1977 27. MathiesenERS, SaurbreyN, HommelE, ParvingHH: Prevalenceofmicroalbuminuriainchildren withtype1(insulin-dependent)diabetesmellitus. Diabetologia29: 640633, 1986 28. Brchner-MortensenJ, DitzelJ, MogensenCE, RodbroP: Microvascularpermeabilitytoalbuminand glomerularfiltrationrateindiabeticandnormalchildren. Diabetologia16: 307311, 1979 29. MortensenHB, MarinelliK, NorgaardK, MainK, KastrupKW, IbsenKK, VillumsenJ, ParvingHH: Anation-widecross-sectionalstudyofurinaryalbuminexcretionrate, arterialbloodpressureand Blood glucose control in Danish children with type 1 Diabetes mellitus. Danish Study Group of DiabetesinChildhood. DiabetMed10: 887977, 1990 30. DahlquistG, RudbergS: Theprevalenceofmicroalbuminuriaindiabeticchildrenandadolescents anditsrelationtopuberty. ActaPaediatrScand76: 7958000, 1987 31. ErmanA, vanDykDJ, RabinovM, BonerG, RosenfeldJB: Urinaryalbuminexcretioninthehealthy population. IsrJMedSci26: 389392, 1990 32. HollRW, GrabertM, ThonA, HeinzeE: Urinaryexcretionofalbumininadolescentswithtype1 Diabetes: Persistentversusintermittentmicroalbuminuriaandrelationshiptodurationofdiabetes, sex, andmetaboliccontrol. DiabetesCare22: 15551560, 1999 33. HuttunenNP, KaarM, PuukkaR, AkerblomHK: Exercise-inducedproteinuriainchildrenandadolescentswithtype1(insulindependent)Diabetes. Diabetologia21: 495497, 1981 34. ChiumelloG, BognettiE, MeschiF, CarraM, BalzanoE: Earlydiagnosisofsubclinicalcomplications ininsulindependentdiabeticchildrenandadolescents. JEndocrinolInvest12: 101104, 1989 (suppl3) 35. LabordeK, Levy-MarchalC, KindermansC, DechauxM, CzernichowP, SachsC: Glomerularfunction andmicroalbuminuriainchildrenwithinsulin-dependentdiabetes. PediatrNephrol4: 39433, 1990 36. MullisP, KochliHP, ZuppingerK, SchwarzHP: Intermittentmicroalbuminuriainchildrenwithtype 1diabetesmellituswithoutclinicalevidenceofnephropathy. EurJPediatr147: 385388, 1988 37. ElisesJS, GriffithsPD, HockingMD, TaylorCM, WhiteRH: Simplifiedquantificationofurinaryprotein excretioninchildren. ClinNephrol30: 225229, 1988 38. GinevriF, PiccottiE, AlinoviR, DeToniT, BiaginiC, ChiggeriGM, GusmanoR: Reversibletubular proteinuriaprecedesmicroalbuminuriaandcorrelateswiththemetabolicstatusofdiabeticchildren. PediatrNephrol7: 2326, 1993 39. HouserMT: Characterizationofproteinuriausingrandomurinesamples. IntJPediatrNephrol7: 197202, 1986 40. HjorthL, HelinI, GrubbA: Age-relatedreferencelimitsforurinelevelsofalbumin, orosomucoid, immunoglobulinGandproteinHCinchildren. ScandJClinLabInvest60: 6573, 2000 41. SchultzCJ, Konopelska-BahuT, DaltonRN, CarrollTA, StrattonI, GaleEA, NeilA, DungerDB: Microalbuminuriaprevalencevarieswithage, sex, andpubertyinchildrenwithtype1diabetes followedfromdiagnosisinalongitudinalstudy. OxfordRegionalProspectiveStudyGroup. Diabetes Care22: 495502, 1999 42. GibbD, ShahV, PreeceM, BarrattTM: Variabilityofurinealbuminexcretioninnormalanddiabetic children. PediatrNephrol3: 414419, 1989 43. SchultzCJ, DaltonRN, TurnerC, NeilHA, DungerDB: Freezingmethodaffectstheconcentration andvariabilityofurineproteinsandtheinterpretationofdataonmicroalbuminuria. TheOxford RegionalProspectiveStudyGroup. DiabetMed17: 714, 2000 44. YapC, YapHK, ChioLF: Urinemicroalbumin/creatinineratiosinSingaporechildren. JSingapore PaediatrSoc33: 101106, 1991 300 Bibliography NationalKidneyFoundation potassium/DOQI 45. JeffersonIG, GreeneSA, SmithMA, SmithRF, GriffinNKG, BaumJD: Urinealbumintocreatinine ratio-responsetoexerciseindiabetes. ArchDisChild60: 305310, 1985 46. CesariniPR, FerreiraSR, VivoloMA, ZanellaMT: Differenturinaryalbuminresponsestosubmaximal exercise by normoalbuminuric diabetic children and controls. Brazilian J Med Biol Res 29: 16031610, 1996 47. MurakamiM, YamamotoH, UedaY, MurakamiK, YamauchiK: Urinaryscreeningofelementary andjuniorhigh-schoolchildrenovera13-yearperiodinTokyo. PediatrNephrol5: 5053, 1991 48. LinCY, ShengCC, ChenCH, LinCC, ChouP: Theprevalenceofheavyproteinuriaandprogression riskfactorsinchildrenundergoingurinaryscreening. PediatrNephrol14: 953959, 2000 49. VehaskariVM, RapolaJ: Isolatedproteinuria: Analysisofaschool-agepopulation. JPediatr101: 661688, 1982 50. WagnerMG, SmithFGJr, TinglofBOJr, CornbergE: Epidemiologyofproteinuria. Astudyof4, 807 schoolchildren. JPediatr73: 825832, 1968 51. RandolphMF, GreenfieldM: Proteinuria. Asix-yearstudyofnormalinfants, preschool, andschoolagepopulationspreviouslyscreenedforurinarytractdisease. AmJDisChild114: 631638, 1967 52. JohnsonA, HeapGJ, HurleyBP: Asurveyofbacteriuria, proteinuriaandglycosuriainfive-year-old schoolchildrenincanberra. MedJAust2: 122124, 1974 53. WolmanIJ: Theincidence, causesandintermittencyofproteinuriainyoungmen. AmJMedSci 210: 86100, 1945 54. KuninCM, DeutscherR, PaquinAJr: Urinarytractinfectioninschoolchildren: Anepidemiologic, clinicalandlaboratorystudy. Medicine(Baltimore)43: 91130, 1964 55. MeadowSR, WhiteRH, JohnstonNM: PrevalenceofsymptomlessurinarytractdiseaseinBirmingham schoolchildren. I. Pyuriaandbacteriuria. BMJ3: 8184, 1969 56. MitchellN, StapletonFB: Routineadmissionurinalysisexaminationinpediatricpatients: Apoor value. Pediatrics86: 345349, 1990 57. HamillSM, BlackfanKD: Frequencyandsignificanceofalbuminintheurinesofnormalchildren. AmJDisChild1: 139163, 1911 58. DodgeWF, WestEF, SmithEH, BruceHIII: Proteinuriaandhematuriainschoolchildren: Epidemiologyandearlynaturalhistory. JPediatr88: 327347, 1976 59. HoggRJ, HarrisS, LawrenceDM, HenningPH, WiggN, JureidiniKF: Renaltractabnormalities detectedinAustralianpreschoolchildren. JPaediatrChildHealth34: 420424, 1998 60. SilverbergDS: City-widescreeningforurinaryabnormalitiesinschoolboys. CanMedAssocJ7: 410422, 1974 61. SilverbergDS, AllardMJ, UlanRA, BeamishWE, LentleBC, McPheeMS, GraceMG: City-wide screeningforurinaryabnormalitiesinschoolgirls. CanMedAssocJ109: 981985, 1973 62. Bashford HH: Adolescent albuminuria: Incidence, significance, and after-history. Lancet 2: 13051307, 1926 63. MuellerPW, CaudillSP: Urinaryalbuminexcretioninchildren: Factorsrelatedtoelevatedexcretion intheUnitedStatespopulation. RenFail21: 293302, 1999 64. PugiaMJ, LottJA, KajimaJ, SaambeT, SasakiM, KuromotoK, NakamuraR, FusegawaH, Ohta Y: Screeningschoolchildrenforalbuminuria, proteinuriaandoccultbloodwithdipsticks. ClinChem LabMed37: 149157, 1999 65. HoyWE, MathewsJD, McCredieDA, PugsleyDJ, HayhurstBG, ReesM, KileE, WalkerKA, WangZ: Themultidimensionalnatureofrenaldisease: RatesandassociationsofalbuminuriainanAustralian Aboriginalcommunity. KidneyInt54: 12961304, 1998 66. BernardA, StolteH, DeBroeME, MuellerPW, MasonH, LashLH, FowlerBA: Urinarybiomarkers todetectsignificanteffectsofenvironmentalandoccupationalexposuretonephrotoxins. IV. Current informationoninterpretingthehealthimplicationsoftests.",
    "word_count": 599,
    "char_count": 8699,
    "sentence_count": 114,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 63,
      "total_chunks": 77,
      "position": "64/77",
      "content_type": "dietary",
      "content_type_confidence": 3,
      "medical_entities": [
        "albuminuria",
        "proteinuria",
        "potassium",
        "insulin",
        "exercise"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 64,
    "text": "KidneyInt54: 12961304, 1998 66. BernardA, StolteH, DeBroeME, MuellerPW, MasonH, LashLH, FowlerBA: Urinarybiomarkers todetectsignificanteffectsofenvironmentalandoccupationalexposuretonephrotoxins. IV. Current informationoninterpretingthehealthimplicationsoftests. RenFail19: 553566, 1997 67. SmithHW: Comparativephysiologyofthekidney, inSmithHW(ed): TheKidney: Structureand FunctioninHealthandDisease. NewYork, NY, OxfordUniversityPress, 1951, pp520574 68. AtiyehBA, DabbaghSS, GruskinAB: Evaluationofrenalfunctionduringchildhood. PediatrRev 17: 175179, 1996 69. HeilbronDC, HollidayMA, Al-DahwiA, KoganBA: Expressingglomerularfiltrationrateinchildren. PediatrNephrol5: 511, 1991 70. CoultardMG: Maturationofglomerularfiltratiorinpretermandmaturebabies. EarlyHumDev11: 281292, 1985 potassium/DOQI NationalKidneyFoundation Bibliography 301 71. SchwartzGJ, FeldLG, LangfordDJ: Asimpleestimateofglomerularfiltrationrateinfull-terminfants duringthefirstyearoflife. JPediatr104: 849854, 1984 72. DaviesDF, ShockNW: Agechangesinglomerularfiltrationrate, effectiverenalplasmaflow, and tubularexcretorycapacityinadultmales. JClinInvest29: 496507, 1950 73. WessonLG: PhysiologyoftheHumanKidney. NewYork, GruneandStratton, 1969 74. WatkinsDM, ShockNW: Age-wisestandardvalueforCin, CPAH, andTmPAHinadultmales. JClin Invest34: 969, 1955 75. National Kidney Foundation-potassium/DOQIClinicalPracticeGuidelinesforNutritioninChronicRenalFailure. AmJKidneyDis 35: S1-S140, 2000(suppl2) 76. LeveyAS, GreeneT, BurkartJ: Comprehensiveassessmentofthelevelofrenalfunctionattheinitiation ofdialysisintheMDRDstudy. JAmSocNephrology9: 153A, 1998(abstr) 77. ObradorGT, AroraP, KauszAT, RuthazerR, PereiraBJ, LeveyAS: Levelofrenalfunctionatthe initiationofdialysisintheU. S. end-stagerenaldiseasepopulation. KidneyInt56: 22272235, 1999 78. AroraP, Obrador GT, RuthazerR, KauszAT, MeyerKB, JenulesonCS, PereiraBJ: Prevalence, predictors, andconsequencesoflatenephrologyreferralatatertiarycarecenter. JAmSocNephrol 10: 12811286, 1999 79. JungersP, ZingraffJ, AlbouzeG, ChauveauP, PageB, HannedoucheT, ManNK: Latereferralto maintenancedialysis: Detrimentalconsequences. NephrolDialTransplant8: 10891093, 1993 80. SessoR, YoshihiroMM: Timeofdiagnosisofchronicrenalfailureandassessmentofqualityoflife inhaemodialysispatients. NephrolDialTransplant12: 21112116, 1997 81. FinkJC, BurdickRA, KurthSJ, BlahutSA, ArmisteadNC, TurnerMS, ShickleLM, LightPD: Significance ofserumcreatininevaluesinnewend-stagerenaldiseasepatients. AmJKidneyDis34: 694701, 1999 82. IofelY, DawoodM, ValcourtJS, IfuduO: Initiationofdialysisisnotdelayedinwhiteswithprogressive renalfailure. ASAIOJ44: M598-M600, 1998 83. IfuduO, DawoodM, HomelP, FriedmanEA: Excessmorbidityinpatientsstartinguremiatherapy withoutpriorcarebyanephrologist. AmJKidneyDis28: 841845, 1996 84. GuidanceforIndustryPharmacokineticsinPatientswithImpairedRenalFunction: StudyDesign, Data Analysis and Impact on Dosing and Labeling. Washington, DC, ultrasound Department of Health and HumanServices, FoodandDrugAdministration, CenterforDrugEvaluationandResearch, Center forBiologicsEvaluationandResearch, 1998 85. GermanPS: Compliancewithchronicdisease. Hypertension11: 11561160, 1988 86. FrazierPA, Davis-AliSH, DahlKE: Correlatesofnoncomplianceamongrenaltransplantrecipients. ClinTransplant8: 550557, 1994 87. Kiley DJ, Lam CS, Pollack R: A study of treatment compliance following Kidney transplantation. Transplantation55: 5156, 1993 88. DiMatteoMR, LepperHS, CroghanTW: Depressionisariskfactorfornoncompliancewithmedical treatment: Meta-analysisoftheeffectsofanxietyanddepressiononpatientadherence. ArchIntern Med: 21012107, 2000 89. SchneiderMS, FriendR, WhitakerP, WadhwaNK: Fluidnoncomplianceandsymptomatologyin end-stagerenaldisease: Cognitiveandemotionalvariables. HealthPsychol10: 209215, 1991 90. ShawE, AndersonJG, MaloneyM, JaySJ, FaganD: Factorsassociatedwithnoncomplianceof patientstakingantihypertensivemedications. HospitalPharm30: 201203, 1995 91. McLaneCG, ZyzanskiSJ, FlockeSA: Factorsassociatedwithmedicationnoncomplianceinrural elderlyhypertensivepatients. AmJHypertens8: 206209, 1995 92. ChristensenAJ, SmithTW, TurnerCW, HolmanJM, GregoryMC, RichMA: Familysupport, physical impairment, andadherenceinhemodialysis: Aninvestigationofmainandbufferingeffects. JBehav Med15: 313325, 1992 93. BillupsSJ, MaloneDC, CarterBL: Therelationshipbetweendrugtherapynoncomplianceandpatient characteristics, health-relatedqualityoflife, andhealthcarecosts. Pharmacotherapy20: 941949, 2000 94. McGrathJM: Physiciansperspectivesoncommunicatingprescriptiondruginformation. QualHealth Res9: 731745, 1999 95. DusingR, WeisserB, MengdenT, VetterH: Changesinantihypertensivetherapy: Theroleofadverse effectsandcompliance. BloodPress7: 313315, 1998 302 Bibliography NationalKidneyFoundation potassium/DOQI 96. JohnsonMJ, WilliamsM, MarshallES: Adherentandnonadherentmedication-takinginelderlyantihypertensivepatients. ClinNursRes8: 318335, 1999 97. SharknessCM, SnowDA: Thepatientsviewofhypertensionandcompliance. AmJPrevMed8: 141146, 1992 98. MonaneM, BohnRL, GurwitzJH, GlynnRJ, LevinR, AvornJ: Compliancewithantihypertensive therapyamongelderlyMedicaidenrollees: Therolesofage, gender, andrace. AmJPublicHealth 86: 18051808, 1996 99. WrightSJ: Non-compliance: Meaningfulconstructordestructive, sticky, stigmatizinglabel? Edtna ErcaJ24: 3538, 1998 100. 27thBethesdaConference. MatchingtheIntensityofRiskFactorManagementwiththeHazardfor CoronaryDiseaseEvents. September1415, 1995. JAmCollCardiol27: 9571047, 1996 101. HarrisMI, FlegalKM, CowieCC, EberhardtMS, GoldsteinDE, LittleRR, WiedmeyetH-M, ByrdHoltDD: Prevalenceofdiabetes, impairedfastingglucose, andimpairedglucosetoleranceinU. S. adults: TheThirdNationalHealthandNutritionExaminationSurvey, 19881994. DiabetesCare 21: 518524, 1998 102. BurtVL, WheltonP, RoccellaEJ, BrownC, CutlerJA, HigginsM, HoranMJ, LabartheD: Prevalence ofhypertensionintheUSadultpopulation. Hypertension25: 305313, 1995 103. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, Heyse ST, Hirsch R, HochbergMC, HunderGG, LiangMH, PillemerSR, SteenVD, WolfeF: Estimatesoftheprevalence ofarthritisandselectedmusculoskeletaldisordersintheUnitedStates. ArthritisRheum41: 778799, 1998 104. USRenalDataSystem. Excerptsfromthe2000USRenalDataSystemAnnualDataReport: Atlas ofEndStageRenalDiseaseintheUnitedStates. AmJKidneyDis36: S1-S279, 2000(suppl2) 105. ProfilesofGeneralDemographicCharacteristics: 2000CensusofPopulationandHousing, United States. Washington, DC, USGovernmentPrintingOffice, 2001 106. DayJC: PopulationProjectionsoftheUnitedStatesbyAge, Sex, Race, andHispanicOrigin: 1995 to2050. Washington, DC, USGovernmentPrintingOffice, 1996 107. ElixhauserA, KlemstineK, SteinerC, BiermanA: ProceduresinU. S. Hospitals, 1997. Vol. HCUP FactBookNo. 2. Rockville, MD, AgencyforHealthcareResarchandQuality, 2001 108. HCUPnet: Healthcare Cost and Utilization Project. Website: www. ahrq. gov/data/hcup/hcupnet. htm, 7/4 109. McGoldrickMD, BailieGR: Nonnarcoticanalgesics: Prevalenceandestimatedeconomicimpactof toxicities. AnnPharmacother31: 221227, 1997 110. FriesJE: NSAIDgastropathy: Thesecondmostdeadlyrheumaticdisease? Epidemiologyandrisk appraisal. JRheumatol18: 610, 1991 111. RoseBD: Chapter3: RenalCirculationandGlomerularFiltrationRate: ClinicalPhysiologyofAcidBaseandElectrolyteDisorders. NewYork, NY, McGrawHill, 1984 112. LindemanRD, TobinJ, ShockNW: Longitudinalstudiesontherateofdeclineinrenalfunctionwith age. JAmGeriatrSoc33: 278285, 1985 113. PerroneRD, MadiasNE, LeveyAS: Serumcreatinineasanindexofrenalfunction: Newinsights intooldconcepts. ClinChem38: 19331953, 1992 114. PerroneRD, SteinmanTI, BeckGJ, SkibinskiCI, RoyalHD, LawlorM, HunsickerLG: Utilityofradioscopicfiltrationmarkersinchronicrenalinsufficiency: Simultaneouscomparisonof125I-iothalamate, 169Yb-DPTA, andinulin. TheModificationofDietinRenalDiseasesStudy. AmJKidneyDis16: 224235, 1990 115. WilsonDM, BergertJH, LarsonTS, LiedtkeRR: GFRdeterminedbynonradiolabelediothalamate usingcapillaryelectrophoresis. AmJKidneyDis30: 646652, 1997 116. DeinumJ, DerkxFH: Cystatinforestimationofglomerularfiltrationrate? Lancet356: 16241625, 2000 117. ShemeshO, GolbetzH, KrissJP, MyersBD: Limitationsofcreatinineasafiltrationmarkeringlomerulopathicpatients.",
    "word_count": 600,
    "char_count": 8284,
    "sentence_count": 120,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 64,
      "total_chunks": 77,
      "position": "65/77",
      "content_type": "treatment",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium"
      ],
      "entity_count": 1
    }
  },
  {
    "chunk_id": 65,
    "text": "AmJKidneyDis30: 646652, 1997 116. DeinumJ, DerkxFH: Cystatinforestimationofglomerularfiltrationrate? Lancet356: 16241625, 2000 117. ShemeshO, GolbetzH, KrissJP, MyersBD: Limitationsofcreatinineasafiltrationmarkeringlomerulopathicpatients. KidneyInt28: 830838, 1985 118. Levey AS, Perrone RD, Madias NE: Serum Creatinine and renal function. Annu Rev Med 39: 465490, 1988 119. LeveyAS: Assessingtheeffectivenessoftherapytopreventprogressionofrenaldisease. AmJKidney Dis22: 207214, 1993 potassium/DOQI NationalKidneyFoundation Bibliography 303 120. GaultMH, LongerichLL, HarnettJD, WesolowskiC: Predictingglomerularfunctionfromadjusted serumcreatinine. Nephron62: 249256, 1992 121. CockcroftDW, GaultMH: Predictionofcreatinineclearancefromserumcreatinine. Nephron16: 3141, 1976 122. JelliffeRW: Estimationofcreatinineclearancewhenurinecannotbecollected. Lancet1: 975976, 1971 123. SchwartzGJ, GauthierB: Asimpleestimateofglomerularfiltrationrateinadolescentboys. JPediatr 106: 522526, 1985 124. SchwartzGJ, HaycockGB, EdelmannCMJr, SpitzerA: Asimpleestimateofglomerularfiltration rateinchildrenderivedfrombodylengthandplasmacreatinine. Pediatrics58: 259263, 1976 125. BrionLP, BoeckMA, GauthierB, NussbaumMP, SchwartzGJ: Estimationofglomerularfiltration rateinanorecticadolescents. PediatrNephrol3: 1621, 1989 126. BrionLP, FleischmanAR, McCartonC, SchwartzGJ: Asimpleestimateofglomerularfiltrationrate inlowbirthweightinfantsduringthefirstyearoflife: Noninvasiveassessmentofbodycomposition andgrowth. JPediatr109: 698707, 1986 127. CounahanR, ChantlerC, GhazaliS, KirkwoodB, RoseF, BarrattTM: Estimationofglomerular filtrationratefromplasmacreatinineconcentrationinchildren. ArchDisChild51: 875878, 1976 128. BarrattTM, ChantlerC, LedermanS, RigdenSP: Assessmentofrenalfunction. AmJKidneyDis7: 347349, 1986 129. MorrisMC, AllanbyCW, ToselandP, HaycockGB, ChantlerC: Evaluationofaheight/plasma creatinineformulainthemeasurementofglomerularfiltrationrate. ArchDisChild57: 611615, 1982 130. JelliffeRW: Letter: Creatinineclearance: Bedsideestimate. AnnInternMed79: 604605, 1973 131. MawerGE, LucasSB, KnowlesBR, StirlandRM: Computer-assistedprescribingofkanamycinfor patientswithrenalinsufficiency. Lancet1: 1215, 1972 132. HullJH, HakLJ, KochGG, WarginWA, ChiSL, MattocksAM: Influenceofrangeofrenalfunction and Liver disease on predictability of Creatinine clearance. Clin Pharmacol Therapeutics 29: 516521, 1981 133. GatesGF: Creatinineclearanceestimationfromserumcreatininevalues: Ananalysisofthreemathematicalmodelsofglomerularfunction. AmJKidneyDis5: 199205, 1985 134. Bjornsson TD, Cocchetto diabetes mellitus, McGowan FX, Verghese CP, Sedor F: Nomogram for estimating creatinineclearance. ClinPharmacokinet8: 365369, 1983 135. TotoRD, KirkKA, CoreshJ, JonesC, AppelL, WrightJ, CampeseV, OlutadeB, AgodoaL: Evaluation ofserumcreatinineforestimatingglomerularfiltrationrateinAfricanAmericanswithhypertensive nephrosclerosis: ResultsfromtheAfrican-AmericanStudyofKidneyDiseaseandHypertension(AASK) PilotStudy. JAmSocNephrol8: 279287, 1997 136. AgarwalR, NicarM: Acomparativeanalysisofformulasusedtopredictcreatinineclearance. JAm SocNephrol5: 386, 1994 137. DavisGA, ChandlerMH: Comparisonofcreatinineclearanceestimationmethodsinpatientswith trauma. AmJHealthSystPharm53: 10281032, 1996 138. Edwards KDG, Whyte HM: Plasma Creatinine level and Creatinine clearance as a test of renal function. AustAnnMed8: 218224, 1959 139. HallynckT, SoepHH, ThomisJ, BoelaertJ, DaneelsR, FillastreJP, DeRosaF, RubinsteinE, Hatala M, SpoustaJ, DettliL: Predictionofcreatinineclearancefromserumcreatinineconcentrationbased onleanbodymass. ClinPharmacolTherapeutics30: 414421, 1981 140. MogensenCE, HeilskovNS: PredictionofGFRfromserumcreatinine. ActaEndocrinol(Copenh) Suppl238: 109, 1980 141. NankivellBJ, AllenRDM, OConnellPJ, ChapmanJR: Erythrocytesafterrenaltransplantation: Risk factorsandrelationshipwithGFR. ClinTransplant9: 375382, 1995 142. RobinsonBA, FramptonCM, CollsBM, AtkinsonCH, FitzharrisBM: Comparisonofmethodsof assessmentofrenalfunctioninpatientswithcancertreatedwithcisplatin, carboplatinormethotrexate. AustNZJMed20: 657662, 1990 143. RoweJWA, AndresR, TobinJD, NorrisAH, ShockNW: Theeffectofageoncreatinineclearance inmen: Across-sectionalandlongitudinalstudy. JGerontol31: 155163, 1976 144. SalazarDE, CorcoranGB: Predictingcreatinineclearanceandrenaldrugclearanceinobesepatients fromestimatedfat-freebodymass. AmJMed84: 10531060, 1988 304 Bibliography NationalKidneyFoundation potassium/DOQI 145. SanakaM, TakanoK, ShimakuraK, KoikeY, MineshitaS: Serumalbuminforestimatingcreatinine clearanceintheelderlywithmuscleatrophy. Nephron73: 137144, 1996 146. Siersbaek-NielsenK, HansenJM, KampmannJ, KristensenM: Rapidevaluationofcreatinineclearance. Lancet1: 11331134, 1971 147. TougaardL, Brochner-MortensenJ: Anindividualnomogramfordeterminationofglomerularfiltration ratefromplasmacreatinine. ScandJClinLabInvest36: 395397, 1976 148. Yukawa E, Hamachi Y, Higuchi S, Aoyama T: Predictive performance of equations to estimate creatinineclearancefromserumcreatinineinJapanesepatientswithcongestiveheartfailure. AmJ Ther6: 7176, 1999 149. ShullBC, HaughleyD, KoupJR, BaliahT, LiPK: Ausefulmethodforpredictingcreatinineclearance inchildren. ClinChem24: 11671199, 1978 150. TraubSL, JohnsonCE: Comparisonofmethodsofestimatingcreatinineclearanceinchildren. Am JHospPharm37: 195201, 1980 151. GhazaliS, BarrattTM: Urinaryexcretionofcalciumandmagnesiuminchildren. ArchDisChild49: 97101, 1974 152. EvansGO, GriffithsPD: Limitationsconcerningtheuseinchildrenoftherelationshipbetweenplasma creatinineandbodyheighttoderiveglomerularfiltrationrate. AnnClinBiochem18: 295298, 1981 153. HernandezdeAcevedoLH, JohnsonCE: Estimationofcreatinineclearanceinchildren: Comparison ofsixmethods. ClinPharm1: 158161, 1982 154. JelliffeRW, JelliffeSM: Acomputerprogramforestimationofcreatinineclearancefromunstable serumcreatininelevels, age, sex, andweight. MathBiosci14: 1724, 1972 155. PaapCM, NahataMC: Prospectiveevaluationoftenmethodsforestimatingcreatinineclearance inchildrenwithvaryingdegreesofrenaldysfunction. JClinPharmTherapeutics20: 6773, 1995 156. ParkinA, SmithHC, BrocklebankJT: Whichroutinetestforkidneyfunction? ArchDisChild64: 12611263, 1989 157. RuddGD, HullJH, MorrisCR, BryanCK: Estimatingcreatinineclearanceinchildren: Comparison ofthreemethods. AmJHospPharm37: 15141517, 1980 158. vandenAnkerJN, deGrootR, BroerseHM, SauerPJ, vanderHeijdenBJ, HopWC, LindemansJ: Assessmentofglomerularfiltrationrateinpreterminfantsbyserumcreatinine: Comparisonwith inulinclearance. Pediatrics96: 11561158, 1995 159. RolinHAIII, HallPM, WeiR: Inaccuracyofestimatedcreatinineclearanceforpredictionofiothalamateglomerularfiltrationrate. AmJKidneyDis4: 4854, 1984 160. LemannJ, BidaniAK, BainRP, LewisEJ, RohdeRD: Useoftheserumcreatininetoestimateglomerular filtrationrateinhealthandearlydiabeticnephropathy. CollaborativeStudyGroupofAngiotensin ConvertingEnzymeInhibitioninDiabeticNephropathy. AmJKidneyDis16: 236243, 1990 161. CharlesonHA, BaileyRR, StewartA: Quickpredictionofcreatinineclearancewithoutthenecessity ofurinecollection. NZMedJ92: 425426, 1980 162. LewisJ, AgodoaL, CheekD, GreeneT, MiddletonJ, OConnorD, OjoA, PhillipsR, SikaM, Wright JJr: African-AmericanStudyofHypertensionandKidneyDisease. Comparisonofcross-sectional renalfunctionmeasurementsinAfricanAmericanswithhypertensivenephrosclerosisandofprimary formulastoestimateglomerularfiltrationrate. AmJKidneyDis38: 744753, 2001 163. WallerDG, FlemingJS, RamseyB, GrayJ: Theaccuracyofcreatinineclearancewithandwithout urinecollectionasameasureofglomerularfiltrationrate. PostgradMedJ67: 4246, 1991 164. DeSantoNG, CoppolaS, AnastasioP, CoscarellaG, CapassoG, BelliniL, SantangeloR, Massimo L, SicilianoA: Predictedcreatinineclearancetoassessglomerularfiltrationrateinchronicrenal diseaseinhumans. AmJNephrol11: 181185, 1991 165. BedrosF, KasiskeB: EstimatingGFRfromcreatinineclearanceinrenaltransplantrecipients. JAm SocNephrol9: 666A, 1998(abstr) 166. GoerdtPJ, Heim-DuthoyKL, MacresM, SwanSK: Predictiveperformanceofrenalfunctionestimate equationsinrenalallografts. BrJClinPharmacol44: 261265, 1997 167. FillerG, PriemF, VollmerI, GellermannJ, JungK: Diagnosticsensitivityofserumcystatinforimpaired glomerularfiltrationrate. PediatrNephrol13: 501505, 1999 168. SeikalyMG, BrowneR, BajajG, ArantBSJr: Limitationstobodylength/serumcreatinineratioas anestimateofglomerularfiltrationinchildren. PediatrNephrol10: 709711, 1996 potassium/DOQI NationalKidneyFoundation Bibliography 305 169.",
    "word_count": 599,
    "char_count": 8536,
    "sentence_count": 108,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 65,
      "total_chunks": 77,
      "position": "66/77",
      "content_type": "treatment",
      "content_type_confidence": 3,
      "medical_entities": [
        "renal function",
        "creatinine",
        "potassium",
        "serum creatinine"
      ],
      "entity_count": 4
    }
  },
  {
    "chunk_id": 66,
    "text": "PediatrNephrol13: 501505, 1999 168. SeikalyMG, BrowneR, BajajG, ArantBSJr: Limitationstobodylength/serumcreatinineratioas anestimateofglomerularfiltrationinchildren. PediatrNephrol10: 709711, 1996 potassium/DOQI NationalKidneyFoundation Bibliography 305 169. HellersteinS, BerenbomM, AlonUS, WaradyBA: Creatinineclearancefollowingcimetidinefor estimationofglomerularfiltrationrate. PediatrNephrol12: 4954, 1998 170. GuignardJP, TorradoA, FeldmanH, GautierE: Assessmentofglomerularfiltrationrateinchildren. HelvPaediatrActa35: 437447, 1980 171. StakeG: EstimationoftheglomerularfiltrationrateininfantsandchildrenusingiohexolandX-ray fluorescencetechnique, inDepartmentofRadiology, SectionofPaediatricRadiology. Oslo, Norway, UniversityofOslo, 1992 172. SeikalyMG, BrowneR, SimondsN, AtkinsC, AlexanderSR: Glomerularfiltrationrateinchildren followingrenaltransplantation. PediatrTransplant2: 231235, 1998 173. SpringateJE, ChristensenSL, FeldLG: Serumcreatininelevelandrenalfunctioninchildren. AmJ DisChild146: 12321235, 1992 174. WazWR, QuattrinT, FeldLG: Serumcreatinine, height, andweight donotpredictglomerular filtrationrateinchildrenwithIDDM. DiabetesCare16: 10671070, 1993 175. BokenkampA, DomanetzkiM, ZinckR, SchumannG, ByrdD, BrodehlJ: CystatinCAnewmarker ofglomerularfiltrationrateinchildrenindependentofageandheight. Pediatrics101: 875881, 1998 176. StakeG, MonnE, RootweltK, GolmanK, MonclairT: Influenceofurographyonrenalfunctionin children. Adoubleblindstudywithmetrizoateandiohexol. ActaRadiol30: 643646, 1989 177. StakeG, MonnE, RootweltK, MonclairT: Theclearanceofiohexolasameasureoftheglomerular filtrationrateinchildrenwithchronicrenalfailure. ScandJClinLabInvest51: 729734, 1991 178. StakeG, MonnE, RootweltK, MonclairT: Asingleplasmasamplemethodforestimationofthe glomerularfiltrationrateininfantsandchildrenusingiohexol. II: Establishmentoftheoptimalplasma samplingtimeandacomparisonwiththe99Tcm-DTPAmethod. ScandJClinLabInvest51: 343348, 1991 179. Stake G, Monclair T: Asingle plasmasample method forestimation of theglomerular filtration rateininfantsandchildrenusingiohexol. I: Establishmentofabodyweight-relatedformulaforthe distributionvolumeofiohexol. ScandJClinLabInvest51: 335342, 1991 180. StakeG, MonnE, RootweltK, GronbergT, MonclairT: GlomerularfiltrationrateestimatedbyXrayfluorescencetechniqueinchildren: Comparisonbetweentheplasmadisappearanceof99TcmDTPAandiohexolafterurography. ScandJClinLabInvest50: 161167, 1990 181. WalserM: Assessingrenalfunctionfromcreatininemeasurementsinadultswithchronicrenalfailure. AmJKidneyDis32: 2331, 1998 182. ArantBSJr, GreiferI, EdelmannCMJr, SpitzerA: Effectofchronicsaltandwaterloadingonthe tubulardefectsofachildwithFanconisyndrome(cystinosis). Pediatrics58: 370377, 1976 183. RandersE, ErlandsenE: SerumcystatinCasanendogenousmarkeroftherenalfunctionAreview. ClinChemLabMed37: 389395, 1999 184. HollidayMA, HeilbornD, Al-UzriA, HidayatJ, UauyR, ConleySB, ReischJ, HoggRJ: SerialmeasurementsofGFRininfantsusingthecontinuousiothalamateinfusiontechnique. KidneyInt43: 893898, 1993 185. HellersteinS, AlonUS, WaradyBA: Creatinineforestimationofglomerularfiltrationrate. Pediatr Nephrol6: 507511, 1992 186. WinterbornMH, BeethamR, WhiteRHR: Comparisonofplasmadisappearanceandstandardclearancetechniquesformeasuringglomerularfiltrationrateinchildrenwithandwithoutvesico-ureteric reflux. ClinNephrol7: 262270, 1977 187. SchwartzGJ, BrionLP, SpitzerA: Theuseofplasmacreatinineconcentrationforestimatingglomerular filtrationrateininfants, children, andadolescents. PediatrClinNorthAm34: 571590, 1987 188. RossJW, MillerWG, MyersGL, PraestgaardJ: Theaccuracyoflaboratorymeasurementsinclinical chemistry: Astudyof11routinechemistryanalytesintheCollegeofAmericanPathologistsChemistry Surveywithfreshfrozenserum, definitivemethods, andreferencemethods. ArchPatholLabMed 122: 587608, 1998 189. ChiouWL, HsuFH: Anewsimpleandrapidmethdtomonitortherenalfunctionbasedonpharmacokineticconsiderationofendogenouscreatinine. ResCommunChemPatholPharmacol10: 315330, 1975 190. KwongMB, TongTK, MickellJJ, ChanJC: Lackofevidencethatformula-derivedcreatinineclearance approximates glomerular estimated glomerular filtration rate in pediatric intensive care population. Clin Nephrol 24: 285288, 1985 306 Bibliography NationalKidneyFoundation potassium/DOQI 191. JacobsonP, WestN, HutchinsonRJ: Predictiveabilityofcreatinineclearanceestimatemodelsin pediatricbonemarrowtransplantpatients. BoneMarrowTransplant19: 481485, 1997 192. FongJ, JohnstonS, ValentinoT, NottermanD: Length/serumcreatinineratiodoesnotpredictmeasuredcreatinineclearanceincriticallyillchildren. ClinPharmacolTherapeutics58: 192197, 1995 193. Gbadegesin RA, Adeyemo AA, Asinobi AO, Osinusi potassium: Inaccuracy of the Schwartz formula in estimatingglomerularfiltrationrateinNigerianchildren. AnnTropPaediatr17: 179185, 1997 194. RoccoMV, BuckalewVMJr, MooreLC, ShihabiZK: Capillaryelectrophoresisforthedetermination ofglomerularfiltrationrateusingnonradioactiveiohexol. AmJKidneyDis28: 173177, 1996 195. ZelmanovitzT, GrossJL, OliveiraJ, deAzevedoMJ: Proteinuriaisstillusefulforthescreeningand diagnosisofovertdiabeticnephropathy. DiabetesCare21: 10761079, 1998 196. ZelmanovitzT, GrossJL, OliveiraJR, PaggiA, TatschM, AzevedoMJ: Thereceiveroperatingcharacteristicscurveintheevaluationofarandomurinespecimenasascreeningtestfordiabeticnephropa- thy. DiabetesCare20: 516519, 1997 197. AhnCW, SongYD, KimJH, LimSK, ChoiKH, KimKR, LeeHC, HuhKB: Thevalidityofrandom urinespecimenalbuminmeasurementasascreeningtestfordiabeticnephropathy. YonseiMedJ 40: 4045, 1999 198. SchwabSJ, DunnFL, FeinglosMN: Screeningformicroalbuminuria. Acomparisonofsinglesample methodsofcollectionandtechniquesofalbuminanalysis. DiabetesCare15: 15811584, 1992 199. NgWY, LuiKF, ThaiAC: Evaluationofarapidscreeningtestformicroalbuminuriawithaspot measurementofurinealbumin-creatinineratio. AnnAcadMedSingapore29: 6265, 2000 200. CiavarellaA, SillettiA, ForlaniG, MorottiL, BorgninoLC, DApoteM, VanniniP: Ascreeningtest formicroalbuminuriaintype1(insulin-dependent)Diabetes. DiabetesResClinPractice7: 307312, 1989 201. Webb DJ, Newman DJ, Chaturvedi N, Fuller JH: The use of the Micral-Test strip to identify the presenceofmicroalbuminuriainpeoplewithinsulindependentdiabetesmellitus(IDDM)participating intheEUCLIDstudy. DiabetesResClinPractice31: 93102, 1996 202. PoulsenPL, HansenB, AmbyT, TerkelsenTE, MogensenC: Evaluationofadipsticktestformicroalbuminuriainthreedifferentclinicalsettings, includingthecorrelationwithurinaryalbuminexcretion rate. DiabetesMetab18: 395400, 1992 203. GerberLM, JohnstonK, AldermanMH: Assessmentofanewdipsticktestinscreeningformicroalbuminuriainpatientswithhypertension. AmJHypertens11: 13211327, 1998 204. SchwabSJ, ChristensenRL, DoughertyK, KlahrS: Quantitationofproteinuriabytheuseofproteinto-creatinineratiosinsingleurinesamples. ArchInternMed147: 943944, 1987 205. GinsbergJM, ChangBS, MatareseRA, GarellaS: Useofsinglevoidedurinesamplestoestimate quantitativeproteinuria. NEnglJMed309: 15431546, 1983 206. RodbyRA, RohdeRD, SharonZ, PohlMA, BainRP, LewisEJ: Theurineproteintocreatinineratio asapredictorof24-hoururineproteinexcretionintype1diabeticpatientswithnephropathy. The CollaborativeStudyGroup. AmJKidneyDis26: 904909, 1995 207. WilsonDM, AndersonRL: Protein-osmolalityratioforthequantitativeassessmentofproteinuriafrom arandomurinalysissample. AmJClinPathol100: 419424, 1993 208. ChuNF, FerngSH, ShiehSD, FanCD, ShyhTP, ChuPL: Assessmentofproteinuriabyusingthe Protein/creatinineratioofsingle-voidedurine. JFormosMedAssoc89: 657660, 1990 209. SteinhauslinF, WautersJP: Quantitationofproteinuriainkidneytransplantpatients: Accuracyof theurinaryprotein/creatinineratio. ClinNephrol43: 110115, 1995 210. NathanDM, RosenbaumC, ProtasowickiVD: Single-voidurinesamplescanbeusedtoestimate quantitativemicroalbuminuria. DiabetesCare10: 414418, 1987 211. CottieroRA, MadaioMP, LeveyAS: Glomerularfiltrationrateandurinaryalbuminexcretionrate insystemiclupuserythematosus. Nephron140: 140146, 1995 212. YoshimotoM, TsukaharaH, SaitoM, HayashiS, HarukiS, FujiswanaS, SudoM: Evaluationof variabilityofproteinuriaindices. PediatrNephrol4: 136139, 1990 213. IyerRS, ShailajaSN, BhaskaranandN, BaligaM, VenkateshA: Quantitationofproteinuriausing Protein-creatinineratioinrandomurinesamples. IndianPediatr28: 463467, 1991 214. ChaharOP, BundellaB, ChaharCKJ, PurohitM: Quantitationofproteinuriabyuseofsinglerandom spoturinecollection. JIndianMedAssoc91: 8687, 1993 215. MirS, KutukcularN, CuraA: Useofsinglevoidedurinesamplestoestimatequantitativeproteinuria inchildren. TurkJPediatr34: 219224, 1992 potassium/DOQI NationalKidneyFoundation Bibliography 307 216. HouserMT: Assessmentofproteinuriausingrandomurinesamples. JPediatr104: 845848, 1984 217. AbitbolC, ZillerueloG, FreundlichM, StraussJ: Quantitationofproteinuriawithurinaryprotein/ creatinineratiosandrandomtestingwithdipsticksinnephroticchildren. JPediatr166: 243224, 1990 218. SochettE, DanemanD: Screeningteststodetectmicroalbuminuriainchildrenwithdiabetes. JPediatr 112: 744748, 1988 219. FivushBA, JabsK, SullivanEK, FeldLG, KohautE, FineRN: Chronicrenalinsufficiencyinchildren andadolescents: the1996annualreportofNAPRTCS. NorthAmericanPediatricRenalTransplant CooperativeStudy(NAPRTCS). PediatrNephrol12: 328377, 1998 220.",
    "word_count": 594,
    "char_count": 9308,
    "sentence_count": 111,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 66,
      "total_chunks": 77,
      "position": "67/77",
      "content_type": "monitoring",
      "content_type_confidence": 5,
      "medical_entities": [
        "glomerular filtration rate",
        "potassium",
        "insulin"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 67,
    "text": "JPediatr 112: 744748, 1988 219. FivushBA, JabsK, SullivanEK, FeldLG, KohautE, FineRN: Chronicrenalinsufficiencyinchildren andadolescents: the1996annualreportofNAPRTCS. NorthAmericanPediatricRenalTransplant CooperativeStudy(NAPRTCS). PediatrNephrol12: 328377, 1998 220. Kitagawa T: Lessons learned from the Japanese nephritis screening study. Pediatr Nephrol 2: 256263, 1998 221. CommitteeonPracticeandAmbulatoryMedicine: Recommendationsforpreventivepediatrichealth care. Pediatrics96: 14, 1995 222. KaplanRE, SpringateJE, FeldLG: Screeningdipstickanalysis: Atimetochange. Pediatrics100: 919921, 1997 223. AmericanDiabetesAssociation: Diabeticnephropathy. DiabetesCare21: S50-S53, 1998 224. TheEUCLIDStudyGroup: Randomisedplacebo-controlledtrialoflisinoprilinnormotensivepatients with insulin-dependent Diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 17871792, 1997 225. MathiesenER, HommelE, HansenHP, SmidtUM, ParvingH-H: Randomisedcontrolledtrialoflong termefficacyofcaptoprilonpreservationofkidneyfunctioninnormotensivepatientswithinsulin dependentdiabetesandmicroalbuminuria. BMJ319: 2425, 1999 226. RuggenentiP, PaganoE, TammuzzoL, BeniniR, GarattiniL: GruppoItalianoDiStudiEpidemilogici inNefrologia(GISEN). KidneyInt59: 286294, 2001 227. WangPH: WhenshouldACEinhibitorsbegiventonormotensivepatientswithIDDM? Lancet349: 17821783, 1997 228. GrimmRHJr, SvendsenKH, KasiskeB, KeaneWF, WahiMM: Proteinuriaisariskfactorformortality over10yearsoffollow-up. MRFITResearchGroup. MultipleRiskFactorInterventionTrial. Kidney Int63: S10-S14, 1997(suppl63) 229. CouperJJ, ClarkeCF, ByrneGC, JonesTW, DonaghueKC, NairnJ, BoyceD, RussellM, Stephens M, RaymondJ, BatesDJ, McCaulK: Progressionofborderlineincreasesinalbuminuriainadolescents withinsulin-dependentdiabetesmellitus. DiabetMed14: 766771, 1997 230. LeveyAS, PerroneRD, MadaioMP: Laboratoryassessmentofrenaldisease: Clearance, urinalysis andrenalbiopsy, inBrennerBM, RectorFR(eds): TheKidney. Philadelphia, PA, W. B. Saunders, 1991, pp919968 231. NordenAG, ScheinmanSJ, Deschodt-LanckmanMM, LapsleyM, NortierJL, ThakkerRV, UnwinRJ, WrongO: TubularproteinuriadefinedbyastudyofDents(CLCN5mutation)andothertubular diseases. KidneyInt57: 240-249, 2000 232. TomlinsonPA, SmellieJM, PrescodN, DaltonRN, ChantlerC: Differentialexcretionofurinaryproteins inchildrenwithvesicouretericrefluxandrefluxnephropathy. PediatrNephrol8: 2125, 1994 233. WeitgasserR, SchnoellF, GappmayerB, KartnigI: ProspectiveevaluationofurinaryN-acetyl-betaD-glucosaminidasewithrespecttomacrovasculardiseaseinelderlytype2diabeticpatients. Diabetes Care22: 18821886, 1999 234. KordonouriO, HartmannR, MuellerC, DanneT, WeberB: Predictivevalueoftubularmarkersfor thedevelopmentofmicroalbuminuriainadolescentswithdiabetes. FromtheHormoneRes50: S23S27, 1998(suppl1) 235. ReichertLJ, KoeneRA, WetzelsJF: UrinaryIgGexcretionasaprognosticfactorinidiopathicmembranousnephropathy. ClinNephrol48: 7984, 1997 236. BazziC, PetriniC, RizzaV, ArrigoG, BeltrameA, DAmicoG: Characterizationofproteinuriain primaryglomerulonephritides. SDS-PAGEpatterns: Clinicalsignificanceandprognosticvalueoflow molecularweight(tubular)proteins. AmJKidneyDis29: 2735, 1997 237. WooKT, LauYK, LeeGS, WeiSS, LimCH: PatternofproteinuriainIgAnephritisbySDS-PAGE: Clinicalsignificance. ClinNephrol36: 611, 1991 238. ReichertLJ, KoeneRA, WetzelsJF: Urinaryexcretionofbeta2-microglobulinpredictsrenaloutcome inpatientswithidiopathicmembranousnephropathy. JAmSocNephrol6: 16661669, 1995 308 Bibliography NationalKidneyFoundation potassium/DOQI 239. HaraM, YanagiharaT, ItohM, MatsunoM, KiharaI: Immunohistochemicalandurinarymarkersof podocyteinjury. PediatrNephrol12: 4348, 1998 240. HaraM, YanagiharaT, TakadaT, ItohM, MatsunoM, YamamotoT, KiharaI: Urinaryexcretionof podocytesreflectsdiseaseactivityinchildrenwithglomerulonephritis. AmJNephrol18: 3541, 1998 241. HottaO, TagumaY, OoyamaM, YusaN, NaguraH: AnalysisofCD14(cid: 1)cellsandCD56(cid: 1)cells inurineusingflowcytometry: AusefultoolformonitoringdiseaseactivityofIgAnephropathy. Clin Nephrol39: 289294, 1993 242. NakamuraT, UshiyamaC, SuzukiS, HaraM, ShimadaN, SekizukaK, EbiharaI, KoideH: Urinary podocytesfortheassessmentofdiseaseactivityinlupusnephritis. AmJMedSci320: 112116, 2000 243. NakamuraT, UshiyamaC, SuzukiS, HaraM: Urinaryexcretionofpodocytesinpatientswithdiabetic nephropathy. NephrolDialTransplant15: 13791383, 2000 244. WilsonPW, CulletonBF: EpidemiologyofcardiovasculardiseaseintheUnitedStates. AmJKidney Dis32: S56-S65, 1998(suppl3) 245. TheSixthReportoftheJointNationalCommitteeonPrevention, Detection, Evaluation, andTreatment ofHighBloodPressure(JNCVI). Bethesda, MD, USDepartmentofHealthandHumanServices, PublicHealthService, NationalInstitutesofHealth, NationalHeart, LungandBloodInstitute, 1997 246. BurtVL, CutlerJA, HigginsM, HoranMJ, LabartheD, WheltonP, BrownC, RoccellaEJ: Trendsin theprevalence, awareness, treatment, andcontrolofhypertensionintheadultUSpopulation. Data fromthehealthexaminationsurveys, 19601991. Hypertension26: 6069, 1995(erratum27: 1192, 1996) 247. WrightJTJr, DouglasJG, RahmanM: Preventionofcardiovasculardiseaseinhypertensivepatients withnormalrenalfunction. AmJKidneyDis32: S66-S79, 1998(suppl3) 248. MaillouxLU, LeveyAS. Hypertensioninchronicrenaldisease. AmJKidneyDis32: S120-S141, 1998(suppl3) 249. BakrisGL, WilliamsM, DworkinL, ElliottWJ, EpsteinM, TotoRDA, TuttleK, DouglasJ, HsuehW, SowersJ: Preservingrenalfunctioninadultswithhypertensionanddiabetes: Aconsensusapproach. NationalKidneyFoundationHypertensionandDiabetesExecutiveCommitteesWorkingGroup. Am JKidneyDis36: 646661, 2000 250. HCFA-1995: 1995AnnualReport. ESRDcoreindicatorproject. Opportunitiestoimprovecarefor adultin-centerhemodialysispatients. Baltimore, MD, HealthCareFinancingAdministration, DHHS, 1996 251. RoccoMV, FlanaganMJ, BeaverS, FrederickP, GentileDI, McClellanWM, PolderJ, ProwantBF, TaylorL, HelgerssonSD: Reportfromthe1995coreindicatorsforperitonealdialysisstudygroup. AmJKidneyDis30: 165173, 1997 252. NationalHighBloodPressureEducationProgramWorkingGroup. 1995Updateoftheworking group reports on chronic renal failure and renovascular hypertension. Arch Intern Med 156: 19381947, 1995 253. ParvingHH, AndersenAR, SmidtUM: Earlyaggressiveantihypertensivetreatmentreducesrateof declineinkidneyfunctionindiabeticnephropathy. Lancet1: 11751179, 1983 255. PetersonJC, AdlerS, BurkartJM, GreeneT, HebertLA, HunsickerLG, KingAJ, KlahrS, MassrySG, SeifterJL: Bloodpressurecontrol, proteinuriaandtheprogressionofrenaldisease: TheModification ofDietinRenalDiseaseStudy. AnnInternMed123: 754762, 1995 256. OpelzG, WujciakT, RitzE: TheCollaborativeTransplantStudy. Associationofchronickidneygraft failurewithrecipientbloodpressure. KidneyInt53: 217222, 1998 257. LevinA, SingerJ, ThompsonCR: Prevalentleftventricularhypertrophyinthepredialysispopulation: Identifyingopportunitiesforintervention. AmJKidneyDis27: 347354, 1996 258. LazarusJM, BourgoignieJJ, BuckalewVMJr, MilasNC, ParanandiL, PetersonJC, PorushJG, Rauch S, SoucieJM, StollarC: Achievementandsafetyofalowbloodpressuregoalinchronicrenal disease. ModificationofDietinRenalDiseaseStudyGroup. Hypertension29: 641650, 1997 259. JungersP, MassyZA, NguyenKhoaT, FumeronC, LabrunieM, LacourB, Descamps-LatschaB, Man NK: Incidenceandriskfactorsofatheroscleroticcardiovascularaccidentsinpredialysischronic renalfailurepatients: Aprospectivestudy. NephrolDialTransplant12: 25972602, 1997 260. FoleyRN, ParfreyPS, HarnettJD, DentFM, MurrayDC, BarrePC: Impactofhypertensiononcardiomyopathy, morbidityandmortalityinend-stagerenaldisease. KidneyInt49: 13791385, 1996 potassium/DOQI NationalKidneyFoundation Bibliography 309 261. FoleyRN, ParfreyPS, SarnakMJ: Clinicalepidemiologyofcardiovasculardiseaseinchronicrenal disease. AmJKidneyDis32: 112119, 1998 262. ZagarPG, NikolicJ, BrownRH, CampbellMA, HuntWC, PetersonD, VanStoneJ, LeveyA, Meyer KB, KlagMJ, JohnsonHK, ClarkE, SadlerJH, TeredesaiP: Ucurveassociationofbloodpressure andmortalityinhemodialysispatients. KidneyInt54: 561569, 1998 263. BuckalewVMJr, BergRL, WangSR, PorushJG, RauchS, SchulmanG: Prevalenceofhypertension in1, 795subjectswithchronicrenaldisease: Themodificationofdietinrenaldiseasestudybaseline cohort. ModificationofDietinRenalDiseaseStudyGroup. AmJKidneyDis28: 811821, 1996 265. National Kidney Foundation-DOQIclinicalpracticeguidelinesforthetreatmentofanemiaofchronicrenalfailure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am J Kidney Dis 30: S192-S240, 1997 (suppl3) 266. National Kidney Foundation-potassium/DOQIClinicalPracticeGuidelinesforAnemiaofChronicKidneyDisease: Update2000. AmJKidneyDisease77: S182-S288, 2001(suppl1) 267.",
    "word_count": 598,
    "char_count": 8668,
    "sentence_count": 107,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 67,
      "total_chunks": 77,
      "position": "68/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "renal failure",
        "nephropathy",
        "nephritis",
        "potassium",
        "insulin",
        "dialysis",
        "screening"
      ],
      "entity_count": 7
    }
  },
  {
    "chunk_id": 68,
    "text": "Am J Kidney Dis 30: S192-S240, 1997 (suppl3) 266. National Kidney Foundation-potassium/DOQIClinicalPracticeGuidelinesforAnemiaofChronicKidneyDisease: Update2000. AmJKidneyDisease77: S182-S288, 2001(suppl1) 267. McGonigleRJ, WallinJD, ShadduckRK, FisherJW: Erythropoietindeficiencyandinhibitionoferythropoiesisinrenalinsufficiency. KidneyInt25: 437444, 1984 268. RadtkeHW, ClaussnerA, ErbesPM, ScheuermannEH, SchoeppeW, KochKM: Serumerythropoietin concentrationinchronicrenalfailure: Relationshiptodegreeofanemiaandexcretoryrenalfunction. Blood54: 877884, 1979 269. LogeJP, LangeRD, MooreCV: Characterizationoftheanemiaassociatedwithchronicrenalinsufficiency. AmJMed24, 1958 270. RossRP, McCreaJB, BesarabA: Erythropoietinresponsetobloodlossinhemodialysispatientsis bluntedbutpreserved. ASAIOJ40: M880-M885, 1994 271. NaetsJP, GarciaJF, TousaaintC, BusetM, WaksD: Radioimmunoassayoferythropoietininchronic uraemiaofanephricpatients. ScandJHaematol37: 390394, 1986 272. WorldHealthOrganization: NutritionalAnemia. ReportofaWHOScientificGroup. Geneva, Switzerland, WHO, 1968 273. WorkingPartyforEuropeanBestPracticeGuidelinesfortheManagementofAnaemiainPatients WithChronicRenalFailure: Europeanbestpracticeguidelinesforthemanagementofanaemiain patientswithchronicrenalfailure. NephrolDialTransplant14: 150, 1999(suppl5) 274. ErslevAJ, BesarabA: Therateandcontrolofbaselineredcellproductioninhema-tologicallystable uremicpatients. JLabClinMed126: 283286, 1995 275. FisherJW: Mechanismoftheanemiaofchronicrenalfailure. Nephron25: 106111, 1980 276. BesarabA, LevinA: Definingarenalanemiamanagementperiod. AmJKidneyDis36: S13-S23, 2000 277. ChandraM, MillerME, GarciaJF, MosseyRT, McVicarMI: Serumimmunoreactiveerythropoietin levelsinpatientswithpolycystickidneydiseaseascomparedwithotherhemodialysispatients. Nephron39: 2629, 1985 278. EschbachJWJr, FunkD, AdamsonJ, KuhnI, ScribnerBH, FinchCA: Erythropoiesisinpatientswith renalfailureundergoingchronicdialysis. NEnglJMed276: 653688, 1967 279. CollinsAJ, MaJZ, XiaA, EbbenJ: Trendsinanemiatreatmentwitherythropoietinusageandpatient outcomes. AmJKidneyDis32: S133-S141, 1998(suppl4) 280. ParfreyPS, FoleyRN, HarnettJD, KentGM, MurrayDC, BarrePE: Outcomeandriskfactorsforleft ventriculardisordersinchronicuraemia. NephrolDialTransplant11: 12771285, 1996 281. LevinA, FoleyRN: Cardiovasculardiseaseinchronicrenalinsufficiency. AmJKidneyDis36: S24S30, 2000(suppl3) 282. KauszAT, ObradorGT, PereiraBJ: Anemiamanagementinpatientswithchronicrenalinsufficiency. AmJKidneyDis36: S39-S51, 2000(suppl3) 283. LocatelliF, ConteF, MarcelliD: TheimpactofhematocritlevelsandErythropoietintreatmenton overallandcardiovascularmortalityandmorbidity: TheexperienceofLombardyRegistry. NDT13: 16421644, 1998 284. MuirheadN, fortheCanadianErythropoietinStudyGroup: Associationbetweenrecombinanthuman erythropoietinandqualityoflifeandexercisecapacityofpatientsreceivinghaemodialysis. BMJ 300: 573578, 1990 285. TheUSRecombinantErythropoietinPredialysisStudyGroup: Double-blind, placebocontrolledstudy ofthetherapeuticuseofrecombinanthumanerythropoietinforanemiaassociatedwithchronicrenal failureinpredialysispatients. AmJKidneyDis18: 5059, 1991 310 Bibliography NationalKidneyFoundation potassium/DOQI 286. Austrian Multicenter Study Group of rHuEPO in predialysis patients: Effectiveness and safety of recombinanthumanerythropoietininpredialysispatients. Nephron61: 399403, 1992 287. WinearlsCG: Recombinanthumanerythropoietin: 10yearsofclinicalexperience. NephrolDial Transplant13: 38, 1998 288. LevinA, ThompsonCR, EthierJ, CarlisleEJ, TobeS, MendelssohnD, BurgessE, JindalK, BarrettB, SingerJ, DjurdjevO: Leftventricularmassindexincreaseinearlyrenaldisease: Impactofdecline inhemoglobin. AmJKidneyDis34: 125134, 1999 289. TaralovZ, KoumtchevE, LyutakovaZ: Erythrocyteferritinlevelsinchronicrenalfailurepatients. Folia Medica(Plovdiv)40: 6570, 1998 290. ClyneN, JogestrandT, LinsLE, PehrssonSK: Progressivedeclineinrenalfunctioninducesagradual decreaseintotalhemoglobinandexercisecapacity. Nephron67: 322326, 1994 291. IshimuraE, NishizawaY, OkunoS, MatsumotoN, EmotoM, InabaM, KawagishiT, KimCW, Morii H: Diabetesmellitusincreasestheseverityofanemiainnon-dialyzedpatientswithrenalfailure. J Nephrol11: 8386, 1998 292. deKlerkG, WilminkJM, RosengartenPC, VetRJ, GoudsmitR: Serumerythropoietin(ESF)titersin anemiaofchronicrenalfailure. JLabClinMed100: 720734, 1982 293. UrabeA, SaitoT, FukamachiH, KubotaM, TakakuF: Serumerythropoietintitersintheanemiaof chronicrenalfailureandotherhematologicalstates. IntJCellCloning5: 202208, 1987 294. SilverbergDS, IainaA, PeerG, KaplanE, LeviBA, FrankN, SteinbruchS, BlumM: Intravenousiron supplementationforthetreatmentoftheanemiaofmoderatetoseverechronicrenalfailurepatients notreceivingdialysis. AmJKidneyDis27: 234238, 1996 295. LinJL, KouMT, LeuML: Effectoflong-termlow-dosealuminum-containingagentsonhemoglobin synthesisinpatientswithchronicrenalinsufficiency. Nephron74: 3338, 1996 296. ClyneN, JogestrandT: Effectoferythropoietintreatmentonphysicalexercisecapacityandonrenal functioninpredialyticuremicpatients. Nephron60: 390396, 1992 297. Portoles J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A: Cardiovascular effects of recombinanthumanerythropoietininpredialysispatients. AmJKidneyDis29: 541548, 1997 298. DimitrakovD, KumchevE, TllkianE: Studyoftheeffectofrecombinanterythropoietinonrenalanaemiainpredialysispatientswithchronicrenalfailure. FoliaMedica(Plovdiv)36: 3136, 1994 299. KlahrS, BreyerJA, BeckGJ, DennisVW, HartmanJA, RothD, SteinmanTI, WangSR, Yamamoto ME: Dietaryproteinrestriction, bloodpressurecontrol, andtheprogressionofpolycystickidney disease. ModificationofDietinRenalDiseaseStudyGroup. JAmSocNephrol5: 20372047, 1995(erratum6: 1318, 1995) 300. HowardAD, MooreJJr, WelchPG, GougeSF: Analysisofthequantitativerelationshipbetween anemiaandchronicrenalfailure. AmJMedSci297: 309313, 1989 301. LimVS, FangmanJ, FlaniganMJ, DeGowinRL, AbelsRT: Effectofrecombinanthumanerythropoietin onrenalfunctioninhumans. KidneyInt37: 131136, 1990 302. BesarabA, CaroJ, JarrellB, BurkeJ, FrancosG, MallonE, KarschR: Effectofcyclosporineand delayedgraftfunctiononposttransplantationerythropoiesis. Transplantation40: 624631, 1985 303. BrodJ, HornychA: Effectofcorrectionofanemiaontheglomerularfiltrationrateinchronicrenal failure. IsrJMedSci3: 5359, 1967 304. RothD, SmithRD, SchulmanG, SteinmanTI, HatchFE, RudnickMR, SloandJA, FreedmanBI, Williams WWJr, ShadurCA: Effectsofrecombinanthumanerythropoietinonrenalfunctioninchronicrenal failurepredialysispatients. AmJKidneyDis24: 777784, 1994 305. KuriyamaS, TomonariH, YoshidaH, HashimotoT, KawaguchiY, SakaiO: Reversalofanemiaby erythropoietintherapyretardstheprogressionof chronicrenalfailure, especiallyinnondiabetic patients. Nephron77: 176185, 1997 306. HayashiT, SuzukiA, ShojiT, TogawaM, OkadaN, TsubakiharaY, ImaiE, HoriM: Cardiovascular effectofnormalizingthehematocritlevelduringerythropoietintherapyinpredialysispatientswith chronicrenalfailure. AmJKidneyDis35: 250256, 2000 307. SchwartzAB, PriorJE, MintzGS, KimKE, KahnSB: Cardiovascularhemodynamiceffectsofcorrectionofanemiaofchronicrenalfailurewithrecombinant-humanerythropoietin. TransplantProc23: 18271830, 1991 308. DonnelleyS, ShahBE: Erythropoietindeficiencyinhyporeninemia. AmJKidneyDis33: 947953, 1999 potassium/DOQI NationalKidneyFoundation Bibliography 311 309. ChaplinH, MollisonPL: Redcelllifespaninnephritisandinhepaticnephrosis. ClinSci12: 351, 1953 310. BesarabA, CaroJ, JarrellBE, FrancosG, ErslevAJ: Dynamicsoferythropoiesisfollowingrenal transplantation. KidneyInt32: 526536, 1987 311. CavillI: Ironstatusasmeasuredbyserumferritin: Themarkeranditslimitations. AmJKidneyDis 34: S12-S17, 1999(suppl2) 312. Sunder-PlassmannG, HorlW: Erythropoietinandiron. ClinNephr47: 141157, 1997 313. Eckard potassium-U, Mollmann M, Neumann R: Erythropoietin in polycystic Kidney. J Clin Invest 84: 11601166, 1989 314. IkizlerTA, HakimRM: Nutritioninend-stagerenaldisease. KidneyInt50: 343357, 1996 315. KlahrS, LeveyAS, BeckGJ, CaggiulaAW, HunsickerL, KusekJW, StrikerG: Theeffectsofdietary proteinrestrictionandblood-pressurecontrolontheprogressionofchronicrenaldisease. ModificationofDietinRenalDiseaseStudyGroup. NEnglJMed330: 877884, 1994 316. GrahamKA, ReaichD, ChannonSM, DownieS, GoodshipTH: Correctionofacidosisinhemodialysis decreaseswhole-bodyproteindegradation. JAmSocNephrol8: 632637, 1997 317. PositionoftheAmericanDieteticAssociation: Cost-effectivenessofmedicalnutritiontherapy. JAm DietAssoc95: 8891, 1995 318. BergstromJ: Nutritionandmortalityinhemodialysis. JAmSocNephrol6: 13291341, 1995 319. LowrieEG, HuangWH, LewNL, LiuY: Therelativecontributionofmeasuredvariablestodeath riskamonghemodialysispatients, inFriedmanEA(ed): DeathonHemodialysis. Amsterdam, The Netherlands, KluwerAcademic, 1994, pp121141 320. HakimRM, LazarusJM: Initiationofdialysis.",
    "word_count": 600,
    "char_count": 8874,
    "sentence_count": 112,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 68,
      "total_chunks": 77,
      "position": "69/77",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "erythropoietin"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 69,
    "text": "LowrieEG, HuangWH, LewNL, LiuY: Therelativecontributionofmeasuredvariablestodeath riskamonghemodialysispatients, inFriedmanEA(ed): DeathonHemodialysis. Amsterdam, The Netherlands, KluwerAcademic, 1994, pp121141 320. HakimRM, LazarusJM: Initiationofdialysis. JAmSocNephrol6: 13191328, 1995 321. HollandD, LamM: Predictorsofhopitalizationanddeathamongstpre-dialysispatients: Aretrospectivestudy. NephrolDialTransplant15: 650658, 2000 322. IkizlerTA, WingardRL, HarvellJ, ShyrY, HakimRM: Associationofmorbidity withmarkersof nutritionandinflammationinchronichemodialysispatients: Aprospectivestudy. KidneyInt55: 19451951, 1999 323. StenvinkelP, HeimburgerO, PaultreF, DiczfalusyU, WangT, BerglundL, JogestrandT: Strong associationbetweenmalnutrition, inflammation, andatherosclerosisinchronicrenalfailure. Kidney Int55: 18991911, 1999 324. KoppleJD, GreeneT, ChumleaWC, HollingerD, MaroniBJ, MerrillD, ScherchLK, SchulmanG, WangSR, ZimmerGS: Relationshipbetweennutritionalstatusandtheglomerularfiltrationrate: ResultsfromtheMDRDstudy. KidneyInt57: 16881703, 2000 325. IkizlerTA, GreeneJH, WingardRL, ParkerRA, HakimRM: Spontaneousdietaryproteinintakeduring progressionofchronicrenalfailure. JAmSocNephrol6: 13861391, 1995 326. MitchWE, MaroniBJ: Nutritionalconsiderationsinthetreatmentofpatientswithchronicuremia. MinerElectrolyteMetab24: 285289, 1998 327. MitchWE, MaroniBJ: Factorscausingmalnutritioninpatientswithchronicuremia. AmJKidneyDis 33: 176179, 1999 328. BallmerPE, ImoberdorfR: Influenceofacidosisonproteinmetabolism. Nutrition11: 462468, 1995 329. TonshoffB, BlumWF, MehlsO: Derangementsofthesomatotropichormoneaxisinchronicrenal failure. KidneyInt58: S106-S113, 1997(suppl58) 330. SaborioP, HahnS, HisanoS, LattaK, ScheinmannJI, ChanJC: Chronicrenalfailure: Anoverview fromapediatricperspective. Nephron80: 134148, 1998 331. BoirieY, BreyerM, GagnadouxMF, NiaudetP, BressonJL: Alterationsofproteinmetabolismby metabaolicacidosisinchildrenwithchronicrenalfailure. KidneyInt58: 236241, 2000 332. PanichiV, MiglioriM, DePietroS: Creactiveproteininpatientswithchronicrenaldiseases. Ren Fail23: 551562, 2001 333. EustaceJA, AstorB, MuntnerPM, IkizlerTA, CoreshJ: Inflammationandacidosisareimportant independentpredictorsofhypoalbuminuriainrenalinsufficiency. JAmSocNephrol12: 201A, 2001 (abstr) 334. BistrianBR: RoleofthesystemicinflammatoryresponsesyndromeinthedevelopmentofproteincaloriemalnutritioninESRD. AmJKidneyDis32: S113-S117, 1998(suppl4) 335. BistrianBRK: Thesystemicinflammatoryresponseanditsimpactonironnutritureinend-stagerenal disease. AmJKidneyDis34: S35-S39, 1999(suppl2) 312 Bibliography NationalKidneyFoundation potassium/DOQI 336. BergstromJ, LindholmB: Malnutrition, cardiacdisease, andmortality: Anintegratedpointofview. AmJKidneyDis32: 834841, 1998 337. TomK, YoungVR, ChapmanT, MasudT, AkpeleL, MaroniBJ: Long-termadaptiveresponsesto dietaryproteinrestrictioninchronicrenalfailure. AmJPhysiol268: E668-E677, 1995 338. KoppleJD, BergR, HouserH, SteinmanTI, TeschanP: Nutritionalstatusofpatientswithdifferent levelsofchronicrenalinsufficiency. ModificationofDietinRenalDisease(MDRD)StudyGroup. KidneyInt27: S184-S194, 1989(suppl27) 339. CogginsCH, DwyerJT, GreeneT, PetotG, SnetselaarLG, VanLenteF: Serumlipidchangesassociatedwithmodifiedproteindiets: ResultsfromthefeasibilityphaseoftheModificationofDietin RenalDiseaseStudy. AmJKidneyDis23: 514523, 1994 340. ParkJS, JungHH, YangWS, KimHH, KimSB, ParkSK, HongCD: Proteinintakeandthenutritional statusinpatientswithpre-dialysischronicrenalfailureonunrestricteddiet. KoreanJInternMed12: 115121, 1997 341. PollockCA, IbelsLS, ZhuFY, WarnantM, CatersonRJ, WaughDA, MahonyJF: Proteinintakein renaldisease. JAmSocNephrol8: 777783, 1997 342. Walser M, Mitch WE, Maroni BJ, Kopple JD: Should Protein intake be restricted in predialysis patients? KidneyInt55: 771777, 1999 343. ChauveauP, BartheN, RigalleauV, OzenneS, CastaingF, DelclauxC: Outcomeofnutritional statusandbodycompositionofuremicpatientsonaverylowproteindiet. AmJKidneyDis34: 500507, 1999 344. WilliamsB, HattersleyJ, LaywardE, WallsJ: Metabolicacidosisandskeletalmuscleadaptationto lowproteindietsinchronicuremia. KidneyInt40: 779786, 1991 345. AparicioM, ChauveauP, DePrecigoutV, BouchetJL, LasseurC, CombeC: Nutritionandoutcome onrenalreplacementtherapyofpatientswithchronicrenalfailuretreatedbyasupplementedvery lowproteindiet. JAmSocNephrol11: 708716, 2000 346. WalserM, HillSB, WardL, MagderL: Acrossovercomparisonofprogressionofchronicrenal failure: Ketoacidsversusaminoacids. KidneyInt43: 933939, 1993 347. MazouzH, KacsoI, GhazaliA, ElEsperN, MoriniereP, MakdassiR, HardyP, WesteelPF, Archard JM, PrunaA, FournierA: Riskfactorsofrenalfailureprogressiontwoyearspriortodialysis. Clin Nephrol51: 355-366, 1999 348. MonteonFJ, LaidlawSA, ShaibJK, KoppleJD: Energyexpenditureinpatientswithchronicrenal failure. KidneyInt30: 741747, 1986 349. AndoA, OritaY, NakataK, TsubakiharaY, TakamitsuY, UedaN, YanaseM, AbeH: Effectoflow proteindietandsurplusofessentialaminoacidsontheserumconcentrationandtheurinaryexcretion ofmethylguanidineandguanidinosuccinicacidinchronicrenalfailure. Nephron24: 161169, 1979 350. StenvinkelP, HeimburgerO, TuckCH, BerglundL: Apo(a)-isoformsize, nutritionalstatusandinflammatorymarkersinchronicrenalfailure. KidneyInt53: 13361342, 1998 351. WalserM, HillS: Canrenalreplacementbedeferredbyasupplementedverylowproteindiet? J AmSocNephrol10: 110116, 1999 352. CupistiA, GuidiA, GiovannettiS: Nutritionalstateofseverechronicrenalfailurepatientsonalowproteinsupplementeddiet. ContribNephrol81: 161168, 1990 353. SugimotoT, KikkawaR, HanedaM, ShigetaY: Effectofdietaryproteinrestrictiononproteinuriain non-insulin-dependentdiabeticpatientswithnephropathy. JNutrSciVitaminol37: S87-S92, 1991 (suppl) 354. GuarnieriG, ToigoG, SitulinR, CrapesiL, DelBiancoMA, ZanettovichA, FacciniL, LucchesiA, OldrizziL, RugiuC: Nutritionalassessmentinpatientswithearlyrenalinsufficiencyonlong-term lowproteindiet. ContribNephrol53: 4050, 1986 355. DiLandroD, DattiloGA, RomagnoliGF: Comparativeoutcomeofpatientsonaconventionallow proteindiet versusasupplementeddiet inchronicrenalfailure. ContribNephrol81: 201207, 1990 356. VetterK, KaschubeI, MetznerC, LindenauK, FrohlingPT: EvaluationofnutritionalstatusintheGDR trial. ContribNephrol81: 208213, 1990 357. BarsottiG, CiardellaF, MorelliE, CupistiA, MantovanelliA, GiovannettiS: Nutritionaltreatment ofrenalfailureintype1diabeticnephropathy. ClinNephrol29: 280287, 1988 potassium/DOQI NationalKidneyFoundation Bibliography 313 358. JenkinsD, BurtonPR, BennettSE, BakerF, WallsJ: Themetabolicconsequencesofthecorrectionof acidosisinuraemia. NephrolDialTransplant4: 9295, 1989 359. HuangXH, RantalaihoV, WirtaO, PasternackA, HiltunenTP, KoivulaT, MalminiemiK, NikkariT, LehtimakiT: Angiotensin-convertingenzymeinsertion/deletionpolymorphismanddiabeticalbuminuriainpatientswithNIDDMfollowedUpfor9years. Nephron80: 1724, 1998 360. ZellerK, WhittakerE, SullivanL, RaskinP, JacobsonHR: Effectofrestrictingdietaryproteinonthe progressionofrenalfailureinpatientswithinsulin-dependentdiabetesmellitus. NEnglJMed324: 7884, 1991 361. DAmicoG, GentileMG: Dietarycontrolmayinfluenceseveralriskfactorsinpatientswithchronic renalfailure. ContribNephrol81: 2934, 1990 362. ParilloM, RiccardiG, PacioniD, IovineC, ContaldoF, IserniaC, DeMarcoF, PerrottiN, Rivellese A: Metabolicconsequencesoffeedingahigh-carbohydrate, High-fiberdiettodiabeticpatientswith chronickidneyfailure. AmJClinNutr48: 255259, 1988 363. GoodshipTH, MitchWE, HoerrRA, WagnerDA, SteinmanTI, YoungVR: Adaptationtolow-Protein dietsinrenalfailure: Leucineturnoverandnitrogenbalance. JAmSocNephrol1: 6675, 1990 364. WoodrowG, OldroydB, SmithMA, TurneyJH: Measurementofbodycompositioninchronicrenal failure: ComparisonofskinfoldanthropometryandbioelectricalimpedancewithdualenergyX-ray absorptiometry. EurJClinNutr50: 295301, 1996 365. GuarnieriGF, ToigoG, SitulinR, CarraroM, TamaroG, LucchesliA, OldrizziL, RugiuC, Maschio G: Nutritionalstateinpatientsonlong-termlow-proteindietorwithnephroticsyndrome. KidneyInt 27: S195-S200, 1989(suppl27) 366. MaroniBJ, StaffeldC, YoungVR, ManatungaA, TomK: Mechanismspermittingnephroticpatients toachievenitrogenequilibriumwithaprotein-restricteddiet. JClinInvest99: 24792487, 1997 367. MitchWE, WalserM, SteinmanTI, HillS, ZegerS, TungsangaK: Theeffectofaketoacid-amino acidsupplementtoarestricteddietontheprogressionofchronicrenalfailure. NEnglJMed311: 623629, 1984 368. MilasNC, NowackMP, AkpeleL, CastaldoL, CoyneT, DoroshenkoL, KigawaL, Korzec-Ramirez D, ScherchLK, SnetselaarL: Factorsassociatedwithadherencetothedietaryproteinintervention intheModificationofDietinRenalDiseaseStudy. JAmDietAssoc95: 12951300, 1995 369. GillisBP, CaggiulaAW, ChiavacciAT: NutritioninterventionprogramoftheModificationofDiet inRenalDiseaseStudy: Aself-managementapproach.",
    "word_count": 600,
    "char_count": 8844,
    "sentence_count": 102,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 69,
      "total_chunks": 77,
      "position": "70/77",
      "content_type": "dietary",
      "content_type_confidence": 7,
      "medical_entities": [
        "potassium",
        "malnutrition",
        "insulin"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 70,
    "text": "JAmDietAssoc95: 12951300, 1995 369. GillisBP, CaggiulaAW, ChiavacciAT: NutritioninterventionprogramoftheModificationofDiet inRenalDiseaseStudy: Aself-managementapproach. JAmDietAssoc95: 12881294, 1995 370. CoyneT, OlsonM, BradhamK, GarconM, GregoryP, ScherchL: Dietarysatisfactioncorrelated withadherenceintheModificationofDietinRenalDiseaseStudy. JAmDietAssoc95: 13011306, 1995 371. DolecekT, OlsenMB, CaggiulaAW, DwyerJT, MilasC, GillisBP, HartmannJA, DiChiroJT: RegistereddietitiantimerequirementsintheModificationofDietinRenalDiseaseStudy. JAmDietAssoc 95: 13071312, 1995 372. SherrardDJ, HerczG, PeiY, MaloneyNA, GreenwoodC, ManuelA, SaiphooC, FentonSS, Segre GV: Thespectrumofbonediseaseinend-stagerenalfailureAnevolvingdisorder. KidneyInt43: 436442, 1993 373. BushinskyDA: Thecontributionofacidosistorenalosteodystrophy. KidneyInt47: 18161832, 1995 374. CoenG, Manni M, AddariO, BallantiP, PasqualiM, ChiccaS, MazzaferroS, MapoletanoI, NapoletanoI, SardellaD, BonucciE: Metabolicacidosisandosteodystrophicbonediseaseinpredialysischronicrenalfailure: Effectofcalcitrioltreatment. MinerElectrolyteMetab21: 375382, 1995 375. HsuCH: Arewemismanagingcalciumandphosphatemetabolisminrenalfailure? AmJKidney Dis29: 641-649, 1997 376. SherrardDJ: Controlofrenalbonedisease. SeminDial7: 284287, 1994 377. SlatopolskyE, BrickerNS: Theroleofphosphorusrestrictioninthepreventionofsecondaryhyperparathyroidisminchronicrenaldisease. KidneyInt4: 141145, 1973 378. KatesDM, SherrardDJ, AndressDL: Evidencethatserumphosphateisindependentlyassociated withserumPTHinpatientswithchronicrenalfailure. AmJKidneyDis30: 809813, 1997 379. LlachF, MassrySG: Onthemechanismofsecondaryhyperparathyroidisminmoderaterenalinsufficiency. JClinEndocrinolMetab61: 601606, 1985 380. BudisavijevicM, CheekD, PlothD: Calciphylaxisinchronicrenalfailure. JAmSocNephrol7: 978982, 1996 314 Bibliography NationalKidneyFoundation potassium/DOQI 381. BraunJ, OldendorfM, MoshageW, HeidlerR, ZeitlerE, LuftFC: Electronbeamcomputedtomography in the evaluation of cardiac calcification in chronic Dialysis patients. Am J Kidney Dis 27: 394401, 1996 382. AndressDL, MaloneyNA, EndresDB, SherrardDJ: Aluminum-associatedbonediseaseinchronic renalfailure: Highprevalenceinalong-termdialysispopulation. JBoneMinerRes1: 391398, 1986 383. FerreiraM: Diagnosisofrenalosteodystrophy: Whenandhowtousebiochemicalmarkersandnoninvasivemethods: Whenbonebiopsyisneeded. NephrolDialTransplant15: S8-S14, 2000(suppl) 384. MallucheHH, LangubMC, Monier-FaugereMC: Theroleofbonebiopsyinclinicalpracticeand research. KidneyInt73: S20-S25, 1999(suppl73) 385. SlatopolskyE, BrownA, DussoA: Pathogenesisofsecondaryhyperparathyroidism. KidneyInt73: S14-S19, 1999(suppl73) 386. WangM, HerczG, SherrardDJ, MaloneyNA, SegreGV, PeiY: Relationshipbetweenintact184 parathyroidhormoneandbonehistomorphometricparametersindialysispatientswithoutaluminum toxicity. AmJKidneyDis26: 836844, 1995 387. QiQ, Monier-FaugereMC, GengZ, MallucheHH: Predictivevalueofserumparathyroidhormone levelsforboneturnoverinpatientsonchronicmaintenancedialysis. AmJKidneyDis26: 622631, 1995 388. EastwoodJB, BordierPJ, deWardenerHE: Somebiochemical, histological, radiologicalandclinical featuresofrenalosteodystrophy. KidneyInt4: 128140, 1973 389. TorresA, LorenzoV, HernandezD, RodriguezJC, ConcepcionMT, RodriguezAP, HernandezA, deBonisE, DariasE, Gonzalez-PosadaJM: Bonediseaseinpredialysis, hemodialysis, andCAPD patients: EvidenceofabetterboneresponsetoPTH. KidneyInt47: 14341442, 1995 390. SlatopolskyE, FinchJ, DendaM, RitterC, ZhongM, DussoA, MacDonaldPN, BrownAJ: Phosphorus restrictionpreventsparathyroidglandgrowth. HighphosphorusdirectlystimulatesPTHsecretionin vitro. JClinInvest97: 25342540, 1996 391. WilsonL, FelsenfeldA, DreznerMK, LlachF: Altereddivalentionmetabolisminearlyrenalfailure: Roleof1, 25(OH)2D. KidneyInt27: 565573, 1985 392. HamdyNA, KanisJA, BenetonMN, BrownCB, JuttmannJR, JordansJG, JosseS, MeyrierA, Lins RL, FaireyIT: Effectofalfacalcidolonnaturalcourseofrenalbonediseaseinmildtomoderaterenal failure. BMJ310: 358363, 1995 393. Delmez JA, SlatopolskyE. Hyperphosphatemia: Its consequences and treatmentin patients with chronicrenaldisease. AmJKidneyDis19: 303317, 1992 394. LlachF: Hyperphosphatemiainend-stagerenaldiseasepatients: Pathophysiologicalconsequences. KidneyInt73: S31-S37, 1999(suppl73) 395. KhoslaS, MeltonLJIII, WermersRA, CrowsonCS, OFallonW, RiggsB: Primaryhyperparathyroidism andtheriskoffracture: apopulation-basedstudy. JBoneMinerRes14: 17001707, 1999 396. BruceDG, StJohnA, NicklasonF, GoldswainPR: Secondaryhyperparathyroidisminpatientsfrom WesternAustraliawithhipfracture: Relationshiptotypeofhipfracture, renalfunction, andvitamin Ddeficiency. JAmGeriatrSoc47: 354359, 1999 397. VestergaardP, MollerupCL, FrokjaerVG, ChristiansenP, Blichert-ToftM, MosekildeL: Cohortstudy ofriskoffracturebeforeandaftersurgeryforprimaryhyperparathyroidism. BMJ321: 598602, 2000 398. AtsumiK, KushidaK, YamazakiK, ShimizuS, OhmuraA, InoueT: Riskfactorsforvertebralfractures inrenalosteodystrophy. AmJKidneyDis33: 287293, 1999 399. CocoM, RushH: Increasedincidenceofhipfracturesindialysispatientswithlowserumparathyroid hormone. AmJKidneyDis36: 11151121, 2000 400. BlockGA, PortFK: Re-evaluationofrisksassociatedwithhyperphosphatemiaandhyperparathyroidism in Dialysis patients: recommendations for a change in management. Am J Kidney Dis 35: 12261237, 2000 401. BlockGA, Hulbert-ShearonTE, LevinNW, PortFK: Associationofserumphosphorusandcalcium xphosphateproductwithmortalityriskinchronichemodialysispatients: anationalstudy. AmJ KidneyDis31: 607617, 1998 402. LauK: Phosphateexcessandprogressiverenalfailure: Theprecipitation-calcificationhypothesis. KidneyInt36: 918937, 1989 403. AvramMM, FeinPA, BonominiL, MittmanN, LoutobyR, AvramDK, ChattopadhyayJ: Predictors potassium/DOQI NationalKidneyFoundation Bibliography 315 ofsurvivalincontinuousambulatoryperitonealdialysispatients: Afive-yearprospectivestudy. Perit DialInt16: S190-S194, 1996(suppl1) 404. CarlstedtF, LindL, WideL, LindahlB, HanniA, RastadJ, LjunghallS: Serumlevelsofparathyroid hormonearerelatedtothemortalityandseverityofillnessinpatientsintheemergencydepartment. EurJClinInvest27: 977981, 1997 405. MartinezI, SarachoR, MontenegroJ, LlachF: Theimportanceofdietarycalciumandphosphorous in the secondary hyperparathyroidism of patients with earlyrenal failure. Am J Kidney Dis 29: 496502, 1997 406. PittsTO, PirainoBH, MitroR, ChenTC, SegreGV, GreenbergA, PuschettJB: Hyperparathyroidism and1, 25-dihydroxyvitaminDdeficiencyinmild, moderate, andsevererenalfailure. JClinEndocrin Metab67: 876-881, 1988 407. StJohnA, ThomasMB, DaviesCP, MullanB, DickI, HutchisonB, vanderSA, PrinceRL: Determinants ofintactparathyroidhormoneandfree1, 25-dihydroxyvitaminDlevelsinmildandmoderaterenal failure. Nephron61: 422427, 1992 408. ReichelH, DeibertB, Schmidt-GaykH, RitzE: Calciummetabolisminearlychronicrenalfailure: Implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6: 162169, 1991 409. vonLilienfeld-ToalH, GerlachI, KlehrHU, IssaS, KeckE: Immunoreactiveparathyroidhormonein earlyandadvancedrenalfailure. Nephron31: 116122, 1982 410. CheungAK, ManolagasSC, CatherwoodBD, MoselyCAJr, MitasJA, BlantzRC, DeftosLJ: Determinantsofserum1, 25(OH)2Dlevelsinrenaldisease. KidneyInt24: 104109, 1983 411. FajtovaVT, SayeghMH, HickeyN, AliabadiP, LazarusJM, LeBoffMS: Intactparathyroidhormone levelsinrenalinsufficiency. CalcifTissueInt57: 329335, 1995 412. RixM, AndreassenH, EskildsenP, LangdahlB, OlgaardK: Bonemineraldensityandbiochemical markersofboneturnoverinpatientswithpredialysischronicrenalfailure. KidneyInt56: 10841093, 1999 413. YumitaS, SuzukiM, AkibaT, AkizawaT, SeinoY, KurokawaK: Levelsofserum1, 25(OH)2Din patientswithpre-dialysischronicrenalfailure. TohokuJExpMed180: 4556, 1996 414. ChristensenMS, NielsenHE: Parathyroidfunctionafterrenaltransplantation: Interrelationshipsbetweenrenalfunction, serumcalciumandserumparathyroidhormoneinnormocalcemiclong-term survivors. ClinNephrol8: 472476, 1977 415. MallucheHH, RitzE, LangeHP, KutscheraL, HodgsonM, SeiffertU, SchoeppeW: Bonehistology inincipientandadvancedrenalfailure. KidneyInt9: 355362, 1976 416.",
    "word_count": 593,
    "char_count": 8204,
    "sentence_count": 96,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 70,
      "total_chunks": 77,
      "position": "71/77",
      "content_type": "dietary",
      "content_type_confidence": 6,
      "medical_entities": [
        "potassium",
        "phosphorus",
        "dialysis",
        "hemodialysis",
        "hyperphosphatemia"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 71,
    "text": "ClinNephrol8: 472476, 1977 415. MallucheHH, RitzE, LangeHP, KutscheraL, HodgsonM, SeiffertU, SchoeppeW: Bonehistology inincipientandadvancedrenalfailure. KidneyInt9: 355362, 1976 416. McGonigleRJ, WallinJD, HusserlF, DeftosLJ, RiceJC, ONeillWJJr, FisherJW: Potentialroleof parathyroidhormoneasaninhibitoroferythropoiesisintheanemiaofrenalfailure. JLabClinMed 104: 1016-1026, 1984 417. SahaH: CalciumandvitaminDhomeostasisinpatientswithheavyproteinuria. ClinNephrol41: 290296, 1994 418. MessaP, MioniG, TurrinD, GuerraUP: Thecalcitonin-calciumrelationcurveandcalcitoninsecretory parametersinrenalpatientswithvariabledegreesofrenalfunction. NephrolDialTransplant10: 22592265, 1995 419. TessitoreN, VenturiA, AdamiS, RoncariC, RugiuC, CorgnatiA, BonucciE, MaschioG: Relationship betweenserumvitaminDmetabolitesanddietaryintakeofphosphateinpatientswithearlyrenal failure. MinerElectrolyteMetab13: 3844, 1987 420. CoenG, MazzaferroS, CostantiniS, BallantiP, CarrieriMP, GiordanoR, SmacchiA, SardellaD, BonucciE, TaggiE: Bonealuminumcontentinpredialysischronicrenalfailureanditsrelationwith secondary hyperparathyroidism and 1, 25(OH)2D3 treatment. Miner Electrolyte Metab 15: 295302, 1989 421. TougaardL, SorensenE, ChristensenMS, Brochner-MortensenJ, RodbroP, SorensenAW: Bone compositionandparathyroidfunctioninchronicrenalfailure. ActaMedScand202: 3338, 1977 422. MadsenS, OlgaardK, LadefogedJ: Renalhandlingofphosphateinrelationtoserumparathyroid hormonelevels. ActaMedScand200: 710, 1976 423. BedaniPL, TamarozziR, PinnaL, GilliP, PeriniL, FarinelliA: Earlyskeletalchangesofthehand phalangesinpatientswithchronicrenalfailure. IntJArtifOrgans8: 325330, 1985 424. ArataRO, CamposC, MautalenCA: Effectofparathyroidhormoneonboneresorptioninuremic patients. Medicina(Mex)36: 113120, 1976 316 Bibliography NationalKidneyFoundation potassium/DOQI 425. ArnaudCD: Hyperparathyroidismandrenalfailure. KidneyInt4: 8995, 1973 426. ReissE, CanterburyJM, EgdahlRH: Experiencewitharadioimmunoassayofparathyroidhormone inhumansera. TransAssocAmPhysicians81: 104115, 1968 427. MassrySG, CoburnJW, LeeDB, JowseyJ, KleemanCR: Skeletalresistancetoparathyroidhormone inrenalfailure. Studiesin105humansubjects. AnnInternMed78: 357364, 1973 428. SlatopolskyE, RobsonAM, ElkanI, BrickerNS: Controlofphosphateexcretioninuremicman. J ClinInvest47: 18651874, 1968 429. CoburnJW, KoppelMH, BrickmanAS, MassrySG: Studyofintestinalabsorptionofcalciumin patientswithrenalfailure. KidneyInt3: 264272, 1973 430. CoburnJW, PopovtzerMM, MassrySG, KleemanCR: Thephysicochemicalstateandrenalhandling ofdivalentionsinchronicrenalfailure. ArchInternMed124: 302311, 1969 431. IshimuraE, NishizawaY, InabaM, MatsumotoN, EmotoM, KawagishiT, ShojiS, OkunoS, Kim M, MikiT, MoriiH: Serumlevelsof1, 25-dihydroxyvitaminD, 24, 25-dihydroxyvitaminD, and25hydroxyvitaminDinnondialyzedpatientswithchronicrenalfailure. KidneyInt55: 10191027, 1999 432. NielsenSP, SorensenOH, LundB, BarenholdtO, MunckO, PedersenK: Calciummetabolismin patientswithchronicnon-dialyticrenaldisease. CalcifTissueRes21: 202209, 1976(suppl) 433. HutchisonAJ, WhitehouseRW, BoultonHF, AdamsJE, MawerEB, FreemontTJ, GokalR: Correlation ofbonehistologywithparathyroidhormone, vitaminD3, andradiologyinend-stagerenaldisease. KidneyInt44: 1071-1077, 1993 434. SuzukiM, HirasawaY: Renalosteodystrophyinearlychronicrenalfailure. ContribNephrol22: 2838, 1980 435. CoenG, MazzaferroS, BallantiP, SardellaD, ChiccaS, ManniM, BonucciE, TaggiF: Renalbone diseasein76patientswithvaryingdegreesofpredialysischronicrenalfailure: Across-sectional study. NephrolDialTransplant11: 813819, 1996 436. MadsenS, OlgaardK, LadefogedJ: Degreeandcourseofskeletaldemineralizationinpatientswith chronicrenalinsufficiency. ScandJUrolNephrol12: 243249, 1978 437. LocalMedicareReviewPolicyWebsite. Website: www. lmrp. net, 6/26/01 438. BurnDJ, BatesD: Neurologyandthekidney. JNeurolNeurosurgPsychiatry65: 810821, 1998 439. FraserC, ArieffA: Nervoussystemmanifestationsofrenalfailure, inSchrierRW, GottschalkCW (ed): DiseasesoftheKidney. Boston, MA, Little, Brown, 1993, pp28042809 440. BazziC, PaganiC, SorgatoG, AlbonicoG, FellinG, DAmicoG: Uremicpolyneuropathy: Aclinical andelectrophysiologicalstudyin135short-andlong-termhemodialyzedpatients. ClinNephrol35: 176181, 1991 441. WetterTC, StiasnyK, KohnenR, OertelWH, TrenkwalderC: Polysomnographicsleepmeasuresin patientswithuremicandidiopathicrestlesslegssyndrome. MovDisord13: 820824, 1998 442. WeinrauchLA, DEliaJA, GleasonRE, KeoughJ, MannD, KennedyFP: Autonomicfunctionintype Idiabetesmellituscomplicatedbynephropathy. Across-sectionalanalysisinthepresymptomatic phase. AmJHypertens8: 782789, 1995 443. CampeseVM, RomoffMS, LevitanD, LaneK, MassrySG: Mechanismsofautonomicnervoussystem dysfunctioninuremia. KidneyInt20: 246253, 1981 444. SternerNG, NilssonH, RosenU, LiljaB, SundkvistG: Relationshipsamongglomerularfiltrationrate, albuminuria, andautonomicnervefunctionininsulin-dependentandnon-insulin-dependentdiabetes mellitus. JDiabetesComplications11: 188193, 1997 445. DiPaoloB, CappelliP, SpisniC, AlbertazziA, RossiniPM, MarchionnoL, GambiD: Newelectrophysiologicalassessmentsfortheearlydiagnosisofencephalopathyandperipheralneuropathyinchronic uraemia. IntJTissueReact4: 301307, 1982 446. SavazziGM, MigoneL, CambiV: Theinfluenceofglomerularfiltrationrateonuremicpolyneuropathy. ClinNephrol13: 6472, 1980 447. GoelMK, GulatiPD, JankiS, RamSR, RainaV, RizviSN: Observationsonperipheralneuropathy inchronicuraemics. JAssocPhysiciansIndia26: 341346, 1978 448. NielsenVK: Theperipheralnervefunctioninchronicrenalfailure. VI. Therelationshipbetweeen sensoryandmotornerveconductionandkidneyfunction, azotemia, age, sex, andclinicalneuropathy. ActaMedScand194: 455462, 1973 449. KnollO, DierkerE: Detectionofuremicneuropathybyreflexresponselatency. JNeurolSci47: 305312, 1980 potassium/DOQI NationalKidneyFoundation Bibliography 317 450. TeschanPE, GinnHE, BourneJR, WardJW, HamelB, NunnallyJC, MussoM, VaughnWK: Quantitativeindicesofclinicaluremia. KidneyInt15: 676697, 1979 451. SavazziGM: Nerveconductiontimesinuremia. IntJArtifOrgans4: 211212, 1981 452. KutnerNG: Assessingend-stagerenaldiseasepatientsfunctioningandwell-being: measurement approachesandimplicationsforclinicalpractice. AmJKidneyDis24: 321333, 1994 453. TarlovAR, WareJEJr, GreenfieldS, NelsonEC, PerrinE, ZubkoffM: TheMedicalOutcomesStudy. Anapplicationofmethodsformonitoringtheresultsofmedicalcare. JAMA262: 925930, 1989 454. RettigRA, SadlerJH, MeyerKB, WassonJH, ParkersonGRJr, KantzB, HaysRD, PatrickDL: Assessing healthandqualityoflifeoutcomesindialysis: AreportonanInstituteofMedicineworkshop. Am JKidneyDis30: 140155, 1997 455. DeOreoPB: Hemodialysispatient-assessedfunctionalhealthstatuspredictscontinuedsurvival, hospitalization, anddialysis-attendancecompliance. AmJKidneyDis30: 204212, 1997 456. JohansenKL: Physicalfunctioningandexercisecapacityinpatientsondialysis. AdvRenalReplTher 6: 141148, 1999 457. KutnerNG, CardenasDD, BowerJD: Rehabilitation, agingandchronicrenaldisease. AmJPhys MedRehabil71: 97101, 1992 458. IfuduO, MayersJ, MatthewJ, TanCC, CambridgeA, FriedmanEA: Dismalrehabilitationingeriatric inner-cityhemodialysispatients. JAMA271: 2933, 1994 459. HarrisLE, LuftFC, RudyDW, TierneyWM: Clinicalcorrelatesoffunctionalstatusinpatientswith chronicrenalinsufficiency. AmJKidneyDis21: 161166, 1993 460. BardageC, IsacsonDG: Hypertensionandhealth-relatedqualityoflife. Anepidemiologicalstudy inSweden. JClinEpidemiol54: 172181, 2001 461. HallSE, Criddle RA, ComitoTL, PrinceRL: A case-controlstudyofqualityof lifeandfunctional impairmentinwomenwithlong-standingvertebralosteoporoticfracture. OsteoporosInt9: 508515, 1999 462. SchneiderSM, PougetI, StacciniP, RampalP, HebuterneX: Qualityoflifeinlong-termhomeenteral nutritionpatients. ClinNutr19: 2328, 2000 463. AhroniJH, BoykoEJ: ResponsivenessoftheSF-36amongveteranswithdiabetesmellitus. JDiabetes Complications14: 3139, 2000 464. BeusterienKM, NissensonAR, PortFK, KellyM, SteinwaldB, WareJE: Theeffectsofrecombinant humanerythropoietin onfunctionalhealthand well-beinginchronic dialysispatients. J AmSoc Nephrol7: 763773, 1996 465. RevickiDA, BrownRE, FeenyDH, HenryDA, TeehanBP, RudnickMR, BenzRL: Health-relatedquality oflifeassociatedwithrecombinanthumanerythropoietintherapyforpredialysischronicrenaldisease patients. AmJKidneyDis25: 548554, 1995 466.",
    "word_count": 590,
    "char_count": 8359,
    "sentence_count": 111,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 71,
      "total_chunks": 77,
      "position": "72/77",
      "content_type": "dietary",
      "content_type_confidence": 4,
      "medical_entities": [
        "albuminuria",
        "potassium",
        "insulin"
      ],
      "entity_count": 3
    }
  },
  {
    "chunk_id": 72,
    "text": "J AmSoc Nephrol7: 763773, 1996 465. RevickiDA, BrownRE, FeenyDH, HenryDA, TeehanBP, RudnickMR, BenzRL: Health-relatedquality oflifeassociatedwithrecombinanthumanerythropoietintherapyforpredialysischronicrenaldisease patients. AmJKidneyDis25: 548554, 1995 466. EschbachJW, AbdulhadiMH, BrowneJK, DelanoBG, DowningMR, EgrieJC, EvansRW, Friedman EA, GraberSE, HaleyNR: Recombinanthumanerythropoietininanemicpatientswithend-stage renaldisease. ResultsofaphaseIIImulticenterclinicaltrial. AnnInternMed111: 9921000, 1989 467. EvansRW, RaderB, ManninenDL: Thequalityoflifeofhemodialysisrecipientstreatedwithrecombinanthumanerythropoietin. CooperativeMulticenterEPOClinicalTrialGroup. JAMA263: 825330, 1990 468. MorenaF, AracilF, PerezR, ValderrabanoF: Controlledstudyontheimprovementofqualityoflife inelderlyhemodialysispatientsaftercorrectingend-stagerenaldisease-relatedanemia. AmJKidney Dis27: 548-556, 1996 469. RoccoMV, GassmanJJ, WangSR, KaplanRM: Cross-sectionalstudyofqualityoflifeandsymptoms inchronicrenaldiseasepatients: TheModificationofDietinRenalDiseaseStudy. AmJKidneyDis 29: 888896, 1997 470. KorevaarJC, JansenMA, MerkusMP, DekkerFW, BoeschotenEW, KredietRT: Qualityoflifein predialysisend-stagerenaldiseasepatientsattheinitiationofdialysistherapy. TheNECOSADStudy Group. PeritDialInt20: 6975, 2000 471. ShidlerNR, PetersonRA, KimmelPL: Qualityoflifeandpsychosocialrelationshipsinpatientswith chronicrenalinsufficiency. AmJKidneyDis32: 557566, 1998 472. KlangB, BjorvellH, ClyneN: Qualityoflifeinpredialyticuremicpatients. QualLifeRes5: 109116, 1996 473. FujisawaM, IchikawaY, YoshiyaK, IsotaniS, HiguchiA, NaganoS, ArakawaS, HamamiG, 318 Bibliography NationalKidneyFoundation potassium/DOQI MatsumotoO, KamidonoS: Assessmentofhealth-relatedqualityoflifeinrenaltransplantandhemodialysispatientsusingtheSF-36healthsurvey. Urology56: 201206, 2000 474. GriepMI, VanderNiepenP, SennesaelJJ, MetsTF, MassartDL, VerbeelenDL: Odourperception inchronicrenaldisease. NephrolDialTransplant12: 20932098, 1997 475. SacksCR, PetersonRA, KimmelPL: Perceptionofillnessanddepressioninchronicrenaldisease. AmJKidneyDis15: 3139, 1990 476. ManninenDL, EvansRW, DuganMK: Workdisability, functionallimitations, andthehealthstatus ofkidneytransplantationrecipientsposttransplant. ClinTransplant5: 193203, 1991 477. ChurchillDN, TorranceGW, TaylorDW, BarnesCC, LudwinD, ShimizuA, SmithEKM: Measurement ofqualityoflifeinend-stagerenaldisease: thetimetrade-offapproach. ClinInvestMed10: 1420, 1987 478. BlackSA, GoodwinJS, MarkidesKS: Theassociationbetweenchronicdiseasesanddepressive symptomatologyinolderMexicanAmericans. JGerontolSeriesABiolSciMedSci53: M188-M194, 1998 479. CagneyKA, WuAW, FinkNE, JenckesMW, MeyerKB, BassEB, PoweNR: Formalliteraturereview ofqualityofllifeinstrumentsusedinendstagerenaldisease. AmJKidneyDis36: 327336, 2000 480. HunsickerLG, AdlerS, CaggiulaA, EnglandBK, GreeneT, KusekJW, RogersNL, TeschanPE: PredictorsoftheprogressionofrenaldiseaseintheModificationofDietinRenalDiseaseStudy. KidneyInt51: 19081919, 1997 481. PeiY, CattranD, GreenwoodC: Predictingchronicrenalinsufficiencyinidiopathicmembranous glomerulonephritis. KidneyInt42: 960966, 1992 482. ChitaliaVC, WellsJE, RobsonRA, SearleM, LynnKL: Predictingrenalsurvivalinprimaryfocal glomerulosclerosisfromthetimeofpresentation. KidneyInt56: 22362242, 1999 483. LeveyAS: NephrologyForum: Measurementofrenalfunctioninchronicrenaldisease. KidneyInt 38: 167-184, 1990 484. WalserM: Progressionofchronicrenalfailureinman. KidneyInt37: 11951210, 1990 485. Mitch WE, WalserM, Buffington GA, Lemann J: A simple method of estimatingprogression of chronicrenalfailure. Lancet2: 13261328, 1976 486. RekolaS, BergstrandA, BuchtH: DeteriorationofGFRinIgAnephropathyasmeasuredby51CrEDTAclearance. KidneyInt40: 10501054, 1991 487. AustinSM, LiebermanJS, NewtonLD, MejiaM, PetersWA, MyersBD: Slopeofserialglomerular filtrationrateandtheprogressionofdiabeticglomerulardisease. JAmSocNephrol3: 13581370, 1993 488. DillonJJ: Thequantitativerelationshipbetweentreatedbloodpressureandprogressionofdiabetic renaldisease. AmJKidneyDis22: 798802, 1993 489. GallMA, NielsenFS, SmidtUM, ParvingHH: Thecourseofkidneyfunctionintype2(non-insulindependent)diabeticpatientswithdiabeticnephropathy. Diabetologia36: 10711078, 1993 490. HannedoucheT, AlbouzeG, ChauveauP, LacourB, JungersP: Effectsofbloodpressureandantihypertensivetreatmentonprogressionofadvancedchronicrenalfailure. AmJKidneyDis21: 131137, 1993 491. BiesenbachG, JankoO, ZazgornikJ: SimilarrateofprogressioninthepredialysisphaseintypeI andtypeIIdiabetesmellitus. NephrolDialTransplant9: 10971102, 1994 492. LeveyAS, AdlerS, CaggiulaA, EnglandBK, GreeneT, HunsickerL, KusekJW, RogersNL, Teschan physical examination: EffectsofdietaryproteinrestrictionontheprogressionofmoderaterenaldiseaseintheMDRD Study. JAmSocNephrol7: 26262625, 1996 494. YipJW, JonesSL, WisemanMJ, HillC, VibertiG: Glomerularhyperfiltrationinthepredictionof nephropathyinIDDM: A10-yearfollow-upstudy. Diabetes45: 17291733, 1996 495. EllisD, LloydC, BeckerDJ, ForrestKY, OrchardTJ: Thechangingcourseofdiabeticnephropathy: Low-densitylipoproteincholesterolandbloodpressurecorrelatewithregressionofproteinuria. Am JKidneyDis27: 809818, 1996 496. BaboolalK, EvansC, MooreRH: Incidenceofend-stagerenaldiseaseinmedicallytreatedpatients withseverebilateralatheroscleroticrenovasculardisease. AmJKidneyDis31: 971977, 1998 497. BerrutG, BouhanickB, FabbriP, GuilloteauG, BledF, LeJeuneJJ, FressinaudP, MarreM: Microalbuminuriaasapredictorofadropinglomerularfiltrationrateinsubjectswithnon-insulin-dependent diabetesmellitusandhypertension. ClinNephrol48: 9297, 1997 potassium/DOQI NationalKidneyFoundation Bibliography 319 498. NielsenS, SchmitzA, RehlingM, MogensenCE: TheclinicalcourseofrenalfunctioninNIDDM patientswithnormo-andmicroalbuminuria. JInternMed241: 133141, 1997 499. MassyZA, KhoaTN, LacourB, Descamps-LatschaB, ManNK, JungersP: Dyslipidaemiaandthe progression of renal disease in chronic renal failure patients. Nephrol Dial Transplant 14: 23922397, 1999 500. RuggenentiP, PernaA, ZoccaliC, GherardiG, BeniniR, TestaA, RemuzziG: Chronicproteinuric nephropathies. II. Outcomesandresponsetotreatmentinaprospectivecohortof352patients: DifferencesbetweenwomenandmeninrelationtotheACEgenepolymorphism. GruppoItaliano diStudiEpidemologiciinNefrologia(GISEN). JAmSocNephrol11: 8896, 2000 501. HannedoucheT, ChauveauP, KalouF, AlbouzeG, LacourB, JungersP: Factorsaffectingprogression inadvancedchronicrenalfailure. ClinNephrol39: 312320, 1993 502. ShahBV, LeveyAS: Spontaneouschangesintherateofdeclineinreciprocalserumcreatinine: Errors inpredictingtheprogressionofrenaldiseasefromextrapolationoftheslope. JAmSocNephrol2: 11861191, 1992 503. LeveyAS, GreeneT, BeckGJ, CaggiulaAW, KusekJW, HunsickerLG, KlahrS: Dietaryprotein restrictionandtheprogressionofchronicrenaldisease: WhathavealltheresultsoftheMDRDStudy shown? JAmSocNephrol10: 24262439, 1999 504. MitchWE: NephrologyForum: Dietaryproteinrestrictioninpatientswithchronicrenalfailure. Kidney Int40: 326341, 1991 505. BiesenbachG, ZazgornikJ: Highmortalityandpoorqualityoflifeduringpredialysisperiodintype IIdiabeticpatientswithdiabeticnephropathy. RenFail16: 263272, 1994 506. BakrisGL, CopleyJB, VicknairN, SadlerR, LeurgansS: Calciumchannelblockersversusother antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 16411650, 1996 507. BakrisGL, MangrumA, CopleyJB, VicknairN, SadlerR: Effectofcalciumchannelorbeta-blockade ontheprogressionofdiabeticnephropathyinAfricanAmericans. Hypertension1997: 744750, 1997 508. HovindP, RossingP, TarnowL, SmidtUM, ParvingHH: Progressionofdiabeticnephropathy. Kidney Int59: 702709, 2001 509. USRenalData System. USRDS1999Annual DataReport. Bethesda, MD, NationalInstitutesof Health, NationalInstituteofDiabetesandDigestiveandKidneyDiseases, 1999 510. ShulmanNB, FordCE, HallWD, BlaufoxMD, SimonD, LangfordHG, SchneiderKA: Prognostic valueofserumcreatinineandeffectoftreatmentofhypertensiononrenalfunction. Resultsfromthe hypertensiondetectionandfollow-upprogram. TheHypertensionDetectionandFollow-upProgram CooperativeGroup. Hypertension13: I80-I93, 1989 511. WalkerWG: Hypertension-relatedrenalinjury: Amajorcontributortoend-stagerenaldisease. Am JKidneyDis22: 164173, 1993(erratum22: 626, 1993) 512. KropJS, CoreshJ, ChamblessLE, ShaharE, WatsonRL, SzkloM, BrancatiFL: Acommunity-based studyofexplanatoryfactorsfortheexcessriskforearlyrenalfunctiondeclineinblacksvswhites withdiabetes: TheAtherosclerosisRiskinCommunitiesstudy. ArchInternMed159: 17771783, 1999 513. BreyerJA, BainRP, EvansJK, NahmanNSJr, LewisEJ, CooperM, McGillJ, BerlT: Predictorsof theprogressionofrenalinsufficiencyinpatientswithinsulin-dependentdiabetesandovertdiabetic nephropathy. TheCollaborativeStudyGroup. KidneyInt50: 16511658, 1996 514. KleinR, KleinBE, MossSE, CruickshanksKJ, BrazyPC: The10-yearincidenceofrenalinsufficiency inpeoplewithtype1diabetes. DiabetesCare22: 743751, 1999 515.",
    "word_count": 600,
    "char_count": 8978,
    "sentence_count": 109,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 72,
      "total_chunks": 77,
      "position": "73/77",
      "content_type": "evidence",
      "content_type_confidence": 4,
      "medical_entities": [
        "renal failure",
        "nephropathy",
        "potassium",
        "insulin",
        "antihypertensive"
      ],
      "entity_count": 5
    }
  },
  {
    "chunk_id": 73,
    "text": "TheCollaborativeStudyGroup. KidneyInt50: 16511658, 1996 514. KleinR, KleinBE, MossSE, CruickshanksKJ, BrazyPC: The10-yearincidenceofrenalinsufficiency inpeoplewithtype1diabetes. DiabetesCare22: 743751, 1999 515. SamuelssonO, AttmanPO, Knight-GibsonC, LarssonR, MulecH, WedelH, WeissL, AlaupovicP: Plasmalevelsoflipoprotein(a)donotreflectprogressionofhumanchronicrenalfailure. Nephrol DialTransplant11: 22372243, 1996 516. NakanoS, OgiharaM, TamuraC, KitazawaM, NishizawaM, KigoshiT, UchidaK: Reversed circadianbloodpressurerhythmindependentlypredictsendstagerenalfailureinnon-insulin-dependentdiabetesmellitussubjects. JDiabComp13: 224231, 1999 517. Samuelsson O, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, AlaupovicP: Lipoproteinabnormalitiesareassociatedwithincreasedrateofprogressionofhuman chronicrenalinsufficiency. NephrolDialTransplant12: 19081915, 1997 518. RuggenentiP, GambaraV, PernaA, BertaniT, RemuzziG: Thenephrologyofnon-insulin-dependent 320 Bibliography NationalKidneyFoundation potassium/DOQI Diabetes: Predictorsofoutcomerelativetodiversepatternsofrenalinjury. JAmSocNephrol9: 23362343, 1998 519. TuWH, PetittiDB, BiavaCG, TulunayO, HopperJJr: Membranousnephropathy: Predictorsof terminalrenalfailure. Nephron36: 118124, 1984 520. TothT, TakebayashiS: Factorscontributingtotheoutcomein100adultpatientswithidiopathic membranousglomerulonephritis. IntUrolNephrol26: 93106, 1994 521. JacobsenS, StarklintH, PetersenJ, UllmanS, JunkerP, VossA, RasmussenJM, TarpU, PoulsenLH, vanOvereemHansenG, SkaarupB, HansenTM: Prognosticvalueofrenalbiopsyandclinical variables in patients with lupus nephritis and normal serum Creatinine. Scand J Rheumatol 28: 288299, 1999 522. RavidM, BroshD, Ravid-SafranD, LevyZ, RachmaniR: Mainriskfactorsfornephropathyintype 2diabetesmellitusareplasmacholesterollevels, meanbloodpressure, andhyperglycemia. Arch InternMed158: 9981004, 1998 523. RosmanJB, LangerK, BrandlM, Piers-BechtTP, vanderHemGK, terWeePM, DonkerAJ: Proteinrestricteddietsinchronicrenalfailure: Afouryearfollow-upshowslimitedindications. KidneyInt 27: S96-S102, 1989(suppl27) 524. LocatelliF, AlbertiD, GrazianiG, BucciantiG, RedaelliB, GiangrandeA: Prospective, randomised, multicentretrialofeffectofproteinrestrictiononprogressionofchronicrenalinsufficiency. Northern ItalianCooperativeStudyGroup. Lancet337: 12991304, 1991 525. YokoyamaH, TomonagaO, HirayamaM, IshiiA, TakedaM, BabazonoT, UjiharaU, Takahashi C, OmoriV: Predictorsoftheprogressionofdiabeticnephropathyandthebeneficialeffectofangiotensin-convertingenzymeinhibitorsinNIDDMpatients. Diabetologia40: 405411, 1997 526. StandardsofMedicalCareforPatientswithDiabetesMellitus, PositionStatement. ClinicalPractice Recommendations2001. DiabetesCare24: S33-S43, 2001(suppl1) 527. Diabetic Nephropathy, Position Statement. Clinical Practice Recommendations 2001, www. diabetes. org/clinicalrecommendations/Supplement101/S69. htm, 6/26/01 528. TheDiabetesControlandComplicationsTrialResearchGroup: Theeffectofintensivetreatmentof diabetesonthedevelopmentandprogressionoflong-termcomplicationsininsulin-dependentdiabetesmellitus. NEnglJMed329: 977986, 1993 529. MicroalbuminuriaCollaborativeStudyGroup, UnitedKingdom: Intensivetherapyandprogression toclinicalalbuminuriainpatientswithinsulindependentdiabetesmellitusandmicroalbuminuria. BMJ311: 973977, 1995 530. UnitedKingdomProspectiveDiabetesStudyGroup: UKProspectiveDiabetesStudy33: Intensive bloodglucosecontrolwithsulphonylureasorinsulincomparedwithconventionaltreatmentandrisk ofcomplicationsinpatientswithtype2diabetes. Lancet352: 837853, 1998 531. OhkuboY, KishikawaH, ArakiE, MiyataT, IsamiS, MotoyoshiS, KojimaY, FuruyoshiN, Shichiri M: Intensive insulin therapy prevents theprogression of diabetic microvascular complications in Japanesepatientswithnon-insulin-dependentdiabetesmellitus: Arandomizedprospective6-year study. DiabetesResClinPract28: 103117, 1995 532. GaedePV, VedelP, ParvingHH, PedersenO: Intensifiedmultifactorialinterventioninpatientswith type2diabetesmellitusandmicroalbuminuria: TheStenotype2randomisedstudy. Lancet353: 617622, 1999 533. NationalHighBloodPressureEducationProgramWorkingGrouponHypertensionControlinChildrenandAdolescents: Updateonthe1987TaskForceReportonHighBloodPressureinChildren andAdolescents: AworkinggroupreportfromtheNationalHighBloodPressureEducationProgram. Pediatrics98: 649658, 1996 534. BrownMJ, PalmerCR, CasaigneA, deLeeuwPW, ManciaG, RosenthalT, RuilopeLM: Morbidity andmortalityinpatientsrandomisedtodouble-blindtreatmentwitalong-actingcalcium-channel blockerordiuretictheInternationalNifedipineGITSStudy: InterventionasaGoalinHypertension Treatment(INSIGHT). Lancet356: 366-372, 2000 535. HanssonL, LindholmLH, EkbomT, DahlofB, LankeJ, SchersenB, WesterP-O, HednerT, deFaire U: STOP-Hypertension-2StudyGroup. Randomisedtrialofoldandnewantihypertensivedrugsin elderlypatients: CardiovascularMortalityandMrobidityintheSwedishTrialinOldPatientswith Hypertension-2Study. Lancet354: 17511756, 1999 536. ParvingHH: Diabetichypertensivepatients. Isthisagroupinneedofparticularcareandattention? DiabetesCare22: B76-B79, 1999(suppl2) potassium/DOQI NationalKidneyFoundation Bibliography 321 537. UKProspectiveDiabetesStudyGroup: Tightbloodpressurecontrolandriskofmacrovascularand microvascularcomplicationsintype2diabetes. BMJ317: 703713, 1998 538. HanssonL, ZanchettA, CarruthersSG, BahlofB, ElmsfeldtD, JuliusS, MenardJ, RahnKH, Wedel H, WesterlingS: Effectsofintensivebloodpressureloweringalow-doseaspirininpatientswith hypertension: PrincipalresultsoftheHypertensionOptimalTreatment(HOT)randomizedtrial. The HOTStudyGroup. Lancet351: 17551762, 1998 539. RuggenentiP, RemuzziG: Angiotensin-convertingenzymeinhibitortherapyfornondiabeticprogressiverenaldiseas. CurrOpinNephrolHypertens6: 489495, 1997 540. WeirMR, DworkinL: Antihypertensivedrugs, dietarysalt, andrenalprotection: Howlowshould yougowithwhichtherapy? AmJKidneyDis32: 122, 1998 541. LewisEJ, HunsickerLG, ClarkeWR, BerlT, PohlMA, LewisJB, RitzE, AtkinsRC, etal: Renoprotective effectoftheangiotensin-receptorantagonistirbesartaninpatientswithnephropathyduetotype2 Diabetes. NEnglJMed345: 851860, 2001 542. BrennerBM, CooperME, deZeeuwD, KeaneWF, MitchWE, ParvingH-H, RemuzziG, Snappinn SM, ZhangZ, ShahinfavS: TheRENAALStudyInvestigators. Effectsoflosartanonrenalandcardiovascularoutcomesinpatientswithtype2diabetesandnephropathy. NEnglJMed345: 861869, 2001 543. EstacioROM, JeffersBW, HiattWR, BiggerstaffSL, GiffordN, SchrierRW: Theeffectofnisoldipine ascomparedwithenalapriloncardiovascularoutcomesinpatientswithnon-insulin-dependentdiabetesandhypertension. NEnglJMed338: 645652, 1998 544. HanssonL, LindholmLH, NiskanenL, LankeJ, HednerT, NiklasonA, LuomanmakiK, DahlofB, de FaireU, MorlinC, KarlbergBE, WesterPO, BjorckJ: Effectofangiotensin-converting-enzymeinhibitioncomparedwithconventionaltherapyoncardiovascularmorbidityandmortalityinhypertension: TheCaptoprilPreventionProject(CAPPP)randomisedtrial. Lancet353: 611616, 1999 545. YusufS, SleighP, PogueJ, BoschJ, DaviesR, DagenaisG: Effectsofanangiotensin-convertingenzymeinhibitor, ramipril, oncardiovasculareventsinhigh-riskpatients. TheHeartOutcomesPreventionEvaluationStudyInvestigators. NEnglJMed342: 143153, 2000 546. JafarTH, SchmidCH, LandaM, GiatrasI, TotoRDA, RemuzziG, MaschioG, BrennerBM, etal, fortheAIPRDStudyGroup: Angiotensin-convertingenzymeinhibitorsandtheprogressionofnondiabeticrenaldisease: Ameta-analysisofpatientleveldata. AnnInternMed135: 7387, 2001 547. AgodoaLY, AppelL, BakrisGL, BeckGJ, BourgoignieJJM, BriggsJP, CharlestonJ, CheekD, ClevelandW, DouglasJG, DouglasM, DowieD, FaulknerM, GabrielA, GassmanJ, GreeneT, HallY, HebertL, HiremathL, JamersonK, JohnsonCJ, KoppleJ, KusekJ, LashJ, LeaJ, LewisJB, Lipkowitz M, MassryS, MiddletonJ, MillerER3rd, NorrisK, OConnorD, OjoA, PhillipsRA, PogueV, RahmanM, RandallOS, RostandS, SchulmanG, SmithW, Thornley-BrownD, TisherCC, TotoRD, WrightJTJr, XuS: AfricanAmericanStudyofKidneyDiseaseandHypertension(AASK)StudyGroup. Effectoframiprilvsamlodipineonrenaloutcomesinhypertensivenephrosclerosis: Arandomized controlledtrial. JAMA285: 27192728, 2001 548. TeschanPE, BeckGJ, DwyerJT, GreeneT, KlahrS, LeveyAS, MitchWE, SnetselaarLG, etal: Effect ofaketoacid-aminoacid-supplementedverylowproteindietontheprogressionofadvancedrenal disease: AreanalysisoftheMDRDfeasibilitystudy. ClinNephrol50: 273283, 1998 549. PedriniMT, LeveyAS, LauJY, ChalmersTC, WangPH: Theeffectofdietaryproteinrestrictionon theprogressionofdiabeticandnondiabeticrenaldiseases: Ameta-analysis. AnnInternMed124: 627632, 1996 550. KasiskeBL, LakatuaJD, MaJZ, LouisTA: Ameta-analysisoftheeffectsofdietaryproteinrestriction ontherateofdeclineinrenalfunction. AmJKidneyDis31: 954961, 1998 551. KrolewskiAS, WarramJHG, ChristliebAR: HypercholesterolemiaAdeterminantofrenalfunction lossanddeathsinIDDMpatientswithnephropathy. KidneyInt45: S125-S131, 1994(suppl45) 552. ManttariM, TiulaE, AlikoskiT, ManninenV: Effectsofhypertensionanddyslipidemiaonthedecline inrenalfunction. Hypertension. Hypertension26: 670675, 1995 553. GallMA, HougaardP, Borch-JohnsenK, ParvingH-H: Riskfactorsfordevelopmentofincipientand overtdiabeticnephropathyinpatientswithnon-insulindependentdiabetesmellitus: Prospective, observationalstudy. BMJ314: 783788, 1997 554.",
    "word_count": 593,
    "char_count": 9307,
    "sentence_count": 94,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 73,
      "total_chunks": 77,
      "position": "74/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "nephropathy",
        "nephritis",
        "creatinine",
        "potassium",
        "serum creatinine",
        "insulin"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 74,
    "text": "Hypertension. Hypertension26: 670675, 1995 553. GallMA, HougaardP, Borch-JohnsenK, ParvingH-H: Riskfactorsfordevelopmentofincipientand overtdiabeticnephropathyinpatientswithnon-insulindependentdiabetesmellitus: Prospective, observationalstudy. BMJ314: 783788, 1997 554. MuntnerPM, CoreshJ, SmithJC, EckfeldtJ, KlagMJ: Plasmalipidsandriskofdevelopingrenal dysfunction: Theatherosclerosisriskincommunitiesstudy. KidneyInt58: 293301, 2000 555. ScanferlaF, ToffolettoPP, RoncaliD, BazzatoG: Associatedeffectofhepatichydroxymethylglutaryl 322 Bibliography NationalKidneyFoundation potassium/DOQI coenzymeAreductase(cid: 1) angiotensinconvertingenzymeinhibitorsonthe progressionofrenal failureinhypertensivesubjects. AmJHypertens4: 868, 1991 556. HommelE, AndersenP, GallM-A, NielsenFSA, JensenBSS, RossingP: Plasmalipoproteinsand renalfunctionduringsimvastatintreatmentindiabeticnephropathy. Diabetologia35: 447451, 1992 557. NielsenS, SchmitzO, MollerN, PorksenN, KlausenIC, AlbertiKGMM: Renalfunctionandinsulin sensitivityduringsimvastatintreatmentintype2(non-insulin-dependent)diabeticpatientswithmicroalbuminuria. Diabetologia36: 10791086, 1993 558. ThomasME, HarrisKP, RamaswamyC, HattersleyJM, WheelerDC, VargheseZ, WilliamsJD, Walls J, MoorheadJF: Simvastatintherapyforhypercholesterolemicpatientswithnephroticsyndromeor significantproteinuria. KidneyInt44: 11241129, 1993 559. ArandaArcasJL, SanchezRAM, GuijarroC, AraqueA, PulidoF, PragaM, DamianoA: Effectof pravastatinonhypercholesterolemiaassociatedwithproteinuria. AnnMedInterna11: 523527, 1994 560. LamKSL, ChengIKP, JanusED, PangRWC: Cholesterol-loweringtherapymayretardtheprogression ofdiabeticnephropathy. Diabetologia38: 604609, 1995 561. RaynerBL, ByrneMJ, vanZylSmitR: Aprospectiveclinicaltrialcomparingthetreatmentofidiopathic membranousnephropathyandnephroticsyndromewithsimvastatinanddiet, versusdietalone. Clin Nephrol46: 219-224, 1996 562. SmuldersYMR, VanEedenAE, StehouwerCDA, WeijersRNM, SlaatsEH, SilberbuschJ: Canreductioninhypertriglyceridemiaslowprogressionofmicroalbuminuriainpatientswithnon-insulin-dependentdiabetesmellitus? EurJClinInvest27: 9971002, 1997 563. TonoloG, CiccareseM, BrizziP, PudduL, SecchiG, CalviaP: Reductionofalbuminexcretionrate innormotensivemicroalbumiurictype2diabeticpateintsduringlong-termsimvastatintreatment. DiabetesCare20: 18911895, 1997 564. OlbrichtCJ, WannerC, ThieryJ, BastenA: SimvastatininNephroticSyndromeStudyGroup. Simvastatininnephroticsyndrome. KidneyInt71: S113-S166, 1999 565. NishimuraM, SasakiT, OishiA, OishiM, KonoS, ToyaY: Angiotensinconvertingenzymeinhibitor andprobucolsuppresstime-dependentincreaseinurinarytypeIVcollagenexcretionofNIDDMwith earlynephropathy. JAmSocNephrol10: 131A, 1999(abstr) 566. BuemiM, AllegraA, CoricaF, AloisiC, GiacobbeM, PettinatoG: Effectoffluvastatinonproteinuria inpatientswithimmunoglobulinAnephropathy. ClinPharmacolTher64: 427431, 2000 567. FriedLF, OrchardTJ, KasiskeBL: Theeffectoflipidreductiononrenaldiseaseprogression: Ametaanalysis. KidneyInt59: 260269, 2001 568. AlbertazziA, DiLiberatoL, DanieleF, BattistelV, ColombiL: Efficacyandtolerabilityofrecombinant humanerythropoietintreatmentinpre-dialysispatients: Resultsofamulticenterstudy. IntJArtifOrgans 21: 1218, 1998 569. JungersP, ChoukrounG, OualimZ, RobinoC, NguyenAT, ManNK: Beneficialinfluenceofrecombinanthumanerythropoietintherapyontherateofprogressionofchronicrenalfailureinpredialysis patients. NephrolDialTransplant16: 307312, 2001 570. StovesJ, InglisH, NewsteadCG: Arandomizedstudyoforalvsintravenousironsupplementation inpatientswithprogressiverenalinsufficiencytreatedwitherythropoietin. NephrolDialTransplant 18: 967974, 2001 571. SilverbergDS, BlumM, AgbariaZ, DeutschV, IronyM, SchwartzD, BaruchR, YachninT, Steinbruch S, IainaA: Theeffectofi. v. ironaloneorincombinationwithlow-doseerythropoietinintherapid correctionofanemiaofchronicrenalfailureinthepredialysisperiod. ClinNephrol55: 212219, 2001 572. ThadhaniR, PascualM, BonventreJV: Acuterenalfailure. NEnglJMed334: 14481460, 1996 573. AdcoxMJ, CollinsB, ZagerRA: Thedifferentialdiagnosisofacuterenalfailure. ContempIssues Nephrol25: 7377, 1992 574. PernaA, RemuzziG: Abnormalpermeabilitytoproteinsandglomerularlesions: Ameta-analysisof experimentalandhumanstudies. AmJKidneyDis27: 3441, 1996 575. DeckerT, Kofoed-EnevoldsenA, NorgaardK, Borch-JohnsenK, Feldt-RasmussenB, JensenT: Microalbuminuria: Implicationsformicroandmacrovasculardisease. DiabetesCare15: 11811191, 1992 576. NelsonRG, KnowlerWC, PettittDJ, BennettPH: KidneyDiseaseinDiabetes: DiabetesinAmerica potassium/DOQI NationalKidneyFoundation Bibliography 323 (ed2). Washington, DC, NationalDiabetesDataGroup, USDepartmentofHealthandHuman Services, 1995, pp349400 577. ReportandrecommendationsoftheSanAntonioConferenceonDiabeticNeuropathy. Diabetes37: 10001004, 1988 578. MogensenCE: Microalbuminuriapredictsclinicalproteinuriaandearlymortalityinmaturity-onset Diabetes. NEnglJMed310: 356360, 1984 579. JarrettRJ, VibertiGC, ArgyropoulosA, HillRD, MahmudU, MurrellsTJ: Microalbuminuriapredicts mortalityinnon-insulin-dependentdiabetes. DiabetMed1: 1719, 1984 580. JensenT, Borch-JohnsenK, Kofoed-EnevoldsenA, DeckertT: Coronaryheartdiseaseinyoungtype 1(insulin-dependent)diabeticpatientswithandwithoutdiabeticnephropathy: Incidenceandrisk factors. Diabetologia144148, 1987 581. GallMA: Albuminuriainnon-insulin-dependentdiabetesmellitus. Prevalence, causes, andconsequences. DanMedBull44: 465485, 1997 582. DeckertT, Kofoed-EnevoldsenA, NorgaardK, Borch-JohnsenK, Feldt-RasmussenB, JensenT: Microalbuminuria: Implicationsformicroandmacrovasculardisease. DiabetesCare15: 11811191, 1992 583. MogensenCE, DamsgaardEM, FrolandA, NielsenS, deFineOlivariusN, SchmitzA: Microalbuminuriainnon-insulin-dependentdiabetes. ClinNephrol38: 528538, 1992 584. GilbertRE, CooperME, McNallyPC, OBrienRC, ToftJ, JerumsG: Microalbuminuria: Prognostic andtherapeuticimplicationsindiabetesmellitus. DiabetesMed11: 636645, 1994 585. AlzaidAA: MicroalbuminuriainpatientswithNIDDM: Anoverview. DiabetesCare19: 7989, 1996 586. DinneenSF, GersteinHC: Theassociationofmicroalbuminuriaandmortalityinnon-insulin-dependent diabetesmellitus. Asystematicoverviewoftheliterature. ArchInternMed157: 14131418, 1997 587. VibertiGC, Yip-MessentJ, MorocuttiA: Diabeticnephropathy. Futureavenue. DiabetesCare15: 12161225, 1992 588. OrchardTJ, StevensLK, ForrestKY-Z, FullerJH: Cardiovasculardiseaseininsulin-dependentdiabetes mellitus: SimilarratesbutdifferentriskfactorsintheUScomparedwithEurope. IntJEpidemiol27: 976983, 1998 589. EpsteinM, ParvingHH, RuilopeLM: Surrogateendpointsandrenalprotection: Focusonmicroalbuminuria. BloodPressSuppl2: 5257, 1997 590. StehouwerCD, DonkerAJ: Clinicalusefulnessofmeasurementofurinaryalbuminexcretionindiabetesmellitus. NethJMed42: 175186, 1993 591. PanayiotouBN: Microalbuminuria: Pathogenesis, prognosisandmanagement. JIntMedRes22: 181201, 1994 592. deCotretPR: Relationshipsamongdiabetes, microalbuminuria, andACEinhibition. JCardiovasc Pharmacol32: S9-S17, 1998(suppl2) 593. McKennaK, ThompsonC: Microalbuminuria: Amarkertoincreasedrenalandcardiovascularrisk indiabetesmellitus. ScottMedJ42: 99104, 1997 594. MogensenCE: Microalbuminuria, bloodpressureanddiabeticrenaldisease: Originanddevelopmentofideas. Diabetologia42: 263285, 1999 595. PoirierSJ: Preservingthediabetickidney. JFamPract46: 2127, 1998 596. Feldt-RasmussenB, Borch-JohnsenK, DeckertT, JensenG, JensenJS: Microalbuminuria: Animportant diagnostictool. JDiabetesComplications8: 137145, 1994 597. StephensonJM, KennyS, StevensLK, FullerJH, LeeEJ: Proteinuriaandmortalityindiabetes: The WHOMultinationalStudyofVascularDiseaseinDiabetes. DiabetesMed12: 149155, 1994 598. LeeK-U, ParkJY, KimSW, LeeMII, KimGS, ParkS-potassium, ParkJ-S: Prevalenceandassociatedfeatures ofalbuminuriainKoreanswithNIDDM. DiabetesCare18: 793799, 1995 599. JohnL, RaoPSSS, KanagasabapathyAS. Prevalenceofdiabeticnephropathyinnon-insulindependentdiabetics. IndianJMedRes94: 2429, 1991 600. HowardBV, LeeET, CowanLD, FabsitzRR, HowardWJ, OopikAJ, RobbinsDC, SavagePJ, Yeh JL, WeltyTK: CoronaryheartdiseaseprevalenceanditsrelationtoriskfactorsinAmericanIndians. TheStrongHeartStudy. AmEpidemiol142: 254268, 1995 601. NelsonRG, SieversML, KnowlerWC, SwinburnBA, PettittDJ, SaadMF, GarrisonRJ, LiebowIM, HowardBV, BennettPH: LowincidenceoffatalcoronaryheartdiseaseinPimaIndiansdespitehigh prevalenceofnon-insulin-dependentdiabetes. Circulation81: 987995, 1990 324 Bibliography NationalKidneyFoundation potassium/DOQI 602. KleinR, KleinBEK: Visiondisordersindiabetes: DiabetesinAmerica. Washington, DC, USDepartmentofHealthandHumanServices, 1995, pp293338 603. ChaversBM, MauerSM, RamsayRC, SteffesMW: Relationshipbetweenretinalandglomerular lesionsinIDDMpatients. Diabetes43: 441446, 1994 604. ParvingH-H, GallM-A, SkttP, JrgensenHE, LkkegaardH, JrgensenF, NielsenB, LarsenS: Prevalenceandcausesofalbuminuriainnon-insulin-dependentdiabeticpatients. KidneyInt41: 758762, 1992 605. VigstrupJ, MogensenCE: Proliferativediabeticretinopathy: Atriskpatientsidentifiedbyearlydetectionofmicroalbuminuria. ActaOphthalmol(Copenh)63: 530534, 1985 606.",
    "word_count": 594,
    "char_count": 9141,
    "sentence_count": 114,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 74,
      "total_chunks": 77,
      "position": "75/77",
      "content_type": "evidence",
      "content_type_confidence": 5,
      "medical_entities": [
        "potassium",
        "insulin"
      ],
      "entity_count": 2
    }
  },
  {
    "chunk_id": 75,
    "text": "KidneyInt41: 758762, 1992 605. VigstrupJ, MogensenCE: Proliferativediabeticretinopathy: Atriskpatientsidentifiedbyearlydetectionofmicroalbuminuria. ActaOphthalmol(Copenh)63: 530534, 1985 606. Estacio RO, McFarlingE, Biggerstaff S, JeffersBW, Johnson D, SchrierRW: Overt albuminuria predictsdiabeticretinopathyinHispanicswithNIDDM. AmJKidneyDis31: 947953, 1998 607. NationalHighBloodPressureEducationProgramWorkingGroupReportonHypertensioninDiabetes. Bethesda, MD, NationalInstitutesofHealth, NationalHeart, Lung, andBloodInstitute, 1995 608. ExecutiveSummaryoftheThirdReportoftheNationalCholesterolEducationProgram(NCEP)Expert PanelonDetection, EvaluationandTreatmentofHighBloodCholesterolinAdults(AdultTreatment PanelIII). JAMA285: 24862497, 2001 609. Managementofdyslipidemiainadultswithdiabetes. DiabetesCare24: S58-S61, 2001(suppl1) 610. Aspirintherapyindiabetes. DiabetesCare24: S62-S63, 2001(suppl1) 611. Consensusdevelopmentconferenceonthediagnosisofcoronaryheartdiseaseinpeoplewithdiabetes. DiabetesCare21: 15511559, 1998 612. GrundySM, BenjaminIJ, BurkeGL, ChaitA, EckelRH, HowardBV, MitchWE, SmithSCJr, Sowers JR: Diabetesandcardiovasculardisease. AstatementforhealthcareprofessionalsfromtheAmerican HeartAssociation. Circulation100: 11341146, 1999 613. Diabeticretinopathy. DiabetesCare24: S73-S76, 2001(suppl1) 614. Diabeticretinopathy. PreferredPracticePattern. SanFrancisco, calcium, AmericanAcademyofOphthalmology(AAO), 1998 615. AmericanOptometricAssociationConsensusPanelonDiabetes: CareofthePatientWithDiabetes Mellitus(ed2). StLouis, MO, AmericanOptometricAssociation, 1998 616. Proceedingsofaconsensusdevelopmentconferenceonstandardizedmeasuresindiabeticneuropathy. DiabetesCare15: 10801107, 1992 617. Borch-JohnsenK, AndersenPK, DeckertT: Theeffectofproteinuriaonrelativemortalityintype1 (insulin-dependent)diabetesmellitus. Diabetologia28: 590596, 1985 618. NelsonRG, PettittDJ, CarraherMJ, BairdHR, KnowlerWC: Effectofproteinuriaonmortalityin NIDDM. Diabetes37: 14991504, 1988 619. Ritz E, Orth SR: Nephropathy in patients with type 2 Diabetes mellitus. N Engl J Med 341: 11271133, 1999 620. FoleyRN, ParfreyPS, HarnettJD: Clinicalandechocardiographicdiseaseinpatientsstartingendstagerenaldiseasetherapy. KidneyInt47: 186192, 1995 621. ParfreyPS, FoleyRN: Theclinicalepidemiologyofcardiacdiseaseinchronicrenalfailure. JAm SocNephrol10: 16061615, 1999 622. CulletonBF, LarsonMG, WilsonPW, EvansJC, ParfreyPS, LevyD: Cardiovasculardiseaseand mortalityinacommunity-basedcohortwithmildrenalinsufficiency. KidneyInt56: 22142219, 1999 623. LevyD, GarrisonRJ, SavageDD: Prognosticimplicationsofechocardiographicallydeterminedleft ventricularmassintheFraminghamHeartStudy. NEnglJMed322: 15611566, 1990 624. MorbidityandMortality: 1998ChartbookonCardiovascular, Lung, andBloodDiseases. Bethesda, MD, USDeptofHealthandHumanServices, 1998 625. WannametheeSG, ShaperAG, PerryIJ: Serumcreatinineconcentrationandriskofcardiovascular disease: Apossiblemarkerforincreasedriskofstroke. Stroke28: 557563, 1997 626. BetoJA, BansalVK: Interventionsforotherriskfactors: Tobaccouse, physicalinactivity, menopause, andhomocysteine. AmJKidneyDis32: S112-S119, 1998(suppl3) 627. KasiskeBL: Hyperlipidemiainpatientswithchronicrenaldisease. AmJKidneyDis32: S142-S156, 1998(suppl3) 628. BianchiS, BigazziR, CampeseVM: Microalbuminuriainessentialhypertension: Significance, pathophysiology, andtherapeuticimplications. AmJKidneyDis34: 973995, 1999 potassium/DOQI NationalKidneyFoundation Bibliography 325 629. SarnakMJ, CoronadoBE, GreeneT, WangS-R, KusekJW, BeckGJ, LeveyAS: Cardiovascular diseaseriskfactorsinchronicrenalinsufficiency. ClinNephrol2002(inpress) 630. KeaneWF: Proteinuria: Itsclinicalimportanceandroleinprogressiverenaldisease. AmJKidney Dis35: S97-S105, 2000(suppl1) 631. CulletonBF, WilsonPWF: Thrombogenicriskfactorsforcardiovasculardiseaseindialysispatients. SeminDialysis12: 117125, 1999 632. MassyZA: Importanceofhomocysteine, lipoprotein(a)andnon-classicalcardiovascularriskfactors (fibrinogenandadvancedglycationend-products)foratherogenesisinuraemicpatients. Nephrol DialTransplant15: 8191, 2000 633. CoreshJ, LongeneckerJC, MillerERIII: Epidemiologyofcardiovascularriskfactorsinchronicrenal disease. JAmSocNephrol9: S24-S30, 1998(suppl) 634. RuilopeLM, SalvettiA, JamersonK, HanssonL, WarnoldI, WedelH, ZanchettiA: Renalfunction andintensiveloweringofbloodpressureinhypertensiveparticipantsofthehypertensionoptimal treatment(HOT)study. JAmSocNephrol12: 218225, 2001 635. SchillaciG, ReboldiG, VerdecchiaP: High-normalserumcreatinineconcentrationisapredictorof cardiovascularriskinessentialhypertension. ArchInternMed161: 886891, 2001 636. PahorM, ShorrRI, SomesGW, CushmanWC, FerrucciL, BaileyJE, ElamJT, ApplegateWB: Diureticbasedtreatmentandcardiovasculareventsinpatientswithmildrenaldysfunctionenrolledinthe systolichypertensionintheelderlyprogram. ArchInternMed158: 13401345, 1998 637. MannJF, GersteinHC, PogueJ, BoschJP, YusufS: Renalinsufficiencyasapredictorofcardiovascular outcomesandtheimpactoframipril: TheHOPErandomizedtrial. AnnInternMed134: 629636, 2001 638. SechiLA, ZingaroL, DeCarliS, SechiG, CatenaC, FalletiE, DellAnnaE, BartoliE: Increased serumlipoprotein(a)levelsinpatientswithearlyrenalfailure. AnnInternMed129: 457461, 1998 639. SechiLA, ZingaroL, CatenaC, PerinA, DeMarchiS, BartoliE: Lipoprotein(a)andapolipoprotein(a) isoformsandproteinuriainpatientswithmoderaterenalfailure. KidneyInt56: 10491057, 1999 640. FriedLP, KronmalRA, NewmanAB, BildDE, MittelmarkMB, PolakJF, RobbinsJA, GardinJM: Risk factorsfor5-yearmortalityinolderadults: TheCardiovascularHealthStudy. JAMA279: 585592, 1998 641. Matts JP, Karnegis JN, Campos computed tomography, Fitch LL, Johnson JW, Buchwald H: POSCH Group: Serum creatinineasanindependentpredictorofcoronaryheartdiseasemortalityinnormotensivesurvivors ofmyocardialinfarction. JFamPract36: 497503, 1993 642. HemmelgarnBR, GhaliWA, QuanH, BrantR, NorrisCM, TaubKJ, KnudtsonML: Poorlong-term survivalaftercoronaryangiographyinpatientswithrenalinsufficiency. AmJKidneyDis37: 6472, 2001 643. DamsgaardEM, FrolandA, JorgensenOD, MogensenCE: Microalbuminuriaaspredictorofincreasedmortalityinelderlypeople. BMJ300: 297300, 1990 644. BeattieJN, SomanSS, SandbergKR, YeeJ, BorzakS, GargM, McCulloughPA: Determinantsof mortalityaftermyocardialinfarctioninpatientswithadvancedrenaldysfunction. AmJKidneyDis 37: 11911200, 2001 645. FriedmanPJ: Serumcreatinine: Anindependentpredictorofsurvivalafterstroke. JInternMed229: 175-179, 1991 646. WagenerDK, HarrisT, MadansJH: Proteinuriaasabiomarker: Riskofsubsequentmorbidityand mortality. EnvironRes66: 160172, 1994 647. LjungmanS, WikstrandJ, HartfordM, BerglundG: UrinaryalbuminexcretionApredictorofrisk ofcardiovasculardisease. Aprospective10-yearfollow-upofmiddle-agednondiabeticnormaland hypertensivemen. AmJHypertens9: 770778, 1996 648. CulletonBF, LarsonMG, ParfreyPS, KannelWB, LevyD: Proteinuriaasariskfactorforcardiovascular diseaseandmortalityinolderpeople: Aprospectivestudy. AmJMed109: 18, 2000 649. MiettinenH, HaffnerSM, LehtoS, RonnemaaT, PyoralaK, LaaksoM: Proteinuriapredictsstroke andotheratheroscleroticvasculardiseaseeventsinnondiabeticandnon-insulin-dependentdiabetic subjects. Stroke27: 20332039, 1996 650. AgewallS, WikstrandJ, LjungmanS, FagerbergB: Usefulnessofmicroalbuminuriainpredicting cardiovascularmortalityintreatedhypertensivemenwithandwithoutdiabetesmellitus. RiskFactor InterventionStudyGroup. AmJCardiol80: 164169, 1997 651. JagerA, KostensePJ, RuheHG, HeineRJ, NijpelsG, DekkerJM, BouterLM, StehouwerCD: Microal326 Bibliography NationalKidneyFoundation potassium/DOQI buminuriaandperipheralarterialdiseaseareindependentpredictorsofcardiovascularandallcausemortality, especiallyamonghypertensivesubjects: Five-yearfollow-upoftheHoornStudy. ArteriosclerThrombVascBiol19: 617624, 1999 652. YudkinJS, ForrestRD, JacksonCA: Microalbuminuriaaspredictorofvasculardiseaseinnon-diabetic subjects. IslingtonDiabetesSurvey. Lancet2: 530533, 1988 653. KligerAS: ClinicalpracticeguidelinesandperformancemeasuresinESRD. AmJKidneyDis32: S173-S176, 1998(suppl4) 654. KligerAS, HaleyWE: Clinicalpracticeguidelinesinend-stagerenaldisease: Astrategyforimplementation. JAmSocNephrol10: 872877, 1999 655. JaeschkeR, GuyattGH, SackettDL: Usersguidestothemedicalliterature. III. Howtouseanarticle aboutadiagnostictest. B. Whataretheresultsandwilltheyhelpmeincaringformypatients? The Evidence-BasedMedicineWorkingGroup. JAMA271: 703707, 1994 656. LaupacisA, WellsG, RichardsonWS, TugwellP: Usersguidestothemedicalliterature. V. Howto useanarticleaboutprognosis. Evidence-BasedMedicineWorkingGroup. JAMA272: 234237, 1994 657. Planandoperationofthethirdnationalhealthandnutritionexaminationsurvey, 19881994. Vital andHealthStatistics, Series1. 407. Bethesda, MD, NationalCenterforHealthStatistics, 1994 658. EzzatiT, WakesbergJ, ChuA: Sampledesign: Third nationalhealthand nutritionexamination survey, 19881994. VitalandHealthStatistics, Series2. Bethesda, MD, NationalCenterforHealth Statistics, 1992 659. KasiskeBL, KeaneWF: Laboratoryassessmentofrenaldisease: Clearance, urinalysis, andrenal biopsy, inBrennerBM, RectorFCJr(eds): TheKidney.",
    "word_count": 597,
    "char_count": 9170,
    "sentence_count": 124,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 75,
      "total_chunks": 77,
      "position": "76/77",
      "content_type": "evidence",
      "content_type_confidence": 6,
      "medical_entities": [
        "nephropathy",
        "albuminuria",
        "proteinuria",
        "potassium",
        "calcium",
        "insulin"
      ],
      "entity_count": 6
    }
  },
  {
    "chunk_id": 76,
    "text": "VitalandHealthStatistics, Series2. Bethesda, MD, NationalCenterforHealth Statistics, 1992 659. KasiskeBL, KeaneWF: Laboratoryassessmentofrenaldisease: Clearance, urinalysis, andrenal biopsy, inBrennerBM, RectorFCJr(eds): TheKidney. Philadelphia, PA, W. B. Saunders, 1996, pp 11371173 660. CoreshJ, TotoRD, KirkKA, WheltonPK, MassrySG, JonesC: Creatinineclearanceasameasure ofGFRinscreeneesfortheAfrican-Americanstudyofkidneydiseaseandhypertensionpilotstudy. AmJKidneyDis32: 3242, 1998 661. CoreshJ, AstorB, McQuillanG: Calibrationandrandomvariationoftheserumcreatinineassay ascriticalelementsofusingequationstoestimateglomerularfiltrationrate. AmJKidneyDis2002 (inpress) 662. ChaversBM, SimonsonJ, MichaelAF: Asolid-phasefluorescentimmunoassayforthemeasurement ofhumanurinaryalbumin. KidneyInt25: 576578, 1984 663. ReportoftheExpertCommitteeontheDiagnosisandClassificationofDiabetesMellitus. Diabetes Care20: 11831197, 1997 664. StataStatisticalSoftware: Release6. 0. CollegeStation, transplant, StataCorp, 1999 665. WatsonPE, WatsonID, BattRD: Totalbodywatervolumesforadultmalesandfemalesestimated fromsimpleanthropometricmeasurements. AmJClinNutr33: 2739, 1980 666. MaroniBJ, SteinmanTI, MitchWE: Amethodforestimatingnitrogenintakeofpatientswithchronic renalfailure. KidneyInt27: 5865, 1985 667. GotchF, KeenML: CareofthePatientonDialysis: IntroductiontoDialysis. NewYork, NY, Churchill Livingston, 1991, pp101179 potassium/DOQI NationalKidneyFoundation Bibliography 327 CLINICAL PRACTICE GUIDELINES potassium/DOQI CLINICAL PRACTICE GUIDELINES For Chronic Kidney Disease: Evaluation, Classification and Stratification For Chronic Kidney Disease Made possible through an educational grant from Amgen, Founding and Principal Sponsor of National Kidney Foundation-potassium/DOQI. Additional implementation support was received from Ortho Biotech Products, L. P. and Bayer Diagnostics. 30 East 33rd Street New York, NY 10016 Phone 800 622-9010 www. Kidney. org ISBN 1-931472-10-6 National Kidney Foundation Order No. potassium/DOQI-156 Amgen Part No. P35181 potassium/DOQI Learning System (KLS)",
    "word_count": 181,
    "char_count": 2092,
    "sentence_count": 27,
    "metadata": {
      "source_file": "ckd_evaluation_classification_stratification.pdf",
      "extraction_date": "2025-12-31T14:23:22.851757",
      "document_type": "medical_guideline",
      "language": "en",
      "keywords": [
        "chronic kidney disease",
        "renal"
      ],
      "chunk_index": 76,
      "total_chunks": 77,
      "position": "77/77",
      "content_type": "monitoring",
      "content_type_confidence": 3,
      "medical_entities": [
        "chronic kidney disease",
        "potassium",
        "classification"
      ],
      "entity_count": 3
    }
  }
]